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ABSTRACT 
The de novo synthesis of various aromatic compounds from derivatives of dioxinone I is reported 
(Scheme I). Using the vinyl dioxinone II for cross metathesis reactions allowed a series of dioxinone 
ketones IV to be constructed. The aromatization reaction the substrates, catalyzed by DABCO, was 
developed to allow synthesis of 6-aryl and 6-alkyl salicylates V.
1
 
 
Scheme I. Sythesis of 6-substituted salicylates. 
Furthermore, using the same intermediates VI, oxidation to the dioxinone-diones VII was discovered 
(Scheme II). These compounds were found to undergo a similar aromatization process but yielded 
hydroquinones VIII. 
 
Scheme II. Synthesis of Hydroquinones VIII. 
A novel de novo route to γ-resorcylates XI, XV, and XIX was also developed. 2  Aromatization 
proceeded under Appel-type reaction conditions to give the γ-resorcylates with various substitution 
patterns. Three complementary routes were developed for the synthesis of substrates. The first 
involved cross metathesis of vinyl dioxinone II with homoallylic esters IX to give the acid X (Scheme 
III).  
                                                     
1
 Blencowe, P. S.; Barrett, A. G. M. Can. J. Chem. 2012, 90 (11), 975. 
2
 Blencowe, P. S.; Barrett, A. G. M. Eur. J. Org. Chem. 2014, (22), 4844. 
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Scheme III. Synthesis of γ-resorcylates XI. 
A second route involved using keto-dioxinones XII as starting materials (Scheme IV). Aldol addition 
of tert-butyl acetate derivatives XIII to XII followed by dehydration and ester cleavage provided the 
aromatization substrates XIV. 
 
Scheme IV. Synthesis of γ-resorcylates XV. 
In a third route, the use of benzyl acetate derivatives XVII for aldol additions to keto-dioxinones XVI 
followed by hydrogenolysis, gave the β-hydroxy acid compounds XVIII (Scheme V). Aromatization 
of these substrates proceeded under the same Appel-type conditions to give the γ-resorcylates XIX.  
 
Scheme V. Synthesis of γ-resorcylates XIX. 
Further expanding this methodology the unsaturated amide XX and β-hydroxy amide XXII were 
constructed in a similar manner to before (Scheme VI). Conditions were developed to allow the 
aromatization of these substrates giving 6-aminosalicylate XXI. 
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Scheme VI. Synthesis of 6-aminosalicylate XXI. 
A route to acid chloride XXIII was explored in this work as it would be useful synthetic intermediate 
(Scheme VII). In situ IR evidence is presented for this compound however attempted isolation from 
solution resulted in formation of the dimer XXIV. 
 
Scheme VII. Synthesis of dioxinone dimer XXIV. 
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Å       Angstrom (10
-10
 metres) 
Ac       acetyl 
Anal.       analysis 
aq.       aqueous 
Ar       aryl 
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Boc       tert-butyloxycarbonyl 
bp       boiling point 
BHT      butylated hydroxytoluene 
br       broad 
Br      bromide 
Bu      butyl 
°C       degrees Celsius 
calcd.      calculated 
cat.       catalytic 
CDI       carbonyl diimidazole 
CI       chemical ionization 
δ       chemical shift 
d       doublet 
DABCO     1,4-diazabicyclo[2.2.2]octane 
DBU       1,8-diazabicyclo[5.4.0]undec-7-ene 
DCB      o-dichlorobenzene 
dd       doublet of doublets 
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DIBAL-H      diisobutylaluminium hydride 
DMAP       4-dimethylaminopyridine 
DMB      2,4-dimethoxybenzyl 
DMF       N,N-dimethylformamide 
DMP       Dess-Martin periodinane 
DMSO       dimethylsulfoxide 
dr       diastereomeric ratio 
dt       doublet of triplets 
EDCI       N-(3-dimethylaminopropyl)-N’- 
ethylcarbodiimide 
ee       enantiomeric excess 
EI       electron ionization 
equiv       equivalent(s) 
ESI       electrospray ionization 
Et       ethyl 
Et2O       diethyl ether 
Et3N       triethylamine 
EtOAc       ethyl acetate 
h       hour 
HAT      histone acetyltransferase 
HeLa      Henrietta Lacks cells 
HMDS       hexamethyldisilizane 
HMPA       hexamethylphosphoramide 
HMPT      hexamethylphosphorous triamide 
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HRMS       high-resolution mass spectrometry 
Hsp90       heat shock protein 90 
Hz       Hertz 
i       iso 
IBX      2-iodoxybenzoic acid 
IR       infrared spectroscopy 
J       coupling constant 
L       litre 
LDA       lithium diisopropylamide 
LDL      low-density lipoprotein    
μ       micro (10-6) 
µW      microwave 
m       multiplet 
M       molar 
m       meta 
Me       methyl 
MeOH       methanol  
MHz      mega (10
6
) Hertz 
min       minute(s) 
mL       millilitre(s) 
mol       mole(s) 
MOM       methoxymethyl ether 
mmol       millimole(s) 
mp       melting point 
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MS       molecular sieves 
n       normal 
NF-κB      Nulcear Factor kappa B 
NMO      N-methylmorpholine oxide 
NMR       nuclear magnetic resonance 
NOESY      nuclear overhauser effect spectroscopy 
Nu       nucleophile 
o       ortho 
OTf      triflate 
p       para 
PCC      pyridium chlorochromate 
pH       potential hydrogen 
Ph       phenyl 
PhMe       toluene 
PKS       polyketide synthase 
PMB       para-methoxybenzyl 
ppm       parts per million 
PPTS      pyridinium para-toluenesulfonate 
Pr       propyl 
pTSA       para-toluenesulfonic acid 
q       quartuplet 
quin.      quintuplet 
R       general substituent 
rr      regioisomeric ratio 
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s       singlet 
s      secondary 
sep      septuplet 
t or tert      tertiary 
t      triplet 
TBAF       tetrabutylammonium fluoride 
TBS       tert-butyldimethylsilyl 
td       triplet of doublets 
tt       triplet of triplets 
TFA       trifluoroacetic acid 
TFAA      trifluoroacetic anhydride 
THF       tetrahydrofuran 
TIPS       triisopropylsilyl 
TLC       thin layer chromatography 
TMS       trimethylsilyl 
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Introduction 
Aromatic compounds are ubiquitous throughout chemistry and its applications. Whether it is for the 
core of the latest blockbuster drug or functional material, the synthesis of aromatic hydrocarbons has 
been a feature of organic chemistry since the 19
th
 century.
1
 At that time, coal tar provided an 
inexpensive and abundant source of benzene, phenols, and polycyclic aromatic hydrocarbons (PAHs); 
and synthetic routes to substituted benzene compounds were by functionalization of one of these 
cheap starting materials.  This led to the development of aromatic electrophilic and nucleophilic 
substitution reactions; reactions that have been taught to generations of chemistry.
2
 
Another common area taught to chemistry students is heteroaromatic chemistry. Reactions taught in 
this context consist of, for example, the Paal-Knorr synthesis of pyrroles or the Fischer indole 
synthesis. In these cases, pre-functionalized, acyclic starting materials undergo an aromatization 
reaction to give the target heteroaromatic compound. This strategy of producing aromatic compounds 
beginning from non-aromatic precursors is often referred to as de novo aromatic synthesis (Scheme 
1). 
 
Scheme 1. A conceptual picture of De novo synthesis. Hexasubstituted-benzene 1 is made by cyclization of acyclic building 
block III, itself already constructed from I and II. 
Classical aromatic substitution chemistry can often result in formation of ortho, meta and para 
mixtures. As such, the synthesis of highly substituted aromatic rings can often involve linear multi-
step routes negating the use of cheap starting materials.
1
 Using de novo approaches can avoid these 
problems; introducing substituents to an acylic starting material provides complete regioselectivity 
and can allow highly convergent synthesis of aromatic compounds. Furthermore, de novo synthesis 
can offer access to novel compounds not easily available by aromatic functionalization chemistry. 
In the remainder of this introduction will be an outline of some of the strategies that have been used in 
the regioselective synthesis of densely functionalized benzenoid compounds from acyclic precursors. 
Of course there have been many reviews in this area of chemistry and rather than providing an 
exhaustive list of de novo methods, the outline will contain some of the main strategies that have been 
developed, including some of their applications as examples.
3
 Some examples will also be shown to 
directly compare the efficiency of aromatic functionalization and de novo strategies. The methods 
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covered will mainly be de novo synthesis of benzene compounds; heteroaromatic synthesis and the 
synthesis of fused compounds are largely not covered.  
Having introduced strategies for de novo synthesis, some of the synthetic methods nature employs for 
aromatic compounds will be discussed including chemists who have attempted to mimic them. At this 
point, a discussion of dioxinone compounds and their use in synthesis will ensue before returning to 
biomimetic concepts and how, when combined with dioxinone derivatives, they are leading to 
emerging methods in de novo aromatic synthesis.  
Research within the Barrett group at Imperial College will then be discussed giving a detailed picture 
of what was known before the current research began, as well as developments that were made 
concurrently. Following this, the aims of the project will be outlined, and the research carried out will 
be presented in the subsequent results and discussion sections. 
1.1 Benzenes by De Novo Synthesis 
The following de novo methods of benzene synthesis are loosely divided into sections by virtue of 
their broad underlying strategy. This allows the many ways in which de novo synthesis has been 
explored to be appreciated.  
1.1.1 Formation and Cyclization of Dienylketenes 
Dienylketenes readily undergo 6π-electrocyclization resulting in benzene derivatives. There are many 
ways for their generation and the following sections cover the Danheiser benzannulation reaction, 
cyclization of hexadienoic acids, and the Wulff-Dötz reaction as methods for accessing this 
intermediate. 
1.1.1.1 The Danheiser Benzannulation Reaction 
The discovery of the Danhesier benzannulation was preceded by the benzannulation of enoic-ketenes 
and alkynes. This process was first discovered by Smith and Hoehn; reaction of diphenyl ketene (2) 
and phenylacetylene (3) gave 3,4-diphenylnaphthalen-1-ol (4) (Scheme 2).
4
 This was proposed to 
occur through a dienylketene intermediate. 
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Scheme 2. Smith and Hoehn’s naphthol synthesis. 
Following numerous contributions one of the major examples of this process is the Danheiser 
benzannulation which sees the conversion of a cyclobutenone and acetylenic derivative to give a 
highly substituted aromatic compound in a regiocontrolled manner (Scheme 3).
5
 Heating of 
cyclobutenedione 5 leads to a reversible four-electron electrocyclic cleavage to give vinylketene 7 
which undergoes a [2+2] regiospecific cycloaddition with acetylene component 6.  Four-electron 
cleavage of the 2-vinylcyclobutenone 8 forms dienylketene 9. 6π-electrocyclization of the 
dienylketene affords a cyclohexadienone that can tautomerize to give phenol compound 10.  
 
Scheme 3. Danheiser’s aromatization of dienylketenes. 
As alternative precursors to vinylketene intermediate 7 a route using a Wolff rearrangement was 
developed (Scheme 4). Rearrangement of diazo compound 11 gave vinylketene 12 that could react 
with an alkyne as before. This expands the versatility of the cycloaddition method through the range 
of substrates available.
6
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Scheme 4. Wolff rearrangement in the generation of dienylketenes. 
The scope of these reactions was further increased by use of cyclobutenediones as starting materials in 
an intramolecular process (Scheme 5).
7
  Addition of aryllithium reagents to 18 gives cyclobutenol 19, 
which undergoes conrotary ring opening to give dienylketene 20. 6π-Electrocyclization of the 
dienylketene 20 gives fused 1,4-hydroquinones 21. Alternatively, addition to fused dione 22 with an 
arylmagnesium reagent gave the cyclobutenol 23. Aromatization of the cyclobutenol followed by 
oxidation gives quinone 24. Further to this, the addition of alkynyl lithium reagents to 22 gives yne-
eneylketene intermediates, an oxidation state higher, resulting in direct isolation of quinones (Moore 
cyclization, not pictured).
8
 
 
Scheme 5. Liebeskind’s  organometallic additions to cyclobutenediones and aromatization reactions. 
1.1.1.2 Hexadienoic Acids 
Activation of hexadienoic acids 25 also lead to formation of dienylketenes with subsequent 6π-
electrocyclization (Tables 1 and 2). The required substrates can easily be constructed via Stobbe 
condensation or by Wittig reaction. 
9,
 
10
 The first use of these substrates for aromatic synthesis was by 
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Ramage et al. who prepared phosphinic-carboxylic acid mixed anhydrides in the presence of base to 
give the m-hydroxybenzoic acids.
11
 
 
Entry
b 
R
1
 R
2
 Yield 
1 H Me 50 
2 Me H 59 
3 Ph Me 47 
4 Me Ph 62 
5 Me o,o-Br, NO2-C6H3 56 
a) R3 = H, R4 = Me.  b) i) N-methylmorphiline, 
P(O)Ph2Cl, CH2Cl2, −23  °C; ii) NEt3, −23 to 25 
°C. 
Table  1. Activation of 25 as phosphinic-
carboxylic mixed anhydrides by Ramage et al. 
Entry R
1
 R
2
 R
3
 R
4
 
Yield 
(%) 
1
12
 PhS Me Me Et 95
c
 
2 Br Me H Et 89
b
 
3 Ph OMe H Et 88
b
 
4
13
 β-glucopyranosyl H H Et 91b 
5
14
 o-BnO-napthyl Et H Me 78
a
 
6 2-furyl Me H Me 87
a
 
7
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H Et 90
a
 
8 
 
H Et 85
a
 
a) ClCO2Et, NEt3, THF. b) i) ClCO2Et, NEt3, THF; ii) NaOH, EtOH. c) 
(CF3CO)2, NEt3; ii) NaBH4, EtOH. 
Table 2. Activation of hexadienoic acids 25 by Serra. 
Further work by Serra, who improved the activation by use of ethyl chloroformate as the activating 
agent, demonstrated applicability for a range of substrates. Heteroatom, aryl, alkyl, and glycosidyl 
substituents were all compatible with the cyclization protocol giving excellent yields. Similar to these 
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examples, but without the requirement for direct activation, was the intramolecular cyclization of the 
dienylacids 28 (Scheme 6).
16
 Due to the presence of the enol ether, heating of 28 alone provided 
phenols 29.  
 
Scheme 6. Paquette’s enol ether assisted aromatization reaction. 
1.1.1.3 The Wulff-Dötz Benzannulation 
The Wulff-Dötz reaction is the reaction of an α,β-unsaturated Fischer carbene complex with an alkyne 
to give an arene-Cr(CO)3 complex: a [3+2+1]-benzannulation (Scheme 7).
17
  After initial loss of 
carbon monoxide from the carbene 30 by mild heating (typically 45–60 °C), coordination of a 
molecule of alkyne 31 forms α,β-unsaturated carbene intermediate III. Insertion of CO then generates 
the dienylketene-Cr(CO)3 complex IV. Electrocyclic ring closure followed by tautomerization gives 
the arene-Cr(CO)3 complex 32. This is a similar dienylketene intermediate generated in methods 
highlighted above. In this case however, the formation of the dienylketene is within the coordination 
sphere of a metal allowing the phenols 32 to be formed under very mild conditions. Unsymmetrical 
alkynes are regiochemically incorporated in correlation with their steric differential; the larger 
substituent incorporated ortho to the hydroxy group. 
18
 
 
Scheme 7. Postulated mechanism for the Wulff-Dötz reaction. 
In light of the effectiveness of the Wulff-Dötz reaction, it has been used widely in synthesis and in a 
number of natural products. En route to the macrocycle (–)-kendomycin, the reaction allowed a 
20 
 
heavily substituted benzene derivative 35 to be prepared from the alkyne 33 (Scheme 8).
19
 Here, mild 
air oxidation of the mixture liberated the phenol free from its chromium complex.  Another densely 
functionalized phenol 37 was produced by a partial Wulff-Dötz reaction.
20
 Preformed dienylcarbene 
complex 36, underwent carbonylation and aromatization to give the carbazole in 65 % yield towards a 
synthesis of carbazoquinocin C. 
 
Scheme 8. Application of the Wulff-Dötz in synthetic steps towards (–)-kendomycin and carbazoquinocin C. 
1.1.2 Eneyne Molecules as Substrates for Aromatization 
Benzene synthesis involving eneynes cover a vast array of different reactions, mechanisms and 
strategies. Here, Bergmann cyclizations, dehydro Diels-Alder, Diels-Alder, and trimerization 
reactions are discussed. 
1.1.2.1 Bergmann and Myers-Saito Cyclizations 
The Bergmann cyclization was first applied to synthetic molecules before the discovery of its 
occurrence in nature.
21
 The cyclization of acyclic enediynes 38 to give 1,4-biradical 39 was first 
discovered by Bergman and coworkers and the high temperature required suggested that it would not 
be possible at the ambient temperatures of nature (Scheme 9).
22
 Related to this, is the Myers-Saito 
Cyclization in which the cyclization of eneyne allene systems 41 gives biradical 42.
23
 Allenes of type 
41 are highly reactive and so the Myers-Saito cyclization of acyclic molecules is generally more facile 
than Bergmann cyclization.
24
 
21 
 
 
Scheme 9. Mechanisms of the Bergmann and Myer-Saito cyclizations. 
Natural cyclic enediynes occur in a number of antitumor antibiotics such as the calicheamicins, 
esperamicins, and neocarzinostatin. Elucidation of the mode of action of these antibiotics led to an 
understanding of how the substrates could be stabilized at ambient temperatures as well as triggered to 
undergo cyclization when required.
25
 For example the active site of calicheamicins contain a cyclic 
enediyne, calicheamicinone (44) (Scheme 10). In the laboratory, triggering of the Bergmann 
cyclization was achieved by addition of triphenylphosphine; attack at the allylic trisulfide of 44 led to 
Michael addition of the resulting thiol to generate the more highly strained intermediate I.
26
 Now 
activated for cyclization, I gives the biradical II, which is deuterated by the solvent resulting in 45. 
 
Scheme 10. Triggering calicheamicinone (44) to undergo a Bergmann cyclization deuterium trapping of the biradical. 
With regard to the rate of cyclization, a theory was postulated that the distance between the acetylenic 
carbon atoms governs the rate of cyclization.
27
 More recently another more general theory was 
proposed based on the differential molecular strain between the ground and transition states.
28
 With 
regard to the Myers-Saito cyclization, the formation of a s-cis-enyne-allene can be sufficient to trigger 
cyclization. For example, treatment of 46 with TFA in the presence of 1,4-cyclohexadiene forms the 
enyne-allene 47, which undergoes a very facile Myers-Saito cyclization to give the aromatized 
product lactone 48 (Scheme 11). 
29
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Scheme 11. Acid mediated formation of a enyne-allene 46 and Myers-Saito cyclization. 
In order to allow more facile aromatization of Bergmann enediyne substrates, rearrangement to the 
more reactive eneyne-allene forms have been attempted. One example of where this has been 
achieved is through formation of a vinylidene complex 50 (Scheme 12).
30
 Thermyolysis the complex 
50 required heating at only 100 °C compared to 190 °C required for aromatization of the 
uncomplexed enediyne 49.
31
 
 
Scheme 12. Rearrangement of enediyne 49 to more reactive vinylidene complex 50, that aromatizes to 51. 
1.1.2.2 Dehydro Diels-Alder Reactions for De Novo Aromatic Synthesis. 
The “dehydrogenated” version of the Diels-Alder is known as the dehydro Diels-Alder; the 
tetradehydro-Diels-Alder being more highly oxidized is capable of generating bent cyclic allenes- 
isomers of benzenes.
32
 Many variants on substrates and their synthesis have been envisaged based on 
intra- and intermolecular reactions, as well as variation in starting materials.
33
   
Danheiser demonstrated that the conjugated enynes of 52a–c undergo intramolecular [4+2] 
cycloaddition with alkynes to give benzene compounds 53a–c under heat or with protic and Lewis 
acids (Scheme 13).
34
 The use of phenolic additives increased the yields obtained in these reactions but 
not the rate, while use of protic or Lewis acids enabled reactions to be carried out at 0 °C. The initial 
23 
 
isoaromatic cyclic allenes from these reactions are proposed to undergo rearrangement via either 
proton or radical mediated hydrogen atom transfer pathways.
35
  
 
Scheme 13. Danheiser’s cyclizations of eneynes under thermal and acid catalyzed reaction conditions. 
Later, Yamamoto and co-workers reported a complimentary regiospecific palladium catalyzed 
intermolecular method for homodimerization of conjugated enynes (Scheme 14).
36
 Beginning with the 
enynes 54 or 55, the conversion to homodimers was observed without trimerization and, in a 
regiospecific manner to give the benzene derivatives 56 and 57. This was then extended to produce 
unsymmeterical compounds from cross cycloaddition of the enynes. Cycloaddition of 58 or 59, with 
symmetrical diynes such as 60, gave 61 and 62 respectively in a regioselective fashion.
37
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Scheme 14. Yamamoto’s intermolecular eneyne homo-cycloadditions and cross-cycloadditions. 
1.1.2.3 Diels Alder Reactions 
Diels-Alder reactions of 2-pyrones are have been widely used for de novo construction of benzene 
compounds.
38
 The general concept proceeds by [4+2] cycloaddition of alkynes to pyrones 63 
generates highly strained bicyclooctadeienes 64, which is followed by extrusion of CO2 to give the 
aromatic products 65 (Scheme 15). Cycloaddition of alkenes to pyrone 63 gives more stable 
bicyclooctenes 66, and extrusion of CO2 gives dihydrobenzenes 67. Elimination of a leaving group 
can give the benzene 68.   
25 
 
 
Scheme 15. General Diels-Alder reactions of alkynes or alkenes with 2-pyrone 63 as applied for benzene synthesis. 
This method has been used in methodology and natural product chemistry alike. Towards highly 
functionalized benzene derivatives, alkylated pyrones 69 were heated with unsymmetrical alkynes 70 
(Scheme 16).
39
 Use of unsymmetrical alkynes in such Diels Alder reactions can lead to mixtures of 
regioisomers however in this case, use an acetylenic ester 70 allowed sufficient distinction for highly 
regioselective formation of benzoate 71 over regioisomer 72.  
 
Scheme 16. Regioselectivity achieved in Diels-Alder reaction of an unsymmetrical alkyne 70 with 2-pyrone 69. 
Within natural product synthesis the Diels-Alder strategy for de novo benzene synthesis has solved 
numerous problems. In a synthesis of imeluteine (73), trimethoxy ethene is used as the reactive 
partner with pyrone 74 (Scheme 17).
40
 The Diels-Alder cyclization and decarboxylation was followed 
by treatment with base to facilitate loss of methanol to give 75. Ester saponification followed by 
decarboxylation gave rise to the target natural product imeluteine (73). 
 
Scheme 17. Diels-Alder addition of trimethoxyethene and 2-pyrone 74 towards a synthesis of imeluteine (73). 
In a synthesis of lasalocid A (76) a salicylate was required (Scheme 18). Despite attempts of Diels-
Alder reaction of pyrone 77 with alkoxy propynes or synthetic equivalents, none were found to be 
reactive.
41
 However, it was found ynamines could also be active as dienophiles for the Diels-Alder 
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reactions with 2-pyrone 77. Diels-Alder reaction of N,N-diethyl-1-amino-1-propyne with pyrone 77 
occurred at room temperature in 89% yield. The required dibenzylalkyne 78 reacted similarly well to 
give the aminosalicylate 79 in 60% yield, which was further converted to lasalocid A. 
 
Scheme 18.  Diels-Alder reaction of 2-pyrone 77 with a ynamine 78. 
Application of the Diels-Alder strategy also enabled a synthesis haouamine A (80); a architecturally 
unique alkaloid containing a cyclophane macrocycle and a highly deformed aromatic ring (Scheme 
19).
42
 Formation of the macrocycle by biaryl synthesis methods or alkylation failed and so de novo 
approaches were investigated. This first involved the synthesis of pyrone 81, with the nitrogen-
tethered alkyne awaiting an intramolecular, macrocylization Diels-Alder reaction- a first of its kind. 
Reaction proceeded at 250 °C to give adduct 82 and treatment with potassium carbonate gave 80 in 
21% yield (with 30% of recovered 81) and 10:1 selectivity for the desired atropisomer. While the 
yield was low, this represented the first synthesis of 80 and a novel macrocyclization strategy. 
 
Scheme 19.  De novo synthesis using a Diel’s Alder reaction of pyrone 81 employed by Baran for synthesis of 
haouamine A (80). 
To further improve the synthesis of haouamine A (80) and its atropisomer, an alternative de novo 
synthesis of the phenol ring was investigated (Scheme 20).
43
 This time the cyclohexenone 
intermediate 83 was chosen as the target for synthesis, the sp
3
 hybridization making this a less 
strained species. Oxidation of 83 would then allow access to the desired phenol. The oxidant of 
choice, to avoid oxidation of the core, was found to be N-tert-butylbenzenesulfinimidoyl chloride 
(84).
44
 Brief exposure of 83 to the oxidant gave the desired phenol 85 in 60% yield (23% 83) and 
demethylation provided the natural product 80.  
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Scheme 20. De novo synthesis of haouamine A (80) by an oxidation strategy. 
1.1.2.4 [2+2+2] Trimerizations 
Trimerization of alkynes is a very useful and widely applied method for the synthesis of benzene 
derivatives.
45
 In 1866 the thermal (ca 400 °C) cyclization of acetylene to give benzene was reported 
and later, in 1949 the first transition metal variant of the reaction was reported being catalyzed by a 
large number of transition metals.
46
 In the case of homo-trimerization, the regioselectivity of 1,2,4 vs 
1,3,5-substituted arenes must be considered (Scheme 21). Excellent results are obtained with respect 
to this regioselectivity using titanium calixarene catalysts as illustrated by Ladipo et al.
47
 Virtually 
complete regioselectivity is imparted by the steric effects directing insertion of the third alkyne into a 
titanacyclopentadiene.  
 
Scheme 21. Ladipo’s highly regioselective alkyne trimerizations for formation of 1,2,4-substituted arenes. 
Moving to a more complex situation, selective cross-trimerization is even more challenging as 
including regioselectivity issues, there are also chemoselective issues meaning multiple products may 
be obtained. For the intermolecular variant, selectivity can be achieved through selective formation of 
the intermediate metallocyclopentadiene and its further reaction with an alkyne, similar to the 
example above.  Takahashi et al. were able to develop a one-pot sequential procedure to give highly 
selective benzene formation of three different alkynes (Scheme 22). 
48
 Treatment of Cp2ZrCl2 (91), 
with n-Buli, followed by ethylene gives rise to a zirconacyclopentane I which selectively reacts with 
only one alkyne in the acetylene atmosphere. At 50 °C under a nitrogen atmosphere a second alkyne 
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is incorporated to give unsymmetrical zirconacyclopentadiene II. Introduction of the third alkyne with 
copper chloride gives benzene 92 in 85% yield. Only 2% of side product 93 was formed from 
unselective alkyne insertion. 
 
Scheme 22. Sequential trimerization of three different alkynes via a zirconiumcyclopentadiene II. 
Moving towards catalytic processes and alternative mechanisms for selective cross-trimerization 
Yamamoto et al. have investigated the sequential formation of enynes, followed by [4+2] cyclo 
addition as a formal [2+2+2] process (Scheme 23).
49
 The first step is a regio and chemoselective 
coupling of a terminal alkyne 94 (donor alkyne) to an alkyne possessing an electron-withdrawing 
group 95 (acceptor alkyne). Further reaction with the diyne 96 gives pentasubstituted-benzene 97 in 
56% yield. 
 
Scheme 23. Sequential alkyne trimerization via enynes I for formal [2+2+2] cyloadditions. 
1.1.3 Synthesis of Aromatics by Condensation reactions. 
Much early de novo synthesis of phenolic compounds revolved around condensation reactions of 
ketones 98 with dicarbonyl species such as dialdehydes 99 to give nitro-phenols 100 (Scheme 24).
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Expanding this concept, but combining disubstituted ketones 101, with keto-aldehyes or 1,3-diketones 
(102) as the electrophile is more useful, giving rise to more highly substituted aromatics 103. When 
using unsymmetrical ketones 101, care must be taken to allow preferential enolization and, with 
regards to the β-diketone 102, use of ketones, aryl ketones, or aldehydes can provide some 
selectivity.
51
 A range of different electron withdrawing groups can be incorporated as exemplified in 
the synthesis of 1,3-cyano-nitro biaryl 106.
 52
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Scheme 24. Synthesis of phenols and hydroxy-benzoates through condensation reactions. 
Similar concepts are again applied to produce dihydroxy benzoate derivatives (Scheme 25). Here, use 
of aldol condensations is common, but also Claisen condensations to allow incorporation of the 
second hydroxy group. For example, self condensation of diethyl acetonedicarboxylate 107 proceeds 
by aldol condensation followed by Claisen condensation to give highly substituted aromatic 108.
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Crossed condensations can also be used, however reaction of 111 gives a mixture of 112 and 113, 
arising from Claisen condensation and arising from aldol condensation respectively.
54
. 
 
Scheme 25. Formation of dihydroxy-benzoates through intramolecular condensation reactions. 
1.1.3.1 Isoxazoles 
Aside from a judicious choice of functional groups present in condensation reactions, other methods 
for regiocontrol in condensation aromatizations have been investigated. Use of isoxazoles as masked 
β-dicarbonyl compounds were investigated as precursors for aromatic compounds (Scheme 26).55 
Hydrogenation of 114 gives rise to the dienamine-dicarbonyl 115. On treatment with aqueous 
hydrochloric acid, 115 is converted to a mixture of 116 and 117 arising from a choice of cyclizations. 
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Scheme 26. Formation of β-resocinols 116 and 117 through intramolecular Mannich reaction. 
 In order to probe the intermediates in this process, partial hydrogenolysis of 114 gave 118 followed 
by hydrolysis to give 119 (Scheme 27). When the second isoxazole was reduced, a mono enamine 120 
was obtained. On treatment with aqueous hydrochloric acid the sole regioisomer formed was 117. 
This demonstrated that cyclization of these systems involves direct loss of ammonia and that 
tetracarbonyl intermediates are not formed under the conditions; loss of ammonia is favored over loss 
of water. Utilizing this selectivity, double isoxazoles 121 and 114 could be hydrogenated, the 
bisenamine intermediates undergoing cyclization to give the respective resorcinols 116 and 117 
selectively (< 5% of other regioisomers obtained).  
 
Scheme 27. Use of isoxazoles as masked β-dicarbonyls for synthesis of resorcinol products. 
1.1.3.2 Lewis Acid Mediated Cyclizations 
In the condensation reactions shown above, regioselectivity is an element that must be rigorously 
controlled to provide truly useful syntheses. One way such regioselectivity has been elegantly 
controlled is by use of 1,3-bis(trimethylsilyloxy)-1-methoxybuta-1.3-diene 124 (Chan’s diene) 
(Scheme 28).
56
 This bis-silylated reagent was introduced as the dianion equivalent of methyl 
acetoacetate. However, 124 can condense with various electrophiles under Lewis acidic conditions. It 
was found that the reactivity of 124 with electrophiles is as follows: aldehyde > conjugated position of 
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a β-oxy-α,β-unsaturated ketone ≈ isolated ketone > carbonyl positions of a β-oxy-α,β-unsaturated 
ketone > acetal or monothioacetal > conjugate position of β-oxy-α,β-unsaturated ester or ester 
carbonyl.
57
  
 
Scheme 28. Lewis acid mediated reactivity of Chan’s diene with various electrophiles. 
To illustrate this reactivity are the following examples. Reaction of 124 with acetal ketone 126 occurs 
first at the ketone to give 127 in 41% as the sole regioisomer. Alternatively, use of ketoaldehyde-silyl 
enol ether 128 gives alternative regioisomer 129; the diene reacting firstly with the silyl enol ether. 
Continuing down the reactivity scale, with β-oxy-α,β-unsaturated ketone 130, reaction occurs first at 
the β-position to give 6-methyl salicylate 131a. Alternatively, addition of 124 to ketone 132 occurs 
first followed by ring closure at the mixed thioacetal/acetal to give the alternative regioisomer, 4-
methyl salicylate 133. 
Chan’s diene proved useful in more complex methodology and natural product synthesis (Scheme 
29). Reacting two equivalents of the diene 124 with a variety of electrophiles gave 4-substituted 
homophthalates 134 in a single step. Use of anhydrides as the electrophiles proved equally useful as 
orthoesters. In the case of isobutyric anhydride, significant quantities of methyl 6-methyl-3,5-
dioxoheptanoate were also observed, presumably due to steric effects of the isopropyl group on the 
aromatization step.
58
 
 
Scheme 29. Synthesis of homophthalates using Chan’s diene (124). 
This methodology for homophthalate synthesis was applied to the rapid construction of sclerin (135) 
(Scheme 30).
59
 Formation of a variant on Chan’s diene from 3-oxo-methylpentanoate gave the bis-
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silyl ether 137, which when reacted in a 2:1 ratio with trimethyl orthoformate, gives penta-substituted 
homophthalate 138. Further methylation with LDA gives 139, and ring closure under basic conditions 
concludes this highly concise, biomimetic synthesis of sclerin (135).  
 
Scheme 30. Application of Chan’s diene in synthesis of Sclerin (135). 
Furthermore, towards syntheses of Δ1-tetrahydrocannibol 1 (Δ1-THC) (140), 141 could be converted 
through reaction with Chan’s diene (124), to γ-resorcylate 142 which once decarboxylated gives a 
concise route to olivetol (not shown), used in conventional routes to Δ1-THC (Scheme 31). 60 
Alternatively, conversion of 141 to the corresponding acid chloride 143, resulted in a reversal of the 
reactivity with Chan’s diene and gave the regioisomeric β-resorcylate 144. Further selective 
electrophilic aromatic substitution at the 3-position and ether ring formation gives 145 with no 
chromenylation at the other vacant position.  Alkaline hydrolysis and decarboxylation gave Δ1-THC. 
 
Scheme 31. Application of Chan’s diene in synthesis of Δ1-tetrahydrocannibol (140). 
1.1.4 Synthesis of Aromatics Using Metathesis 
Metathesis, for the synthesis of aromatics, is most common amongst syntheses of benzene-fused or 
heteroaromatic compounds and often may be used for substrate synthesis, but not as an actual 
aromatization reaction.
 61
 For example, Donohoe et al. have developed a synthesis of pyridines where 
a condensation reaction is used for the aromatization step (Scheme 32).
62
 In constructing the 
substrates however, cross metathesis of a homoallylic alcohol and enone, 146 and 147 for example, is 
the key step. Oxidation of this product gives the unsaturated 1,5-dicarbonyl compound 148 as the 
aromatization substrate. 
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Scheme 32. Cross metathesis and oxidation for the synthesis of a 1,5-dicarbonyl compound 148 as precursor to pyridine 149. 
Huang and Wang made use of ring closing metathesis, again for substrate construction (Scheme 33).
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Here ring closing metathesis of the propen-1-ol 150 is used to form the second ring of the naphthalene 
product. Dehydration then occurs in presence of silica gel to give the desired aromatic product 151. 
 
Scheme 33. Formation of naphthalene 151 by a cross metathesis-elimination sequence. 
Using cross metathesis for direct formation of aromatic benzene derivatives is less common, but one 
example is the synthesis of naphthol 152 (Scheme 34).
64
 Here, treatment of α,β-unsaturated ketone 
153 with Grubbs second generation metathesis catalyst gives rise to ring closing metathesis and 
spontaneous tautomerization gives the naphthol 152.  
 
Scheme 34. Direct formation of naphthol 152 by cross metathesis. 
The concept of ring closing metathesis of an α,β-unsaturated ketone with a suitable allyl fragment was 
further broadened allowing a synthesis of phenols (Scheme 35).
65
 The trienone 154 (from a vinyl 
lithium addition to 2-ethylacrolein and oxidation) underwent ring closing metathesis to give the 
phenol 155 in 97% yield, and using this methodology, tri-substituted phenols could be accessed in 
high yield. Furthermore, regioisomeric trienes such as 156 also underwent similar transformation. 
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Scheme 35. Ring closing metathesis for formation of substituted phenols 155 and 157. 
Wishing to simplify the routes to substrate, trienes such as 158 were constructed by vinyl Grignard 
addition to 2,3-disubstituted acroleins, followed by oxidation (Scheme 36).
66
 On ring closing 
metathesis of 158, the exo-alkene 159 was obtained in 86% yield. The phenol product 160 could be 
obtained by isomerization with [RhCl(cod)]2 in 95 % yield. Wishing to utilize this second step to 
introduce further functionality, it was demonstrated that under Mizoroki-Heck conditions, cross 
coupling of 161 with a diazonium tetrafluoroborate salt 162 and aromatization, gave phenol 163. 
 
Scheme 36. Ring closing metathesis of 158 followed by isomerization to give phenol 160 and cross coupling-isomerization 
of exo-alkene 161 to give benzyl substituted phenol 163. 
1.1.5 De Novo Synthesis vs Aromatic Derivitization 
Having examined some of the de novo methods that can be used in synthesis of small molecules and 
natural products, the following section will illustrate the effectiveness of de novo methods for benzene 
synthesis. Comparing de novo methods against traditional aromatic derivatization chemistries for the 
synthesis of a natural product and a synthetic drug compound will show that de novo methods can be 
most efficient in terms of yields and brevity of synthetic sequence. 
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1.1.5.1 Cribrostatin 6 
The natural product cribrostatin 6 (164) was found to inhibit growth of antibiotic-resistant gram-
positive bacteria and pathogenic fungi, as well as exhibiting some in vitro anticancer activity and so 
significant synthetic efforts have been put towards its synthesis. The synthesis of 164 has been 
reported four times in the literature, twice by de novo methods and twice by functionalization of a pre-
existing aromatic molecule (Scheme 37).  
 
Scheme 37. Synthetic routes employed towards Cribrostatin 6 (124). 
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Martin’s synthesis of Cribrostatin was based on the benzannulation developed by Moore and co-
workers and begins with addition of a lithiated alkyne 165 to cyclobutenedione 166.
67
 Heating of 167 
results in formation of a yne-eneylketene which can aromatize with radical interception of the 
imidazole ring to give 168. While this final process occurs in a low 26% yield, the synthesis is concise 
(4 steps) with no protecting group manipulation, giving 164 in 14% overall yield.  
The route employed by Markey and Kelly however, begins with 2-methyl resorcinol 169, involving 
linear manipulations of the aromatic unit to form intermediate 170.
68
 Cross coupling of 170 with a 
SEM-protected imidazole, further bromination, cross coupling with allyltributyltin, and, a protecting-
group swap gives intermediate 171. Ring closure, deprotection, and oxidation complete the synthesis 
of 164 in 13 steps and a 3% overall yield. A similarly lengthy synthesis is that of Nakahara and 
Kubo.
69
 Elaboration of a benzenoid precursor 172 allows a modified Pomeranz-Fritsch isoquinoline 
synthesis, which after reduction of nitrile 174 allows construction of the imidazole ring completing 
164 in 10 steps in a 1% overall yield. Notably, although both Kelly and Kubo’s syntheses were 
chronologically before Martin’s synthesis, the main concept of Martin’s synthesis was developed 
some 17 years previous to isolation of the natural product! 
The only improvement in overall yield of 164 is by another de novo synthesis, from Harrowven and 
co-workers.
70
 Their synthesis begins with a pyridine nitrile 175 which undergoes reduction, acylation, 
and treatment with POCl3 to give imidazopyridine 176. The addition of the squarate 177 occurs 
predominantly at the more electrophilic ketone to give 178. The fundamental benzannulation step then 
follows and, using flow chemistry, cribrostatin 6 164 is obtained on exposure to air. 
1.1.5.2 Oxidation to Triphenyl Compounds 
Another example of the power of de novo synthesis of aromatic compounds is the homogenous 
palladium catalysis dehydrogenation of substituted cyclohexenones to phenols (Scheme 38).
71
The 
terphenyl 179 was identified as an allosteric inhibitor of the human luteinizing hormone receptor 
implicated in fertility and ovarian cancer.
72
 While the synthesis of intermediate compound 180 can be 
made via two Suzuki cross couplings in 19 % overall yield, a more efficient route involves de novo 
construction of the central phenol. Aldol condensation of 4-methylacetophenone (183) with 
benzaldehyde (184) followed by a Robinson annulations gives cyclohexenone 185.
73
 Application of 
the dehydrogenative conditions then gives the terphenol 180 in 83% overall yield. The ready 
availability of Diels-Alder adducts such as 186, which can be converted to 3,4-dimethylbenzoic acid 
187, further demonstrates the use of this method.   
37 
 
 
Scheme 38. Oxidation as a strategy towards terphenyl 180. 
At present it would be difficult for a de novo process to rival the efficiency and scale of synthesis for 
simple aromatic molecules that could be more easily obtained by classical aromatic chemistry. 
However, as illustrated in the above examples, de novo synthesis demonstrates more value for the 
synthesis of highly substituted aromatics or those with less common substitution patterns. 
1.1.6 Biosynthesis and Biomimetic Synthesis of Aromatic Natural 
Products 
Prior to invention of all laboratory methods covered, the first de novo synthesis of aromatic 
compounds was conducted by nature. Many of the aromatic units observed in polyketide natural 
products are produced through aromatization reactions of polycarbonyl chains, constructed 
themselves using a series of condensation reactions.
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1.1.6.1 The Polyketide Biosynthesis Hypothesis 
The biosynthesis of polyketide natural products from polycarbonyls was first proposed by Collie. It 
wasn’t until later that Birch confirmed, through radiolabelling experiments, their biosynthetic 
construction via acetate units and subsequent transformations to give aromatics and other polyketides; 
a theory that has come to be known as the Collie-Birch polyketide hypothesis.
74,75
 Using radiolabelled 
acetic acid 188 Birch was able to predict the isotopic pattern that would be exhibited in the production 
of 6-methylsalicyclic acid (190) by the mould Penicillium griseofulvum (Scheme 39).
76
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Scheme 39. A radiolabelling experiment by Birch, The isotopic pattern of the 6-methylsalicyclic acid (190) was predicted by 
his biosynthesis theory. 
This was the first in vivo experimental support for the polyketide hypothesis, and similar studies show 
the same mechanisms occur in a wide range of natural products.
74
 The currently accepted concepts of 
the polyketide hypothesis can be seen in the biosynthesis of 6-methylsalicyclic acid (190) (Scheme 
40).
 
 
 
Scheme 40. Biosynthesis of 6-methylsalicyclic acid (190). 
Condensation of an acetate unit I with malonyl coenzyme A II, followed by decarboxylation gives an 
enzyme bound thioester III. A further decarboxylative condensation, again with malonyl coenzyme 
A, gives tri-carbonyl IV. Repeated iterations of this sequence can then allow longer polycarbonyl 
chains to be constructed. In addition to chain extension, further modification of intermediate IV is 
possible. For 190, reduction followed by dehydration gives the enone VI. Further chain extension to 
the tri-carbonyl VII, cyclization and release from the enzyme provide 190. 
1.1.6.2 Biomimetic Synthesis of Resorcylates 
Based on the biosynthetic route of aromatic compounds many groups became interested in 
reproducing such reactions in the laboratory. Harris et al., has published extensively towards this 
goal.
77  
In one instance the biomimetic synthesis of aromatic compounds based on triketo-ester 
compound 191a was explored.
 
(Scheme 41) 
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Scheme 41. Cyclizations of the triketo-ester 191a. 
Harris found that 191a could be produced by self-Claisen condensation of 2 equivalents of methyl 
acetoacetate (192). Treatment of the 191a above pH 4, was found to result in a highly selective aldol 
condensation to give the β-resorcylate compound 193a. Furthermore, it was shown that with careful 
choice of reaction conditions, the 191a could undergo different possible cyclizations. Use of aqueous 
basic conditions resulted in Claisen condensation to give acylphloroglucinol 194. Treatment of 191a 
under acidic conditions, gave either 2-pyrone 195 or 4-pyrone 196. 
This work showed that polycarbonyl compounds could be produced synthetically and, their 
cyclization to β-resorcylates may allow synthesis of natural products containing such moieties. There 
were limitations however as only simple substrates had been considered. Using highly basic 
conditions for the polycarbonyl synthesis and difficulties in handling such compounds would prevent 
its application in more complex β-resorcylate synthesis.  
It was postulated by Barrett that combination of polycarbonyl synthesis using dioxinone chemistry 
may facilitate synthesis of more complex molecules based on this biomimetic concept. Dioxinone 
compounds and their use in the synthesis will now be introduced, before considering the unification of 
this chemistry with biomimetic aromatic synthesis. 
1.2 Dioxinones and Their Application in Synthesis. 
2,2,6-Trimethyl-4H-1,3-dioxin-4-one 197, otherwise known as the diketene-acetone adduct is a 
convenient precursor to acetylketene (198) (Scheme 42).
78
 Despite commercial preparations of 
diketene (199) in acetone, the presence of 197 was not initially recognized until its structure was 
elucidated from IR and UV spectral properties by Carroll and Bader, later confirmed with 
1
H NMR.
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On heating, dioxinone 197 undergoes a reversible loss of acetone to give acylketene (198) which has 
been observed by IR spectroscopy at 5 K.
80
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Scheme 42. Synthesis of dioxinone 197 and generation of acylketene 198. 
Thermyolysis of dioxinone 197 alone will form the homodimer of acylketene. More usefully, 
thermyolysis of 197 is carried out in the presence of a suitable nucleophile such as an alcohol or 
amine to give β-ketoesters or β-ketoamides respectively. While this is not the only method to generate 
acetylketene, dioxinone 197 provides a convenient, safe and nonlachrymatory alternative to diketene 
for aceto-acetylation reactions.
81
 Irradiation of dioxinone 197 at 254nm has been used for the 
generation of 198.
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Apart from aceto-acetylation reactions the use of dioxinone molecules in synthesis has been applied 
for a diverse range of applications. The following examples display the reactivity of dioxinone 
derivatives and how they have been applied to solving synthetic challenges. 
1.2.1 Dioxinones in Macrocycle Formation Strategies 
Derivatives of dioxinone have been used extensively for the intramolecular capture of pendant 
nucleophiles, representing an excellent process for the formation of medium-sized rings and 
macrocycles (Scheme 43).
83
 This method was used for formation of formation of ring sizes 4–77 and, 
towards the synthesis of several macrocyclic natural products including, (+)-diplodialide A (200), (–)-
kromycin (201), (–)-A26771B, ikarugamycin, Deschlorocallipeltoside A, and callipeltoside A.84 The 
reported yields are generally good even for the least energetically favorable 8−10 membered rings 205 
and 200. 
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Scheme 43. Formation of various size lactones and lactams from dioxinones. 
In one instance, Hoye’s synthesis of intermediate 206 towards callipeltoside A, a tetraol precursor 
underwent the desired dual macrolactonization and, hemiketal formation took place in 53% yield 
without the formation of any other constitutional isomers. Here the regioselective lactonization of the 
secondary alcohol in preference of the primary hydroxyl group was conformational in origin.  
One limitation of this method is the formation of 6-membered lactones, where oligomerization is 
favored. Literature explanations for this are either that the correct orientation of the hydroxyl group 
required for nucleophilic addition is not possible or, hydrogen bonding between the hydroxyl and 
acetyl groups forms a favourable 6 membered conformation leading to oligomer formation.
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1.2.2 Tandem IMDA Macrocycle Formation 
Using dioxinones for intramolecular macrocycle formation was a part of a strategy employed towards 
hirsutellone B (210) (Scheme 44).
86
 In this case however, a tandem procedure with an intramolecular 
Diels-Alder (IMDA) was also employed. Use of vinyl dioxinone 211 enabled an IMDA reaction with 
the pendant diene, while the tethered amine underwent macrocycle formation. This reaction generated 
three bonds, 3 rings and four stereocentres to give the correct diastereoisomer 212 in 50% yield via an 
endo transition state. Despite being later unable to effect the required ring contraction for the natural 
product, a highly convergent strategy for synthesis of the core was developed. 
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Scheme 44. Tandem IMDA-macrocycle formation of 212 towards a synthesis of hirsutellone B (210). 
1.2.3 Dioxinones in Prins Cyclizations 
Other than forming macrocycles dioxinone derivatives have been used in several other ways. In a 
synthesis of (–)-exiguolide (213), a key dioxinone fragment was employed twice as a partner in Prins 
cyclizations (Scheme 45).
87
 Firstly, dioxinone 214 and aldehyde 215 underwent and intermolecular 
Prins coupling to create a 2,6,-cis-tetrahydropyran ring 216. After removal of the dioxinone fragment, 
a second dioxinone fragment could be introduced by Yamaguchi esterification and after several 
manipulations, 217 was obtained. The stage was set for a second Prins cyclization. Treatment of 217 
with scandium triflate resulted in an intramolecular Prins reaction, building another pyran ring and 
forming the 16-membered macrocycle 218.  
 
Scheme 45. Prins cyclizations of dioxinones for macrocycle and THP formation. 
1.2.4 Dioxinones in Friedel-Crafts Type Reactions 
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While acylketenes generated from dioxinones are most widely reacted with oxygen and nitrogen 
nucleophiles, they also participate in Friedel-Crafts reactions with electron-rich aromatic rings 
(Scheme 46). In a synthesis of taiwaniaquinol B a double annulation is performed by intramolecular 
Friedel-Crafts acylation followed by alkylation.
88
 Silylation of the Meldrum’s acid derivative 220 
gives the dioxinone I, which after retro-Diels-Alder reaction, undergoes Friedel-Crafts acylation with 
the dimethoxy-benzene ring to give enol II. Trifluoromethanesulfonic acid acid then promotes the 
second ring formation and, decarboxylation of III under the thermal reaction conditions, generated the 
cis-fused tricycle 221 as a single diastereoisomer in 73% yield.  
 
Scheme 46. Intramolecular Friedel-Crafts reaction of a dioxinone in a tandem sequence towards taiwanaquinol B (219). 
1.2.5 Dioxinones in Heterocycle Synthesis. 
Numerous heterocyclic compounds have also been constructed using dioxinone derivatives, 
demonstrating some different ways in which the thermally generated acylketene species react.
89
 While 
the 6-lactones highlighted above are more difficult to form, pyrones such as 222 are more easily 
formed by 6π-electrocyclic ring closure of the enoneketene II (Scheme 47).85 Nucleophilic addition of 
urea (224) to the acetylketene from dioxinone 197, followed by condensation gives uracil 225.
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Furthermore, the acylketene from dioxinone 197 also undergoes [2+4] cycloaddition with imines such 
as 226 to give the oxazine 227.
91
 
44 
 
 
Scheme 47. Application of dioxinones in heterocycle synthesis. 
1.3 Barrett’s Resorcylate Synthesis: Combining Dioxinone Chemistry with 
Biomimetic Synthesis. 
Syntheses of resorcylate natural products building from an aromatic core can often suffer setbacks due 
to protecting group manipulations and lengthy synthesis routes.
92
 Inspired by the polyketide 
biosynthesis of aromatic natural products and, biomimetic synthesis of simple resorcylates by Harris, 
Barrett et al. saw the opportunity to apply dioxinone compounds for the synthesis of polycarbonyls 
and more complex natural product targets (Scheme 48). 
 
Scheme 48. Barrett’s hypothesis for biomimetic synthesis of β-resorcylate compounds 193 from diketo-dioxinone pre-
cursors 228. 
Beginning with a dioxinone 197, functionalization would give rise to the diketo-dioxinone 228. This 
could then undergo ketene generation and reaction with an appropriate alcohol to generate a triketo-
ester 191. Aromatization using the known conditions would then lead to the β-resorcylate 193.  
With regards to the aromatization step of this hypothesis; while the aromatization of triketo-esters 191 
was known at the outset, the aromatization of diketo-dioxinones 228 was discovered during Barrett’s 
methodology studies (Scheme 49).
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 More explicitly, thermyolysis of diketo-dioxinone 228a in the 
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presence of methanol gave triketo-ester 191a and, aromatization with caesium carbonate followed by 
acidification, gave resorcylate 193a in 87% yield. In an alternative one-pot procedure, heating 228a 
with methanol in a sealed tube gave rise to the resorcylate 193a directly in 82%. However, diketo-
dioxinone 228a also undergoes aromatization itself, and when treated with triethylamine gave 
benzodioxinone 229a in 96% yield. Aromatization of diketo-dioxinones similar to 228a have been 
performed under a variety of other mild basic or acidic conditions, or in some cases, occur 
spontaneously. Furthermore, the benzodioxinones 229 obtained can undergo solvolysis under basic 
conditions to give the resorcylate 193. Alternative transformations of benzodioxinones 229 are known 
including reduction, aminolysis, decarboxylation and, photolysis to the quinoketene, allowing a wide 
range of products to be obtained.
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Scheme 49. Aromatization routes for diketo-dioxinone 228a. 
The following sections show how this initial hypothesis has come to fruition and, through 
development of natural product and methodology chemistry, how many aromatic compounds have 
been prepared from dioxinone derivatives. 
1.3.1 Application of  Dioxinone Derivatives in Synthetic Studies 
Towards Aromatic Compounds 
1.3.1.1 Synthesis of S-(–)-Zearalenone 
The first application by Barrett et al. of using dioxinone derivatives in de novo synthesis was the 
synthesis of resorcylate acid lactone S-(–)-zearalenone (230) (Scheme 50).95 The macrocycle would 
be formed using cross metathesis of aromatic diene 193b. The aromatic 193b would be available from 
ketene generation, trapping with the requisite alcohol 231, followed by aromatization of the triketo-
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ester 191b. The key diketo-dioxinone fragment would be constructed by a vinylogous Mukaiyama 
Aldol reaction between the O,O-silyl ketene acetal 232 and aldehyde 233. 
 
Scheme 50. Retrosynthetic analysis of S-(–)zearalenone (230). 
In practice, the vinylogous Mukaiyama reaction of 232 and 233 gave mono-protected dioxinone diol 
234 in 61% yield (Scheme 51). Sequential oxidation of the free alcohol and then deprotection of the 
second alcohol followed by further oxidation gave diketo-dioxinone fragment 228b. Thermyolysis 
and ketene generation of dioxinone 228b followed by reaction with alcohol 231 gave triketo-ester 
191b. Base mediated intramolecular aldol addition followed by acidification resulted in condensation 
and hydrolysis of the ketal to give aromatic diene 193b. The synthesis was completed by cross 
metathesis with Grubbs-Hoveyda second generation catalyst (G-H II) to give 230 in 71%. Attempted 
metathesis at of triketo-ester intermediate 191b resulted in intractable mixtures but, did contain some 
of the natural product 230. In a modified procedure, the last steps could be telescoped giving a slight 
increase in yield and more operational simplicity. Thus, thermyolysis of diketo-dioxinone 228b, 
ketene trapping followed by aldol condensation (mediated by caesium carbonate and acidic Dowex 
resin) and, cross metathesis gave S-(–)-zearalenone 230 in 63% yield. 
 
Scheme 51. Synthesis of S-(–)- zearalenone. 
This report also contained further synthesis of three further natural products 15G256-β (235), 
15G256-τ, and, 15G256-π all involving synthesis of diketo-dioxinone compounds 228 (Scheme 52). It 
is the synthesis of such diketo-dioxinone derivatives that is incorporated in all routes for synthesis of 
beta-resorcylate containing molecules by Barrett. 
To 15G256-β, vinylogous Mukaiyama aldol reaction between 232 and 236a gave dioxinone keto-ester 
237a in 80% yield. More conveniently, lithium enolate addition of commercial dioxinone 197 to a 
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benzotriazole ester 238 (or acid chloride 236a), gave 237a in 63% yield. Dioxinone keto-ester 237a is 
acylated by formation of its magnesium enolate and reaction with acid chloride 239 to give 240a.
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Treatment of 240a with a Pd(0) source and a π-allyl scavenger (morpholine) led to deallylation and 
decarboxylation resulting in diketo-dioxinone intermediate 228c. This intermediate was carried 
through aromatization to give marine antifungal agent 15G256-β 235 as well as the closely related 
compounds 15G256-π and 15G256-τ (not shown). 
 
Scheme 52. Synthetic route to 15G256 antifungal agents. 
The double acylation strategy used in the synthesis of 15G256 compounds was then used to form the 
diketo-dioxinone fragments required for the synthesis of other β-resorcylate molecules in 
methodology and natural product studies.  
1.3.1.2 Hexasubstituted Benzene Synthesis  
The double acylation of 197 has been applied to give an expedient synthesis of dioxinones 241 
containing additional alkyl (R
2
) and allyl (R
3
) substituents, resulting in hexa-substituted benzene 
derivatives 242 (Scheme 53). 
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Acylation of dioxinone keto-ester 237 proceeds as before to give 
diketo-dioxinones 240 and introduce a substituent R
2
 (the ester fragment CO2R
1
 is kept in place, 
although if desired could easily be decarboxylated as above (Scheme 52)). Allylation catalyzed by 
Pd(PPh3)4 proceeds in a regioselective manner to give 241 and introduce substituent R
3
 and, in the 
same pot, aromatization by treatment with Cs2CO3 gives 242. When R
2
 was an α-branched group (iPr, 
cyclopropyl, phenyl, 2-furyl) the aromatization proceeded in a moderate 42-59% yield and in some 
cases required use of silica. However, in less substituted moieties (Me, Et, 2-phenylethyl) cyclization 
proceeded more efficiently in 83-90% yield. 
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Scheme 53. Synthetic routes to hexasubstituted benzene compounds. 
Rather than allylation of 240 with allyl acetate, various substituted allylic acetates could be used to 
introduce a variety of different allyl substituents R
3
.
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 Cyclization of 241 in these cases proceeded 
well although slightly lower than when the allyl group was unsubstituted.  
1.3.1.3 Synthetic Studies Towards Lactonamycin 
The double acylation of dioxinone 197 was also applied in a route to lactonamycin for the synthesis of 
dihydroxy-isoindolinone-carboxylates (243) as EF-ring precursors (Scheme 54).
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  Acylation of 
dioxinone keto-esters 237b–c with sarcosine derived acid chloride 244 gave di-keto dioxinones 240b–
c. The ester moiety was desired in the final product so was kept in place, and treatment of 240b–c 
with triethylamine gave benzodioxinones 242a–b. Based induced methanolysis of 242a–b, followed 
by removal of the SES group with Bu4F and concurrent lactamization, gave the desired isoindolinones 
243a–b.  After methylation and triflation of 243b to give isoindoline 246, conversion to a boronic 
ester provided a coupling partner for Suzuki coupling with bromide 247. Subsequent ester hydrolysis 
and intramolecular Friedel-Crafts acylation of 248 provide pentacycle 249 after acetate protection. 
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Scheme 54. Barrett’s application of de novo synthesis towards lactonamycin. 
1.3.1.4 Synthesis of Anthraquinones (250) and Macrosporin (251) 
Use of an intramolecular Friedel-Crafts acylation was combined with the de novo synthesis chemistry 
once more for access to anthraquinones (250) and the natural product macrosporin (251) (Scheme 
55).
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  Dioxinone keto-ester 237a was acylated with a phenylacetic acid derivative, as described 
previously, then subjected to Pd(PPh3)4 catalyzed deallylation and decarboxylation. The morpholine 
served as both a π-allyl scavenger, as well as a base for aromatization of diketo-dioxinone 
intermediate 252, to give benzodioxinone 253 in a high yielding one-pot procedure.  
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Scheme 55. Synthesis of anthraquinones (250) and application to macrosporin (251). 
Methylation of 253 gave phenol-ethers 254, however attempts at cyclization to the anthrones 256 
directly were not successful. The ethers 254 were subjected to treatment with methanolic potassium 
carbonate to give 6-benzyl resorcylates 255 in quantitative yields. Cyclization of resorcylates 255 was 
achieved by heating in Polyphosphoric acid (PPA) to give anthrones 256 in 38–63% yields. Oxidation 
with cerium ammonium nitrate gave 9,10-anthraquinones 250 in good yield. 
The methodology for synthesis of anthraquinones was used for a synthesis of anthraquinone fungi-
derived macrosporin 251. From intermediate 257 hydrogenolysis followed by treatment with 
trimethysilyl triflate gave anthrone 258 in 76% yield (2 steps). Attempted cyclization of benzyl 
protected 258 or debenzylated phenol of 258 with PPA gave only decomposition. Although 256a–f 
contain unprotected phenols, these are deactivated through hydrogen-bonded to the ester.  
Oxidation of 258 with CAN did not proceed as for 256a–g, so it is likely the free phenol at C-7 is 
problematic again. Instead the oxidation of 258 was achieved with oxygen and copper bromide to give 
macrosporin (251) in 81% yield.  
1.3.1.5 Allyl Migration in Diketo-dioxinone Synthesis 
During the synthesis of related β-resorcylate natural products, an interesting observation was made. If 
morpholine was not used as a scavenger in the deallylation of 259, then decarboxylation and Tsuji-
Trost allylation can occur to give decarboxylation and migration of the allyl moiety (I) (Scheme 56). 
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Scheme 56. Discovery of an allyl migration reaction. 
This reaction was investigated further through the synthesis of angelicoin A (261) (Scheme 57).
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When the prenyl-substituted diketo-dioxinone 240d was treated with Pd(PPh3)4 and caesium 
carbonate, it underwent prenyl migration and decarboxylation to give straight chain product 262a in 
50% yield and, branched intermediate 263a in 10% yield. From crossover experiments (albeit on 
slightly different substrates) the reaction is proposed to occur through an intermolecular prenyl 
transfer.  Finally, silyl-deprotection and lactonization under basic conditions gave angelicoin A (261) 
in 33% over 5 linear steps from dioxinone 197. 
 
Scheme 57. Synthesis of angelecoin A (261). 
Concentration was found to be an important factor in the prenyl-migration reaction. While normally 
conducted at 0.200 M concentration, if conducted at 0.014 M concentration, a different set of products 
was observed (Scheme 58).
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 At 0.200 M concentration, compounds 262b and 263b are isolated. 
However, at 0.014 M concentration 242c and 229a were the dominant reaction products. The two 
products 242c and 229a arise, because at lower concentration the intramolecular aromatization 
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reaction becomes competitive with intermolecular decarboxylation/prenylation reaction. These results 
also suggest that II and III are intermediates on the pathway to I. The observed regiochemistry in the 
prenylation of III to I is identical to previously observed (cf. Synthesis of hexasubstituted-
resorcylates, Scheme 53), reaction occurring at the most acidic methylene position. 
 
Scheme 58. Product distribution from prenyl migration reactions. 
1.3.1.6 Synthesis of Hericenone J and Herecenol A 
Application of the allyl-migration reaction of diketo-dioxinones was then extended in the synthesis of 
several other natural products.
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  In the synthesis of hericenone J (265) and herecenol A (266) the 
geranyl side chain was required (Scheme 59).  After acylation, dioxinone keto-ester 240e was treated 
with (Pd(PPh3)4 but the conditions were changed from the synthesis of angelecoin A (261). Geranyl 
migration took significantly longer than allyl or prenyl migration, and the addition of base led to 
decomposition. After allowing 15 h for geranyl migration, addition of silica gel led to aromatization 
under acidic conditions to give benzodioxinone 262d as the sole regioisomer, without branching and, 
in trans form. Methylation gave phenolic ether 268 which was either lactonized, to give hericenone J 
(265) (24%, 8 steps), or reduced to give hericenol A (266) (21%, 8 steps). 
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Scheme 59. Synthesis of hericenone J (265) and hericenol A (266). 
1.3.1.7 Synthesis of Mycophenolic Acid 
Similar in structure to hericenone J (265) but with six aromatic substituents and a different sidechain 
is mycophenolic acid (269) (Scheme 60).
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 During this synthesis, some limitations of the de novo 
strategy were encountered. The additional benzene substituent necessitated beginning the synthesis 
with methylated dioxinone keto-ester 270. However, during the acylation of 270, due to the presence 
of the methyl group, O-acylation could not be suppressed. Subjecting 271 to Pd(PPh3)4  did not result 
in the allyl migration, but gave pyrone 272.  
 
Scheme 60. Synthesis of mycophenolic acid (269). 
Alternatively, the methyl substituent was installed after aromatic ring formation (Scheme 61). The β-
resorcylate 273 (constructed in a similar manner to hericenone J) was treated with iodine and tert-
butyl amine to give iodoether 274 and diiodo compound 275. The Iodo-ether of 274 acted as a 
protecting group for the double bond, allowing application of more forcing conditions for 
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electrophilic bromination which gave 276. Treatment of 276 with DABCO-(AlMe3)2 complex and a 
palladium catalyst, resulted in methylation and deprotection of the double bond to give the hexa-
substituted 277 in 72 % yield as only the (E) isomer. Hydrolysis with LiOH provided mycophenolic 
acid (269). 
 
Scheme 61. Barrett’s synthesis of mycophenolic acid (269). 
1.3.1.8 Synthesis of Cristatic Acid Methyl Ester 
Even larger allylic side chains have also been shown to be compatible in the migration reaction as 
demonstrated in the synthesis of cristatic acid methyl ester (278) (Scheme 62).
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 While the migration 
reaction took 15 h for a geranyl moiety (Scheme 59), 70 h were required for conversion of 275 to 
diketo-dioxinone 276. This then underwent the usual aromatization reaction followed by 
isopropylidene cleavage to give cristatic acid methyl ester 278. Here the delicate nature of the 
decarboxylative migration and aromatization conditions are typified in the compatibility with the 
delicate iso-butylene substituted furan.   
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Scheme 62. Synthesis of cristatic acid methyl ester (278). 
1.3.2 Use of Dianion chemistry in Synthesis of Aromatic Compounds 
from Dioxinones 
The examples of natural product synthesis and methodology discussed so far have seen acylation of 
ketoester-dioxinones 237 to provide diketo-ester-dioxinones 240 (Scheme 63). In most cases 
subsequent decarboxylation is carried out, with or without allyl migration, to give diketo-dioxinones 
263 or 228.  The diketo-dioxinones then undergo ketene generation and trapping followed by 
aromatization to give 260, or simply direct aromatization to give 262. 
 
Scheme 63. General synthesis of diketo-dioxinones β-resorcylates 260 and 262 by acylation chemistry. 
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A more direct way to access diketo-dioxinones 228 is through the acylation of parent dioxinone 197, 
as displayed in another synthesis of (S)-(–)-zearalenone (230) (Scheme 64).107 In this case, addition of 
dioxinone 197 to acylbenzotriazole 279 gave ketal-protected diketo-dioxinone 280. Cross metathesis 
with alcohol 281 gives substrate 282, with all the requisite functionality in position. In another 
divergence from the first synthesis of 230 (Scheme 51), the macrocycle was formed through 
intramolecular ketene trapping—a tactic which has been previously employed in natural product 
synthesis as a solution to macrolactonization steps that can often be poor yielding. Intramolecular 
ketene trapping provides macrocycle 283 which, through aromatization, contracts to give 14-
membered resorcylate acid lactone 230. 
 
Scheme 64. A second generation synthesis of (S)-(–)-zearalenone (230). 
Further developing the synthesis of diketo-dioxinones 228, dioxinone 197 has been acylated to give 
keto-dioxinone 284a (Scheme 65).
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 The synthesis of keto-dioxinone 284a was optimized and 
acylimidazole (285) was the optimum acylating agent, with the addition of diethylzinc to enhance the 
acylation.
109
  
 
Scheme 65. Synthesis of keto-dioxinone 284a. 
Keto-dioxinone 284a can be further acylated through formation of its dianion and as such, this 
molecule and analogues have been a key starting material for the synthesis of diketo-dioxinones 228. 
These include synthesis of a number of different products and the following sections will disclose 
how keto-dioxinones 284 have been used in natural product and small molecule chemistry (Scheme 
66).  
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Scheme 66. Synthetic products produced from keto-dioxinones 284. 
1.3.2.1 Synthesis of Curentaren A 
Perhaps the most ambitious resorcylate acid lactone syntheses attempted so far is the synthesis of 
cruentaren A (286) (Scheme 67).
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 Previous syntheses of this molecule start from aromatic entities 
and involve lactonization and ring closing alkyne metathesis followed by lindlar reduction to give the 
desired (Z)-isomer. The first idea was that intramolecular macrolactonization by ketene trapping and 
aromatization could provide the macrocycle and aromatic unit in one step.   
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Scheme 67. Synthesis of Creuntaren A (286). 
However, due to difficulties in the synthesis of the side chains the final strategy involved 
macrolactonization using ring closing alkyne metathesis. Nevertheless, use of the resorcylate 
formation strategy allowed formation of aromatic 286 in 55% yield. Interestingly, formation of the 
aromatic gave some of the methylated phenolic compound also, presumably due to dimethylacetal 
formation of the intermediate poly-carbonyl compounds. This reaction was also carried out on gram-
scale presenting the largest scale that Barrett et al. has reported employing formation of tri-keto esters 
from ketene trapping and subsequent aromatization. 
1.3.2.2 Synthesis of LL-Z1640-2 
Once more, keto-dioxinone 284a was used, applied to a synthesis of tumor inhibitor LL-X1640-2 287 
(Scheme 68).
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 Acylation of 284a with Weinreb amide 300 gave diketo-dioxinone 228f, precursor for 
a macrocyclization/aromatization reaction. Heating of 228f resulted in macrocycle formation and 
sequential treatment with caesium carbonate and acetic acid gave resorcylic acid lactone 301 in 55% 
yield. Selective methylation of the resorcylate core, deprotection and oxidation provided the desired 
natural product 287.  
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Scheme 68. Synthesis of LL-Z1640-2 (287). 
1.3.2.3 Synthetic Studies Towards Tragoponol 
A limitation of the methodology for resorcylic acid lactone synthesis was observed in studies towards 
unsymmetrical resorcylate dimer tragoponol (302) (Scheme 69).
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 Highly functionalized resorcylate 
303 had been synthesized using the developed resorcylate chemistry. Reaction of 303 with keto-
dioxinone 284a gave diketo-dioxinone 228g in 76% yield; setting the stage for generation of the 
second aromatic ring. Selective desilylation with HF or N
n
Bu4F gave the desired alcohol 304. 
However, in attempts to purify or isolate alcohol 304, quantitative formation of δ-lactone 305 
occurred. Attempts to carry out the desilylation during ketene trapping also failed to produce the 
desired macrocycle.  
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Scheme 69. Synthetic efforts towards tragoponol (302). 
1.3.2.4 Synthesis of W1278 Oligo-esters 
Towards oligo-esters W1278A, B and C (290) some interesting findings were made as regard to the 
thermyolysis of dioxinone molecules (Schemes 70 and 71).
108a
 As now commonplace, acylation of 
keto-dioxinone 284a with a Weinreb amide 306 gave the desired diketo-dioxinone 228c (Scheme 70). 
Heating in the presence of alcohol 307, followed by aromatization and deprotection gave the β-
resorcylate 309. This was then heated with another molecule of diketo-dioxinone 228c and gave 
desired ester 310 in 45% yield. Unfortunately at the required reaction temperature for ketene 
generation, lactonization competed for reaction with 228c and benzolactone 311 was also formed in 
21%. 
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Scheme 70. Synthesis of intermediate 310. 
To overcome the use of such high temperature ketene generation the acylketene adduct was varied, 
affecting the temperature at which thermolysis was possible (Scheme 71). Various dioxinones (197 
and 311a–c) were heated with nucleophile 312 for a set period of time. The yield of keto-ester 313 
ranged from 5–95% indicating different rates of thermyolysis.  Acetophenone adduct 311c appeared 
to give very rapid reaction, perhaps accelerated through overlap of the phenyl π-system with the σ* 
orbital the O–CO bond, or alternatively through the enhanced radical stabilizing ability of the 
diphenyl moiety.
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 The ability to tune the thermyolysis temperature of dioxinones makes them useful 
in cases where certain substrates are unstable. 
 
Scheme 71. Thermyolysis of various dioxinones. 
Applied to the W1278 oligo-esters at hand, alternative diketo-dioxinone 228h was constructed 
(Scheme 72). Reaction of 309 with 228h at a lower thermyolysis temperature of 80 °C gave 
aromatized product 310 in a much improved 72% yield.  The synthesis of the W1278A, B and C (290) 
could then be completed. Following deprotection of the Silyl ether, repeated used of diketo-dioxinone 
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228h allows additional resorcylate units to be added to the molecule, in a yield of 60% yield per 
repeated sequence. 
 
Scheme 72. Synthesis of W1278 oligo-esters (290). 
1.3.2.5 Double β-Resorcylate Oligomers 
Aside from the naturally occurring W1278 oligoesters, keto-dioxinone 284a has also been used in the 
synthesis of novel double resorcylate oligomers 294a–e (Scheme 73).114 Reaction of keto-dioxinone 
284a with bisamides 314a–e resulted in formation of bisdiketo-dioxinone compounds 315a–e. 
Treatment of 315 a–e with triethylamine led to aromatization and opening of benzodioxinones 316a–e 
gave the double resorcylate compounds 294a–e. Notably, choice of appropriate amide partner allows 
a double resorcylate pyridine 294d and a terphenyl resorcylate 294c to be obtained. 
 
Scheme 73. Synthesis of double β-resorcylates. 
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1.3.2.6 Synthesis of 6-Amino-Resorcylates 
Keto-dioxinone 284a has also proved a key intermediate at the core of methodologies for the 
synthesis of an array of small resorcylate molecules. The first example is in the synthesis of 6-
substituted β-resorcylates from a crossed Claisen condensation reaction with functionalized α-amino 
acids (Scheme 74).
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 The dienolate of keto-dioxinone 284a was treated with diethylzinc followed by 
addition of a Weinreb amide or an acyl imidazole (Acyl imidazoles were more reactive in this 
acylation when sterically hindered amino acids were used).
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 Treatment of diketo-dioxinones 317 
with triethylamine and aromatization gave a range of β-resorcylates 318 and 319.The novel amino 
resorcylates produced in this study were tested against various cancer cell lines and displayed 
promising ability as selective CDK2 inhibitors. This methodology also shows that it is possible to 
generate a wide array of novel resorcylate structures, which can serve as small molecule starting 
points for medicinal chemistry, with tolerance for a range of functional groups and without protecting 
groups. 
 
Scheme 74. Synthesis of 6-substituted β-resorcylates. 
1.3.2.7 Synthesis of 2-Pyridones 
Aside from the specific keto-dioxinone 284a, analogues of this compound have also been used in 
development of methodology for synthesis of pyridinones 320 (Scheme 75).
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 Synthesis of an array 
of keto dioxinones 284 proceeded by reaction of dioxinone 197 with acyl imidazole. Condensation of 
284 with ammonium acetate gave enamine-dioxinones 321 that on heating underwent intramolecular 
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cyclization to give 6-substituted-4-hydroxy-2-pyridinones 320. Use of slightly modified conditions 
gave an N-alkylated analogue 322. This methodology gave overall yields of 45–64% from dioxinone 
197 with only one purification required and again, a wide incorporation of functional groups were 
tolerated under the conditions. 
 
Scheme 75. synthesis of 4-hydroxy-2-pyridinones. 
1.3.2.8 Synthesis of 5-Amino Resorcylates 
The heat shock protein 90 HSP90 inhibitors 323 and 324 were developed by Astex and Pfizer 
pharmaceutical companies respectively for use in oncology (Scheme 76).
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 The syntheses reported 
for these molecules involved beginning with a resorcylate starting material and use phenolic 
protection and derivatization of the aromatic core. It was hoped that a biomimetic de novo strategy 
applying diketo-dioxinone chemistry would offer a more suitable synthesis of these pharmaceutically 
relevant molecules.
119
 
 
Scheme 76. β-resorcylamides developed for oncology treatments. 
65 
 
The synthesis of 323 began with conversion of iso-valeric acid (325) to imidazoyl 326 which was 
used for acylation of the lithium enolate of dioxinone 197 to give keto-dioxinone 284b (Scheme 77). 
Generation of the dienolate of keto-dioxinone 284b with diethylzinc and use of ethyl formate as the 
electrophile gave keto-aldehyde dioxinone 327. Without isolation, aldehyde 327 was aromatized to 
give 5-substituted β-resorcylate core 328. Addition of iso-indoline 329 with iso-propylmagnesium 
chloride to benzodioxinone 328 yielded AT13387 (323) in 70%. Including synthesis of the iso-
indoline sidechain, this route gave 323 in 13% yield over 9 synthetic manipulations in contrast to the 
reported synthesis (from a benzoic acid derivative) of 13 steps with an overall 3% yield. The 
chemistry was also extended to the core of Pfizer’s compound 324. Synthesis of the 5-chloro-
substituted resorcylate 330 by the same route followed by opening with iso-indoline 331 gave 324. 
 
Scheme 77. Synthesis of the commercial resorcylamides 323 and 324. 
The development of the methodology shows that not only 6-alkyl resorcylates could be synthesized 
but 5-alykl resorcylates were readily available. Indeed, the formylation step was applied for the 
general synthesis of 5-substituted β-resorcylate derivatives.120 
1.3.2.9 Synthesis of Pentasubstitued. Orthogonally Oxygenated Benzene Derivatives  
Keto-dioxinone 284a has also been used in an alternative aromatization mode within the Barrett group 
(Scheme 78). Condensation of DMF-DMA at the active methylene position of keto-dioxinone 284a 
gives rise to the enamine 332.
 121
 Addition of various magnesium acetylides to 332 gave eneyne 
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dioxinone substrates 333, predominantly as the desired E-isomer, and treatment with ICl or NBS gave 
rise to the halogenated aromatics 334. The final compounds are of synthetic interest because they 
contain multiple sites for further selective functionalization. 
 
 
Scheme 78. Synthesis of orthogonally oxygenated benzene derivatives 334. 
1.3.3 Key Benefits of the Barrett Methodology 
In Summary, by combining biomimetic synthesis of aromatic compounds with the synthetic utility of 
dioxinones for polycarbonyl synthesis, the methodology developed by Barrett et al. allows the concise 
synthesis of a diverse array of novel aromatic derivatives as well as larger natural products. There are 
several key advantages to this de novo methodology over synthesis from aromatic precursors. 
The relative stability of dioxinone derivatives compared to polycarbonyl compounds (cf. Harris et al.) 
allows stepwise introduction of substituents under milder conditions. In the case of small molecules, 
this allows regioselective formation of resorcylate molecules without the requirement for protecting 
groups and with a wide variety and number of aromatic substituents incorporated. As the case of 
AT13387 (323) shows, these routes can be higher yielding when compared to aromatic derivatization 
chemistries. 
The synthesis of resorcylic acid lactone natural products using the late-stage aromatization strategy 
allows for a highly efficient macrolactonization step to be conducted easily via ketene trapping and 
without the requirement for phenolic protecting groups. Excellent functional group tolerance is 
exhibited and high complexity is generated in a single step making this an attractive route to this class 
of natural products. 
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New classes of aromatics such as the amino resorcylates have been developed which have showed 
useful bioactivity. The fact that these are novel compounds suggest that traditional aromatic 
chemistries may be inefficient at forming them and have perhaps eluded the imagination of organic 
chemists. Whether such molecule classes would’ve been explored without the invention of this 
methodology could be debated. However, where synthesis of a certain class of molecule is restricted, 
then exploration of the chemical properties of that class is also restricted.    
1.4 Research Aims and Description 
The main aims of this project lie in the further development of synthetic methodology; in particular, 
de novo synthesis of aromatic compounds using dioxinone derivatives as starting materials. Previous 
methodology developed towards this goal was based on formation of diketo-dioxinones 228 and their 
aromatization to give β-resorcylates 193 (Scheme 79).  
 
Scheme 79. Methodology previously developed by Barrett et al. 
As shown earlier in the biosynthesis of 6-methylsaliclic acid 190, partially reduced poly-carbonyl 
compounds are also aromatized in nature to give aromatic products (Scheme 40). Based on these 
concepts, the hypothesis was that heating dioxinone 335 in an alcohol would form the partially 
reduced polycarbonyl compound 336 and aromatization via an intramolecular aldol condensation 
would give salicylates 131 (Scheme 80). 
 
Scheme 80. Hypothesis for a synthesis of salicylates 131. 
Reduced polycarbonyl compounds could be further exploited (Scheme 81). If dioxinone 337 could be 
constructed then the reduced polycarbonyl compound 338 would be easily accessible.  Dieckmann 
cyclization of 338 could then give γ-resorcylates 142. This would regioisomerically complement the 
Barrett methodology for synthesis of β-resorcylates 193.  
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Scheme 81. Hypothesis for a synthesis of γ-resorcylates 142. 
Chapter 2 shows initial synthetic route for the synthesis of reduced substrates 335 and 337. The 
salicylates 131 and γ-resorcylates 142 are important classes of molecules and information on their use 
and synthesis is provided in subsequent chapters. Chapter 3 provides details on the applications of 
salicylates 131 and the methodology that has developed for their synthesis. Chapter 4 provides similar 
information pertaining to γ-resorcylates 142.  
During the development of these methodologies, the synthesis of other types of aromatic molecules 
339, 340, 341 were also explored (Figure 1). In chapters 5 and 6 the methodology for synthesis of 
these molecules will be discussed. 
.  
Figure 1. Methodology was developed for additional aromatic products. 
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Synthesis of Dioxinone Carbaldehyde 350 and Development of 
Routes to Cyclization Substrates 
1.5 Retrosynthesis of Aromatization Substrates 
Considering the substrates for the proposed aromatization processes outlined in the introduction 
(Chapter 1, Schemes 80 and 81, 335 and 337), a retrosynthesis for compounds of the general structure 
342 (R = aryl or alkyl, either regioisomer) was carried out (Scheme 82). Depending on which 
regioisomer of 342 is chosen, then retrosynthetically breaking the double bond there is a choice of two 
different pathways for Wittig reactions to be carried out.  Following route A, a combination of either 
dioxinone phosphonium salt 343 and malonaldehyde 344, or dioxinone aldehyde 346 and 
phosphonium salt 347, would give 342. Alternatively, following route B, phosphonium salt 349 and 
dioxinone aldehyde 350 would give 342. Furthermore, dioxinone aldehyde 350 could be prepared 
through several routes. Addition of the lithium enolate of dioxinone 197 to formaldehyde followed by 
oxidation or, direct formylation, would give aldehyde 350. Alternatively, aldehyde 350 could be 
produced by reduction from either Weinreb amide 351 or thioester 352. All of these strategies towards 
the substrates 342 were investigated and are detailed throughout this chapter. 
 
Scheme 82. Retrosynthesis for the dioxinone ketones and esters of the general structure 342. 
1.6 Synthesis of the Aromatization Substrates 
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1.6.1 Towards Route A Employing Dioxinone Phosphonium Salt 343 
 
 
Scheme 83. Synthesis of dioxinone ester 337a through a Wittig reaction of phosphonium salt 343 and aldehyde 344. 
Beginning with route A, the bromo dioxinone 345 was refluxed with triphenylphosphine in benzene to 
give phosphonium salt 343 in 83 % yield (Scheme 83).
122
 The synthesis of the required aldehyde 344 
proved to be more challenging due to its instability. According to the literature, Meldrum’s acid 353 
was heated with triethyl orthoformate to give the corresponding ethyl enol ether, which was then 
hydrolyzed to give formylmeldrum’s acid 354.123 Heating of 354 in tert-butanol gave after distillation 
aldehyde 344 that existed as a keto-enol mixture in solution. Using aldehyde 344 immediately, a 
Wittig reaction with 343 was conducted and gave ester 337a in 11% yield. Further attempts to 
improve the yield of this reaction were hindered by the instability of aldehyde 334 (which 
decomposed within 12 h even when stored at −20 °C), which due to its high degree of enolisation is 
prone to aldol condensations and polymerization. 
1.6.2 Towards Route A Employing Dioxinone  Aldehyde 346 
Continuing with route A we considered the alternative Wittig pairing, dioxinone aldehyde 346 and 
phosphonium salt 347 (Scheme 84). Phosphonium salt 347 is known in the literature but the aldehyde 
346 has only been obtained in very low yield (as a product during the oxygenation of a silyl dienol 
ether with triphenyl phosphate ozonide) and was only partially characterized.
124
 Commencing with 
bromo dioxinone 345, displacement with sodium acetate gave 355 which was hydrolyzed to primary 
alcohol 348 (Scheme 84).
125
 Oxidation of 348 to aldehyde 346 could be achieved using Dess-Martin 
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periodinane, however purification proved problematic due to the instability of aldehyde 346 to silica 
gel chromatography. Use of freshly prepared manganese dioxide proved optimal and gave desired 
aldehyde 346 in 84% yield.
126
 Interestingly, the use of commercially sourced manganese dioxide for 
oxidation of 348 led to decomposition. This disparity is most likely due to differing morphologies of 
the catalyst in this heterogeneous reaction.  
 
 
Scheme 84. Synthesis of dioxinone aldehyde 346 and attempted Wittig reaction with 347. 
The acid 356 was treated with triphenylphosphine to give phosphonium salt 347 as a Wittig partner 
for aldehyde 346.
127
  Unfortunately reaction of 346 and 347 failed to give any of acid 357a and only 
decomposition of aldehyde 346 was observed.
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1.6.3 Towards  Route B Employing Dioxinone Aldehyde 350   
With some success in route A, route B was also examined. Towards a synthesis of dioxinone aldehyde 
350, reaction of dioxinone 197 with formaldehyde was first attempted (Scheme 85). Monomeric 
formaldehyde in THF was generated by codistillation from paraformaldehye in presence of p-
toluenesulfonic acid.
129
 This solution was added to the lithium enolate of dioxinone 197 however only 
alcohol 358 was isolated in 9% yield, from reaction at the α-position.  A similar situation was 
observed in reaction with chloromethyl methyl ether (MOM-Cl) which gave methyl ether 359 in 28% 
yield. 
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Scheme 85.  Attempted reactions of the lithium enolate of dioxinone 197 with electrophiles formaldehyde and chloromethyl 
methyl ether towards aldehyde 350. 
Attempting a more direct route to 337b, a one-pot formylation-Horner Wadsworth Emmons procedure 
was examined (Scheme 86).
130
  The lithium enolate of dioxinone 197 was added to N-formyl 
carbazole 361 followed by addition of triethylphosphonoacetate which resulted in successful reaction 
with isomerization to give 337b in 9% yield. The parent carbazole 360 was isolated from this reaction 
in 70% which might suggest that formylation had taken place but the intermediate aldehyde 350 was 
unstable to the reaction conditions.  Using tert-Butoxycarbonylmethyl)triphenylphosphonium bromide 
(349a) in place of the phosphonate 362 failed to give any of the corresponding Wittig product (not 
shown). 
 
Scheme 86. A one-pot formylation-Horner Wadsworth Emmons procedure for synthesis of ester 337b. 
1.6.4 Synthesis of Aldehyde 350 by Reduction Methods 
Continuing to target aldehyde 350 the reduction of Weinreb amide 351 was considered (Scheme 87). 
Carbamoyl chloride 364 was produced in 78% yield by treatment of N,O-dimethylhydroxylamine 
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hydrochloride (363) with triphosgene. This was then used to acylate dioxinone 197 to give the desired 
Weinreb amide compound 351 in 71% yield. 
 
Scheme 87. Synthesis of Weinreb amide 351. 
Weinreb amide 351 was treated with di-iso-butylaluminium hydride at −78 °C and then subjected to 
work up aided by Rochelle’s salt (Scheme 88). The main product isolated was not the desired 
aldehyde 350 but in fact enamine 365. Traces of an aldehyde compound (tentatively assigned as 350) 
were observed in the crude 
1
H NMR spectrum of this reaction however this was not isolated after 
silica gel chromatography.
131
  
 
Scheme 88. Reduction of Weinreb amide 351 with (iBu2AlH)2. 
Taking into account the instability of aldehyde 350 and that it may also be consumed in formation of 
enamine 365, the reduction was attempted again but in a telescoped procedure, whereby the reduction 
was followed immediately by Wittig reaction (Scheme 89). A two step procedure was developed in 
which, after quenching the di-iso-butylaluminium hydride mediated reduction with methanol, the 
intermediate aldehyde 350 was directly subjected to Wittig reaction with a phosphorane. 
In this way reaction with the phosphorane 366a gave rise to ethyl ester 337b in 45–50% yield. In a 
similar manner, keto-phosphoranes 367a and 367b were applied in the procedure however the ketone 
355a was only isolated in 7–12% yield and p-nitrophenylketone 355 was not observed at all.132 
Heating up to 80 °C for longer periods in these cases gave no improvement in yield. From the reaction 
mixtures the unreacted phosphorane could be mostly recovered but enamine 365 was observed in all 
cases as a major side product. 
74 
 
 
Scheme 89. A telescoped procedure for reduction of Weinreb amide 351 and subsequent Wittig rection to give 337b and 
335a. 
1.6.5 Attempted Isolatation of Aldehyde 350 
Having limited charaterisation of aldehyde 350 an alternative synthesis was sought that would allow 
for its easy isolation and enable further reactions to be assayed.  It was envisaged that a heterogeneous 
Fukuyama reduction would proceed under mild conditions and allow for simple isolation of aldehyde 
350 by filtration. 
Synthesis of the Fukuyama substrate thioester 352 began with carboxylic acid 368 (Scheme 90).
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Addition of Ghosez’s reagent to 368 was expected to form the corresponding acid chloride, and after 
addition of ethanethiol and pyridine the desired thioester 352 was obtained in 72%. Treatment of the 
thioester 352 with triethylsilane in the presence of 10 mol% palladium on charcoal gave an 
intermediate mixture A, the components of which were unknown. Attempted separation of this 
mixture by chromatography resulted in decomposition. 
  
Scheme 90. Formation of thioester 352, its Fukuyama reduction and subsequent Wittig reaction. 
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Interestingly, when leaving A for several days the mixture partitioned into two separate oils B and C. 
The first oil B appears to be related to the triethylsilane. The second oil C however, is tentatively 
assigned as aldehyde 350. Indeed, an aliquot of mixture C underwent reaction with phosphorane 366b 
and the Wittig product 337a was observed.   
 
 
 
Figure 2. 1H NMR spectra in CDCl3 for Fukuyama reduction of thioester 352. Top: Mixture A. Middle:  Mixture B. Bottom: 
Mixture C. 
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Examining the 
1
H NMR spectrum of A (Figure 2; top spectrum) shows two doublets (7.23, 5.52 ppm, 
J = 11.7) indicative of a trans double bond. The spectrum of B (Figure 2; middle spectrum) indicates 
the presence of two different silyl related impurities, possibly siloxanes. The spectrum of C (Figure 2; 
bottom spectrum) appears to indicate a mixture of both the silyl impurities present in B and a new 
aldehyde compound. To explain these observations trans-silylenol ether 369 is proposed as a possible 
structure for an intermediate in mixture A, and C is proposed to be aldehyde 350 (Scheme 91). 
 
Scheme 91. Postulated intermediates formed during the Fukuyama reduction. 
To determine if mixture A did in fact contain silyl enolether 369, further derviatization of this mixture 
was attempted. Cookson’s diene (4-phenyl-1,2,4-triazoline-3,5-dione) (370) is a highly reactive 
dienophile and is commonly used as a derivatization agent for dienes.
134
  The unknown mixture A  
was added to the diene 370 however none of adduct 371 was detected (Scheme 92). In a control 
reaction, reaction of vinyl dioxinone 372 reacted with Cookson’s diene to give, after isomerization, 
adduct 373. 
 
Scheme 92. Attempted derivatization of unknown A using Cookson’s diene 370 and a control reaction. 
1.7 Conclusion to Synthesis of  Carbaldehyde 350 and Development of Route 
to Cyclization Substrates 
After exploring several routes to 335 and 337, use of Weinreb amide 351 in a telescoped reduction-
Wittig procedure appeared to be the most viable route (Scheme 93). The starting materials for this 
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reaction sequence were both stable and the Wittig reactions proceeded in moderate yields. Moreover, 
this route allowed an initial amount of dioxinone ester 337b and ketone 335a to be produced and this 
material was used to investigate the intramolecular aldol and Dieckmann cyclization reactions 
proposed in the introduction (Chapter 1, Scheme 80 and 81). These studies are covered in chapters 3 
and 4. 
  
Scheme 93. Synthesis of target ester 335a and ketone 337b. 
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Synthesis of Salicylates from Dioxinone Derivatives 
1.8 Introduction to Salicylic Acid Derivatives: Their Applications and 
Synthesis 
1.8.1 Applications of Salicyclic Acid Derivatives 
Salicylic acid derivatives have been used for a variety of purposes including medicine, flavouring, 
fragrances, cosmetics, materials and agrochemicals (Figure 3). In the simplest forms acetylsalicylic 
acid (aspirin, 374) and salicylic acid have long been used for analgesic and antipyretic effects as well 
as prevention of myocardial infarction.
135
 In fact, 40000 t is consumed each year.
136
 Methyl salicylate 
(oil of wintergreen, (375) also has a long history as use in fragrance, flavours and in topical pain 
treatments.
135
  
 
Figure 3. Simple salicylic acid derivatives and their industrial applications. 
Within agrochemicals 3,6-dichloro-2-methoxybenzoic acid (Dicamba, 376) is used widely as a 
herbicide to control broadleaved weeds and grassy weeds, but also has uses in fine chemicals 
manufacturing of chemiluminescence and color-developing agents.
137
 Furthermore, 3,5-di-tert-
butylsalicylic acid (377) is used in materials such as pressure sensitive recording  paper and charge 
control additives in toner.
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Several natural products contain the salicyclic acid moiety within their framework and exhibit a wide 
range of biological activities (Figure 4). Many of these are 6-substituted macrocyclic salicylates. Of 
these, Salicylihalamide A and B, Apicularen A (378), marinomycins A–D exhibit a range of anti-
cancer activites.
139
 The Marinomycins also exhibit antibacterial activity and the fungal metabolites 
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CJ-12,950 (379) and CJ-13,357 are potent inducers of the LDL recetor gene in vitro.
140
 Other 6-
substituted salicylates natural products include the long chain anacardic acid derivatives (380) that 
exhibit anti-bacterial properties and the diacetylenic natural product frutescin (381).
141
 
 
Figure 4. Some isolated natural products containing the salicylates motif and their biological activities.  
1.8.2 Synthesis of Salicyclate Derivatives 
Commonly synthesis of bulk salicylates is by the Kolbe-Schmitt reaction of a phenolic compounds.
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Further modification can then be performed by esterification at the carboxylic acid or phenol groups, 
or via classical aromatic substitution chemistry. Typically syntheses of the more complex natural 
products detailed above are by derivatisation of aromatics often using cross coupling chemistries for 
introduction of the C6 aromatic substituent.
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1.8.2.1 De Novo Sythesis of Salicylates 
De novo methods for salicylate synthesis have also been examined but are less common. Oxidative 
cyclization of the β-keto ester 392 gave rise to methylsalicylate (375) (Scheme 94).144 Only one 
substrate was examined in this reaction so while the route may be generally applicable to other 
salicylate derivatives, further substitution of the aromatic ring was not examined.  
 
Scheme 94. Oxidative cyclization for the synthesis of methyl salicylate (375). 
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As outlined in the introduction, the reaction of 1,3-bis(silyl enol ethers) with β,β-dicarbonyl species 
gives rise to salicylates in a substrate controlled regioselective manner (Chapter 1, Scheme 28). 
Further to this It was found that use of 1,1-diacetylcyclopropane (394), in similar reaction with 393 
mediated by TiX4, gave rise to the ring opened, halogenated salicylates 395 (Scheme 95).
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Introduction of a substituent at R
1
 did result in a significant drop in yield however a range of 
functionality was incorporated.  
 
Scheme 95. Titanium(IV) chloride mediated [3+3] additions. 
A more general approach to salicylates is the gold-catalyzed cycloaromatization of dienynes 396 to 
give a range of 6-substituted salicylates 131 (Scheme 96).
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 Electron poor or rich aryl, linear or 
branched alkyl, alkenyl, alkynyl, and, silyl dienyne carboxylic acids underwent cyclization in 61-78% 
yield. A proposed mechanism for this reaction is that the gold catalyst co-ordinates to the electron rich 
alkyne 396 followed by s-trans to s-cis isomerization to give II. Intramolecular nucleophilic addition 
at the electrophilic carbon centre gives eight-membered ring III. Addition to the oxonium ion forms 
the bicycle IV which undergoes final aromatization causing opening of the four-membered ring to 
give the product 131 with regeneration of the catalytic species. 
 
Scheme 96. Gold-catalyzed cycloaromatization of dienynes to give 6-substituted salicylates. 
Intramolecular Wittig reactions have also been used for the de novo synthesis of salicylates (Scheme 
97). Reactions of the formyl chromones 397 via domino ‘Michael-retro-Michael-Wittig’ reactions 
with the phosphorane 398 resulted in 4-(2-hydroxybenzoyl) salicylate compounds 399.
147
 The domino 
process is proposed to involve a Michael addition of phosphorane 398 to the chromone 397, followed 
by a retro-Micahel reaction opening to give I. An intramolecular Wittig reaction then forms the new 
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aromatic ring. A range of salicylates could be formed in moderate yields with substitution dependant 
on the availability of formyl chromones 397.  
  
 
Scheme 97. Domino ‘Michael-retro-Michael-Wittig’reactions for synthesis of 4-(2-hydroxybenzoyl) salicylate 
compounds 399. 
Given their prevalence in nature and the proposed biosynthesis of such aromatic compounds, some 
attempts of biomimetic syntheses of salicylates have been examined. These are based around reduced 
polycarbonyl pre-cursors and intramolecular aldol condensations. Scott found that reduction of 
tetraacetic lactone 195 gives the 6-acetonyl-5,6-dihydro-4-hydroxy-2-pyrone 400 (Scheme 98).
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Treatment of this pyrone with potassium hydroxide results in formation of a reduced trianion capable 
of intramolecular aldol addition and loss of water on acidification to give 6-methylsalicylic acid (190). 
In this case the substrate was limited to species that could be reduced selectively; reduction of 6-
phenacyl-4-hydroxy-2-pyrone resulted in reduction of the side chain ketone preferentially to the 
alkene. 
 
Scheme 98. Formation of methylsalicylic acid 190 from pyrone 195 reported by Scott. 
In a similar vein, addition of acetoacetate dianions 401 to formylketones 402 gave partially reduced 
poly-carbonyls 403 capable of intramolecular aldol cyclization and dehydration to give salicylates 131 
(Scheme 99).
149
 When employing formylacetone in this reaction, the more bulky tert-butyl 
acetoacetate had to be employed to prevent competing self condensation reactions. 
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Scheme 99. Previously reported biomimetic syntheses of salicylates reported by Harris. 
Bearing in mind the uses of salicylates outlined in this introduction we were encouraged to develop 
our initial results to provide a useful route to salicylates to incorporate a range of functional groups 
and to be able to develop regioselective methods for this process. Such a process would be of use to 
academic and industrial chemists involved in the development of new salicylate derivatives. 
1.9 Results and Discussion 
1.9.1 Aromatization of Ketone 335a 
As described earlier, the ketone 335a was prepared through a telescoped reduction-Wittig procedure 
(Chapter 2, Scheme 93). With ketone 335a in hand, formation of ester 336a and subsequent 
aromatization reaction to salicylate 131b could be explored (Scheme 100). 
 
Scheme 100. The hypothesis that ketone 335a woud undergo ester formation and intramolecular aldol condensation.. 
The ketone 335a was subjected to heating at 120 °C in the presence of iso-propanol to give the enonic 
intermediate 336a as a mixture of regioisomers and keto-enol forms (Scheme xx). On continued 
heating 336a underwent aromatization with concomitant loss of water to give the salicylate 131b. 
This initial result prompted the development of a more efficient synthetic route to ketone 335a, as 
well as optimization of the aromatization reaction.  
 
Scheme 101. Ketene trapping and aromatization of the ketone 335a. 
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1.9.2 Retrosynthesis of Ketone 335a: Proposal of a Cross Metathesis 
Route 
The initial synthesis of ketone 335a was a telescoped procedure consisting of reduction of a Weinreb 
amide and subsequent Wittig reaction (Chapter 2, Scheme 93). This reaction proceeded by 
intermediate aldehyde 350 that could not be isolated and only gave low yields of the ketone 335a. 
Cross metathesis was considered as an alternative for the synthesis of ketone 335a and also the 
regioisomeric ketone 404, (which was expected to be able to form the same intermediate 336a) 
(Scheme 102). 
 
 
Scheme 102. Retrosynthetic analysis for the synthesis of 404 and 335a. 
The enone 404 could be produced by cross metathesis of the allylic dioxinone 405 and phenylvinyl 
ketone (406) (Route 1). Alternatively enone 335a could be available from the known vinyl dioxinone 
372 and homoallylic ketone 407 (Route 2). In developing a synthesis for the aromatization substrate, 
both of these possible syntheses were investigated. 
1.9.3 Synthesis Towards Ketones 404 and 335a 
1.9.3.1 Synthetic Studies Towards Ketone 404 via Route 1 
Investigations of route 1 began with attempts to synthesize novel allyl dioxinone 405 (Scheme 103). 
tert-Butyl acetate 408 underwent Claisen condensation with ethyl but-3-enoate 409 to give the keto-
ester 410. Following literature precedent for synthesis of dioxinone derivatives, keto-ester 410 was 
treated with acetone, acetic anhydride and catalytic sulfuric acid however failed to give rise to the 
desired dioxinone 405.
150
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Scheme 103. Attempted synthesis of dioxinone 405 via condensation of acetone with 410. 
In an alternative route to dioxinone 405, Meldrum’s acid 353 was acylated with vinylacetic acid 411 
which gave rise to a mixture of terminal and internal alkenes 412 and 413 (Scheme 104). Heating of 
Meldrum’s acid derivatives is expected to give rise to an acylketene which can then undergo 
cycloaddition with acetone to give dioxinones.
 150,151
 In this case, thermyolysis of 412 and 413 gave a 
complex mixture and only a small yield of isomerized dioxinone 414 could be isolated.  Interestingly, 
protonation of the lithium enolate of 414, generated with LiHMDS at −78 °C in THF, occurred to give 
a mixture of alkenes 415 and 414 (similar reaction of methyl sorbate, in the presence of HMPT or 
HMPA, gives solely the deconjugated product 1,3-diene 
152
). 
 
Scheme 104. Attempted synthesis of alkene 405 via cycloaddition of acetone to an acylketene. 
As an alternative synthesis of terminal alkene 405, use of elimination from chloro-dioxinone 418 was 
examined (Scheme 105). The synthesis of 418 began with a Claisen condensation; reaction of tert-
Butyl acetate (408) with ethyl 4-chlorobutanoate (416) gave 1,3-ketoester 417. Treatment of 417 with 
acetone, acetic anhydride and catalytic sulfuric acid gave the desired chloro-dioxinone 418.  
 
Scheme 105. Formation of the chloro-dioxinone 418. 
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Treatment of 418 with triethylamine or sodium acetate gave no reaction, even on heating the mixtures 
for a prolonged period (Scheme 106). Moving to a stronger sterically hindered base also proved 
ineffective. Treatment of 418 with potassium tert-butoxide resulted in formation of a cyclopropane 
compound 419. With this in mind, it was clear that a more facile elimination would be required to 
give access to the dioxinone 405.  
 
Scheme 106. Attempted synthesis of alkene 405 via elimination from halide 418. 
A very mild method for formation of double bonds is the elimination of selenoxides, a method that 
doesn’t usually require addition of base and would occur at ambient temperatures.153  To this end, the 
chloride 418 was treated with the lithium anion of benzeneselenol to give the selenide 420 in 72% 
yield (Scheme 107). In the first instance, oxidation of the selenide 420 at −10 °C with mCPBA gave 
the selenoxide 421 that could be observed by crude 
1
H NMR as a mixture of diasteromers 
contaminated with 3-chlorobenzoic acid. Warming to 40 °C resulted in elimination of the selenoxide 
421 to give the desired alkene 405 in 20% yield (Table 3, Entry 1). The reaction was repeated without 
isolation of the intermediate selenoxide and gave 405 in 58% yield (Table 3, Entry 2). In both of these 
examples however, observation of starting material and other products in the crude mixtures were 
observed by 
1
H NMR. 
 
Scheme 107. Synthesis of selenide 420 and its oxidation and selenoxide elimination to give alkene 405. 
In order to improve conversion of the starting material (and oxidize the phenylselenic acid PhSeOH 
produced to phenyl seleninic acid, PhSeO2H) increased amounts of mCPBA were used in subsequent 
trials (Table 3, Entries 3–5). In these entries a larger scale was used which allowed identification of 
some of the side products. The selenone 423 was isolated in two cases (Entries 4 and 5) and results 
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from over-oxidation of the starting material, due to necessity for heating to effect the elimination. 
Another side product isolated was alcohol 422, and some other unidentified impurities were observed 
in small amounts during this reaction. 
 
Entry
a) 
Scale (mmol) mCPBA Yield of isolated Products 
405 422 423 Selenide SM 
1
b) 
0.12 1 20 -- -- -- 
2 0.15 1.2 58 -- -- -- 
3 0.55 1.6 11 5 -- 10 
4 0.46 2 23 5 6 7 
5
c)
 0.46 2 28 11 14 9 
a) Reaction Conditions: Oxidation with m-CPBA at -10 °C for 0.5 h, then reflux for 2.5 h, 
CH2Cl2. b) After elimination stirred at 25 °C and selenoxide isolated by workup, then subjected in 
reflux in CH2Cl2 to give 405. c) vinyl acetate (10 equiv) added after oxidation step.  
Table 3. Oxidation and elimination of selenide 420. 
 
The observation of side products 422 and 423 in this reaction are due to a number of factors. The m-
chlorobenzoic acid produced in the reaction has a retarding effect on the selenoxide elimination step, 
and promotes electrophilic olefin addition.
154 
Although not specifically observed, phenylselenic acid 
generated during the syn elimination is in equilibrium with diphenyl diselenide and phenylseleninic 
acid, that under the mildly acidic reaction conditions could also give rise to β-hydroxy selenides. In 
one case (Table 3, entry 5) a sacrificial alkene, vinyl acetate, was added however this didn’t give a 
significant increase in yield.
155
  
Applying the most optimal conditions (Table 3, Entry 2) on a 0.5 mmol scale proved to be 
problematical. The yields of 405 varied greatly (20–50% yield) and numerous side products in 
addition to 422 and 423 were encountered. As a result, adequate quantities of the alkene 405 were not 
available for cross metathesis reactions to be investigated. Returning to the retrosynthetic analysis 
(Scheme 102), we then examined route 2. 
1.9.3.2 Synthetic Studies Towards Ketone 335a via Route 2 
Towards known vinyl dioxinone 372, Claisen condensation of tert-butylacetate 408 with ethyl 3-
chloropropionate 424 gave tert-butyl 5-chloro-3-oxopentanoate 425 (Scheme 108).
156
 Condensation of 
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425 with acetone gave dioxinone 426 and elimination by treatment with triethylamine, according to 
the procedure of Blechert et al., gave 372 in 73% yield over the 3 steps.
157
 
 
Scheme 108. Synthesis of vinyl dioxinone 372. 
 
Cross metathesis of vinyl dioxinone 372 with homoallylic ketone 407 (itself prepared by allyl 
Grignard addition to benzaldehyde followed by PCC oxidation) was then examined (Scheme 109). In 
the presence of catalyst 427a only small amounts of self-metathesis products 428 and 429 were 
obtained. Alternatively, cross metathesis of homoallylic alcohol 430a with vinyl dioxinone 372, 
provided the desired product 431a in 81% yield. The cross metathesis of enones with homoallylic 
alcohols has been significantly developed by Donohoe et al. for construction of 1,5-dicarbonyls 
subsequently used in heterocycle synthesis.
158
 Use of their conditions (Sealed Tube, CH2Cl2, 0.1 M, 
55 °C, 18 h, Zhan-1B catalyst 432 (5 mol%)) for cross metathesis of 430a and 372 however, gave 
431a in only 17% yield. 
 
Scheme 109. Oxidation of 430a and cross metathesis reactions of 407 and 430. 
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1.9.3.3 Oxidation of the Dioxinone Alcohol 431a to Ketone 335a 
The oxidation of the cross metathesis product 431a to the ketone 335a was then examined (Table 4). 
First attempts with PCC or MnO2 gave no reaction and after a prolonged period decomposition was 
observed (Table 4, Entries 1 & 2). Ley-Griffiths oxidation also resulted in no oxidation (a control 
reaction of p-anisyl alcohol giving full conversion to p-anisaldehyde) (Table 4, Entry 3).
159
 Swern 
oxidation of 431a gave a mixture of products containing ketone 335a in 47% yield but also an 
intractable mixture of other products possibly due to chlorination as has been observed with aryl vinyl 
ketones (Table 4, Entry 4).
160
 Modified Oppenhauer oxidation gave 335a but it was heavily 
contaminated with excess 2,4-dinitrobenzaldehyde oxidant which could not be separated (Table 4, 
Entry 5).
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The use of IBX in DMSO for oxidation of 431a gave over oxidation and resulted in isolation of the 
diketone 433a (Table 4, Entry 6).
162
 IBX is known to carry out α-hydroxylation of a variety of 
enolizable ketones.
163
  Higher yields of 335a were achieved by oxidation with IBX in EtOAc (Table 
4, Entry 7) to give the desired compound in 67%, the reactivity of IBX tempered by its lower 
solubility in EtOAc.
164
 The best results obtained were with use of Dess-Martin-periodinane (DMP), 
which at 0 °C gave 335a in 77% yield (Table 4, Entry 9).
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Entry Oxidation conditions
a 
Reaction outcome: Yields (%) 
431a  335a  433a 
1 PCC, CH2Cl2. 100 -- -- 
2 MnO2, CH2Cl2. 100 -- -- 
3 TPAP, NMO, CH2Cl2. 100 -- -- 
4 (COCl)2, DMSO, NEt3, CH2Cl2, −78 to −15 °C. -- 47
b
 -- 
5 AlMe3 (10 mol%), 2,4-dinitrobenzaldehyde, PhMe, 3 h. -- 71
b
 -- 
6 IBX, DMSO, 24 h. 15 -- 30 
7 IBX, EtOAc, 80 °C. -- 67 -- 
8 DMP, CH2Cl2. -- 40 -- 
9 DMP, CH2Cl2, 0 °C. -- 77 -- 
a)  Reactions performed at 25 °C unless otherwise stated. b) Yield of impure compound (see text).  
Table 4. Conditions applied for the oxidation of alcohol 431a. 
1.9.4 Optimisation of the Aromatization Reaction of Ketone 335a 
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With a more efficient synthesis of ketone 335a available, its aromatization to salicylate 131b could 
then be investigated (Scheme 110). The conversion of 335a to 131b can be broken down into two 
constituent steps: thermyolysis of dioxinone 335a to generate a substituted acylketene and its reaction 
with an alcohol to give 336a; aromatization of intermediate 336a to salicylate 131b. 
 
Scheme 110. Ketene generation, trapping and aromatization converting 335a to 131b. 
We investigated the ketene generation and ester formation step first. Heating the dioxinone 335a for 
45 min, complete conversion to the enone 336a was observed. This compound could not be isolated 
by chromatography however 
1
H NMR of the crude mixture indicated good conversion in this process 
(Figure 5, 2
nd
 Spectrum). 
Given that 12 h were required for complete aromatization under thermal conditions and that the 
ketene generation and trapping appeared complete in 45 min the addition of DABCO was considered. 
The use of a base would increase the rate of intramolecular aldol reaction, and DABCO may undergo 
conjugate addition to 336a aiding isomerization of the double bond. Accordingly, after 45 min not 
only was trapping complete but aromatization had begun (Figure 5, 3
rd
 and 4
th
 Spectra). 
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Figure 5. 1H NMR spectra for converstion of 335a to 131b. 1st Spectrum: The starting material 335a. 2nd Spectrum: 
Heating of 335a at 120 °C for 45 min, ketene generation and trapping gave 336a. 3rd Spectrum: Heating of 335a at 
120 °C for 45 min with DABCO (1 equiv), ketene generation and trapping gave 336a; aromatization of 336a has 
begun. 4th Spectrum) Heating of 335a at 120 °C for 1.5 h with DABCO (10 equiv) results in full conversion to 
131b. 
Following these initial observations it was unknown whether heat was required for the aromatization 
step or whether this could occur at room temperature. Following heating of dioxinone for 45 min the 
intermediate 336a obtained was treated with Cs2CO3, quinuclidine or Barton’s base however in each 
case only decomposition of the mixture was observed (Table 5, Entries 1, 2 & 3). Addition of 
DABCO to intermediate 336a did give some conversion to the desired product however, 
decomposition was also observed in this instance (Table 5, Entry 4). These results show that 
aromatization of 336a was more efficient with heating. 
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Table 5. Attempted aromatization conditions of intermediate 336a at 20 °C. 
In order to improve the yield of the ketene trapping/aromatization process a range of conditions were 
trialed for conversion of 335a to 131b (Table 6). To repeat the earlier aromatization result the ketone 
335a was heated conventially for 26 h in toluene which gave 131b in 53 % (Table 6, Entry 1). 
Addition of DABCO (10 eqv.) gave 131b in 55% yield after 1.5 hours (Table 6, Entry 2). Similarly, 
131b was obtained in 47% with just 1 equivalent of DABCO, and prolonged heating gave no 
significant increase in yield (Table 6, Entries 3 and 4). Molecular sieves seem to impart little effect on 
the outcome and would prevent interference from any adventitious water (Table 6, Entry 5). Also, the 
presence of DABCO during the trapping had no effect on the overall yield (Table 6, Entry 6). The 
control experiment without any additional base gave only 14% of 131b in 8 h and, given that trapping 
is complete within 45 min, it is clear DABCO has an accelerating effect on the aromatization process 
converting 336b to 131b (Table 6, Entry 7).  
Other methods investigated for the aromatization reaction of 335a involved a sealed tube method 
which gave 131b in 28% yield (Table 6, Entry 8). Use of acetic acid as an additive gave 131b in only 
21% yield, a pyrone side product was also observed by 
1
H NMR spectroscopy of the crude mixture 
(Table 6, Entry 9). 
 
 
 
 
 
Entry Additive Conc., M Time, h Outcome 
1 Cs2CO3 0.02 4 Decomposition 
2 Quinuclidine 0.04 14 Decomposition 
3 Barton’s Base 0.04 14 Decomposition 
4 DABCO 0.02 4 Trace 131b with decomposition 
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Entry Additive (equiv) Solvent Conc., 
M 
Temperature 
(method) 
Time, h Yield of 
131b, % 
1 - PhMe 0.08 120
b
 26  53 
2 DABCO (10) EtOAc 0.05 120 (µW) 1.5  55 
3 DABCO (1) EtOAc 0.05 120 (µW) 2  47 
4 DABCO (1 EtOAc 0.05 120 (µW) 8  51 
5 DABCO (10), 4 Å MS EtOAc 0.03 120 (µW) 1.5  48 
6
c
 DABCO (10) EtOAc 0.01 120 (µW) 2.25  49 
7 - EtOAc 0.05 120 (µW) 8  14 
8 4 Å MS CH2Cl2 0.02 120 (sealed tube) 21  28 
9 Acetic Acid (10) PhMe 0.025 125 (sealed tube) 1.5  21 
a) iPrOH (40 equiv) used in all Experiments b) Conventional reflux c)  DABCO added after the ketene trapping was 
complete (45 min), and reaction heated for a further 1.5 h; purified by loading mixture directly onto silica. 
Table 6. Conditions investigated for aromatization of 335a to salicylates 131b. 
As discussed in the introduction, diketo-dioxinones underwent aromatization under basic conditions 
to give the corresponding benzodioxinones in high yield. In contrast to this, treatment of the reduced 
compound 335a with triethylamine, Hunig’s base or 5 M HCl resulted only in decomposition (Table 
7). This could be due to the trans geometry of the double bond preventing the required intramolecular 
aldol reaction. 
 
Entry Reagent
a 
Solvent Conc., M Temperature Time (h) Outcome 
14 NEt3 DCM 0.1 25 14  Decomposition 
15 AcOH DCM 0.1 25 14  335a  
16 DIPEA DCM 0.05 25 4.5  335a 
17 DIPEA DCM 0.05 25 48  Decomposition 
18 5M HCl MeOAc 0.02 25 18  Decompoition 
19 NH4OAc EtOH 0.25 45 14  Decomposition 
a) Excess reagent used. 
Table 7. Conditions attempted for the aromatization of 335a to benzodioxinone 434. 
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1.9.5 Aromatization of Further Substrates with Optimised Conditions 
Having developed a synthetic route to the enone 335a and optimized conditions for its aromatization 
to give salicylate 131b the reaction was extended to incorporate a range of alkyl and aryl substituents 
(Scheme 111). The homoallylic alcohols 430a–k were prepared according to the literature by 
Grignard addition to the corresponding aldehydes. Cross metathesis of the homoallylic alcohols 430a–
k with vinyl dioxinone 372a gave 431a–j in 55–88% yields. In some cases an increased amount of 
catalyst (10 vs. 5 mol%) 427a and vinyl dioxinone 372a (2 vs. 1.5 equiv) was used which gave a 
significant increase in yield in the cross metathesis step (86 vs. 26% for furan 431a). In these cases, 
self-metathesis of vinyl dioxinone 372a was also observed but this was less than 10%. The pyridine 
containing alcohol 430k failed to undergo cross metathesis under these conditions, probably due to 
the coordinating ability of the nitrogen lone pair.
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Initially the oxidation of 431a–j to give the enones 355a–j was investigated using the 2 best sets of 
conditions developed (Table 4, Entries 7 and 9). Comparing the oxidation of 431a–f, yields of 335a–f 
were 10–31% higher using DMP and so this oxidant was used in subsequent oxidations of 431g–i. In 
the case of furan 431f the yield for oxidation was slightly lower compared to other substrates which 
may have been due to butenolide formation from over-oxidation.  
Aromatization of the ketones 335a–j under the newly developed conditions gave rise to a range of 6-
alkyl/aryl salicylates 131b–j in 46–67% yield. Of note, is that the nature of the para-substituent on the 
aryl unit (R) had little effect on the aromatization yield with both electron donating (335e) and 
electron withdrawing groups (335b) undergoing aromatization with comparable efficiency. However, 
the yield of the aromatization was influenced by steric factors. The least sterically hindered ketone 
335g underwent aromatization in highest yield. Consistent with this is the observation that sterically 
hindered mesityl compound 335j failed to undergo aromatization.  
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Scheme 111. Overall route to salicylates 131b–j. 
1.10 Conclusion to Synthesis of Salicylates from Dioxinone Derivatives 
A novel route to synthesize 6-aryl and alkyl salicylates has been developed (Scheme 111). Cross 
metathesis of vinyl dioxinone 372a with homoallylic alcohols 430a–k gave dioxinone derivatives 
431a–j. Oxidation of 431a–j was explored by a number of methods and DMP was the optimal 
oxidant. The ketene generation and trapping of the resultant enedione ketenes from 335a–j, and their 
aromatization to salicylates 131b–j, was investigated under several reaction conditions using 335a.  
The use of DABCO as a catalyst provided a significant rate enhancement to the aromatization 
reaction. 
The hypothesis made in the introduction was correct; the reduced compounds 355 underwent ketene 
generation, trapping and aromatization to give the salicylate products 131 (Scheme 112). The reaction 
provides a novel route to the functionalized salicylates and an addition to the synthetic chemists 
armory. Furthemore, this work compliments the previously developed methodology for β-resorcylate 
synthesis, giving the 4-deshydroxy compounds. 
 
95 
 
 
Scheme 112. Comparison of the reaction for salicylate formation to the previously developed reaction for β-resorcylates. 
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Synthesis of γ-Resorcylates from Dioxinone Derivatives 
1.11 Introduction to γ-Resorcylic Acid Derivatives: Their Applications and 
Synthesis 
1.11.1 Applications of γ-Resorcylic Acid Derivatives 
γ-Resorcylic acid (435) (2,6-hydroxybenzoic acid) derivatives occur widely in nature and in man-
made materials, exhibiting a wide range of uses in disparate fields. In the simplest form, the parent γ-
resorcylic acid (435) and 3,5-di-tert-butyl-γ-resorcylic acid (436) have been used for forming 
complexes through the carboxylate anion coordination to lanthanide cations (Figure 6).
167
 As well as 
providing binding information on the novel complexes synthesized, they exhibited very high 
luminescence which could be useful in new luminescent materials or optical sensors. Furthermore, 
3,5-Di-tert-butyl-γ-resorcylic acid (436) and its ester derivatives have shown effectiveness against 
platelet aggregation and atherosclerosis.
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Figure 6. Applications of γ-resorcylic acid (435) and 3,5-di-tert-butyl-γ-resorcylic acid (436). 
In biological applications, the γ-resorcylic anilides 437 are known as anthelmintics and the antibiotic 
methicillin 438 contains an important methylated resorcylic anilide that reduces affinity for β-
lactamases (Figure 7).
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 The hydroxamic derivatives 439 have been used for their acaricidal and mite 
ovicidal activity against citrus red mite, desert spider mite and european red mite.
170
  
 
Figure 7. Biological applications of γ-resorcylic anilides 437 and 438, and hydroxamic derivatives 439. 
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Applied in polymer manufacturing, azo and disazo γ-resorcylic acids (440 and 441) were found to be 
excellent dyes and stabilizers for polypropylene and other thermoplastic resins, exhibiting excellent 
brilliance, and fastness to light and cleaning (Figure 8).
171
 A range of aromatic substituents on the azo 
side chains and γ-resorcylic acid core conferred different colours in the resultant dyes.  
 
Figure 8. Application of γ-resorcylic derivatives as dyes. 
Furthermore, the γ-resorcylate moiety appears in several natural products that exhibit interesting 
biological activities (Figure 9). The naturally occurring penicillide (442) and derivatives thereof show 
biological activity including inhibition of cholesterol ester transfer protein (CETP) and, oxytocin 
antagonism.
172
 (–)-Berkelic acid (443) shows activity towards an aggressive ovarian cancer cell line 
OVCAR-3.
173
 
 
Figure 9. Naturally occurring γ-resorcylate containing compounds and their biological targets. 
1.11.2 De Novo Synthesis of γ-Resorcylates 
The synthesis of resorcinol derivatives from resorcinol (1,3-dihydroxybenzene) can be problematical  
and so de novo syntheses may be used as alternatives.
174
 De novo synthesis of γ-resorcylate products 
is uncommon in the literature, but one example is from the work of Doyle et al. (Scheme 113). 
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Enedione-diazoester 444 undergoes aromatization on treatment with sub-stoichiometric amounts of 
sodium hydroxide to give mono-substituted γ-resorcylate 142b. The reaction is postulated to proceed 
by first deprotonation of 44 then isomerization of the double bond to give I. A second isomerization is 
then followed by electrocyclic ring closure to give III. Subsequent loss of dinitrogen and a 1,2-methyl 
shift, followed by protonation and enolization gives the product 142b.
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Scheme 113. Postulated mechanism for the aromatization of enedione-diazoesters as proposed by Doyle et al. 
The reaction occurred at lower yields when more bulky esters were employed: an iso-propyl ester and 
tert-butyl ester gave the corresponding γ-resorcylates in 59% and 54%. The synthesis of the substrate 
and aromatization were combined into a one pot reaction (Scheme 114). Here, the authors increased 
the scope of the methodology by intercepting the equivalent first anion I with a suitable Michael 
acceptor, such as β-nitro styrene, and were able to incorporate a variety of aromatic groups in this 
fashion.  
 
Scheme 114. One pot synthesis of  γ-resorcylate 142c including formation of a enedione-diazoester followed by addition to a 
Michael acceptor and aromatization. 
Recent research within the Barrett research program outlined in the main introduction has been aimed 
at the synthesis of functionalized β-resorcylate derivatives, using diketo-dioxinones. Given the utility 
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of this chemistry, development of similar methods might also allow versatile and useful routes to 
regioisomeric γ-resorcylate products. Given the wide application of γ-resorcylates outlined, new 
methods for their synthesis would be of value to the synthetic chemistry community. 
1.12 Investigation of Aromatization Reactions for the Synthesis of γ-
Resorcylates 
Using the route developed (chapter 2) allowed the synthesis of 337b (Scheme 115). The generation of 
an acylketene intermediate from 337b and ester formation to give triketone 338b would be 
investigated. This triketone 338b could subsequently be used in the proposed Dieckmann cyclization 
to give γ-resorcylates 142d. 
 
Scheme 115. Synthesis of ester 337b and proposed Dieckmann cyclization. 
1.12.1 Synthesis and Investigation into the Dieckmann 
Cyclisation of 5-Oxoheptenedioates 
Heating of dioxinone 337b in the presence of iso-propanol gave triketo compound 338b as a mixture 
of trans regioisomers, and keto-enol forms (Scheme 116). Dieckmann cyclisation of 338b to give γ-
resorcylate 142d was then attempted using numerous bases. It was found that caesium carbonate and 
potassium tert-butoxide resulted in no formation of the desired product and only decomposition of the 
starting material was observed. When 338b was treated with tertiary amines triethylamine, DIPEA, 
DABCO and DBU degradation of the starting material was observed and no desired product could be 
isolated. Cyclisation of 338b was also attempted in 2 M aqueous potassium hydroxide; however, no 
aromatic products could be detected by NMR, only saponification of one or both esters.   
100 
 
 
Scheme 116. Synthesis of diester 338b and attempted Dieckmann cyclization with various bases. 
Two reasons for the failure of the Dieckmann cyclization of 338b were postulated. Firstly, the enoate 
in the cyclization was not electrophilic enough for the reaction to progress. Secondly, the double bond 
E geometry could prevent the intramolecular Claisen reaction. 
Given the possibility that the double bond geometry could hinder the cyclization, Hunter 
isomerization of 338b under basic catalytic conditions was attempted in order to induce isomerisation 
and aromatization (Scheme 117).
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 However, the sulphide addition to the double bond was 
irreversible and only phenyl sulphide 447 was obtained.
177
 Reaction of phenylsulphide 447 with 
potassium tert-butoxide in THF/tert-butanol resulted in liberation of thiophenol but no aromatic 
product 142d was isolated. 
 
Scheme 117. Attempted Hunter isomerisation of 338b to afford thioether 447 and subsequent attempted Dieckmann 
cyclization. 
To increase the electrophilicity of the Dieckmann substrate 338, a synthesis of phenyl ester 338c was 
attempted (Scheme 118). Reduction of Weinreb amide 351, quenching with methanol and, Wittig 
reaction with phosphorane 366c gave a mixture of phenyl and methyl esters 337c–d in 33% combined 
yield. Heating this mixture with iso-propanol resulted formation of the iso-propyl diesters 338c–d 
and, pyrone 448 although these could not be fully purified. Interestingly formation of the pyrone 448 
shows that the diester 338c is able to undergo an intramolecular acylation reaction. However, it also 
shows that in this case, O-acylation is favorable over the desired C-acylation. 
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Scheme 118. Synthesis of phenyl ester 337c and attempted trapping resulting in formation of pyrone 448. 
1.12.2 Synthesis and Investigation into the Dieckmann 
cyclisation of 3-hydroxy-5-oxoheptanedioates (450)  
While investigating the 5-oxoheptenedioates (338) above, the use of more flexible β-hydroxy-esters 
450 were investigated as alternative substrates for the synthesis of γ-resorcylates (Scheme 119). The 
β-hydroxy-ester 450 would be available by thermyolysis of dioxinone 449. 
 
Scheme 119. 3-hydroxy-5-oxoheptanedioate 450 as a possible aromatization substrate.  
The benzyl ester 449a was chosen as the first substrate; this would allow its facile removal should the 
free carboxylic acid be required for future strategies (Scheme 120). The synthesis of 449a began with 
addition of the lithium enolate of dioxinone 197 to acid chloride 236b which gave keto-ester 237g in 
42% yield. The ketone could then be selectively reduced to give the β-hydroxy ester 449a.  
 
Scheme 120. Synthesis of β-hydroxy ester 449a. 
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Upon heating, dioxinone 449a underwent reaction with iso-propanol to give the desired di-ester 450a 
and Dieckmann cyclization of this substrate was examined (Scheme 121). Various conditions were 
investigated for conversion of β-hydroxy ester 450a to resorcylate 142d. Treatment with potassium 
tert-butoxide resulted in partial hydrolysis of the benzyl ester. The use of a milder procedure 
involving TBAF (as has previously been employed in Lacey-Deickmann reactions for acyltetronic 
acid synthesis), or Barton’s guanidine base resulted in no reaction and recovery of starting material.178  
 
Scheme 121. Synthesis of the diester 450a and subsequent attempted Dieckmann cyclization reactions. 
As the β-hydroxy ester 450a had failed to undergo aromatization to γ-resorcylate 142d, conversion of 
the hydroxy functionality into a better leaving group was examined. Attempted mesylation of 449a 
resulted in no reaction however it could be converted to its silyl ether 452 (Scheme 122). 
 
Scheme 122. Synthesis of silyl ether 452. 
The silyl ether 452 was heated in the presence of iso-propanol to give the diester 453 (Scheme 123). 
Once again various conditions were tested for the desired Dieckmann cyclization. Treatment with 
NaN(SiMe3)2 or with LiN(SiMe3)2 at 20 °C resulted in no reaction. On heating with LiN(SiMe3)2 or 
reaction with potassium tert-butoxide, elimination of the silyl ether was observed but none of γ-
resorcylate 142d was obtained. 
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Scheme 123. Synthesis of the diester 453 and subsequent attempted Dieckmann cyclization reactions. 
1.12.3 Intramolecular Acylation Reactions of Dioxinone-Esters 
for γ-Resorcylate Synthesis 
Having explored Dieckmann cyclization of diesters for synthesis of γ-resorcylates to no avail, further 
activation of the substrates towards intramolecular acylation was required. The O-cyclization of 
phenyl ester 338c to pyrone 448 (Scheme 118) showed that introducing a phenyl ester sufficiently 
increased the electrophilicity of the carbonyl group to activate it towards intramolecular acylation. 
With this in mind, use of an acid chloride as an activated carbonyl species was then considered 
(Scheme 124).  
Hydrogenolysis of benzyl ester 453 gave the acid 454. The acid 454 was then treated with Ghosez’s 
reagent followed by 2,4,6-collidine resulting in formation of lactone 455. The preferred pathway for 
reaction was again O-acylation.  
 
Scheme 124. Synthesis of carboxylic acid 454 and its conversion to lactone 455. 
In order to prevent O-acylation during the reaction a different starting material was chosen. Keeping 
the dioxinone fragment in place would prevent O-acylation leaving C-acylation as the only option. 
Thus, the keto-ester 449a was subjected to hydrogenolysis to give β-hydroxy acid 456 (Scheme 125). 
The hydroxyl functionality was left unprotected in order to allow for dehydration with Burgess 
reagent during the reaction. 
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Scheme 125. Synthesis of β-hydroxy acid 456 and its aromatization reaction with Burgess reagent to give γ-resorcylate 
457a. 
Accordingly, reaction of 456 with Burgess reagent gave the aromatized product 457a in 20 % yield in 
addition to 34% of dehydrated acid 458a. Treatment of the acid 458a with more Burgess reagent also 
gave 457a. In the conversion of β-hydroxy acid 456 to 457a the order of the two dehydration events is 
not known. However, reaction of silyl ether 459 with Burgess reagent gave bisamide 460 in 77% yield 
(Scheme 126). This suggests that in the above reaction (Scheme 125, 456 to 457a) the hydroxy group 
of 456 is first dehydrated to give 458a, which once activated (as a ketene or sulfonamide), reacts in an 
intramolecular acylation reaction. 
 
Scheme 126. Treatment of the protected β-hydroxy acid 459 with Burgess reagent to give acylcarbamate 460. 
In order to optimize the aromatization reaction of acid 458a, a shorter synthesis of this substrate was 
developed (Scheme 127). Based on the work developed for the synthesis of salicylates (Chapter 3) 
cross metathesis was used once again. Treatment of crotonyl chloride 461 with tert-butanol and 
triethylamine gave homoallylic ester 462a in 73% yield. Cross metathesis of 462a with vinyl 
dioxinone 372a was successful and gave 337a in 82% yield. Treatment of 337a with trifluoroacetic 
acid gave the required acid 458a. 
 
Scheme 127. Synthesis of the acid 458a from crotonyl chloride 461.  
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1.12.4 Optimisation of Conditions for Aromatization of 
Dioxinone Acid 458a  
Treatment of acid 458a with Burgess reagent had resulted in successful reaction to give the desired 
aromatic product 457a (Scheme 125). Different conditions were then investigated to optimize 
conditions for this aromatization reaction. Considering the reactivity of acid 458a, it was expected to 
form dienyl-ketene 463 that may undergo a 6 electrocyclization to give 457a (Scheme 128). 
 
Scheme 128 Formation of γ-resorcylate 457a may be possible from dienylketene 463. 
To form the dienyl ketene 463, acid 458a was treated with Ghosez’s reagent followed by addition of 
2,4,6-collidine (Scheme 129). The aromatic 457a was isolated in 33% yield. TLC analysis of this 
reaction indicated that conversion to the product 457a started to occur before addition of the base, 
suggesting that it was superfluous. Accordingly, treatment of 458a with Ghosez’s reagent for an 
extended period gave the γ-resorcylate 457a in a 74% yield. 
 
Scheme 129. Treatment of 458a with Ghosez’s reagent resulted in formation of γ-resorcylate 457a. 
The reactivity of 458a upon activation with Ghosez’s reagent is similar to the previous cyclizations of 
dienylketenes outlined in the introduction section. Thus, further conditions for the aromatization of 
458a were examined, some following literature procedures (Table 8). 
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Entry Reagents (equiv) Temp (°C) Solvent Time 
(h) 
Yield of 
5a(%)   
1 (COCl)2 (5) 
Reflux CH2Cl2 48       9 
2 (COCl)2 (1.5), DMF (0.2) 25 CH2Cl2 20       50 
3
a
 i) NaH (1.1), (COCl)2 (1) DMF (1)  
25 THF 19       38 
4 Burgess Reagent (1.5) 70 MeCN 2       47 
5 Ghosez’s Reagent  (1.3) 25 CH2Cl2 2       74 
6 CCl4 (1.2), PPh3 ( 1.5). 25  CH2Cl2 18       26 
7 CCl4 (1.2), PPh3 (1.5) 
Reflux CH2Cl2 3       76 
8 CBr4 (1.2), PPh3 (1.5) 
Reflux CH2Cl2 3       73 
a) Sequential addition: NaH 2 h; (COCl)2 1 h; DMF 16 h. 
Table 8. Conditions for aromatization of 458a to 457a. 
Initially methods using oxalyl chloride for generation of the acid chloride were examined. Treatment 
with Paquette’s conditions refluxing the acid 458a in oxalyl chloride gave the product 457a in 9% 
yield (Table 8, Entry 1).
179
 This was significantly improved by using a sub-stoichiometric amount of 
DMF and reducing the reaction temperature to 25 °C, to give 457a in 50% yield (Table 8, Entry 2). 
Interestingly when 458a was treated with excess oxalyl chloride and excess DMF, 457a was not 
obtained but instead 464 was obtained in 33% (Scheme 130). The occurrence of 464 could be 
explained through decarboxylation of 458a, followed by formylation, aromatization and further 
formylation. 
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Scheme 130. Treatment of the acid 458a resulted in the unexpected formation of the aldehyde 464. An x-ray crystal 
structure of 464 confirmed its identity. 
Generation of the acid chloride under neutral conditions, using sodium hydride to first generate the 
sodium salt of 458a, followed by treatment with oxalyl chloride then DMF, gave 457a in 38 % (Table 
8, Entry 3). The remaining mass balance consisted solely of starting material 458a and several 
attempts were made to increase the conversion. Increasing the amount of sodium hydride and reaction 
time to ensure full deprotonation, or increasing the amount of oxalyl chloride and DMF, resulted in no 
further increases in conversion or isolated yield. 
Appel reactions conditions were used next as it was thought that not only would this create the acid 
chloride under mild conditions but the presence of triphenylphosphine could aid in the isomerisation 
of the double bond and thus promote aromatization. The reaction was tried at room temperature 
(Table 8, Entry 6) and gave 457a in 26% yield and some other minor impurities observed by crude 
1
H 
NMR. The same reaction in refluxing CH2Cl2 improved the yield giving the desired γ-resorcylate 
457a in 76 % (Table 8 Entry 7), and when substituting CCl4 for CBr4, 457a was isolated in 73% 
(Table 8, Entry 8). While use of Appel conditions didn’t increase the yield over the initial result using 
Ghosez’s reagent (Table 8, Entry 5), the two sets of conditions gave alternative protocols that could 
later be applied to further substrates. 
1.12.5 Retrosynthesis for Substrate Synthesis of Dioxinone Acids 
Using Cross Metathesis Strategies 
With conditions for the aromatization in hand, a larger range of substrates was explored to gain 
greater synthetic utility from this new intramolecular aromatization reaction. Ideally, 3 substituents 
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R
1–R3 could be incorporated to allow synthesis of tri-substituted γ-resorcylates i.e. hexa-substituted 
benzene derivatives (Scheme 131). 
 
Scheme 131. Proposed synthesis of substituted γ-resorcylates. 
As cross metathesis had be used for the synthesis of substrate 458a, this route was used for more 
complex substrates (Scheme 132). Retrosynthesis for substitution at position R
1
 would be through 
synthesis of the appropriate dioxinone fragment 372, available by acid-catalyzed condensation of 
acetone with a 1,3-ketoester such as 465. Retrosynthesis for substitution at position R
2
, or R
3
 was 
proposed using vinyl dioxinone 372a. The introduction of aryl groups directly attached to the 
homoallylic ester fragment 462 would come from deconjugative protonation of Horner-Wadsworth-
Emmons adducts 466. The alkyl substituted ester 462 would be available from tert-butyl crotonate 
(471) by deconjugative alkylation with appropriate electrophiles. 
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Scheme 132. Retrosynthetic analysis of the possible routes for substituted substrates 458 based on cross metathesis as the 
key step.  
1.12.5.1 Synthesis of Cross Metathesis Substrates 
Based on the synthetic plans developed (Scheme 132), construction of the substrates 458 required for 
the cross metathesis reactions were investigated (Scheme 133–135). Starting with R1, introduction of 
a methyl substituent was examined
 
meaning construction of a dioxinone ring was required (Scheme 
133). Addition of the lithium enolate of tert-butylacetate (408) to methacrolein gave hydroxy-ester 
472 in 87% yield. Swern oxidation of 472 resulted in the formation of keto-ester 465a, which after 
condensation with acetone gave dioxinone 372b. 
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Scheme 133. Synthesis of methyl dioxinone 372b. 
The synthesis of aryl-substituted homoallylic ester 462d was achieved as follows (Scheme 134). 
Bromo tert-butylacetate (473) was subjected to an Arbuzov reaction with triethylphosphite to give 
phosphonate 467a. Horner-Wadsworth-Emmons reaction of 467a with acetophenone gave the internal 
alkene 466a that was subjected to deconjugative protonation, giving terminal alkene 462d in 52% 
yield. 
 
Scheme 134. Horner-Wadsworth-Emmons route to cross metathesis partner 462d. 
Introduction of an aryl substitutent at the ester α position began with bromo phenylacetic acid 474 
(Scheme 135). Reaction with thionyl chloride and catalytic DMF gave the corresponding acid 
chloride intermediate I which was reacted with tert-butanol to give ester 475. Arbuzov reaction of 475 
with triethylphosphite gave the phosphonate 469a. Deprotonation of 473a and reaction with 
acetaldehyde (470) installed the aryl group in the correct position. Unfortunately, attempted 
deconjugative protonation of 466b as before, was unsuccessful; an inseparable mixture of 462g and 
starting material, 466b, was obtained. 
 
Scheme 135. Unsuccessful Horner-Wadsworth-Emmons route to the cross metathesis partner 462g. 
Installation of an alkyl group at the ester α position was achieved by deconjugative alkylation of tert-
butyl crontonate (475) (Scheme 136). The use of HMPA with LDA in this procedure means only α-
alkylated products should be observed.
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 Use of methyl iodide and benzyl bromide as alkylating 
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agents proved effective and the homoallylic esters 462b–c were isolated in good yield. The use of 
secondary bromides was ineffective and did not result in alkylation. This was also the case for MOM-
Cl, and use of 1,3-dibromopropane gave only mixtures of products that were inseparable by 
distillation or chromatography. Schlessinger has reported these latter two electrophiles to undergo 
alkylation in 94 and 92% yield respectively when using ethyl crotonate suggesting that the steric bulk 
is responsible for failure in these instances.
180
 Use of acetaldehyde as the electrophile gave alcohol 
462e in 63%, which was protected as TBS ether 462f. 
 
Scheme 136. Deconjugatve alkylation of tert-butyl acrylate (471) for synthesis of cross metathesis substrates. 
1.12.6 Cross Metathesis for Synthesis of Aromatization 
Substrates 
With some substrates in hand, their cross metathesis reactions were investigated (Table 9). Cross 
metathesis reaction of vinyl dioxinone 372a with t-butyl ester 462a in dichloromethane at reflux gave 
the unsaturated ester 337a in 82% yield (Table 9, Entry 1). Ester deprotection of 337a with 
trifluoroacetic acid (TFA) gave the carboxylic acid 458a in 95% yield as a single regioisomer. 
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Entry 462  (equiv) 372 (equiv) R1 R2 R3 Cross Metathesis Conditions 337 (%) 458 (%) 
1 a (1.0) a (1.5) H H H 427aa, CH2Cl2, 2.5 h, 40 °C 337a (82) 458a (95) 
2 b (1.0) a (1.5) H H Me 427aa, CH2Cl2, 2.5 h, 40 °C 337e (0) 
458b (97) 
3 b (1.0) a (1.5) H H Me 427ab, C6F5CF3, 16 h, 70 °C 337e (43) 
4 b (1.0) a (1.5) H H Me 427ab, C6F6, 16 h, 70 °C 337e (46) 
5 b (3.0) a (1.0) H H Me 427ab, C6F5CF3, 16 h, 70 °C 337e (24) 
 6 b (1.0) a (3.0) H H Me 427ab, C6F5CF3, 2 h, 70 °C 337e (68) 
 7 c (1.0) a (3.0) H H Bn 427ab, C6F5CF3, 2 h, 70 °C 337f (61) 458c (96) 
 8 e (1.0) a (3.0) H H CH(OH)CH3 427a
b, C6F5CF3, 2 h, 70 °C --
c  
 9 f (1.0) a (3.0) H H CH(OSi(Me)2
tBu)CH3 427a
b, C6F5CF3, 4 h, 70 °C 337g (54) 458d
d (91) 
 10  d (1.0) a (3.0) H Ph H 427a,b or cb, C6F5CF3, 14 h, 70 °C --
c  n/a 
 11 a (1.0) b (3.0) Me H H 427a,b or cb, C6F5CF3, 16 h, 70 °C --
c  n/a 
a) 5 mol% catalyst used. b) 10 mol% catalyst used. c) No cross metathesis products observed. d) R3 = CH(OH)CH3. 
Table 9. Conditions for cross metathesis reactions of 462 with 372 and ester cleavage for synthesis of 458a–d. 
In contrast, attempted cross metathesis of vinyl dioxinone 372a with ester 462b in dichloromethane 
was unsuccessful, however, reaction in perfluorotoluene as solvent at 70 °C with catalyst 427a gave 
the desired product 337e in 43% yield (Table 1, Entries 2 and 3). During purification of 337e partial 
isomerization to the more substituted alkene meant 337e was isolated as a mixture of regioisomers.
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The use of perflourobenzene gave no significant increase in yield and subsequently perfluorotoluene 
was used, as it was the more economical of the two (Table 1, Entry 4). Use of excess ester 462b 
resulted in a decrease in yield but when 3 equivalents of vinyl dioxinone 372a were employed, 
product 337e was obtained in 68% yield (Table 1, Entries 5 and 6). These reaction conditions were 
subsequently applied to the cross metathesis of vinyl dioxinone 372a with ester 462c giving the 
desired alkene 337f in 61% yield as a mixture of regioisomers (Table 1, Entry 7).  Cross metathesis of 
alkene 462e with 372a was not possible but cross metathesis of the corresponding TBS ether 462f 
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with 372a gave 337g in 61% (Table 1, Entries 8 and 9). The use of di-substituted alkenes 462d and 
372b, in cross metathesis reactions with 372a and 462a respectively, was attempted (Table 1, Entries 
10 and 11), but none of the desired cross metathesis products were formed, even when the metathesis 
catalysts 427b or 427c were employed.
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 Deprotection of the t-butyl esters 337e, 337f and 337g with 
TFA gave the carboxylic acids 458b, 458c, and 458d in 97, 96, and 91% yield respectively. In the 
ester cleavage of 337g the TBS group was also removed.  
1.12.7 Aldol Addition Strategies for Synthesis of Aromatization 
Substrates 458 
The previous route allowed cross metathesis with alkyl substituents α to the ester, however other 
substituents were not tolerated in the substrates. Having encountered these limitations an alternative 
route to unsaturated acids 458, which may allow greater functional group incorporation, was explored 
(Scheme 137). Acid 458 would be available from dehydration of β-hydroxy ester 476, itself the 
product of an aldol addition between a tert-butyl ester 477 and keto-dioxinone 284. The route would 
begin with readily available starting materials; several derivatives of keto-dioxinones 284 are known 
and derivatives of phenylacetic acid are very common and easily accessible.
183
  
 
Scheme 137. Retrosynthetic analysis of 458 using an aldol addition and dehydration strategy. 
1.12.7.1 Aldol Addition for Synthesis of Aromatization Substrates 
The first aldol addition reaction carried out was between tert-butyl acetate (408a) and keto-dioxinone 
284a (Scheme 138). When kept at −78 °C the reaction proceeded to give aldol product 476a in a 48% 
yield. Given that the remaining unreacted keto-dioxinone 284a could be recovered, this reaction was 
considered synthetically useful. 
114 
 
 
Scheme 138. Aldol addition strategy gives the desired β-hydroxy ester 476a and unreacted keto-dioxinone 284a is 
recovered. 
Two more keto-dioxinones 284c and 284d were produced to enable further aromatization substrates to 
be constructed (Scheme 139). Acylation of dioxinone 197 with the acylimidazole 477 gave keto-
dioxinone 284c.
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 The benzyl substituted keto-dioxinone 284d was obtained by alkylation of 284a.
183 
Some of the regioisomer 284e was obtained however this was a minor product. 
 
Scheme 139. Synthesis of the keto-dioxinones 284c and 284d. 
Reaction of tert-butyl acetates 408a–c with keto-dioxinones 248a, 248c and 248d resulted in the 
formation of β-hydroxy esters 476a–e in 42–52% yield (Table 10). The addition reactions showed few 
side products and so it was possible to recover 63–93% of the unreacted keto-dioxinones 248a, 248c 
and 248d. The esters 476a–e underwent facile dehydration with Burgess reagent to give the enoate 
compounds 357h–l as mixtures of regioisomers and these esters were treated with TFA to give the 
required acids 458e–h, also as regioisomeric mixtures. The generation of the carboxylic acids 458 as 
mixtures of regioisomers was of little concern as when subjected to the aromatization reaction, the 
final products would be identical.   
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Entry 248 408 R1 R2 R3 476 (%) 337 (%)  458 (%) 
1 248a 408a H Me H 476a 48 337h 77 458e 76 
2 248a 408b H Me Me 476b 50 337i 77 458f 97 
3 248a 408c H Me Ph 476c 42 337j 75 458g 98 
4 248d 408b Bn Me Me 476d 50 337k 82 458h 85 
5 248c 408a H p-C6H4OMe H 476e 52 337l 81 458i -- 
Table 10. Formation of β-hydroxy esters 476a–e and their conversion to unsaturated acids 458e–h. 
When attempting the ester cleavage of 337l with TFA the desired acid was not obtained but instead 
formation of pyrone 478 occurred (Scheme 140). While in general the mixtures of isomers of 337 
formed after dehydration were inseparable, in the case of 337l two major isomers 337la and 337lb 
were isolated after chromatography. While the E/Z geometry of these isomers couldn’t be 
conclusively determined, nOe measurements indicated the shown regioisomers. Treating each of these 
separately with TFA gave two different results; the more highly conjugated ester 337la gave the 
pyrone 478 while the less conjugated isomer 337lb gave the desired acid 458i. Formation of the 
pyrone may be due to the highly conjugated nature of 337la allowing facile hydrolysis of the 
dioxinone fragment. Prolonged exposure of the acid 458i to TFA converted it fully to pyrone 478 
perhaps via acid catalyzed isomerization and then pyrone formation. 
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Scheme 140. Dehydration of 476 to give regioisomers 337la and 337lb and subsequent formation of pyrone 378. 
1.12.7.2 Aldol addition for Synthesis of β-Hydroxy Acid Aromatization Substrates 
Incoporation of an aryl substituent R
2
 to the aromatization substrate was not possible by the 
dehydration route above (Scheme 140) as formation of the highly conjugated intermediate 337la upon 
dehydration, led to formation of pyrone 478. To avoid intermediate 337, β-hydroxy acids 479 were 
considered as substrates for the aromatization reaction (Scheme 141). To this end, β-hydroxy acid 
479a was subjected to the Appel reaction conditions and γ-resorcylate 457b was obtained in 42% 
yield. The increased amount of reagents was to effect the two dehydrations required. 
 
Scheme 141. Aromatization of β-hydroxy acid 479a to γ-resorcylate 457b. 
The synthesis of the β-hydroxy acid substrates for this reaction was then expanded much in the same 
way as before (Table 11). Aldol addition of benzyl acetates 480a–c to the keto-dioxinones 284a, 
284c, and 284d followed by hydrogenolysis, proceeded to give 479a–e with some unreacted keto-
dioxinone 284 observed. The crude mixture of the aldol addition could be directly subjected to 
hydrogenolysis and the resultant acid easily extracted by work up. The unreacted keto-dioxinone 284 
could also be recovered at this stage if desired.  
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Entry 284 480 R1 R2 R3 479 (%) 
1 284a 480a H Me H 479a 38 
3 284d 480a Bn Me H 479b 56 
5 284c 480a H p-MeO-C6H4 H 479c 43 
2 284d 480b Bn Me Me 479d 41 
4 284a  480c H Me Ph 479e 19 
Table 11. Synthesis of β-hydroxy acids 479a–e. 
For the synthesis of 479e it was found that further simplification of the process was possible (Scheme 
142). Starting with double deprotonation of phenylacetic acid (481) using lithium diispropylamide, 
addition to keto dioxinone 284a, gave the desired β-hydroxy acid 479e in 38 % yield.185 This provides 
a more direct route to the desired β-hydroxy acids 479, and although not fully investigated, the 
dianion of acetic or propanoic acid could also potentially provide substrates 479a–d in a one step 
process. 
 
Scheme 142. Direct synthesis of β-hydroxy acid 479e. 
1.13 Aromatization of Methylated Substrates 
With a range of substrates now available the developed aromatization conditions were applied to the 
methylated substrates 458b and 458e (Scheme 143 and 144). Treatment of 458b with Ghosez’s 
reagent did not afford the desired compound 457c but led to the formation of a mixture of products, of 
which the major constituent was acylated product 482 in 15% yield. This was in stark contrast to the 
earlier aromatization of the unsubstituted compound 458a (Scheme 129) that underwent aromatization 
in 74% when subjected to the same conditions. Some of the other aromatization conditions developed 
were then applied to the methylated substrate 458b. Use of Burgess reagent resulted in a complex 
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mixture and no 457c was isolated. Sequential treatment of 458b with sodium hydride, oxalyl chloride 
and catalytic DMF gave 457c in a 10% yield accompanied by decomposition of the starting material. 
When 458b was subjected to Appel reaction conditions γ-resorcylate 457c was obtained in 49% yield. 
. 
 
Scheme 143. Conditions employed for aromatization of methylated substrate 458b. 
Moving to the next methylated substrate 458e it was found that use of Ghosez’s reagent gave the γ-
resorcylate 457b in 45% yield (Scheme 144). Once again, this was improved by using Appel 
conditions which allowed 457b to be isolated in 62% yield. The lower yield for conversion of 458b to 
457c than 458e to 457b is likely due to the increased steric hindrance as a result of the methyl group α 
to the carbonyl. When this substituent is in the β position (458e) then the steric hindrance for 
nucleophilic attack is reduced.  
 
Scheme 144. Conditions employed for aromatization of methylated substrate 458e. 
The aromatization reaction of methylated substrates 458b and 458e indicated that the Appel reaction 
conditions were most general for the aromatization reaction. None of the electron rich aromatic 
products underwent further acylation reactions as had been observed in the presence of Ghosez 
reagent (Scheme 143, 482) or DMF (Scheme 130, 464). These optimal conditions were then used for  
aromatization of the rest of substrates 458.  
1.14 Application of the Optimised Aromatization Reaction 
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Having produced enoic acids 458a–h and the β-hydroxy esters 479a–e as cyclization substrates they 
were now subjected to the optimal aromatization reaction conditions (Scheme 145).  
 
Scheme 145. Substrates for the aromatization reaction and the products obtained. a) 1,2-dichloroethane used as solvent at 
70 °C. 
 
Scheme 146. Attempted aromatization of 458h to give hexa-substituted γ-resorcylate 457g. 
Generally the aromatization reactions proceeded as expected to give the γ-resorcylates 457a–f, h and 
I. In the case of 458f, heating in DCE at 70 °C was necessary to increase the yield from 18% under 
the standard conditions to 42% of γ-resorcylate 457e, the low reactivity presumably being due to 
steric hindrance. When applied to the more sterically demanding substrate 458h, the desired hexa-
substituted aromatic 458g was not obtained and only decomposition of the starting material was 
observed (Scheme 146). Targeting the same resorcylate 457g, but from the β-hydroxy acid 479d, 
resulted not in resorcylate 457g, but in the β-lactone 483a in 62% yield. Reaction of the β-hydroxy 
acid 479e also resulted in formation of the corresponding β-lactone, 483b, suggesting that this 
reaction pathway is favoured over aromatization when utilizing β-hydroxy acids substituted in the α-
position. In this case however, the lactone formation could be avoided by performing a dehydration 
first, affording the desired γ-resorcylate 457f from the unsaturated acid 458g in 53% yield. 
The substrate 458d was also subjected to the reactions conditions and the chlorinated product 457j 
was obtained in a 5% yield (Scheme 147). On attempting to repeat this experiment the resorcylate 
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457a was obtained in 6% and none of the chlorinated product 457j was obtained. This product likely 
arises through an acid catalyzed retro-aldol reaction of 458d to give unsaturated acid 458a which 
undergoes aromatization to give 457a. In both cases starting material was fully consumed and the 
remaining mass balance consisted of polar compounds along with phosphorous based side products 
not isolated by silica gel chromatography. Further investigation of this process was not carried out. 
 
Scheme 147. Aromatization of the hydroxyl substituted compound 458d to give the chlorinated product 457j. 
Comparing the efficiency of the two aromatization substrates, unsaturated acids 458 and β-hydroxy 
acids 479, is possible for 458e and 479a. They both give the same product 457b and aromatization 
occurred in 67 and 42% yields respectively for the two substrates. The lower yield for aromatization 
of the β-hydroxy acid 479a may be the result of a competitive acid catalyzed retro-aldol reaction. In 
the reaction of 479e to β-lactone 483b in 31 % yield, keto-dioxinone 284a was also obtained in 54% 
suggesting retro-aldol processes can be operative under the reaction conditions.
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1.14.1 Further Reactions of Benzodioxinone γ-Resorcylates 457 
γ-Resorcylate products 457 (benzodioxinones) obtained from the aromatization reaction can undergo 
several further transformations. For example, treatment of benzodioxinone 457 with methanolic 
caesium carbonate gave the γ-resorcylate methyl-2,6-dihydroxy-3,4-dimethylbenzoate 484 (a natural 
product isolated from the heartwood of Picea morrisonicola trees
187
) in 85% (Scheme 148). Further 
functionalization of benzodioxinones 457 are known in the literature, for example undergoing 
reduction with (
i
Bu2AlH)2, LiAlH4, or LiBH4, formation of quinoketenes or triflation followed by 
cross coupling reactions.
188
 
  
Scheme 148. Base mediated opening of the benzodioxinone 457e gave 484. 
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1.15 Conclusion to Synthesis of γ-Resorcylates from Dioxinone Derivatives 
A number of strategies for the synthesis of γ-resorcylates from dioxinone derivatives were 
investigated. Dioxinones such as 337c were constructed to allow synthesis of diesters for the proposed 
Dieckmann cyclization (Scheme 149). However, upon ketene generation and formation of diester 
338c, cyclization to the pyrone 448 occurred showing the preferred mode of reactivity was through O-
acylation.  In another instance, acid 454 was activated as an acid chloride but the same reactivity was 
observed; the lactone 455 obtained as the result of O-acylation. 
 
Scheme 149. O-Acylation was the preferred mode of reactivity rather than Dieckmann cyclization. 
In order to prevent O-acylation, the aromatization of unsaturated dioxinone compounds 458 and 479 
was investigated (Scheme 150). Use of cross metathesis and aldol additions allowed the construction 
of several different substrate classes that successfully underwent aromatization to the desired γ-
resorcylates. 
 
Scheme 150. Overview of γ-resorcylate synthesis routes. 
Of the three substrate classes developed for the aromatization reaction and their requisite routes it is 
not possible to simply say one route is more efficient. While the aromatization reaction was more 
efficient with unsaturated acids 458 than β-hydroxy acids 479 (as demonstrated for 457b) when the 
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whole synthetic route to γ-resorcylates is considered, they are closer in yield. The overall synthesis of 
resorcylate 457b from keto-dioxinone via unsaturated acid 458e is 17% and via 479a is 16%. 
Furthermore, synthesis of γ-resorcylates from β-hydroxy acids 479 involves fewer synthetic steps. 
Additionally, the three routes developed are complementary to one another. The use of cross 
metathesis with vinyl dioxinone 372 allows generation of γ-resorcylates 457 bearing an R3 substituent 
where R
1 
and R
2
 = H. On the other hand use of aldol additions to keto-dioxinones 284 generated γ-
resorcylates 457 where the R
2
 substituent is always present (i.e. R
2
 ≠ H), but R1 and R3 could be 
incorporated conferring a higher level of substitution in some cases. When formation of resorcylate 
457i was not possible from 458i due to formation of pyrone 478, synthesis of the corresponding β-
hydroxy acid 479c and its aromatization to 457i was possible. Equally, when attempted aromatization 
of the β-hydroxy acid 479e gave rise to β-lactone 483b, γ-resorcylate 457f was available from the 
unsaturated acid 458g.
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Extension of Methodology to Other Aromatic Compounds 
1.16 Introduction 
The application of 6-(alkylamino)-salicylates in drug molecules and synthesis is limited. In one 
example, the 6-dimethylamino-salicylate 485 is patented as an inbititor of hyaluronan transport for 
treatment of several diseases including osteoarthrosis and certain types of cancer (Figure 10).
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Figure 10. The 6-(dimethylamino)-salicylate 485 shows in vitro inhibition of hyaluronan transport. 
Although there are relatively few examples highlighting the synthesis of these compounds in the 
literature, both Böhme and Hormi have reported de novo methods for the generation of substituted 6-
alkylamino salicylates (Scheme 151). Böhme has shown that the β-ester enamines 486 undergo a 
condensation with another molecule of 486 to give the amino-salicylates 487 when treated with 
CF3CO2H.
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 A range of amino and R
2
 were tolerated substituents giving the amino-salicylates 487 in 
8–90% yield. In a second example, Hormi has shown that the chloro-malonate 488 can be converted 
to an aniline malonate 489 which cyclizes upon heating to the amino salicylates 490. This is proposed 
to occur via ketene generation and electrocyclization.
191
 
 
Scheme 151. Literature de novo syntheses of 6-alkylamino salicylates. 
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Given the relatively unknown application of these types of amino-salicylate molecules and the limited 
procedures for their synthesis, developing new methods for the selective synthesis of substituted 
examples would be beneficial. 
1.16.1 Hypothesis for Synthesis of 6-Alkylamino-salicylates and 
4-Oxy-pyridones 
During the synthesis of the γ-resorcylates (chapter 4) it was postulated that the acid substrates may 
cyclize be through formation of a dienyl-ketene such as 463 (Scheme 152). Such an intermediate 
would be expected to undergo a 6π-electrocyclization to give the γ-resorcylate 457a. Based on this 
principle it was believed that similar reactions using other cumulenes might be possible. For example, 
cyclization of a dienyl-keteniminium 491 would be expected to provide the 6-(dialkylamino)-
salicylate 492.  
 
 
Scheme 152. Postulated cyclizations to give alkylamino salicylates 492 and 4-oxy-pyridones 494. 
Furthermore, cyclization of the dienylisocyanate 493 could provide 4-oxy-2-pyridones 494, which 
represent a further class of important compounds present in numerous natural products.
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 In a similar 
literature example, acyl azide 495 undergoes Curtius rearrangement to give dienylisocyanate 496 and 
intramolecular acylation of resulted in pyridine 497.
193
 The iodine is postulated to catalyze double 
bond isomerization in this process so a lower temperature could be used; in a solely thermal processes 
a temperature of 230 °C was required.
194
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Scheme 153. Intramolecular acylation of isocyante 496 gives  pyridone 497.   
1.16.1.1 Retrosynthetic Analysis of Substrates 498 and 493 
It was envisaged that the substrates for these cyclization reactions would be easily available using 
similar strategies to those employed in the synthesis of γ-resorcylates (chapter xx). Thus, the 
keteniminium salt 491-OTf would be available from amide substrate 498 by treatment with triflic 
anhydride and collidine according to the conditions of Ghosez et al. (Scheme 154).
195
 The amide 498 
could be formed after dehydration of the β-hydroxy amide 499 that would in turn be the product of an 
aldol addition reaction between keto-dioxinone 284a and N-acetylpyrrolidine (500).  
 
Scheme 154. Retrosynthesis of the substrate 498. 
The isocyanate 493 would be produced from a Curtius rearrangment of the acyl azide 501 (Scheme 
155). This would be made from the acid 502 which could be synthesized by cross metathesis of vinyl 
dioxinone 372 with tert-butylacrylate and ester cleavage. Alternatively, N-Boc-carbamates have been 
used to generate isocyanate intermediates at room temperature by treatment with Tf2O and DMAP, to 
subsequently undergo intramolecular Friedel-Crafts-type cyclizations.
196
 This would require synthesis 
of 503. 
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Scheme 155. Retrosynthesis of the substrates 501 and 503. 
1.16.2 Hypothesis for a Quinone Synthesis 
During development of the salicylates synthesis (chapter 3) an unexpected oxidation reaction was 
observed. Oxidation of alcohol 431a with IBX, when carried out in DMSO resulted in over-oxidation 
to give the 1,2-diketone compound 433a (Scheme 156). It was reasoned that on heating this would 
undergo ketene generation and trapping. Then, as previously observed for the enone substrates, aldol 
condensation would follow yielding quinone 504. 
 
Scheme 156. Over oxidation of alcohol 431a to 433a, and the expected aromatization product 504. 
1.17 Results and Discussion 
1.17.1 Synthesis and Aromatization Studies for 6-Alkylamino-
salicylates  
1.17.1.1 Synthesis of Substrates for Keteniminium Formation 
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Scheme 157. Synthesis of the two substrates 498 and 505. 
The synthesis of the required amide substrate 498 was pursued as outlined in the retrosynthetic 
analysis (Scheme 157).  Thus, addition of acetyl pyrrolidine 500 to keto dioxinone 284 gave rise to 
the β-hydroxy amide 499 in 26% yield with 57% recovery of ketodioxinone 284.  Attempts to 
improve this yield by using three equivalents of amide nulceophile, or addition at −100 °C had little 
effect on the outcome. Transmetallation of the lithium enolate to zinc or cerium has not been 
investigated but may offer an increase in efficiency. Attempted dehydration of 499 with TFA resulted 
in no reaction but use of the Burgess reagent gave the dehydrated amide 498 in 51% yield. With some 
of the acid 458a already in hand, a further substrate for aminosalicylate synthesis was produced by an 
amide coupling reaction with pyrrolidine to give amide 505 in 56% yield. 
1.17.1.2 Aromatization Reactions Towards 6-Alkylamino-salicylates 
 
Scheme 158. Formation of methyl substituted aminosalicylate 492a from the amide 498. 
The aromatization of 498 was then investigated using conditions developed by Ghosez et al. for 
generation on keteniminium salts (Scheme 158).
195
 Addition of the substrate 498 and collidine to a 
mixture of refluxing triflic anhydride in dichloromethane gave rise to the desired aniline product 492a 
in 17−25% yield. The starting material was consumed in this process however the reaction appeared 
to be accompanied by decomposition which could be observed by 
1
H NMR. 
We investigated other methods for the aromatization that might give a cleaner reaction without any 
decomposition (Table 13). Treatment of 505 with phosphorous oxychloride, with and without addition 
base led to decomposition (Table 13, Entries 1 and 2). Application of our previously developed Appel 
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aromatization conditions resulted in only starting material being recovered, as did the use of 
triphosgene or Meerwein’s reagent (Table 13, Entries 3, 4 and 5). Using Meerweins reagent with 
heating resulted in decomposition of the dioxinone fragment, while treatment of 505 with thionyl 
chloride led to complete decomposition (Table 13, Entries 6 and 7). Interestingly use of oxalyl 
chloride resulted in the formation of an adduct 506, the structure of which was confirmed by x-ray 
crystallography (Table 13, Entry 8) (Scheme 159). 
 
Entry Reagent and Conditions
a
 Outcome 
1 POCl3 (1.2 equiv), NEt3 (2.5 equiv), 3 h Decomposition 
2 POCl3 (1.3 equiv), 24 h Decomposition 
3 PPh3 (1.5 equiv), CCl4 (1.2 equiv), 8 h Starting Material 
4 Triphosgene (0.4 equiv × 2), 2 × 4 h Starting Material 
5 Triethyloxonium tetrafluoroborate, 25 °C, 4 h Starting Material 
6 Triethyloxonium tetrafluoroborate, 12 h Dioxinone decomposition 
7 Thionyl Chloride Decomposition 
8 Oxalyl Chloride (2 equiv) 506 89% (see scheme 159) 
a) All reactions carried out in refluxing CH2Cl2 unless otherwise stated. 
Table 13. Conditions attempted for conversion of 505 to 492b. 
 
   
Scheme 159. Formation of the oxalyl chloride adduct 506 and its depiction from the crystal structure.197 
Formation of these adducts have only been observed in a few instances in the literature and such 
dichloro furanones are rare.
198
 A possible mechanism involves addition of oxalyl chloride leading to 
the imminium I, which on loss of carbon dioxide and carbon monoxide gives the chloroiminium II 
and subsequently the chloroenamine III (Scheme 160). This would then undergo further acylation 
with oxalyl chloride to give IV. Attack by chloride, followed by ring closure gives IV and loss of HCl 
would give 506.  
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Scheme 160. Possible mechanism for the formation of 506 from 505. 
Following unsuccessful attempts to improve the yield for the synthesis of amino-salicylates 492, an 
alternative substrate 499 was examined (Scheme 161). It was observed in the synthesis of γ-
resorcylates that β-hydroxy acids undergo aromatization (Chapter 4), and so it was anticipated that β-
hydroxy amide 499 might also be used as a substrate in this instance. Treatment of 499 with triflic 
anhydride and collidine led to aminosalicylate 492a but in only a 7% yield, again accompanied by 
decomposition. Treatment under Appel conditions resulted in no reaction, however treatment with 
oxalyl chloride appeared to lead to the desired product 492a. The resulting mixture of product and 
starting material was resubjected to the reaction conditions, this however led to decomposition. Upon 
repetition of this process, an unidentified oxalyl chloride adduct of the starting material was observed 
by 
1
H NMR. Unfortunately this failed to convert to the product on prolonged heating. Further 
experiments are required to fully understand this reaction and improve yields of the aminosalicylate 
products 492.  
 
Scheme 161. Attempted cyclization reactions of β-hydroxy amide 499. 
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1.17.2 Synthesis of Substrates and Attempted Aromatization 
Reactions for Synthesis of 4-Oxy-2-pyridones. 
The synthesis of substrates towards 4-oxy-2-pyridones followed the retrosynthesis outlined earlier 
(Scheme 155). Cross metathesis of vinyl dioxinone 372a with tert-butyl acrylate using previously 
developed conditions gave the ester 507 which upon treatment with TFA gave carboxylic acid 508 
(Scheme 162). Conversion of the carboxylic acid 508 to the corresponding acid chloride using 
Ghosez’s reagent, followed by direct treatment with NaN3 resulted in formation of acyl azide 509, the 
substrate for the planned Curtius rearrangement.  
To prevent ketene formation of the dioxinone fragment the Curtius rearrangement was performed at a 
suitably mild temperature in the presence of iso-propanol. This gave rise to rearrangement and the 
carbamate 510 was obtained in 76% yield. The minor product 511 was isolated in 9% yield. While the 
desired isocyanate wasn’t directly observed, its occurrence is inferred from isolation of these 
rearranged products. 
 
 
Scheme 162. Synthesis of acyl azide substrate 509, Curtius rearrangement and reaction to carbamate 510.  
With the acyl azide 509 in hand, and suitable conditions for its Curtius rearrangement developed, the 
intramolecular acylation reaction was attempted (Scheme 163). The acyl azide was heated at 75 °C in 
toluene, until the starting material was consumed. Carrying out the reaction at 0.02 M concentration 
provided a complex mixture of products that could not be separated. This result was not improved by 
using a more dilute concentration of 0.001 M and 494 was not observed. 
 
Scheme 163. Attempted Curtius rearrangement and aromatization. 
131 
 
As a complex mixture was observed, a second substrate N-Boc-carbamate 512 was then examined 
(Scheme 164). This could be reacted under a difference set of conditions, perhaps more conducive to 
selective reaction. The acyl azide 509 was heated in toluene and tert-butanol resulting in a Curtius 
rearrangement and trapping of the isocyanate to give N-Boc carbamate 512. This substrate was then 
subjected to variety of conditions for a Friedel-Crafts type acylation. Use of triflic anhydride and 
DMAP or triphosgene and pyridine failed to give the desired pyridone 494; a complex mixture being 
obtained in both cases.
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Scheme 164. Synthesis of the tert-butyl carbamate 512 and attempted aromatization to pyridone 494. 
 
Further investigations into the formation pyridone 494 were not attempted, however some further 
suggestions for experiments are as follows: splitting the process into two steps, first of all observing 
the isocyanate and then secondly, the intramolecular acylation reaction would be helpful. This would 
provide evidence that the isocyanate does indeed form and then allow different conditions to be 
applied for the subsequent step. While a thermal rearrangement may give the isocyanate, treatment 
with a Lewis acid such as BF3.OEt at lower temperatures may also provide an effective solution to the 
problems encountered.
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1.17.3 Towards a Quinone Synthesis 
1.17.3.1 1,2-Diketone Synthesis 
IBX is commonly used in DMSO, one of the few solvents it is soluble in. Reactions of alcohol 431a 
with IBX in DMSO however gave none of the ketone 335a. Instead the over-oxidised product 433a 
was obtained in 30% yield (Scheme 165).
200
 Given the ease at which IBX can carry out oxygen 
transfer and the varied outcomes with enolizable ketones this result isn’t necessarily surprising.201 
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Scheme 165. Oxidation of the alcohol 431a to give the α-dicarbonyl compound 433a. 
As previously mentioned, oxidation of alcohol 431a was more efficient when facilitated by DMP 
(Chapter xx, Scheme xx). Schreiber’s seminal contribution in this field shows that DMP can be also 
used to effect oxidation of acidic methylene positions.
202
 Taking the ketone 335a, conditions using 
triethylamine and collidine as base were attempted, the use of collidine giving a slightly higher 41% 
yield of the diketone 433a (Scheme 166).  The best yields for formation of diketone 433a were 
achieved by oxidation of alcohol 431a with DMP under basic conditions. This gave diketone 433a 
directly in a 45% yield. Starting the reaction at −15 °C the ketone 335a is observed by TLC and by 
warming to room temperature further reaction occurs to the 1,2-diketone. 
 
Scheme 166. Alternative routes to the α-dicarbonyl compound 433a. 
1.17.3.2 Aromatization of the 1,2-Diketones 
Having developed a route to diketone 433a, its intramolecular aldol condensation reaction was then 
examined (Scheme 167). Submitting diketone 433a to the previously developed ketene 
trapping/aromatization conditions we expected formation of the keto-ester 513 which would undergo 
Aldol condensation to give the quinone 504a. 
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Scheme 167. Unexpected formation of the hydroquinone 514a.  
To our surprise the isolated product was actually hydroquinone 514a in 32% yield. Thus, alongside 
aromatization, a reduction reaction had also taken place. No oxidized species could be isolated, 
therefore the reaction conditions were varied in an attempt to determine the reductant. The DABCO 
catalyst was removed but in this case reaction still occurred to give 514a in 8 % (Table 14, Entry 2). It 
is likely that, as observed in the synthesis of salicylates, DABCO catalyzes the intramolecular Aldol 
reaction but is not strictly necessary and is not responsible for the reductive process. Iso-propanol 
could be oxidized, acting as a reductant, however changing the alcohol to n-propanol resulted in no 
increase in yield, hydroquinone 514b being isolated in 31% yield (Table 14, Entry 3). 
Another possibility to explain the formation of hydroquinone 514a is that a disproportionation 
reaction is taking place in this process. The reaction was carried out in the presence of the 
hydroquinone 1,4-dihydroxybenzene. It was hoped this would be oxidized in preference, however the 
hydroquinone 514a was again isolated in 35% yield (Table 14, Entry 4). This doesn’t exclude the 
possibility of a disproportionation reaction, but could suggest that disproportion occurs before the 
Aldol condensation; however none of the expected oxidized products were ever isolated from product 
mixtures. 
Carrying out the reaction open to air under conventional heating also failed to produce any of the 
quinone 504a (Table 14, Entry 5). To improve yields the reaction was attempted at lower 
temperatures and to this end appearance of new products was observed only above 90 °C. Reaction at 
100 °C required 5.5 h for consumption of starting material and no improvement in yield was observed 
(Table 14, Entry 6). 
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Entry
a 
DABCO (equiv) Temperature °C Time (h) Additive Product Yield (%) 
1
b
 10 120 3 - 514a (32) 
2
b
 0 120 3 - 514a (8) 
3
c 
10 120 3 - 514b (31) 
4
b
 10 120 2 1,4-dihydroxybenzene 514a (35) 
5
d
 10 110 20 -
e
 514a (29) 
6
b
 10 100 5.5 - 514a (27) 
a) All reactions conducted at 0.03 M concentration b) iPrOH/EtOAc solvent, microwave heating c) nPrOH/EtOAc solvent, 
microwave heating d) iPrOH/PhMe, conventional reflux. e) Reflux carried out open to atmosphere. 
Table 14. Conditions for conversion of dicarbonyl 433a to hydroquinones 514a and 514b. 
The reactivity of the intermediates 513 and the high temperature required for cyclization suggested 
that it would be difficult to improve yields much further given that no distinct side-products have been 
observed or isolated. To be sure that the low yields during the synthesis and cyclization of diketone 
433a weren’t substrate specific some other substrates were synthesized and subjected to the 
trapping/aromatization conditions (Scheme 168). 
 
Scheme 168. Substrate synthesis and hydroquinone formation of further substrates. 
The two substituted biaryl hydrquinones 514c and 514d were isolated both in 15% over 2 steps. The 
intermediate 1,2-diketone compounds 433 could not be isolated in pure-form in this instance but the 
contaminant in each case was tentatively assigned as the corresponding 1,4-diketone isomer. Upon 
aromatisation only the product of the 1,2-diketones 433b were obtained and no other aromatic 
compounds were observed. The methyl substituted analogue 431g was oxidized to give the 1,2-
diketone 433b in 19% yield but was not continued to the hydroquinone stage. These results confirmed 
that the low yields for formation of the hydroquinones 514 were general. 
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Scheme 169. Retrosynthetic analysis for hydroquinones reveals α-hydroxy ketones.  
The low yield for all examples in conversion of the diketones 433 to the hydroquinones 514 is most 
likely due to the disproportionation that must occur to produce the reduced compound (Scheme 169). 
By retrosynthetic analysis of the hydroquinone product 514 it can be seen that the most suitable 
starting material for this reaction is the α-hydroxy ketone 515. With this in mind some attempts were 
made to produce such substrates. 
1.17.4 Alternative Routes for Hydroquinone Substrates 
1.17.4.1 α-Hydroxylation Routes 
The first route chosen to target the α-hydroxy ketone 515 was to carry out a direct hydroxylation of 
the ketone 335a (Scheme 170). The alpha hydroxylation of 335a was attempted with PhI(OAc)2 in 
MeOH/KOH, this however resulted only in decomposition.
203
 Treatment under acidic conditions 
(PhI(OAc)2 / TFA) returned starting material and several decomposition products.
204
 
 
Scheme 170. Attempted formation of the α-hydroxy ketone 515a. 
The failure to functionalize 335a by direct methods is not only due to its instability to basic 
conditions, but due to the highly conjugated nature of its enol form. This presents multiple reactive 
sites with no significant difference in nuleophilicty.
205
 With direct hydroxylation methods failing, an 
alternative retrosynthetic analysis of the acyloin 515a was considered. 
1.17.4.2 Cross Metathesis for Synthesis of Dithiane Precursors 
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A common route for the synthesis of non-symmetrical acyloins is employing Umpolung chemistry, 
using an acyl anion equivalent.
206
 In this case a dithiane was chosen as a masked acyl anion equivalent 
(Scheme 171). If dithiane additions were successful, then there would be opportunities to produce 
more functionlized compounds through addition of the parent 1,3-dithiane followed by Brook 
rearrangement and further alkylation.
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Scheme 171. Retrosynthetic routes of the acyloin 516. 
Retrosynthetically acyloin 515 is produced via unmasking of dithiane 516. Deprotection of dithianes 
can be effected under mild conditions such as Fujitas conditions [Hg(ClO4)2, CHCl3/MeOH] as 
exemplified in Smith’s synthesis of a spongistatin 1.208 The intermediate 516 could be produced either 
by cross metathesis of 372a and dithiane 517 or alternatively, 1,2 dithiane addition of 519 to the 
aldehyde 518.  
 
Scheme 172. Synthesis of dioxinone aldehyde 518. 
Cross metathesis of vinyl dioxinone 372a with acrolein gave the desired aldehyde 518a in 41% yield 
(Scheme 172). Use of acrolein as solvent in this reaction failed to give any desired cross metathesis 
product. Cross metathesis of 372a with acrolein diethyl acetal was also unsuccessful under these 
conditions however use of higher temperatures with perfluorotoluene gave the diethyl acetal 520 in 
66% yield. Quantitative cleavage of the acetal 520 gave rise to the desired aldehyde 518 in a slightly 
higher overall yield than direct metathesis with acrolein.  
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Addition of dithianes to α, β-unsaturated carbonyl compounds has been the subject of several studies, 
discussing differences between 1,2 and 1,4-addition.
209
 Addition of 2-phenyl-1,3-dithiane to cyclohex-
2-enone at 25 °C results in solely 1,4 addition while addition at −78 °C, and quick quenching (after 10 
min), gives a 13:7 mixture of 1,2 addition and 1-4 addition products; in hexane/THF (9:5), the ratio 
increases to 19:1. 
 The dithiane 519 was added to the aldehyde 518 at −78 °C in THF and the desired compound was 
isolated with some unidentified impurities in approximately 16% yield with starting material 
recovered in 47% yield (Scheme 173). A second attempt in which the reaction as allowed to warm to 
25 °C the starting material was fully consumed, however multiple side products were produced. Side 
products most likely arise from possible conjugate addition to the aldehyde or dioxinone moieties. In 
an attempt to circumvent these problems cerium chloride was used in order to promote 1,2-addition.
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Again traces of the product were observed but could not be isolated in pure form. 
 
Scheme 173. Conditions for synthesis of the dithiane 516a. 
Pursuing the second route based on cross metathesis, construction of substrate 517 began with 
addition of 1,3-dithiane 521 to acrolein to give allylic alcohol 517 in 77% yield (Scheme 174). This 
was subsequently protected as the TBS ether 522.  Unfortunately, on subjecting these two compounds 
to the two different sets of conditions developed for cross metathesis with vinyl dioxinone 372a, none 
of the desired products 516b or 516c were isolated. 
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Scheme 174. Attempted synthesis of the dioxinone 516b and 516c by cross metathesis. 
Failure of the dithiane moieties xx and xx to undergo cross metathesis is likely due to steric 
constraints. While first generation metathesis catalysts perform poorly in metathesis reactions of 
sulfides, second generation catalysts have been shown to be active in metathesis of compounds 
bearing sulfide, disulfide, dithiane functionalities.
211
 The literature precedent for cross metathesis 
compatibility of dithianes suggests that steric effects must be responsible for the failure of cross 
metathesis in these cases.
212
  
1.18 Conclusion of Extension of Methodology to Other Aromatic Compounds 
The methodology previously developed for the synthesis of salicylates (Chapter 3) and γ-resorcylates 
(Chapter 4) enabled the synthesis of further aromatic classes of molecules. Intermediate alcohol-
dioxinone dervivatives 431, developed previously for salicylate synthesis, were used in a synthesis of 
hydroquinones 514 (Scheme 175). The alcohols 431 could be oxidized to the diketone compounds 
433 that underwent ketene generation and trapping of the resultant ketene, followed by aromatization 
and reduction, to give the hydroquinones 514. The hydroquinones obtained may be the result of a 
disproportionation reaction, but further investigation is required to confirm or disprove this. 
 
Scheme 175. Synthesis of hydroquinones 514a–d. 
Exploiting methodology for unsaturated dioxinone synthesis towards γ-resorcylates (Chapter 4), gave 
unsaturated amide 498 and β-hydroxy-amide 499 (Scheme 176). Conditions were explored for the 
aromatization of 498 and 499 to give 6-dialkylamino salicylate 492a. It is postulated that these 
aromatization reactions proceed through a 6π-electrocyclization of a dienylketeniminium intermediate 
139 
 
 
Scheme 176. Synthesis of 6-aminosalicylate 492a from 498 or 499. 
A similar hypothesis was explored for synthesis of 4-oxo-2-pyridones (Scheme 177). However, 6π-
electrocyclization of isocyanate 493 failed to give 494.  
 
Scheme 177. Attempted formation of 2-pyridone 494 was unsuccessful.
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Towards the Synthesis of Higher Polycarbonyl Dioxinone 
Derivatives 
1.19 Introduction 
1.19.1 Biomimetic Synthesis of Naphthalenetriols 
As outlined in the main introduction (chapter 1) biomimetic syntheses of resorcylate and salicylate 
natural products have been carried out from tetracarbonyl compounds. When developed however, the 
polyketide biosynthesis hypothesis was also extended to larger aromatic systems such as napthols, 
hydroxyanthracenes and tetracycline structures.
213
 Wishing to recreate such larger systems in a 
laboratory setting, Harris and co-workers set about producing hexacarbonyl compound 523 (Scheme 
178).
214
  
Their initial approach to 523 was a β-ketoacylation of 1-phenyl-1,3,5,7-octanetetraone with ethyl 
benzoylacetate to give 523 in 19%. A higher yield was achieved through an in situ double β-
ketoacylation of acetylacetone 524, to give 523 in 40% yield.  It was subsequently found that 523 
could lead to several cyclization products depending on the reaction conditions. Treatment with 
aqueous KOH gave 526 as the major product (527 was the minor product along with its hemiketal), 
and subsequent aldol condensation gave the naphthalenetriol 528. Treatment of 523 with pH 8 silica 
gel resulted in isolation of naphthalenetriol 530 in 92% yield, intramolecular acylation of 529 
occurring through the more acidic methylene position. These two naphthalenetriols were air sensitive 
but stable as triacetates. Furthermore, the cyclizations proved to be selective and the formation of 531 
or 532 was not observed. 
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Scheme 178. Synthesis of hexacarbonyl compound 523 and cyclization to give naphthalenetriols under differing reaction 
conditions. 
1.19.2 Biomimetic Synthesis of a Homophthalate  
Most previous research using dioxinones for polycarbonyl synthesis, as outlined in the introduction, 
has been focused on the synthesis of tetra-carbonyl compounds and their aromatization to benzene 
derivatives, including the research presented in earlier sections. In one case the principle concept 
outlined in these syntheses was extended to produce a pentacarbonyl compound, dimethyl 3,5,7-
trioxononanedioate 535 (Scheme 179).
215
 This was produced by a double acetylation of dioxinone 197 
with bis(4-nitrophenyl) carbonate 533 to give the bisdioxinone derivative 534. On heating to effect 
ketene generation and trapping, aromatization to the homophthalate 291 via the only available 
intramolecular aldol cyclization occurs.
216
 Although no direct evidence was provided for formation of 
the pentacarbonyl compound 535, the aromatization proceeded in high yield and without external 
base. 
 
Scheme 179. Synthesis of dimethyl homophthalate 291 as reported by Barrett et al.  
1.19.3 Naphthalenetetraol Natural Products 
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Related to the naphthalenetriols produced by Harris are the naphthalenetetraols which are common 
motifs in several natural products including rubrofusarin (536), nigerone (537) and hypoxyxylerone 
(538) (Scheme 180).
217
 These molecules all exhibit useful biological activities and, given that the 
reported syntheses of these structures involve napthalenetetrols as intermediates, new synthetic routes 
could be useful for their synthesis, and construction of related compounds.   
 
Scheme 180. Natural products produced via naphthalenetetrols and their biological activities. 
1.19.4 Bisdioxinones as Naphthalenetetraol Precursors 
Building on the precedent of bisdioxinone 534 and the selective cyclization of Harris, the diketo-
bisdioxinone 539 is proposed as a possible precursor for naphthalenetetraols 543 and 544 (Scheme 
181). The product of double ketene trapping, diester 540 could undergo two possible aldol 
condensations via cyclization a or b to give 541 or 542 respectively. Upon further aromatization, 541 
can only give 543 while 542 could lead to two possible products, attack through the more acidic 
position of 542 favoring naphthalenetetrol 543. To test this hypothesis a synthesis of the starting 
bisdioxinone 539 would need to be developed.  
 
Scheme 181. Bisdioxinone 539 as a putative precursor to naphthalenetetrols. 
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Reviewing the literature, the methyl protected β-resorcylate 545 when treated with KOH underwent 
hydrolysis and decarboxylation to 546, followed by cyclization to 547 - a pathway that could render 
naphthalenetetrol synthesis from 541 unfeasible and similar to problems encountered in our earlier 
Dieckmann cyclization attempts (Scheme 182).
218
 With regards to intermediate 542, the similar 
protetrone 548 when treated under acidic conditions gave the Dieckmann cyclization product 
naphthacenequinone 549, albeit with a malonamoyl rather than a malonyl moiety.
219
 
 
Scheme 182. Literature reactions of diester 545 and protetrone (548). 
1.19.5 Retrosynthetic Analysis of Bisdioxinone 539 
Using the methodology previously developed in the Barrett group, a retrosynthesis of the bis-
dioxinone 539 was proposed (Scheme 183). It was anticipiated that 539 would be preceeded by 
palladium catalyzed deallylation and decarboxylation of bisdioxinone 550, a product of 
intramolecular acylation of keto-ester-dioxinone 237a and the acid chloride 551.  
 
Scheme 183. Retrosynthetic analysis of the bisdioxinone 539. 
1.20 Results and Discussion 
1.20.1 Synthetic Studies Towards the Bisdioxinone 550 
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The synthesis of the required carboxylic acid 368 (precursor to acid chloride 551) began with addition 
of the lithium enolate of dioxinone 197 to benzyl chloroformate which resulted in the two 
regioisomers 552 and 553, which despite their very close elution values could be separated by 
chromatography (Scheme 184). The desired regioisomer 553 was subjected to hydrogenolysis in the 
presence of palladium on charcoal to give acid 368 in a 42% overall yield from dioxinone 197. 
 
Scheme 184. Carboxylation of dioxinone 197 and subsequent hydrogenation to give the dioxinone acid 368. 
The next step in the synthesis was to convert acid 368 to the corresponding acid chloride 551 and 
investigate its use as an acylation agent. The acid 368 was treated with Ghosez’s reagent at 0 °C for 
0.2 h before being added to the pre-formed magnesium enolate of keto-ester 237a (Scheme 185). The 
starting keto-ester 237a was isolated in 57% as well as a complex mixture of products which did not 
appear to contain the desired bisdioxinone compound 550. In control reactions, taking acid 368 and 
treating with Ghosez’s reagent followed by reaction with ethanol and pyridine gave, albeit in 
moderate yield, the expected ester 554. Also, replacing the acid 368 with acetic acid in reaction with 
Ghosez’s reagent followed by the magnesium enolate of keto-ester 237a resulted in successful 
acylation to give the diketo-dioxinone 555.   
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Scheme 185. Attempted acylation of keto-ester 237a with the dioxinone acid chloride 551, and control reactions. 
 
It is clear that unsuccessful reaction of 237a and 551 is due to this specific acid chloride. Given the 
presence of pyridine in these reaction mixtures, it is expected that in the case of acid chloride 551, 
deprotonation at the acidic methylene position would be possible forming a ketene. If this is indeed 
the case, decomposition or polymerization of the ketene appears to out-compete reaction with the 
magnesium enolate of 237a. 
Due to the base sensitive nature of the acid chloride 551 an attempt was made to react it with Chan’s 
diene (124) (Scheme 186). Chan’s diene (124) is known to react with acetyl chloride without an 
external catalyst to give methyl 3, 5-dioxohexanoate.
220
 Unfortunately reaction of 124 with the acid 
chloride 551 failed to give the triketo-dioxinone 556. A complex mixture of products was observed 
and only methyl acetoacetate was isolated in 15% yield. 
 
Scheme 186. Unsuccessful reaction of the corresponding acid chloride of carboxylic acid 368 with Chan’s diene 124. 
1.20.2 Formation of a Dioxinone Dimer 557 
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Taking the above acylation reaction in its constituent steps, characterization of the acid chloride 551 
was attempted. After addition of Ghosez’s reagent to the carboxylic acid 368 the mixture was 
concentrated in vacuo; however, the acid chloride was not detected but rather a new compound, 557 
was observed (Scheme 187). The product 557 corresponds to a dehydrative dimerization process 
occurring and its structure was confirmed by x-ray crystallography.
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Scheme 187. Unexpected formation of a dioxinone dimer 557 and graphical representation of its structure as determined by 
X-ray crystallography. 
To investigate the formation of dimer 557 and to produce an IR of the acid chloride 551 in-situ, the 
reaction was performed with a Mettler-Toledo ReactIR spectrometer (Graph 1).  IR measurements (16 
scans) were taken every 15 seconds, the initial peaks at 0–30 min due to the introduction of substrate 
and solvent, with cooling taking place until the limitation of the equipment was reached at −14 °C. At 
this temperature, the addition of 1.3 equivalents of Ghosez’s reagent was carried out by injection 
(timepoint: 1 h 20 min). The reaction was then allowed to warm to 25 °C at a rate of 2.5 °C/min so 
when a second 1.3 equivalents of Ghosez’s reagent was added (timepoint: 2 h 12 min) the mixture 
was at room temperature. The reaction was carried out on a 1 mmol scale at 0.04 M concentration in 
CH2Cl2, the large reactor size necessitating more dilute reaction conditions. 
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Graph 1. Monitoring the conversion of 368 to 551 by IR spectroscopy. Specific peaks were selected and their intensity during the course of reaction plotted. 
The peak at 1715–1735 cm−1 corresponds to the dioxinone lactone functionality in carboxylic acid 368. The peaks at 1737 and 1798 cm−1 are indicative of the 
acid chloride 551. The peak at 1633 cm
-1
 corresponds to the amide 558.
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Time h/m/s 
Selected IR traces for addition of Ghosez's reagent to acid 368 
1715–1735 cm^−1 
(lactone 368) 
Peak at 1633 cm^−1 
(amide 558) 
Peak at 1737 cm^−1 
(lactone of Acid Chloride 
551) 
Peak at 1798 cm^−1 (Acid 
Chloride 551) 
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After first addition of Ghosez’s reagent the lactone peak of dioxinone 368 at 1715–1735 cm-1 (after an 
initial downward spike) appears to slowly decrease while a new lactone peak increases at 1737 cm
-1
 
along with an additional peak at 1799 cm
-1
 which would correspond to formation of an acid chloride 
551. During this process the amide 558 (1633 cm
-1
) is also produced at a constant rate matching 
decrease in the 368 lactone peak. When addition of Ghosez’s reagent occurs at room temperature the 
reaction is much quicker and, in less than a minute, the starting acid 368 is consumed, along with 
further acid chloride 551 and amide 558 formation. An aliquot of the final mixture was quenched in 
Ethanol. TLC analysis of this aliquot shows formation of the ethyl ester 554 and none of product 557 
or starting material 368 present. 
These results suggest that when carboxylic acid 368 is treated with Ghosez’s reagent, formation of 
acid chloride 551 occurs and under high dilution (0.04 M), is stable at room temperature for at least 
1h without formation of 557 (Scheme 188). In fact, when the reaction solution from the ReactIR 
experiment was kept at 3 °C under an inert atmosphere, reactions of this solution with ethanol gave 
the expected ethyl ester 554 for 1 week before acid 368 could be observed . Treatment of an aliquot of 
the solution with Hünigs base resulted only in decomposition; formation of the dimer 557 was 
observed on concentration of the solution without base. 
 
Scheme 188. ReactIR experiment and subsequent reaction of the solution of acid chloride 551 with Hünig’s base.    
1.20.3 Possible Mechanism for Formation of Dimer 557 
The mechanism for formation of dimer 557 is unknown but two possible pathways are given below 
(Scheme 189). Path A proceeds via a quaternary ammonium salt and path B via ketene formation 
followed by a concerted [2+4] process. Following path A, the amide 558 is expected to add to acid 
chloride 551 giving the iminium chloride I. The enol form of II can then act as a nucleophile and is 
acylated by another molecule of 551 to give IV. Tautomerisation of IV followed by further 
intramolecular attack leads to the dimer 25 in a stepwise manner. More directly, pathway B follows 
elimination of amide salt from the iminium chloride I resulting in ketene VI that could undergo a 
[2+4] addition with another molecule of VI to give dimer 557. 
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Scheme 189. Two possible mechanisms for the formation of dimer 557 from acid chloride 551. 
1.20.4 Further Synthesis of Dimer 557 and its Subsequent 
Reactions 
Wishing to explore further reactions of dimer 557 some new routes to the carboxylic acid substrate 
368 were developed (Scheme 190). A regioselective formation of the ester 553 would avoid difficult 
purification and may provide a higher yield of dioxinone acid 368. The lithium enolate dioxinone 197 
could be regioselectively halogenated with hexachloroethane to give 559 in 55%, or 1,2-
dibromotetrachloroethane to give 345 in 53%.
222
 These halides could then be subjected to palladium 
catalyzed carbonylation to give the benzyl ester 553 in 43 and 47 % respectively.
223
 In both cases 
dehalogenated starting material (197) was observed showing that, despite facile insertion, 
carbonylation appeared to be the problematic step. 
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Scheme 190. Futher Routes developed to the benzyl ester 553. 
Pursuing a better route to bromo-dioxinone 345, diketene 99 was converted to bromoacetoacetic acid 
560 in 90% yield.
224
 Despite formation of dioxinone 345 in 68% overall yield from 199, the original 
carboxylation route to 553 was still most effective even though not regioselective. With further 
quantities of carboxylic acid 368 now in hand the dimerization reaction could be further examined. 
Carrying this out on 5.4 mmol scale gave an improved 27% yield of 557 (Scheme 191). No doubt the 
low yield is in part due to the difficult isolation of 557, the presence of amide 558 necessitating its 
isolation by crystallization.  
 
Scheme 191. Formation of the dimer 557 was carried out on preparative scale to allow a pure sample to be isolated by 
crystallization. 
1.20.5 Further Reactions of Dimer 557 
Some reactions of 557 were first explored to understand its reactivity (Scheme 192). On heating in 
methanol, the dimer 557 underwent transformation to give the keto-ester 561 in quantitative 
conversion (Scheme 192). The 
1
H NMR (THF-d8) spectrum of 561 indicates both phenolic protons 
are hydrogen bonded and the compound exists solely in its keto-form. Reaction of the dimer 557 with 
caesium carbonate in methanol gave a mixture of hydroxy-coumarins 562 and 563 in a combined 72% 
yield.  Methylation of 557 gave the methylated compound 564 in quantitative yield.
225
 Further 
reactions and synthetic use of the dimer 557 is yet to be explored. 
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Scheme 192. Reactions of the dimer 557. 
1.21 Conclusions to the Synthesis of Higher Polycarbonyl Dioxinone 
Derivatives 
Towards a hexacarbonyl compound and naphtalenetetrols, synthesis of bisdioxinone 550 was 
attempted using an acylation strategy (Scheme 193). Unfortunately, bisdioxinone 550 was not formed 
and consequently, the hypothesis that after deallylation and decarboxylation, thermyolysis in an 
alcohol would give naphthalenetetrols 543 and 544 could not be tested. 
 
Scheme 193. The unsuccessful route to bisdioxinone 550. 
However, IR evidence for the formation of the acid chloride 551 was obtained and this appeared 
stable at 0.04 M (Scheme 194). Interestingly, at a concentration of 0.165 M 551 dimerized to give 
highly substituted benzene compound 557. 
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Scheme 194. Acid chloride 551 underwent dimerization to 557 at a concentration of 0.165 M. 
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Conclusion and Further Work 
1.22 Conclusion 
The research presented shows the application of dioxinone derivatives in the synthesis of aromatic 
compounds by de novo methodology. This work uses the key dioxinone derivatives vinyl dioxinone 
372a, keto-dioxinones 284a, c and d, and the dioxinone acid chloride 551 to produce a range of 
aromatic products (Scheme 195). 
 
Scheme 195. Synthesis of aromatic compounds from dioxinone derivatives. 
Firstly, the vinyl dioxinone 372a was used in cross metathesis with homoallylic alcohols. After 
oxidation these compounds could undergo ketene generation, trapping and aromatization to give 6-
aryl and 6-alkyl salicylates, 131b–g and 131h–j, in a novel biomimetic process (Chapter 3). Building 
on the aromatization of diketo-dioxinones outlined in the introduction, this demonstrates that reduced 
compounds are also capable of aromatization. 
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An unexpected reaction during the synthesis of salicylates led to the synthesis of hydroquinones 
514a–d (Chapter 5). Using cross metathesis once more allowed the construction of dioxinone-diones 
that underwent ketene generation and trapping followed by aromatization to give hydroquinones. 
Interestingly, the expected quinone products weren’t observed and further work is required to 
investigate this reaction and improve the hydroquinone synthesis. 
To complement the known pathways to β-resorcylates, a new aromatization reaction was developed 
for the synthesis of γ-resorcylate compounds 457a, c, d, and j (Chapter 4). Using vinyl dioxinone 
372a allowed construction of some mono-substituted γ-resorcylates. The limitations of cross 
metathesis with vinyl dioxinone 372a were also realized, the reaction becoming less efficient for the 
synthesis sterically challenging substrates. 
In addition to the cross metathesis route, a synthesis of γ-resorcylates 457b, e, f, h, and i, from keto-
dioxinones 284a, c and d was also developed. Aldol additions of tert-butyl acetate derivatives to keto-
dioxinones followed by dehydration and ester cleavage provided substrates for aromatization. 
Alternatively, aldol additions of benzyl acetate derivatives to keto-dioxinones followed by 
hydrogenation provided alternative substrates. Various conditions were investigated for aromatization 
reaction and these routes allowed access to more highly substituted γ-resorcylate compounds although 
a hexa-substituted benzene compound could not be made with the current methodology. 
Keto-dioxinone 284a was found to be useful once more for a synthesis of an amino-salicylate 
compound 492 (Chapter 5). Further studies are required to improve the aromatization reaction in this 
instance however, once optimized, the strategy for substrate synthesis is developed which will provide 
a range of aminosalicylates. 
Finally, the acid chloride 551 was made in-situ however could not be isolated (Chapter 6). This 
compound showed interesting behavior and when concentrated underwent a dimerization reaction to 
give 557. Some further reactions of this dimer were explored to understand its reactivity. 
1.23 Further Work 
1.23.1 Synthesis of More Highly Functionalized Salicylates 
After the publication of our salicylate synthesis Liu et al. published a synthesis of 6-substituted 
salicylates (Scheme 196). This involved using the iodinated benzodioxinone 565 for cross coupling 
with an aryl or alkenyl boronic acid to give biaryl 566. Under the usual esterification conditions, a 
range of 6-substituted aryl and alkenyl salicylates 567 were synthesized. 
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Scheme 196. Liu et al.’s synthesis of 6-substituted salicylate compounds.  
Comparing this to the synthesis presented (Chapter 3) from a synthetic view point, Liu et al.’s route is 
somewhat simpler for the construction of 6-aryl salicylates. It is a two-step process and proceeds in 
much higher overall yield. However, this route is limited by the availability of starting iodo-arene 
565, and the coupling partner must be aryl or alkenyl. The introduction of alkyl substituents is an 
important benefit of the presented methodology; the use of traditional Friedel-Crafts alkylation would 
be complicated by over-alkylation. 
Furthermore Liu et al.’s route is also limited in its ester formation step. A large excess of alcohol is 
used and this could be problematic if a valuable alcohol is required. The ketene trapping involved in 
our methodology means that a large excess of alcohol does not necessarily have to be used. 
Using the methodology later developed (chapter 4), more substituted unsaturated dioxinones 569 
could be constructed (Scheme 197). Aldol addition of ketone enolates of 568 to keto-dioxinones 284 
followed by dehydration would give ketones 569. Aromatization would give the highly substituted 
salicylates 570. 
 
Scheme 197. Proposed synthesis of more densely functionalized salicylates. 
1.23.2 Carbon Nucleophiles for Ketene Trapping 
Another opportunity to note for the presented methodology is that ketene trapping can allow carbon 
nucleophiles to be used during the aromatization reaction (Scheme 198). Some preliminary studies on 
this subject were carried out during this work. Reaction of N-methyl pyrrole 571 with dioxinone 197 
gave 2-acetoacetyl pyrrole 572 in 62% yield. Using a more complex unsaturated dioxinone 337a the 
acetylated pyrrole 573 was obtained in 53% yield.   
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Scheme 198. N-methyl pyrrole for ketene trapping reactions in synthesis and, as proposed for use in aromatization reactions. 
Developing these reactions further it may be possible to react 571 with unsaturated ketones 574 or 
diketo-dioxinones 575 to give, after aromatization, the resorcinol products 576 and 577 respectively. 
This would greatly expand the use of this methodology by incorporating a C–C bond formation into 
the aromatization reaction. These types of structures are also similar to the core natural products such 
as marinopyrrole A (578) and celastramycin A (579). Furthermore, other electron-rich aromatic 
compounds may also undergo similar acylation. A combination of ketene trapping with carbon 
nucleophiles and the chemistry developed within this work as well as previously by Barrett et al., 
could allow range of biaryl resorcinol molecules to be easily constructed. 
1.23.3 Hydroquinone Synthesis 
The 1,4-hydroquinones 514a–d synthesized (Chapter 5) are novel molecules. Some initial biological 
screens have indicated that 514a and 514b are active as anti-fungal agents towards Uromyces viciae-
fabae and Monographella nivalis and this could warrant some further investigation.
226
 A higher 
yielding route to such compounds and their analogues would be required however and this could be 
achieved by formation of α-hydroxy ketones 581.  
An ideal synthesis of hydroquinones 582 would allow rapid construction of such molecules and 
analogues. With further optimization, the use of dithianes presented (Chapter 5) may be a viable 
option, but other masked acyl anion equivalents could also be explored. The use of an unmasked acyl 
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anion equivalent could allow very quick construction of the desired substrates from aldehyde 518 
(Scheme 199). Acyl zirconium species 580 would undergo1,2-addition to dioxinone aldehyde 518 
leading directly to 1,2-acyloin 581.
227
 Under the thermal conditions developed, ketene trapping with 
an alcohol and aromatization would give 1,4-hydroquinones 582.  
 
Scheme 199. Proposed synthesis of 1,4-hydroquinones. 
Furthermore, regioisomeric 1,2-hydroquinones 587 could be constructed from the corresponding 1,4-
acyloin 586 (Scheme 200). A cationic zirconium species 583 can be carbonylated to the η2-acyl 
complex 584 and insertion of an alkyne is known to afford the β-ketoalkenyl complex 585.228 An 
addition of this zirconium species to the dioxinone aldehyde 346 would then give the 1,4-acyloin 586 
and aromatization would provide the 1,2-hydroquinone 587.   
 
Scheme 200. Proposed synthesis of 1,2-hydroquinones. 
1.23.4 Synthesis of Bisdioxinone 539. 
While efforts to produce the bisdioxinone compound 539 were thwarted (Chapter 6) due to the 
instability of the acid chloride 551, an alternative retro synthesis is proposed (Scheme 201). Krische et 
al. have developed methodology employing 1,3-glycols as dialdehyde equivalents for iridium 
catalyzed transfer hydrogenative double allylation reactions.
229
 Employing this method with the 
dioxinone acetate 355 may allow a double allylation reaction to give the bisdioxinone 589, an 
oxidation step away from target biosdioxinone 539. 
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Scheme 201. Proposed synthesis of bisdioxinone 539. 
This method would avoid the formation of unstable dioxinone acid chloride 551 or, the use of highly 
basic conditions. Using this type of catalytic reaction is also known for allylation reactions with 1-
(trifluoromethyl), 1-(trimethylsilyl), and 1-methyl-allyl acetate and so may be possible with the more 
functionalized dioxinone acetate 355.
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1.24 Closing Remarks 
Ultimately, dioxinone derivatives can be used to access a wide range of aromatic molecules. The 
optimization of substrate synthesis and aromatization reactions presented has made these discoveries 
possible and presents great opportunities for progress in novel routes to aromatic compounds. 
Building on inspiration from nature and de novo synthesis, further developments will allow the facile 
synthesis of a wider array of aromatic molecules.
 
Experimental 
1.25 General Methods 
 All reactions were carried out in oven-dried glassware under N2, using commercially 
supplied solvents and reagents unless otherwise stated. n-BuLi was obtained as a 2.5 M 
solution in hexanes and Et2Zn was obtained as a 1.0 M solution in ether from commercial 
suppliers. CH2Cl2 and MeOH were redistilled from CaH2 and THF was redistilled from Na–
benzophenone ketyl. PhMe was redistilled from sodium. Flash chromatography was carried 
out on silica gel (eluents are given in parentheses). Analytical TLC was performed on pre-
coated silica gel F254 aluminum plates with visualization under UV light and by staining with 
acidic vanillin or acidic potassium permanganate solutions. Melting points were determined 
using a hot-stage microscope. IR spectra are recorded as cm
−1
. 
1
H and 
13
C NMR spectra were 
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recorded at 400 and 101 MHz respectively, with the solvent used in each case specified and 
spectra referenced to residual solvent peaks. Where mixtures of regioisomers (rr = 
regioisomer ratio) or diastereoisomers (dr = diastereoisomer ratio) have been characterized 
together, integrals are normalized to the major isomer. Low and high resolution mass spectra 
were recorded by Imperial College London mass spectrometry service. Microanalysis data 
was determined by the London Metropolitan University analytical service. 
1.25.1 General Procedure for preparation of LDA and LiHMDS  
n-BuLi in hexanes (2.5 M, 1.0 equiv) was added dropwise with stirring to (i-Pr)2NH (1.0 
equiv) or (SiMe3)NH (1.0 equiv) in THF at 0 °C and stirred for 15 min. 
1.25.2 General Procedure A For Synthesis of Homoallylic 
Alcohols 430a–k 
The corresponding aldehyde (3.5 mmol) was added dropwise to allylmagnesium bromide 
(1M in diethyl ether, 5 mL) at 0 °C and stirred at 25 °C until complete as indicated by T.L.C 
analysis. The mixture was quenched with addition of saturated aqueous NH4Cl, diluted with 
water and then extracted with ether (× 3). The combined organics were dried (MgSO4), rotary 
evaporated and either chromatographed or distilled (Kughelrohr) to give the homoallylic 
alcohols 430a–k.  
1.25.3 General procedure B for cross metathesis of homoallylic 
alcohols 430a–k 
Catalyst 427a (5–10 mol%) was added with stirring to vinyl dioxinone 372a (1.5–2 equiv) 
and homoallylic alcohol (430a–k, 0.1 M) in CH2Cl2 at reflux and heating was continued for 
14–18 h. The mixture was rotary evaporated and chromatographed to give the corresponding 
dioxinone (431a–j). 
1.25.4 General procedure C for oxidation of dioxinones 431a–j 
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DMP (1.4 equiv) was added with stirring to dioxinone (431a–j, 0.1 M) in CH2Cl2 at 0 °C and 
stirring continued at this temperature for 0.75–3.5 h. The mixture was chromatographed 
eluting with Et2O, and the fractions containing product were rotary evaporated. 
Chromatography of the residue gave the enone–dioxinone (335a–j). 
1.25.5 General procedure D for aromatization of enone–
dioxinones 335a–j 
Molecular sieves (100 mg per 0.1 mmol 335a–335j), DABCO (10 equiv), iso-PrOH (40 
equiv), and enone-dioxinone (335a–j) in EtOAc (0.02 M) were placed in a 10 mL microwave 
vial and microwave heated at 120 °C for 2 h. The resulting mixture was filtered and rotary 
evaporated. The residue was taken up in EtOAc (10 mL) and washed with 1 M aqueous HCl. 
The aqueous layer was extracted further with EtOAc (2 × 10 mL), and the combined organic 
layers were dried (MgSO4), rotary evaporated, and chromatographed to give the 
salicylates 131b–131j. 
1.25.6 General Procedure E for deconjugative alkylation of tert-
butyl crotonate or deconjugative protonation  
HMPA (1.32 equiv) was added dropwise to LDA (1 equiv) in THF (8 mL) at −78 °C. After 
30 min, the ester (1.0 equiv) in THF (5 mL) was added dropwise. After a further 10 min, the 
electrophile (1.0 equiv) was added dropwise. After a further 15 min, AcOH (1.3 equiv) in 
THF (5 mL) was added dropwise. Water (40 mL) was added was added and the mixture 
extracted with Et2O (2 × 50 mL). The combined organic extracts were washed with brine, 
dried (MgSO4), rotary evaporated and purified by either chromatography or Kughelrohr 
distillation to give the the corresponding homoallylic esters. 
1.25.7 General Procedure F for the Cross Metathesis of Alkenes 
462a–f with Alkenes 372a–b 
Catalyst 427a (5–10 mol%) was added with stirring to vinyl dioxinone 372a (1.5–3 equiv) 
and homoallylic ester (462a–f, 0.15 M) in CH2Cl2 at reflux or C6F5CF3 at 70 °C and heating 
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was continued for 2–2.5 h. The mixture was rotary evaporated and chromatographed to give 
the corresponding dioxinone (337a, e–g). 
1.25.8 General Procedure G for Deprotection of t-Butyl Esters 
CF3CO2H (10 equiv) was added with stirring to ester (0.4 M) in CH2Cl2 at 25 °C. After 0.5–
16 h, the resulting mixture was rotary evaporated and the residue dissolved in diethyl ether 
(10 mL) and extracted with saturated aqueous NaHCO3 (5 × 5 mL). The aqueous layer was 
acidified to pH 1 using 3 M aqueous HCl and the mixture extracted with EtOAc (3 × 20 mL). 
The combined EtOAc layers were washed with brine, dried (MgSO4), and rotary evaporated 
to give the carboxylic acid.  
1.25.9 General Procedure H for the Aldol Addition Reaction to 
Ketones 284a–c 
The ester or amide (1.0 equiv) in THF (5 mL) was added dropwise to LDA (1.2 equiv) in 
THF (10 mL) at −78 °C. After a further 1 h, dioxinone ketone (284a–c, 1.0 equiv) in THF (5 
mL) was added dropwise. After a further 15 min, AcOH (1.3 equiv) in THF (5 mL) was 
added dropwise. Water (20 mL) was added and the mixture extracted with EtOAc (3 × 40mL). 
The combined organic extracts were washed with brine, dried (MgSO4), rotary evaporated, 
and chromatographed to give the corresponding products. 
1.25.10 General Procedure I for the Dehydration of β-Hydroxy-
Esters 476a–e and β-Hydroxy-Amide 499 
Et3N
+
SO2N
−
CO2Me (Burgess reagent) (1.5 equiv) was added with stirring to β-hydroxy-ester 
(476a–476e, 499 0.2 M) in MeCN at 70 °C and heating continued for 2–4 h. The residue was 
rotary evaporated and chromatographed to give the corresponding esters 10h–10l and amide 
498. 
1.25.11 General Procedure J for the Aldol Reaction of Esters 
480a–c with Ketones 284a–c Followed by Hydrogenolysis 
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The ester 480a–c (1.0 equiv) in THF (5 mL) was added dropwise to LDA (1.2 equiv) in THF 
(10 mL) at −78 °C. After a further 1 h, dioxinone ketone 284a–c (1.0 equiv) in THF (5 mL) 
was added dropwise. After a further 15 min, AcOH (1.3 equiv) in THF (5 mL) was added 
dropwise. Water (20 mL) was added and the mixture was extracted with EtOAc (3 × 40 mL) 
and the combined organic extracts were washed with brine, dried (MgSO4), the solvent 
evaporated under vacuum and the residue dissolved in THF (20 mL). N2 was bubbled through 
the mixture for 5 min, when Pd/C (10 % by wt.) was added and H2 was bubbled through the 
mixture for 5 min, which was stirred under an H2 atmosphere for 30 min. The mixture was 
filtered through celite, rotary evaporated and the residue worked up as in general procedure G 
to give carboxylic acids 479a–e. 
1.25.12 General Procedure K for the Aromatization of Carboxylic 
Acids 458 or 479 
CCl4 (1.2 equiv for 458, 2.5 equiv for 479) was added with stirring to Ph3P (1.5 equiv for 458, 
3.0 equiv for 479) and carboxylic acid 458 or 479 (0.5 M) in CH2Cl2 and the mixture heated 
at reflux for 3 h. The mixture was rotary evaporated and chromatographed to give the 
corresponding γ-resorcylates 457a–i or β-lactones 483a and 483b. 
1.25.13 General Procedure L for α-Oxidation of Dioxinones 430 
DMP (5.5 equiv) and 2,4,6-collidine (2.3 equiv) were stirred in CH2Cl2 (0.1 M) to give a 
clear solution. Water (3.6 mmol) in CH2Cl2 (0.03 M) was added to the DMP solution 
dropwise with stirring over 1 h. The homoallylic alcohol (0.4 M) in CH2Cl2 was added 
dropwise. After 1 h the mixture was rotary evaporated and then redissolved in Et2O. The 
mixture was washed with 10% Na2S2O3/saturated aqueous NaHCO3 (1:1, × 2), water and 
brine. The combined aqueous washings were reextracted with further Et2O that was then 
washed with water and brine. The combined organic extracts were dried (Na2SO4) rotary 
evaporated and chromatographed to give the diones 433a and 433b. 
1.25.13.1 Methoxy-2,2,8,8-tetramethyl-6-methylene-3,7-dioxa-2,8-disilanon-4-ene (124)231  
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Methyl 3-(trimethylsilyloxy)but-2-enoate (1.10 g, 5.9 mmol) was added dropwise to LDA (7.1 mmol) 
at −78 °C in THF (25 mL) and stirred for 2 min. Trimethylsilyl chloride (1.20 mL, 9.5 mmol) was 
added to the mixture and stirred for 10 min then rotary evaporated. 
n
Hexane was added, the solids 
removed by filtration and the mother liquors were rotary evaporated to give the title compound (917 
mg, 60 %) as a pale yellow oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 4.48 (s, 1 H), 4.15 (d, J = 1.0 Hz, 
1 H), 3.95 (d, J = 1.5 Hz, 1 H), 3.56 (s, 3 H), 0.25 (s, 9 H), 0.22 (s, 9 H). 
13
C NMR (101 MHz, CDCl3, 
ppm) δ:  158.6, 153.4, 89.2, 77.5, 55.0, 0.5, 0.2. In agreement with the literature. 
1.25.13.2 Isopropyl 3-hydroxybiphenyl-2-carboxylate (131b) 
 
According to general procedure D, aromatization of enone–dioxinone 335a (50 mg, 
0.184 mmol) and chromatography (hexanes/Et2O, 100:0 to 19:1) gave 
salicylate 131b (26 mg, 55%) as a colorless solid; mp 53–55 °C (Et2O/pentane). IR (cm
−1): 
1650, 1606, 1597, 1441, 1370, 1278, 1225, 1178, 1097, 922, 897, 814. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 10.96 (s, 1 H), 7.48–7.30 (m, 4 H), 7.30–7.12 (m, 2 H), 7.01 (dd, J = 8.3, 
1.0 Hz, 1 H), 6.78 (dd, J = 7.3, 1.0 Hz, 1 H), 5.05–4.85 (m, 1 H), 0.86 (d, J = 6.4 Hz, 6 
H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 170.4, 161.5, 145.0, 143.2, 133.3, 128.3, 127.6, 
126.6, 122.4, 116.6, 112.6, 69.1, 20.9. HR-MS (EI) m/z calcd for C16H17O3: 257.1178 [M + 
H]
+
; found: 257.1168. Anal. calcd for C16H16O3: C 74.98, H 6.29; found: C 74.90, H 6.37. 
1.25.13.3 Isopropyl 4′-bromo-3-hydroxybiphenyl-2-carboxylate (131c) 
 
According to general procedure D, aromatization of enone–dioxinone 335b (100 mg, 
0.29 mmol) and chromatography (hexanes/Et2O, 100:0 to 9:1) gave salicylate 131c (43 mg, 
45%) as a colorless solid; mp 79–83 °C (Et2O/pentane). IR (cm
−1): 1663, 1600, 1575, 1492, 
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1444, 1363, 1314, 1273, 1209, 1173, 1100, 1066, 918, 807. 
1
H NMR (400 MHz, CDCl3, 
ppm) δ: 11.04 (s, 1 H), 7.54–7.46 (m, 2 H), 7.40 (t, J = 8.1 Hz, 1 H), 7.14–7.06 (m, 2 H), 7.02 
(dd, J = 8.3, 1.0 Hz, 1 H), 6.73 (dd, J = 7.3, 1.0 Hz, 1 H), 4.98 (spt, J = 6.2 Hz, 1 H), 0.91 
(d, J = 6.4 Hz, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 170.1, 161.8, 143.6, 142.2, 133.5, 
130.6, 130.0, 122.2, 120.7, 117.1, 112.2, 69.5, 21.0. MS (CI) m/z: 354 [M(
81
Br) + NH4]
+
, 352 
[M(
79
Br) + NH4]
+
, 337 [M(
81
Br) + H]
+
, 335 [M(
79
Br) + H]
+
. HR-MS (CI) m/z calcd for 
C16H16BrO3: 335.0283 [M + H]
+
; found: 335.0274. Anal. calcd for C16H15BrO3: C 57.33, H 
4.51; found: C 57.25, H 4.56. 
1.25.13.4 Isopropyl 4′-chloro-3-hydroxybiphenyl-2-carboxylate (131d) 
 
According to general procedure D, aromatization of enonedioxinone 335c (69 mg, 
0.23 mmol) and chromatography (hexanes/Et2O, 100:0 to 97:3) gave salicylate 131d (32 mg, 
49%) as a colorless solid; mp 73–76 °C (CHCl3). IR (cm
−1): 1665, 1601, 1576, 1492, 1444, 
1363, 1314, 1272, 1172, 1101, 807. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 11.04 (s, 1 H), 7.40 
(t, J = 7.8 Hz, 1 H), 7.37–7.30 (m, 2 H), 7.20–7.12 (m, 2 H), 7.02 (dd, J = 8.6, 1.2 Hz, 1 H), 
6.73 (dd, J = 7.6, 1.2 Hz, 1 H), 4.98 (spt, J = 6.3 Hz, 1 H), 0.91 (d, J = 6.4 Hz, 6 H). 
13
C 
NMR (101 MHz, CDCl3, ppm) δ: 170.1, 161.8, 143.6, 141.7, 133.5, 132.7, 129.6, 127.7, 
122.3, 117.1, 112.3, 69.4, 21.0. MS (CI) m/z: 310 [M(
37
Cl) + H2O]
+
, 308 [M(
35
Cl) + H2O]
+
, 
293 [M(
37
Cl) + H]
+
, 291 [M(
35
Cl) + H]
+
. HR-MS (CI) m/z calcd for C16H16ClO3: 291.0788 
[M + H]
+
; found: 291.0786. Anal. calcd for C16H15ClO3: C 66.10, H 5.20; found: C 65.98, H 
5.24. 
1.25.13.5 Isopropyl 4′-fluoro-3-hydroxybiphenyl-2-carboxylate (131e) 
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According to general procedure D, aromatization of enone–dioxinone 335d (35 mg, 
0.21 mmol) and chromatography (hexanes/Et2O, 19:1) gave salicylate 131e (17 mg, 51%) as 
a colorless solid; mp 85–87 °C (Et2O/pentane). IR (cm
−1): 1650, 1606, 1513, 1445, 1367, 
1280, 1227, 1213, 1177, 1093, 842, 815. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 11.01 (s, 1 H), 
7.40 (t, J = 7.8 Hz, 1 H), 7.22–7.16 (m, 2 H), 7.10–7.03 (m, 2 H), 7.01 (dd, J = 8.3, 1.5 Hz, 1 
H), 6.74 (dd, J = 7.6, 1.2 Hz, 1 H), 4.98 (spt, J = 6.3 Hz, 1 H), 0.91 (d, J = 6.4 Hz, 6 H). 
13
C 
NMR (101 MHz, CDCl3, ppm) δ: 170.3, 161.7, 143.8, 139.2 133.4, 129.8, 122.5, 116.9, 
114.5, 114.3, 112.5, 69.3, 21.0. MS (CI) m/z: 275 [M + H]
+
. HR-MS (CI) m/z calcd for 
C16H16FO3: 275.1083 [M + H]
+
; found: 275.1081. Anal. calcd for C16H15FO3: C 70.06, H 
5.51; found: C 70.00, H 5.60. 
1.25.13.6 Isopropyl 3-hydroxy-4′-methoxybiphenyl-2-carboxylate (131f) 
 
According to general procedure D, aromatization of enone–dioxinone 335e (37 mg, 
0.12 mmol) and chromatography (hexanes/Et2O, 100:0 to 19:1) gave salicylate 131f (17 mg, 
48%) as a yellow solid; mp 42–45 °C (Et2O). IR (cm
−1): 1655, 1602, 1515, 1446, 1369, 1271, 
1243, 1218, 1175, 1094, 1034, 807. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 10.86 (s, 1 H), 7.38 
(t, J = 7.8 Hz, 1 H), 7.18–7.11 (m, 2 H), 6.98 (dd, J = 8.3, 1.0 Hz, 1 H), 6.94–6.87 (m, 2 H), 
6.77 (dd, J = 7.3, 1.0 Hz, 1 H), 4.97 (spt, J = 6.3 Hz, 1 H), 3.86 (s, 3 H), 0.91 (d, J = 6.4 Hz, 6 
H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 170.5, 161.4, 158.7, 144.6, 135.7, 133.3, 129.4, 
122.6, 116.3, 113.0, 112.8, 69.1, 55.4, 21.1. MS (CI) m/z: 304 [M + H2O]
+
, 287 [M + H]
+
. 
HR-MS (CI) m/z calcd for C17H19O4: 287.1283 [M + H]
+
; found: 287.1275. Anal. calcd for 
C17H18O4: C 71.31, H 6.34; found: C 68.02, H 6.55. 
1.25.13.7 Isopropyl 2-(furan-2-yl)-6-hydroxybenzoate (131g) 
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According to general procedure D, aromatization of enone–dioxinone 335f (30 mg, 
0.12 mmol) and chromatography (hexanes/Et2O, 100:0 to 19:1) gave salicylate 131g (13 mg, 
46%) as a colorless oil. IR (cm−1): 1664, 1606, 1572, 1453, 1374, 1275, 1222, 1178, 1103. 
1
H 
NMR (400 MHz, CDCl3, ppm) δ: 10.67 (s, 1H), 7.47 (d, J = 1.0 Hz, 1 H), 7.40 (t, J = 7.8 Hz, 
1 H), 7.03 (dd, J = 8.3, 1.0 Hz, 1 H), 6.95 (dd, J = 7.3, 1.0 Hz, 1 H), 6.47 (dd, J = 3.4, 2.0 Hz, 
1 H), 6.40 (d, J = 2.9 Hz, 1 H), 5.13 (spt, J = 6.3 Hz, 1 H), 1.12 (d, J = 6.4 Hz, 6 H). 
13
C 
NMR (101 MHz, CDCl3, ppm) δ: 170.0, 161.2, 154.2, 141.7, 133.5, 132.8, 122.3, 118.0, 
112.7, 111.1, 107.1, 69.3, 21.5. MS (CI) m/z: 247 [M + H]
+
. HR-MS (CI) m/z calcd for 
C14H15O4: 247.0970 [M + H]
+
; found: 247.0972. 
1.25.13.8 Isopropyl 2-hydroxy-6-methylbenzoate (131h) 
 
According to general procedure D, aromatization of enone–dioxinone 335g (73 mg, 
0.348 mmol) and chromatography (pentane/Et2O, 100:0 to 98:2) gave salicylate 131h (45 mg, 
67%) as a colorless oil. IR (cm−1): 1727, 1650, 1606, 1580, 1459, 1439, 1365, 1291, 1251, 
1212, 1165, 1100, 1078, 1034, 965, 911, 863, 806, 756, 702. 
1
H NMR (400 MHz, CDCl3, 
ppm) δ: 11.43 (s, 1 H), 7.27 (t, J = 7.8 Hz, 1 H), 6.84 (d, J = 8.3 Hz, 1 H), 6.71 (d, J = 7.3 Hz, 
1 H), 5.34 (spt, J = 6.2 Hz, 1 H), 2.56 (s, 3 H), 1.43 (d, J = 6.4 Hz, 6 H). 
13
C NMR 
(101 MHz, CDCl3, ppm) δ: 171.2, 162.8, 141.3, 133.9, 122.9, 115.6, 112.7, 69.7, 24.2, 22.0. 
MS (ES) m/z: 212 [M + H2O]
+
, 195 [M + H]
+
. Anal. calcd for C11H14O3: C 68.02, H 7.27; 
found: C 67.87, H 7.21. 
1.25.13.9 Isopropyl 2-hydroxy-6-ethylbenzoate (131i) 
 
According to general procedure D, aromatization of enone-dioxinone 335h (76 mg, 
0.339 mmol) and chromatography (pentane/Et2O, 100:0 to 19:1) gave salicylate 131i (41 mg, 
58%) as a colorless oil. IR (cm−1): 1727, 1654, 1606, 1577, 1447, 1363, 1308, 1295, 1245, 
1207, 1167, 1102, 931, 908, 816. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 11.33 (s, 1 H), 7.30 
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(t, J = 8.1 Hz, 1 H), 6.85 (dd, J = 8.3, 1.5 Hz, 1 H), 6.74 (d, J = 7.3 Hz, 1 H), 5.36 (spt, J = 
6.3 Hz, 1 H), 2.96 (q, J = 7.3 Hz, 2 H), 1.43 (d, J = 6.4 Hz, 6 H), 1.23 (t, J = 7.3 Hz, 3 H). 
13
C 
NMR (101 MHz, CDCl3, ppm) δ: 171.0, 162.6, 147.4, 134.1, 121.7, 115.6, 112.2, 69.7, 29.6, 
21.8, 16.5. MS (ES) m/z: 231 [M + Na]
+
, 209 [M + H]
+
. Anal. calcd for C12H16O3: C 69.21, H 
7.74; found: C 69.18, H 7.64. 
1.25.13.10 Isopropyl 2-hydroxy-6-isobutylbenzoate (131j) 
 
According to general procedure D, aromatization of enone–dioxinone 335i (78 mg, 
0.310 mmol) and chromatography (pentane/Et2O, 100:0 to 19:1) gave salicylate 131j (31 mg, 
45%) as a colorless oil. IR (cm−1): 1651, 1606, 1577, 1478, 1363, 1308, 1294, 1250, 1229, 
1202, 1164, 1097, 1062, 911, 833, 803, 763, 709. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 11.35 
(s, 1 H), 7.28 (t, J = 7.8 Hz, 1 H), 6.86 (dd, J = 8.3, 1.5 Hz, 1 H), 6.66 (dd, J = 7.6, 1.2 Hz, 1 
H), 5.37 (spt, J = 6.3 Hz, 1 H), 2.82 (d, J = 7.3 Hz, 2 H), 1.76–1.91 (m, 1 H), 1.43 (d, J = 
6.4 Hz, 6 H), 0.89 (d, J = 6.4 Hz, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 171.2, 162.8, 
144.5, 133.5, 123.7, 115.8, 112.5, 69.6, 45.5, 30.0, 22.5, 21.8. MS (ES) m/z: 259 [M + Na]
+
, 
237 [M + H]
+
. Anal. calcd for C14H20O3: C 71.16, H 8.53; found: C 71.08, H 8.45. 
1.25.13.11 Allyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-oxobutanoate232 (237a) 
 
DMF (catalytic) was added to 3-(allyloxy)-3-oxopropanoic acid (2g, 13.89 mmol) and oxalyl chloride 
(1.33 mL, 15.28 mmol) in THF (28 mL) at 0 °C and the stirred at 25 °C for 15 min.  
2,2,6-Trimethyl-4H-1,3-dioxin-4-one (5.92 g, 41.67 mmol) was added dropwise to LiHMDS (41.67 
mmol) at −78 °C in THF (125 mL) and stirred for 30 min. The acid chloride from above was then 
added and stirred for 30 min then warmed to 25 °C over 1 h. The mixture was acidified to pH 1 with 
1M aq. HCl and the layers separated. The aqueous was reextracted with ether (2 × 50 mL) and the 
combined organics were washed with brine (100 mL), dried (MgSO4), filtered, rotary evaporated and 
chromatographed (petroleum ether/Et2O, 4:1 to 5:3) to give the title compound (1.17 g, 32%) as a 
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yellow oil. IR (cm
−1
): 1720, 1637, 1391, 1376, 1272, 1252, 1201, 1152, 1015, 990, 932, 902, 806.
 1
H 
NMR (400 MHz, CDCl3, ppm) δ: keto: 5.75–6.03 (m, 1 H), 5.20–5.41 (m, 3 H), 4.53–4.76 (m, 2 H), 
3.55 (s, 2 H), 3.50 (s, 2 H), 1.70 (s, 6 H); enol: 12.01 (s, 1H), 5.75–6.03 (m, 1 H), 5.41 (s, 1H), 5.20–
5.41 (m, 2 H),  5.15 (s, 1H), 4.67–4.68 (m, 2 H), 3.13 (s, 2H), 1.70 (s, 6H). 13C NMR (101 MHz, 
CDCl3, ppm) δ: keto: 195.5, 166.0, 163.4, 160.4, 131.1, 119.3, 107.3, 97.1, 66.2, 48.9, 46.9, 24.9; 
enol: 171.6, 170.6, 165.4, 131.6, 118.6, 107.0, 95.8, 91.8, 65.0, 39.3, 24.8. MS (CI) m/z: 286 
[M+NH4]
+
, 269 [M+H]
+
. HR-MS (CI) m/z: calcd for C13H20NO6: 286.1291 [M+NH4]
+
; found: 
294.1306. In agreement with the literature. 
1.25.13.12 Benzyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-oxobutanoate (237g) 
 
DMF (10 µL) was added to a mixture of 3-(benzyloxy)-3-oxopropanoic acid (0.97 g, 5 mmol) and 
oxalyl chloride (0.85 mL, 10 mmol) in CH2Cl2 (25 mL) at 0 °C, stirred for 1.5 h at 20 °C and then 
rotary evaporated to give the corresponding acid chloride used without further purification. 
Dioxinone (2.13 g, 15 mmol) was added dropwise to LiN(SiMe3)2 (16 mmol) at −78 °C in THF and 
stirred for 30 min. The acid chloride from above was added dropwise over 40 min. After a further 20 
min the mixture was quenched with saturated aqueous NH4Cl and acidified to pH 1 with 1 M aqueous 
HCl. The layers were separated and the aqueous reextracted with ether (2 × 50 mL). The combined 
organics were washed with brine (100 mL), dried (MgSO4), rotary evaporated and chromatographed 
(pentane/Et2O, 4:1 to 2:3) to give the title compound (666 mg, 42%) as a yellow oil. IR (cm
−1
): 1718, 
1637, 1391, 1375, 1271, 1253, 1200, 1015, 902, 806, 742, 697. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 
7.34–7.40 (m, 5 H), 5.33 (s, 1 H), 5.20 (s, 2 H), 3.57 (s, 2 H), 3.47 (s, 2 H), 1.70 (s, 6 H). 13C NMR 
(101 MHz, CDCl3, ppm) δ: 195.4, 166.1, 163.4, 160.4, 134.9, 128.7, 128.6, 128.5, 107.3, 97.1, 67.5, 
49.0, 47.0, 24.9. MS (CI) m/z: 336 [M+NH4]
+
, 319 [M+H]
+
. HR-MS (CI) m/z calcd for C17H19O6: 
319.1182 [M+H]
+
; found: 319.1180. Anal. calcd for C17H18O6: C 61.14, H 5.70; found: C 61.13, H 
5.80. 
1.25.13.13 2,2-Dimethyl-6-(2-oxopropyl)-4H-1,3-dioxin-4-one (284a)233 
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Freshly distilled 2,2,6-trimethyl-4H-1,3-dioxin-4-one (50.0 g, 352 mmol) in THF (150 mL) was added 
to LiN(SiMe3)2 (500 mmol) in THF (300 mL) over 0.5 h at −18 to −24 °C with overhead stirring. 
After 0.75 h, diethylzinc (500 mmol) was added dropwise over 1 h maintaining an internal 
temperature of −25 to −22 °C, and after a further 0.75 h the temperature was raised to −10 °C over 0.3 
h. Acetyl imidazole (55.0 g, 499 mmol) was added portionwise over 0.25 h maintaining an internal 
temperature of −12 to −7 °C and stirred a further 2.5 h. Maintaining an internal temperature below 0 
°C, H2O/THF (150 mL, 1:9) was added dropwise followed by 2 M aqueous HCl (250 mL) and tert-
butylmethyl ether (500 mL) and the mixture acidified with 25% aqueous HCl (250 mL) to pH 3. The 
aqueous was extracted with EtOAc (× 3) and the combined organics were rotary evaporated then 
allowed to stand for 24 h. The precipitated solids were removed by filtration and washed 
(pentane/Et2O, 7:3) to give the title compound (30.0 g, 46%) as a pale yellow solid. The mother 
liquors were rotary evaporated and chromatographed (pentane/Et2O, 3:2 to 2:3) to give a further crop 
(9.0 g, 14%) as a pale yellow solid. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.33 (s, 1 H), 3.34 (s, 2 H), 
2.23 (s, 3 H), 1.70 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 201.0, 164.4, 160.7, 107.3, 96.8, 
48.1, 30.3, 25.1. In agreement with the literature. 
1.25.13.14 6-(2-(4-Methoxyphenyl)-2-oxoethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (284c)234 
 
CDI (9.73g, 60 mmol) was added to para-anisic acid (7.6 g, 50 mmol) in THF and the mixture stirred 
for 15 min and then washed with water to give  (1H-imidazol-1-yl)(4-methoxyphenyl)methanone 
(7.85 g; 78%) as a colourless solid used directly in the next step. 
2,2,6-Trimethyl-4H-1,3-dioxin-4-one xx (4 g, 28.17 mmol) was added dropwise to 
LiN(SiMe3)2 (39.44 mol) in THF (50 mL) at −78 °C for 1 h. Diethylzinc (39.44 mmol) was 
added dropwise and the mixture stirred at −30 °C for 0.5 h. The mixture was warmed to −10 °C 
and (1H-imidazol-1-yl)(4-methoxyphenyl)methanone (6.83 g, 33.80 mmol) in THF (5 mL) was added 
and stirred for 2 h. The mixture was acidified with 3 M aqueous HCl and then extracted with 
EtOAc (× 3), washed with brine, dried (MgSO4), rotary evaporated, and chromatographed 
(pentane/Et2O, 3:2 to 0:1) to give the title compound (6.22 g, 80%) as a pale yellow solid. IR 
(cm−1): 1722, 1679, 1634, 1596, 1571, 1508, 1466, 1418, 1404, 1390, 1376, 1332, 1314, 
1256, 1218, 1202, 1190, 1162, 1114, 1013, 987, 960, 934, 868, 834, 813, 790, 753, 663, 634, 
613. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.88–7.97 (m, 2H), 6.93–7.00 (m, 2H), 5.41 (s, 
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1H), 3.89 (s, 3H), 3.85 (s, 2H), 1.71 (s, 6H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 191.4, 165.5, 
164.1, 160.7, 130.6, 128.8, 114.0, 107.2, 96.7, 55.5, 43.0, 24.9.
 
MS (ES) m/z: 294 [M+H]
+
, 
277 [M+H]
+
. HR-MS (ES) m/z: calcd for C15H17O5: 277.1076 [M+H]
+
; found: 277.1082. In 
agreement with the literature. 
1.25.13.15 2,2-Dimethyl-6-(3-oxo-1-phenylbutan-2-yl)-4H-1,3-dioxin-4-one (±) (284d) and 5-
Benzyl-2,2-dimethyl-6-(2-oxopropyl)-4H-1,3-dioxin-4-one (284e)  
  
PhCH2Br (711 µL, 5.98 mmol) was added with stirring to dioxinone ketone 284a (1.00 g, 
5.43 mmol) and 
i
Pr2NH (845 µL, 5.98 mmol) in THF (5.5 mL). After 14 h, the mixture was 
acidified to pH 1 with 1 M aqueous HCl and extracted with EtOAc (2 × 20 mL). The 
combined organic extracts were washed with brine, dried (MgSO4), rotary evaporated and 
chromatographed (pentane/Et2O, 4:1 to 3:2) to give dioxinone ketone 284d (663 mg, 45%) as 
a pale yellow oil and 284e (199 mg, 13 %) as a colourless solid. 
 
2,2-Dimethyl-6-(3-oxo-1-phenylbutan-2-yl)-4H-1,3-dioxin-4-one (±) (284d): IR (cm
−1
): 1718, 
1627, 1497, 1455, 1390, 1375, 1358, 1271, 1253, 1200, 1151, 1079, 1009, 968, 901, 854, 810, 
747, 699, 612. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.12–7.34 (m, 5 H), 5.32 (s, 1 H), 3.57–
3.64 (m, 1 H), 3.23 (dd, J = 14.2, 6.8 Hz, 1 H), 2.95 (dd, J = 14.2, 8.3 Hz, 1 H), 2.19 (s, 3 H), 
1.61 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 202.5, 166.8, 160.4, 137.4, 128.7, 127.0, 
107.0, 96.0, 59.0, 33.8, 29.5, 25.0, 24.8. MS (ES) m/z: 292 [M + NH4]
+
, 275 [M + H]
+
. HR-
MS (ES) m/z calcd for C16H19O4: 275.1283 [M + H]
+
; found: 275.1291. Anal. calcd for 
C16H18O4: C 70.06, H 6.61; found: C 70.16, H 6.73. 
5-Benzyl-2,2-dimethyl-6-(2-oxopropyl)-4H-1,3-dioxin-4-one (284e): IR (cm
−1) ν = 1713, 
1686, 1620, 1585, 1515, 1497, 1455, 1430, 1391, 1375, 1256, 1201, 1161, 1101, 1045, 1023, 
979, 934, 906, 889, 860, 830, 817, 753, 723, 701, 677, 637, 616. 
1
H NMR (400 MHz, CDCl3, 
ppm) δ: 7.11–7.31 (m, 5H), 3.62 (s, 2H), 3.42 (s, 2H), 2.11 (s, 3H), 1.71 (s, 6H). 13C NMR 
(101 MHz, CDCl3, ppm) δ: 201.1, 162.0, 160.5, 139.1, 135.2, 128.5, 128.0, 107.4, 95.6, 45.6, 
30.5, 30.1, 25.1.
 
MS (ES) m/z: 292 [M+NH4]
+
, 275 [M+H]
+
. HR-MS (ES) m/z: calcd for 
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C16H19O4: 275.1283 [M+H]
+
; found: 275.1292. Anal. calcd for C16H18O4: C 70.06. H 6.61; 
found: C 70.15, H 6.73. 
1.25.13.16  (E)-2,2-Dimethyl-6-(4-oxo-4-phenylbut-1-enyl)-4H-1,3-dioxin-4-one (335a) 
 
According to general procedure C, oxidation of dioxinone 431a (329 mg, 1.21 mmol) for 
3.5 h and chromatography (hexanes/Et2O, 7:3 to 1:1) gave enone–dioxinone 335a (255 mg, 
77%) as a yellow solid; mp 58–61 °C (Et2O–pentane). IR (cm
−1): 1714, 1687, 1655, 1597, 
1392, 1369, 1278, 1204, 1019, 991, 905, 816. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 8.04–7.91 
(m, 2 H), 7.74–7.56 (m, 1 H), 7.56–7.36 (m, 2 H), 6.85 (dt, J = 15.7, 7.1 Hz, 1 H), 6.08 
(d, J = 15.6 Hz, 1 H), 5.31 (s, 1 H), 3.93 (dd, J = 7.1, 1.2 Hz, 2 H), 1.73 (s, 6H). 
13
C NMR 
(101 MHz, CDCl3, ppm) δ: 196.3, 162.4, 161.6, 136.2, 133.7, 133.7, 128.8, 128.2, 125.7, 
106.6, 94.6, 41.7, 25.0. MS (ES) m/z: 273 [M + H]
+
. HR-MS (EI) m/z calcd for C16H17O4: 
273.1127 [M + H]
+
; found: 273.1121. Anal. calcd for C16H16O4: C 70.58, H 5.92; found: C 
70.53, H 5.85. 
1.25.13.17  (E)-6-(4-(4-Bromophenyl)-4-oxobut-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 
(335b) 
 
According to general procedure C, oxidation of dioxinone 431b (23 mg, 0.065 mmol) for 2 h 
and chromatography (hexanes–Et2O, 1:1) gave enone–dioxinone 335b (19 mg, 83%) as a 
yellow solid; mp 68–72 °C (Et2O/pentane). IR (cm
−1): 1713, 1693, 1659, 1586, 1391, 1374, 
1273, 1199, 1011, 991, 970, 800. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.85–7.80 (m, 2 H), 
7.67–7.62 (m, 2 H), 6.81 (dt, J = 15.5, 6.9 Hz, 1 H), 6.07 (d, J = 15.6 Hz, 1 H), 5.30 (s, 1 H), 
3.89 (dd, J = 7.1, 1.2 Hz, 2 H), 1.72 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 187.9, 
160.9, 141.9, 134.9, 133.5, 132.2, 132.0, 130.2, 129.1, 128.1, 128.0, 107.2, 100.8, 25.1. MS 
(CI) m/z: 370 [M(
81
Br) + NH4]
+
, 368 [M (
79
Br) + NH4]
+
. Anal. calcd for C16H15BrO4: C 
54.72, H 4.31; found: C 54.63, H 4.21. 
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1.25.13.18  (E)-6-(4-(4-Chlorophenyl)-4-oxobut-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 
(335c) 
 
According to general procedure C, oxidation of dioxinone 431c (82 mg, 0.266 mmol) for 2 h 
and chromatography (hexanes/Et2O, 7:3 to 1:1) gave enone–dioxinone 335c (63 mg, 77%) as 
an orange oil. IR (cm−1): 1711, 1689, 1587, 1376, 1391, 1270, 1200, 1089, 1022, 985, 839, 
784. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.93–7.88 (m, 2 H), 7.50–7.45 (m, 2 H), 6.81 
(dt, J = 15.7, 7.1 Hz, 1 H), 6.07 (dt, J = 15.7, 1.5 Hz, 1 H), 5.31 (s, 1 H), 3.90 (dd, J = 6.8, 
1.5 Hz, 2 H), 1.72 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 195.0, 162.3, 161.7, 140.2, 
134.4, 133.2, 129.6, 129.2, 125.9, 106.6, 94.7, 41.6, 25.0. MS (ES) m/z: 309 [M(
37
Cl) + H]
+
, 
307 [M(
35
Cl) + H]
+
. HR-MS (ES) m/z calcd for C16H16ClO4: 307.0737 [M + H]
+
; found: 
307.0732. Anal. calcd for C16H15ClO4: C 62.65, H 4.93; found: C 62.77, H 4.84. 
1.25.13.19  (E)-6-(4-(4-Fluorophenyl)-4-oxobut-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 
(335d) 
 
According to general procedure C, oxidation of dioxinone 431d (226 mg, 0.774 mmol) for 
3 h and chromatography (hexanes/Et2O, 7:3 to 1:1) gave enone–dioxinone 335d (143 mg, 
67%) as an orange oil. IR (cm−1): 1710, 1692, 1597, 1379, 1275, 1200, 1158, 1021, 846, 
793. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 8.02–7.97 (m, 2 H), 7.20–7.14 (m, 2 H), 6.82 
(dt, J = 15.5, 6.9 Hz, 1 H), 6.07 (d, J = 16.1 Hz, 1 H), 5.30 (s, 1 H), 3.90 (dd, J = 1.2, 7.1 Hz, 
2 H), 1.72 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 194.7, 167.3, 163.5 (d, J = 
239.3 Hz), 161.7, 133.4, 132.5, 130.9 (d, J = 9.6 Hz), 125.8, 116.0 (d, J = 20.9 Hz), 106.6, 
94.6, 41.6, 25.0. HR-MS (CI) m/z calcd for C16H19NO4F: 308.1298 [M + NH4]
+
; found: 
308.1301. Anal. calcd for C16H15FO4: C 66.20, H 5.21; found: C 66.15, H 5.14. 
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1.25.13.20  (E)-6-(4-(4-Methoxyphenyl)-4-oxobut-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 
(335e) 
 
According to general procedure C, oxidation of dioxinone 431e (150 mg, 0.493 mmol) for 
0.75 h and chromatography (hexanes–Et2O, 7:3 to 3.5:10) gave enone–
dioxinone 335e (98 mg, 66%) as a yellow solid; mp 89–92 °C (Et2O/pentane). IR (cm
−1): 
1710, 1674, 1655, 1573, 1374, 1255, 1204, 1182, 1020, 984, 967, 844, 790, 597. 
1
H NMR 
(400 MHz, CDCl3, ppm) δ: 7.97–7.92 (m, 2 H), 6.99–6.94 (m, 2 H), 6.84 (dt, J = 15.4, 
7.0 Hz, 1 H), 6.06 (d, J = 15.7 Hz, 1 H), 5.30 (s, 1 H), 3.89 (s, 3 H), 3.87 (dd, J = 7.3, 1.5 Hz, 
2 H), 1.72 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 194.8, 163.9, 162.5, 161.8, 134.3, 
130.6, 129.2, 125.5, 114.0, 106.5, 94.4, 55.5, 41.5, 25.0. MS (ES) m/z: 303 [M + H]
+
. HR-MS 
(ES) m/zcalcd for C17H19O5: 303.1232 [M + H]
+
; found: 303.1226. Anal. calcd for C17H18O5: 
C 67.54, H 6.00; found: C 67.43, H 6.05. 
1.25.13.21  (E)-6-(4-(Furan-2-yl)-4-oxobut-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (335f) 
 
According to general procedure C, oxidation of dioxinone 431f (94 mg, 0.356 mmol) for 2 h 
and chromatography (hexanes/Et2O, 7:3 to 1:1) gave enone–dioxinone 335f (35 mg, 38%) as 
a yellow oil. IR (cm−1): 1721, 1675, 1655, 1466, 1392, 1376, 1275, 1204, 1019. 
1
H NMR 
(400 MHz, CDCl3, ppm) δ: 7.63 (d, J = 1.0 Hz, 1 H), 7.28–7.25 (m, 1 H), 6.76 (dt, J = 15.6, 
7.3 Hz, 1 H), 6.58 (dd, J = 3.4, 1.5 Hz, 1 H), 6.12–6.04 (m, 1 H), 5.30 (s, 1 H), 3.78 (dd, J = 
7.3, 1.5 Hz, 2 H), 1.71 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 185.1, 162.4, 161.8, 
152.0, 146.9, 132.9, 125.9, 117.9, 112.6, 106.6, 94.6, 41.6, 25.0. MS (ES) m/z: 263 [M + H]
+
. 
HR-MS (ES) m/z calcd for C14H15O5: 263.0919 [M + H]; found: 263.0912. Anal. calcd for 
C14H14O5: C 64.12, H 5.38; found: C 60.65, H 5.34. 
1.25.13.22  (E)-2,2-Dimethyl-6-(4-oxopent-1-enyl)-4H-1,3-dioxin-4-one (335g) 
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According to general procedure C, oxidation of dioxinone 431g (145 mg, 0.684 mmol) for 
1.25 h and chromatography (pentane/Et2O, 1:1 to 2:3) gave enone–dioxinone 335g (78 mg, 
54%) as a yellow oil. IR (cm−1): 1711, 1654, 1593, 1390, 1274, 1273, 1251, 1200, 1158, 
1016, 968, 903, 859, 808.
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.67 (dt, J = 15.7, 7.3 Hz, 1 
H), 6.00 (dt, J = 15.6, 1.5 Hz, 1 H), 5.32 (s, 1 H), 3.39 (dd, J = 7.3, 1.0 Hz, 2 H), 2.24 (s, 3 
H), 1.74 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 204.5, 162.4, 161.8, 132.9, 125.8, 
106.6, 94.7, 46.7, 30.1, 25.0. MS (ES) m/z: 233 [M + Na]
+
, 211 [M + H]
+
. HR-MS 
(ES) m/z calcd for C11H15O4: 211.0965 [M + H]
+
; found: 211.0966. 
1.25.13.23  (E)-2,2-Dimethyl-6-(4-oxohex-1-enyl)-4H-1,3-dioxin-4-one (335h) 
 
According to general procedure C, oxidation of dioxinone 431h (60 mg, 0.265 mmol) for 
0.75 h and chromatography (hexanes/Et2O, 1:1) gave enone–dioxinone 335h (47 mg, 79%) as 
a yellow oil. IR (cm−1): 1711, 1630, 1586, 1460, 1391, 1376, 1276, 1252, 1200, 1096, 1017, 
973, 903, 812. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.66 (dt, J = 15.6, 6.8 Hz, 1 H), 5.98 
(dt, J = 15.7, 1.5 Hz, 1 H), 5.29 (s, 1 H), 3.34 (dd, J = 7.3, 1.5 Hz, 2 H), 2.50 (q, J = 7.3 Hz, 2 
H), 1.71 (s, 6 H), 1.08 (t, J = 7.3 Hz, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 207.3, 
162.4, 161.7, 133.3, 125.6, 106.5, 94.5, 45.5, 36.1, 25.0, 7.6. MS (ES) m/z: 247 [M + Na]
+
, 
225 [M + H]
+
. 
1.25.13.24  (E)-2,2-Dimethyl-6-(6-methyl-4-oxohept-1-enyl)-4H-1,3-dioxin-4-one (335i) 
 
According to general procedure C, oxidation dioxinone 431i (151 mg, 0.594 mmol) for 
1.25 h and chromatography (pentane/Et2O, 7:3 to 1:1) gave enone–dioxinone 335i (101 mg, 
67%) as a yellow oil. IR (cm−1): 1707, 1655, 1594, 1451, 1392, 1373, 1277, 1204, 1105, 
1019, 979, 906, 864, 849, 812. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.68 (dt, J = 15.7, 
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7.3 Hz, 1 H), 6.00 (dt, J = 15.7, 1.5 Hz, 1 H), 5.31 (s, 1 H), 3.34 (dd, J = 7.3, 1.0 Hz, 2 H), 
2.37 (d, J = 7.3 Hz, 2 H), 2.10–2.25 (m, 1 H), 1.74 (s, 6 H), 0.96 (d, J = 6.4 Hz, 6 H). 13C 
NMR (101 MHz, CDCl3, ppm) δ: 206.6, 162.4, 161.8, 133.3, 125.6, 106.5, 94.5, 51.9, 46.3, 
25.0, 24.5, 22.5. MS (ES) m/z: 275 [M + Na]
+
, 253 [M + H]
+
. Anal. calcd for C14H20O4: C 
66.65, H 7.99; found: C 66.74, H 7.90. 
1.25.13.25  (E)-6-(4-Mesityl-4-oxobut-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (335j) 
 
2-Iodoxybenzoic acid (842 mg, 2.94 mmol) was added with stirring to 
dioxinone 431j (310 mg, 0.981 mmol) in EtOAc (7 mL) open to the air at 80 °C for 2 h. The 
mixture was filtered through Celite and rotary evaporated. Chromatography (hexanes/Et2O, 
4:1 to 1:1) of the residue gave enone–dioxinone 335j as a 2:1 mixture of the β,δ-enone: α,β-
enone (207 mg, 67%) as a yellow oil. IR (cm−1): 1713, 1698, 1603, 1373, 1268, 1200, 1148, 
1017, 978, 852, 802, 602. β,δ-Enone: 1H NMR (400 MHz, CDCl3, ppm) δ: 6.87 (s, 2 H), 6.78 
(dt, J = 15.6, 7.8 Hz, 1 H), 6.04 (d, J = 15.7 Hz, 1 H), 5.31 (s, 1 H), 3.63 (dd, J = 7.1, 1.2 Hz, 
2 H), 2.30 (s, 3 H), 2.21 (s, 6 H), 1.73 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 206.5, 
162.4, 161.8, 138.7, 133.8, 132.8, 132.5, 128.6, 125.8, 106.6, 94.7, 47.8, 25.0, 21.1, 19.2. 
α,β-Enone: 1H NMR (400 MHz, CDCl3, ppm) δ: 6.87 (s, 2 H), 6.47–6.29 (m, 2 H), 5.22 (s, 1 
H), 3.16 (d, J = 6.4 Hz, 2 H), 2.30 (s, 3 H) 2.14 (s, 6 H), 1.66 (s, 6 H). 
13
C NMR (101 MHz, 
CDCl3, ppm) δ: 206.5, 162.4, 161.8, 141.6, 138.7, 136.1, 133.8, 132.5, 128.4, 106.6, 94.5, 
36.3 25.0, 21.1, 19.2. MS (CI) m/z: 332 [M + H2O]
+
, 315 [M + H]
+
. Anal. calcd for C19H22O4: 
C 72.59, H 7.05; found: C 72.44, H 6.95. 
1.25.13.26  (E)-tert-Butyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-3-enoate (337a) 
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According to general procedure F, cross metathesis of ester 462a (615 mg, 4.33 mmol) and 
dioxinone 372a (1.00 g, 6.49 mmol) with catalyst 427a (136 mg, 0.217 mmol) in CH2Cl2 (30 
mL) at reflux for 2.5 h and chromatography (pentane/Et2O, 9:1 to 4:1) gave dioxinone ester 
337a (948 mg, 82 %) as a pale yellow solid; mp 112–114 °C (CH2Cl2–pentane).  IR (cm
−1): 
1715, 1656, 1592, 1388, 1374, 1365, 1278, 1258, 1215, 1203, 1180, 1144, 1092, 973, 948, 
935, 904, 870, 841, 796, 765, 750. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.61 (dt, J = 15.6, 
7.3 Hz, 1 H), 5.99 (dt, J = 15.7, 1.5 Hz, 1 H), 5.28 (s, 1 H), 3.16 (dd, J = 7.3, 1.5 Hz, 2 H), 
1.70 (s, 6 H), 1.46 (s, 9 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 169.4, 162.5, 161.7, 133.5, 
125.2, 106.4, 94.4, 81.6, 38.8, 28.0, 25.0. MS (ES) m/z 269 [M + H]
+
. HR-MS (ES) m/z calcd 
for C14H21O5: 269.1389 [M + H]
+
; found: 269.1384. 
1.25.13.27 (E)-Ethyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-2-enoate (337b) 
 
(
i
Bu2AlH)2 (5.37 ml, 5.37 mmol) was added dropwise to 2-(2,2-dimethyl-4-oxo-4H-1,3-
dioxin-6-yl)-N-methoxy-N-methylacetamide ( 1.00g, 4.37 mmol) in THF (44 ml) at −78 oC 
and stirred for 15 min. Methanol (10ml) was added and stirred 5 min. This mixture was 
transferred to a mixture of ethyl (triphenylphosphoranylidene)acetate (1.52 g, 4.37 mmol) in 
THF (44 ml) at 50 
o
C and stirred for 45 min. The mixture was rotary evaporated and 
chromatographed (petroleum ether/Et2O, 4:1 to 13:7) to give the title compound (469 mg, 45 
%) as a colourless oil. IR (cm−1) 1721, 1656, 1374, 1273, 1202. 
1
H NMR (400 MHz, CDCl3, 
ppm) δ: 6.60 (dt, J = 15.2, 7.3 Hz, 1 H), 5.97–6.06 (m, 1 H), 5.29 (s, 1 H), 4.17 (q, J = 7.2 
Hz, 2 H), 3.23 (dd, J = 7.3, 1.5 Hz, 2 H), 1.71 (s, 6 H), 1.27 (t, J = 7.1 Hz, 3 H). 
13
C NMR 
(101 MHz, CDCl3, ppm) δ: 170.3, 162.5, 161.9, 132.9, 125.7, 106.7, 94.8, 61.3, 37.9, 25.1, 
14.3. HR-MS (EI) m/z calcd for C12H17O5: 241.1067 [M+H]; found: 241.1067. Anal. calcd 
for C12H16O5: C 59.99, H 6.71; found: C 59.88, H 6.60. 
1.25.13.28 Phenyl but-3-enoate and (E)-Phenyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-3-
enoate (337c)
235
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Oxalyl chloride (542 µL, 6.4 mmol) was added to vinylacetic acid (0.5 g, 5.81 mmol) in CH2Cl2 (2.4 
mL) followed by DMF (10 µL) and the mixture stirred for 3 h. The mixture was rotary evaporated and 
phenol (547 mg, 5.81 mmol) in CH2Cl2 (1 mL) was added dropwise then stirred at 20 °C for 16 h. The 
mixture was rotary evaporated and chromatographed (pentane/Et2O, 97:3 to 19:1) to give phenyl but-
3-enoate (251 mg, 42%) as a colorless oil used without further purification. IR (cm
−1
): 1754, 1492, 
1328, 1237, 1192, 1162, 1133, 1071, 992, 922, 811, 774, 742, 726, 688.  
1
H NMR (400 MHz, CDCl3, 
ppm) δ: 7.35–7.44 (m, 2 H), 7.19–7.30 (m, 1 H), 7.04–7.15 (m, 2 H), 6.08 (ddt, J = 17.1, 10.2, 7.0 Hz, 
1 H), 5.23–5.36 (m, 2 H), 3.36 (dt, J = 7.0, 1.4 Hz, 2 H). 13C NMR (101 MHz, CDCl3, ppm) δ: 169.9, 
150.6, 129.6, 129.4, 125.8, 121.5, 119.2, 39.1. In agreement with the literature.  
According to general procedure A, reaction of phenyl but-3-enoate (281 mg, 1.73 mmol) and 
dioxinone 372a (400mg, 2.60 mmol) with catalyst 427a (54 mg, 0.087 mmol) for 14 h and 
chromatography (hexanes/Et2O, 4:1 to 1:1) gave dioxinone 337c (577 mg, 76%) as a brown solid, mp 
85–90 °C (Et2O/pentane).  IR (cm
−1
): 1753, 1714, 1656, 1594, 1390, 1374, 1273, 1250, 1192, 1163, 
1128, 1018, 968, 902, 801. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.38–7.44 (m, 2 H), 7.26–7.30 (m, 1 
H), 7.09–7.13 (m, 2 H), 6.72 (dt, J = 15.5, 7.2 Hz, 1 H), 6.15 (dt, J = 15.5, 1.5 Hz, 1 H), 5.36 (s, 1 H), 
3.52 (dd, J = 7.1, 1.7 Hz, 2 H), 1.74 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 168.6, 162.2, 
161.6, 150.4, 131.8, 129.5, 126.2, 126.1, 121.3, 106.6, 95.0, 37.6, 25.0. MS (ES) m/z: 330 [M+MeCN 
+H]
+
, 289 [M+H]
+
. HR-MS (ES) m/z calcd for C16H16O5: 289.1076 [M+H]
+
; found: 289.1067. 
1.25.13.29 Mixture of (E)-phenyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-2-enoate (337c) 
and (E)-methyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-3-enoate (337d) 
 
(
i
Bu2AlH)2 (1M in hexanes, 3.22 mL) was added dropwise to a solution of 2-(2,2-dimethyl-4-oxo-4H-
1,3-dioxin-6-yl)-N-methoxy-N-methylacetamide ( 0.74g, 3.22 mmol) in THF (32 mL) at −78 oC over 
10 minand stirred for a further 20 min. Methanol (6mL) was added and stirred for 5 min. The mixture 
was then transferred by cannula to a mixture of phenyl (triphenylphosphoranylidene)acetate (1.28 g, 
3.22 mmol) in THF (32 mL) at 50 
o
C and stirred for 1 h. Aqueous Sodium potassium tartrate was 
added and the aqueous extracted with ether (× 2) and ethyl acetate (× 2). The combined organics were 
washed with brine, dried (MgSO4),rotary evaporated and chromatographed (petroleum ether/Et2O, 
7:3) to a yellow oil (270 mg, 33%) that was a mixture of methyl and phenyl esters. Phenyl ester: 
1
H 
NMR (400 MHz, CDCl3, ppm) δ: 7.50–7.33 (m, 2 H), 7.33–7.17 (m, 1 H), 7.17–7.03 (m, 2 H), 6.77–
6.67 (dt, J = 15.6, 7.2 Hz,  1 H), 6.13 (dt, J = 15.7, 1.5 Hz, 1 H), 5.33 (s , 1 H),  3.52 (dd, J = 7.3, 1.5 
Hz, 2 H), 1.72 (s, 6 H). HR-MS (EI) m/z calcd for C16H17O5: 289.1067 [M+H]
+
; found: 289.1076. 
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Methyl ester: 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.61 (dt, J = 15.0, 7.3 Hz,  1 H), 6.02 (dt, J = 15.6, 
1.5 Hz, 1 H) 5.30 (s , 1 H), 3.73 (s, 3 H), 3.25 (dd, J = 7.3, 1.5 Hz, 2 H), 1.71 (s, 6 H). 
1.25.13.30 tert-Butyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2-methylbut-3-enoate (±) 
(337e) 
 
According to general procedure F, cross metathesis of ester 462b (80 mg, 0.51 mmol) and 
dioxinone 372a (237 mg, 1.54 mmol) with catalyst 427a (32 mg, 0.05 mmol) in C6F5CF3 (3 
mL) at 70 °C for 2 h and chromatography (pentane/Et2O, 95:5 to 17:3) gave dioxinone ester 
337e (98 mg, 68 %, 1 : 0.75 rr) as a brown oil. IR (cm−1): 1724, 1653, 1637, 1595, 1458, 1390, 
1369, 1271, 1252, 1202, 1149, 1125, 1065, 1015, 966, 901, 846, 804, 743. 
1
H NMR 
(400 MHz, CDCl3, ppm) δ: 6.57–6.64 (m, 1.75 H), 5.96 (dd, J = 15.7, 1.0 Hz, 1 H), 5.30 (s, 
1H), 5.27 (s, 0.75 H), 3.14–3.24 (m, 1 H), 3.08 (d, J = 7.3 Hz, 1.5 H), 1.83 (s, 2.25 H), 1.72 (s, 
6 H), 1.70 (s, 4.5 H), 1.50 (s, 6.75 H), 1.46 (s, 9 H), 1.31 (d, J = 6.8 Hz, 3 H). 
13
C NMR (101 
MHz, CDCl3, ppm) δ: 172.4, 168.5, 166.4, 162.8, 161.8, 161.0, 140.0, 133.7, 130.9, 123.1, 
106.8, 106.5, 94.5, 93.9, 81.3, 80.8, 43.6, 32.8, 28.1, 28.0, 25.1, 25.0, 16.9, 12.7. MS 
(ES) m/z: 283 [M + H]
+
. HR-MS (ES) m/z calcd for C15H23O5: 283.1545 [M + H]
+
; found: 
283.1550. 
1.25.13.31 tert-Butyl 2-benzyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-3-enoate (±) 
(337f) 
 
According to general procedure F, cross metathesis of ester 462c (150 mg, 0.647 mmol) and 
dioxinone 372a (299 mg, 1.94 mmol) with catalyst 427a (41 mg, 0.07 mmol) in C6F5CF3 (4 
mL) at 70 °C for 2.5 h and chromatography (pentane/Et2O, 19:1 to 4:1) gave dioxinone ester 
337f (142 mg, 61 %, 1 : 0.25 rr) as a brown oil. IR (cm−1): 1720, 1651, 1593, 1496, 1478, 
1455, 1391, 1369, 1273, 1250, 1202, 1144, 1018, 970, 902, 843, 806, 740, 699. 
1
H NMR 
(400 MHz, CDCl3, ppm) δ: 7.12–7.32 (m, 6.25 H), 6.77 (t, J = 7.3 Hz, 0.25 H), 6.55 (dd, J = 
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15.7, 8.8 Hz, 1 H), 5.87 (d, J = 15.7 Hz, 1 H), 5.25 (s, 1.25 H), 3.67 (s, 0.5 H), 3.31–3.40 (m, 
1 H), 3.06–3.17 (m, 1.5 H), 2.82–2.92 (m, 1 H), 1.71 (s, 6 H), 1.68 (s, 1.5 H), 1.41 (s, 9 H), 
1.36 (s, 2.25 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 171.3, 168.2, 166.0, 162.5, 161.7, 
160.8, 138.9, 138.1, 137.8, 136.6, 132.5, 129.1, 128.5, 128.4, 128.1, 126.7, 126.3, 124.4, 
106.8, 106.5, 94.7, 94.1, 81.6, 81.1, 51.7, 38.7, 32.9, 32.6, 27.9 27.9, 25.0, 25.0. MS (ES) 
m/z: 376 [M + NH4]
+
, 359 [M + H]
+
. HR-MS (ES) m/z calcd for C21H27O5: 359.1858 [M + 
H]
+
; found: 359.1865. Anal. calcd for C21H26O5: C 70.37, H 7.31; found: C 70.26, H 7.38. 
1.25.13.32 tert-Butyl 2-(1-(tert-butyldimethylsilyloxy)ethyl)-4-(2,2-dimethyl-4-oxo-4H-1,3-
dioxin-6-yl)but-3-enoate (337g) 
 
According to general procedure F, cross metathesis of ester 462f (800 mg, 2.67 mmol) and 
dioxinone 372a (1.232 g, 8.00 mmol) with catalyst 427a (70 mg, 0.267 mmol) in C6F5CF3 
(16 mL) at 70 °C for 7.5 h and chromatography (pentane/Et2O, 9:1 to 17:3) gave dioxinone 
ester 337g (618 mg, 54%, 1:0.6 dr) as a colourless oil. IR (cm
−1
): 1725, 1654, 1595, 1473, 
1462, 1389, 1372, 1272, 1250, 1203, 1152, 1132, 1095, 1019, 979, 902, 831, 810, 775, 749, 
665. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.49–6.62 (m, 1.6 H), 5.89–6.04 (m, 1.6 H), 5.30 
(s, 0.6 H), 5.28 (s, 1.0 H), 4.04–4.19 (m, 1.6 H), 3.10 (dd, J = 9.5, 6.6 Hz, 0.6 H), 3.01 (dd, J 
= 9.3, 7.3 Hz, 1.0 H), 1.69–1.72 (m, 9.6 H), 1.45–1.47 (m, 14.4 H), 1.19 (d, J = 5.9 Hz, 3.0 
H), 1.15 (d, J = 6.4 Hz, 1.8 H), 0.90 (s, 5.4 H) 0.87 (s, 9 H), 0.08 (s, 1.8 H), 0.07 (s, 1.8 H), 
0.06 (s, 3 H), 0.02 (s, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 170.5, 170.1, 162.6, 162.5, 
161.8, 161.7, 137.5, 136.3, 125.2, 125.1, 106.4 (2C), 94.6, 94.3, 81.6, 81.4, 69.8, 69.7, 58.8, 
58.4, 28.1, 28.0, 25.7, 25.6, 25.1, 25.1, 24.9, 22.3, 21.4, 17.9, −4.3, −4.4, −4.9, −5.0. MS (ES) 
m/z: 444 [M+NH4]
+
, 427 [M+H]
+
. HR-MS (ES) m/z: calcd for C22H38SiO6: 427.2522 
[M+H]
+
; found: 427.2525. Anal. calcd for C22H38SiO6: C 61.94, H 8.98, found: C 62.05, H 
9.02. 
1.25.13.33 tert-Butyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-methylbut-3-enoate (337h) 
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According to general procedure I, dehydration of β-hydroxy ester 476a (726 mg, 2.42 mmol) 
for 2.5 h and chromatography (pentane/Et2O, 3:1 to 7:3) gave dioxinone ester 337h (527 mg, 
77%, 1.0:0.4:0.4:0.3 rr) as a yellow oil. IR (cm−1): 1721, 1649, 1584, 1458, 1389, 1368, 1322, 
1272, 1250, 1202, 1139, 1014, 956, 901, 874, 851, 804, 753, 695, 657. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 5.79 (s, 1 H), 5.66–5.72 (m, 0.8 H), 5.25–5.30 (m, 2.1 H), 5.09 (d, J = 12.7 
Hz, 0.6 H), 3.61 (s, 0.4 H), 3.37 (s, 1.2 H), 3.02–3.09 (m, 2.2 H), 2.98 (d, J = 4.4 Hz, 1 H), 
2.14 (d, J = 1.5 Hz, 0.6 H), 2.08 (d, J = 1.0 Hz, 1.8 H), 1.98 (d, J = 1.0 Hz, 3 H), 1.69–1.73 
(m, 8.4 H), 1.67 (s, 3.6 H), 1.48 (s, 1.8 H), 1.44–1.46 (m, 17.7 H). 13C NMR (101 MHz, 
CDCl3, ppm) δ: 169.9, 169.3, 169.1, 169.0, 167.9, 164.4, 163.9, 161.9, 149.1, 148.7, 145.3, 
145.0, 136.0, 121.8, 121.7, 120.7, 120.3, 118.5, 106.7, 106.5, 106.2, 106.1, 95.2, 94.9, 94.9, 
94.4, 93.7, 81.4, 81.2, 81.1, 80.3, 47.9, 44.5, 42.4, 40.9, 40.1, 36.6, 28.2, 28.1, 28.0, 28.0, 
26.9, 25.1, 25.0, 24.9, 19.5, 18.4. MS (ES) m/z: 305 [M + Na]
+
, 283 [M + H]
+
. HR-MS 
(ES) m/z calcd for C15H23O5: 283.1545 [M + H]
+
; found: 283.1547. 
1.25.13.34 tert-Butyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2,3-dimethylbut-3-enoate 
(±) (337i) 
 
According to general procedure I, dehydration of β-hydroxy ester 476b (815 mg, 2.60 mmol) 
for 2 h and chromatography (pentane/Et2O, 4:1 to 3:1) gave dioxinone ester 337i (590 mg, 
77%, 1.0:0.6:0.6 rr) as a yellow oil. IR (cm−1): 1721, 1644, 1583, 1458, 1390, 1369, 1318, 
1271, 1250, 1202, 1145, 1085, 1014, 900, 875, 848, 804, 744. 
1
H NMR (400 MHz, CDCl3, 
ppm) δ: 5.71 (s, 1.0 H), 5.69 (s, 0.6 H), 5.31 (s, 0.6 H), 5.30 (s, 0.6 H), 5.26 (s, 1.0 H), 5.13 (s, 
0.6 H), 5.04 (s, 0.6 H), 3.11 (q, J = 7.2 Hz, 1.0 H), 2.96–3.06 (m, 2.4 H), 2.01–2.02 (m, 3 H), 
1.86 (d, J = 1.0 Hz, 1.8 H), 1.71 (s, 9.6 H), 1.66–1.67 (m, 3.6 H), 1.43 (s, 19.8 H), 1.26 (d, J 
= 6.8 Hz, 3.6 H), 1.23 (d, J = 6.8 Hz, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 172.7, 
172.1, 169.3, 164.7, 164.0, 161.9, 161.8, 161.1, 150.8, 150.4, 141.4, 119.5, 118.9, 115.7, 
106.5, 106.2, 106.1, 95.2, 95.1, 94.4, 81.1, 80.9, 80.8, 50.8, 45.9, 42.9, 39.3, 28.1, 27.9, 25.1, 
24.9, 24.9, 21.2, 17.3, 16.0, 15.6, 15.3. MS (ES) m/z: 314 [M + NH4]
+
, 297 [M + H]
+
. HR-MS 
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(ES) m/z calcd for C16H25O5: 297.1702 [M + H]
+
; found: 297.1704. Anal. calcd for C16H24O5: 
C 64.84, H 8.16; found: C 64.91, H 8.20. 
1.25.13.35 tert-Butyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-methyl-2-phenylbut-3-enoate 
(±) (337j) 
 
According to general procedure I, dehydration of β-hydroxy ester 476c (750 mg, 1.99 mmol) 
for 3.5 h and chromatography (pentane/Et2O, 17:3 to 3:1) gave dioxinone ester 337j (532 mg, 
75%, 1.0:1.0:0.7 rr) as a yellow oil. IR (cm−1): 1721, 1640, 1601, 1583, 1495, 1455, 1390, 
1369, 1311, 1272, 1250, 1202, 1138, 1079, 1014, 967, 901, 875, 854, 806, 754, 699, 626. 
1
H 
NMR (400 MHz, CDCl3, ppm) δ: 7.10–7.34 (m, 13.5 H), 5.76 (s, 0.7 H), 5.61 (s, 1 H), 5.47 
(s, 0.7 H), 5.25 (s, 0.7 H), 5.18 (s, 1 H), 5.16 (s, 1 H), 5.08–- 5.11 (m, 2 H), 4.24 (s, 1 H), 
4.17 (s, 1 H), 2.92 (d, J = 15.7 Hz, 1 H), 2.80 (d, J = 14.7 Hz, 1 H), 1.97 (s, 3 H), 1.76 (s, 
2.1 H), 1.67 (s, 2.1 H), 1.62–1.66 (m, 8.1 H), 1.57–1.61 (m, 6 H), 1.42 (s, 6.3 H), 1.37–1.40 
(m, 18 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 170.6, 170.2, 169.0, 164.6, 163.7, 161.8, 
161.7, 161.1, 149.2, 148.9, 140.3, 137.2, 136.2, 136.0, 128.8, 128.8, 128.8, 128.7, 128.6, 
128.3, 127.7, 127.6, 127.2, 120.5, 120.1, 117.4, 106.5, 106.4, 106.1, 95.6, 95.6, 94.5, 81.9, 
81.7, 81.5, 77.3, 77.2, 76.7, 62.2, 57.8, 54.1, 39.5, 28.0, 27.9, 25.2, 25.1, 25.0, 24.8, 23.1, 
18.9. MS (ES) m/z: 376 [M + NH4]
+
, 359 [M + H]
+
. HR-MS (ES) m/z calcd for C21H27O5: 
359.1858 [M + H]
+
; found: 359.1866. Anal. calcd for C21H26O5: C 70.39, H 7.31; found: C 
70.26, H 7.45. 
1.25.13.36 tert-Butyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2-methyl-3-methylene-5-
phenylpentanoate (±) (337k) 
 
According to general procedure I, dehydration of β-hydroxy ester 476d (404 mg, 1.00 mmol) 
for 2 h and chromatography (pentane/Et2O, 4:1) gave dioxinone ester 337k (317 mg, 82%) as 
a yellow oil. IR (cm−1): 1724, 1626, 1456, 1390, 1369, 1345, 1271, 1250, 1202, 1145, 1095, 
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1075, 1017, 901, 847, 810, 745, 699. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.11–7.32 (m, 5 
H), 5.27 (s, 2 H), 5.21 (s, 1 H), 3.34 (t, J = 7.8 Hz, 1 H), 2.95–3.06 (m, 3 H), 1.59 (s, 3 H), 
1.55 (s, 3 H), 1.42 (s, 9 H), 1.21 (d, J = 6.8 Hz, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 
172.8, 170.7, 161.1, 145.5, 138.3, 128.6, 128.4, 126.6, 114.0, 106.5, 94.5, 80.9, 50.4, 46.1, 
37.2, 27.9, 25.2, 24.5, 16.3. MS (ES) m/z: 387 [M + H]
+
. HR-MS (ES) m/z calcd for 
C23H31O5: 387.2171 [M + H]
+
; found: 387.2175. Anal. calcd for C23H30O5: C 71.48, H 7.82; 
found: C 71.56, H 7.93. 
1.25.13.37 tert-Butyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-(4-methoxyphenyl)but-2-
enoate (337l) 
 
According to general procedure I, dehydration of β-hydroxy ester 476e (486 mg, 1.24 mmol) 
for 4 h and chromatography (pentane/Et2O, 4:1 to 7:3) gave dioxinone ester 337l (376 mg, 
81%, 1:0.4 rr) as a yellow oil. IR (cm−1): 1725, 1702, 1624, 1602, 1513, 1390, 1369, 1274, 
1250, 1203, 1180, 1139, 1029, 1012, 970, 901, 877, 832, 804, 731. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 7.37–7.39 (m, 2 H), 7.11–7.13 (m, 0.8 H), 6.89–6.91 (m, 2 H), 6.84–6.86 (m, 
0.8 H), 6.17 (s, 1 H), 5.94 (s, 0.4 H), 5.42 (s, 1 H), 5.14 (s, 0.4 H), 3.83 (s, 5 H), 3.81 (s, 1.2 
H) 3.35 (0.8 H), 1.76 (s, 6 H), 1.44 (s, 2.4 H), 1.40 (s, 9 H), 1.33 (s, 3.6 H).
13
C NMR (101 
MHz, CDCl3, ppm) δ: 169.6, 169.3, 165.5, 164.2, 161.8, 161.3, 160.3, 159.5, 148.7, 144.9, 
133.8, 132.0, 127.9, 127.8, 120.6, 119.8, 114.1, 114.0, 106.6, 106.4, 96.1, 93.8, 81.3, 80.6, 
55.3, 55.3, 39.2, 34.1, 28.2, 27.9, 25.1, 24.8. MS (ES) m/z: 392 [M + NH4]
+
, 375 [M + H]
+
. 
HR-MS (ES) m/z calcd for C21H26O6: 375.1808 [M + H]
+
; found: 375.1820. Anal. calcd for 
C21H26O6: C 67.36, H 7.00; found: C 67.21, H 7.09. 
1.25.13.38 1-Ethyl 7-isopropyl 5-oxohept-2-enedioate (338b) 
 
 (E)-Ethyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-2-enoate (264 mg, 1.10 mmol) and 
iso-propanol (340 µL, 4.40 mmol) in toluene (5.00 ml) was refluxed for 4.5 h. The solution 
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was rotary evaporated and chromatographed (petroleum ether/ether, 4:1 to 3: 1) to give the 
title compound (200 mg, 75 %, 1:0.7(enol):0.5) as a colourless oil. IR (cm−1) 1721, 1375, 
1180, 1102, 1027. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 11.91 (d, J = 1.5 Hz, 0.7 H), 7.01 (dt, 
J = 15.7, 7.3 Hz, 0.5 H), 6.93 (dt, J = 16.1, 6.8 Hz, 1 H), 6.69 (dt, J = 15.7, 7.3 Hz, 0.7 H), 
6.25 (dt, J = 16.1, 1.5 Hz, 1 H), 5.92 (dt, J = 15.7, 1.5 Hz, 0.5 H), 5.90 (dq, J = 15.7, 1.5 Hz, 
0.7 H), 5.02 - 5.12 (m, 2.2 H), 4.99 (s, 0.7H), 4.12 - 4.24 (m, 4.4 H), 3.58 (s, 2H), 3.48 (dd, J 
= 7.3, 1.5 Hz, 1 H), 3.46 (s, 1 H), 3.27 (dd, J = 6.8, 1.5 Hz, 2 H), 3.21 (dd, J = 7.3, 1.5 Hz, 
1.4H), 1.20 - 1.37 (m, 19.8 H). 
13
C NMR (101 MHz, CHLOROFORM-d) δ: 198.9, 191.9, 
172.4, 170.4, 169.6, 168.2, 166.7, 166.2, 165.6, 152.5, 149.4, 140.0, 138.8, 132.2, 131.2, 
127.6, 125.5, 91.9, 69.4, 69.1, 67.7, 61.3, 61.0, 60.6, 49.4, 47.2, 45.4, 37.9, 37.7, 21.9, 21.7, 
14.2, 14.2. MS (EI) m/z: 243 [M+H]
+
. HR-MS (EI) m/z calcd for C12H19O5: 243.1229 [M+H]; 
found: 243.1232. Anal. calcd for C12H18O5: C 54.49, H 7.49 found: C 54.58; H 7.35. 
1.25.13.39 ((2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)methyl)triphenylphosphonium bromide 
(343)
236
 
 
6-(Bromomethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one xx (500 mg, 2.26 mmol) and triphenylphosphine 
(593 mg, 2.26 mmol) in benzene (5 mL) was refluxed for 1.5 h, and filtered. The solids were washed 
with toluene, hexanes then diethyl ether to give the title compound (910 mg, 83%) as a beige solid. IR 
(cm−1): 1657, 1525, 1480, 1433, 1355, 1254, 1200, 1184, 1154, 1101, 1019, 997, 916, 884, 
839, 762, 717, 692. 1H NMR (400 MHz, CDCl3, ppm) δ: 7.88–7.98 (m, 6 H), 7.79–7.85 (m, 3 
H), 7.69-7.73 (m, 6 H), 5.82 (d, J
3
 = 3.4 Hz, 1 H), 5.64 (d, J = 15.2 Hz, 2 H), 1.41 (s, 6 H). 
MS (EI) m/z: 403 [M−Br+H]+. HR-MS (EI) m/z calcd for C25H24O3P: 403.1463 [M−Br+H]
+
; 
found: 403.1468. 
1.25.13.40 tert-Butyl 3-oxopropanoate (344)237 
 
2,2-Dimethyl-4,6-dioxo-1,3-dioxane-5-carbaldehyde (3.40 g, 19.77 mmol) in benzene (40 mL) and 
tert-butanol (1.60 g, 21.74 mmol) was refluxed for 1.5 h then rotary evaporated and distilled to give 
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the title compound (353 mg, 12%) as a colourless oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ:  Keto 
form: 9.79 (t, J = 2.7 Hz, 1 H), 3.31 (d, J = 2.4 Hz, 2 H), 1.50 (s, 9 H); Enol form: 11.57 (d, J 
= 12.2 Hz, 1 H), 7.06 (dd, J = 12.2, 5.9 Hz, 1 H), 4.98 (d, J = 6.4 Hz, 1 H), 1.50 (s, 9 H). 
13
C 
NMR (101 MHz, CDCl3, ppm) δ: 195.8, 166.0, 163.1, 128.3, 94.9, 82.5, 49.7, 31.2, 28.2, 28.0. 
in agreement with literature. 
1.25.13.41 6-(Bromomethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (345)238 
 
Bromine (5.13 mL, 100 mmol) in CCl4 (20 mL) was added to diketene (8.4  g, 100 mmol) in CCl4 (50 
mL), dropwise at −20 °C over 30 min. The mixture was stirred for a further 1 h then water was added 
dropwise over a further 1 h maintaining an internal temperature of −20 to −30 °C. The mixture was 
then filtered and the solids were dissolved in boiling CCl4. On cooling a precipitate formed which was 
recrystalized from boiling CCl4 to give 4-bromo-3-oxobutanoic acid (16.35 g, 90%) as a light brown 
solid used without further purification. IR (cm
−1
): 1733, 1687, 1441, 1400, 1377, 1321, 1256, 1108, 
1045, 925, 709. 
1
H NMR (400 MHz, CDCl3, ppm) δ: (keto : enol 3.5 : 1) keto: 8.87 (br. s, 1 H), 4.06 
(s, 2 H),  3.81 (s, 2 H); enol: 11.63 (br. s., 1 H), 7.53 (br. s., 1 H), 5.36 (s, 1 H), 3.88 (s, 2 H). 
13
C 
NMR (101 MHz, CDCl3, ppm) δ: 194.3, 176.1, 173.3, 172.0, 90.9, 45.3, 33.7, 28.2. 
Concentrated H2SO4 (160 µL, 2.93 mmol) was added to a mixture of 4-bromo-3-oxobutanoic acid 
(5.3 g, 29.3 mmol), acetic anhydride (5.54 mL, 58.7 mmol) and acetone (4.29 mL, 58.7 mmol) at 0 °C 
and stirred for 0.5 h then a further 2 h at 22 °C. The mixture was poured into cold 10 Aqueous 
Na2CO3 (150 mL) and stirred for 5 min. The aqueous was extracted with CH2Cl2 (3 × 200 mL) and 
the combined organics were dried (MgSO4), rotary evaporated and chromatographed (petroleum 
ether/Et2O, 9:1 to 4:1) to give the title compound (4.92 g, 76 %) as a brown oil. IR (cm
−1
): 1723, 
1635, 1390, 1375, 1272, 1254, 1224, 1200, 1178, 1013, 908, 804, 697. 
1
H NMR (400 MHz, CDCl3, 
ppm) δ: 5.54 (s, 1 H), 3.89 (s, 2 H), 1.73 (s, 6 H). 13C NMR (101 MHz, CDCl3, ppm) δ: 164.3, 160.5, 
107.5, 95.7, 26.9, 24.7. MS (CI) m/z: 240 [M
81
+NH4]
+
, 238 [M
79
+NH4]
+
, 223[M
81
+H]
+
, 221[M
79
+H]
+
. 
HR-MS (CI) m/z calcd for C7H13NO3Br: 238.0079[M+NH4]
+
; found: 238.0085. In agreement with the 
literature. 
1.25.13.42 2,2-Dimethyl-4-oxo-4H-1,3-dioxine-6-carbaldehyde (346)239 
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Manganese dioxide (1.2 g, 13.80 mmol) was added to 6-(hydroxymethyl)-2,2-dimethyl-4H-1,3-
dioxin-4-one (109 mg, 0.69 mmol) in CH2Cl2 (2 mL) and stirred for 48 h. The mixture was filtered 
through celite and rotary evaporated to give the title compound (90 mg, 84 %) as a colourless oil. IR 
(cm
−1
): 1707, 1643, 1627, 1392, 1378, 1279, 1248, 1199, 1159, 1012, 966, 904, 871, 815. 
1
H NMR 
(400 MHz, CDCl3, ppm) δ: 9.50 (s, 1 H), 6.08 (s, 1 H), 1.77 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, 
ppm) δ: 185.5, 160.1, 157.7, 108.5, 104.0, 24.9. In agreement of the literature. 
1.25.13.43  (2-Carboxyethyl)-triphenylphosphonium Bromide (347) 240 
 
3-Bromopropionic acid (2.5 g, 16.34 mmol) and triphenylphosphine (4.29 g, 16.34 mmol) in 
acetonitrile (20 mL) were heated by microwave irradiation at 100 °C for 10 h.  The mixture was rotary 
evaporated to give the title compound (6.7 g, quantitative) as a colourless solid.  IR (cm
−1
): 1728, 
1436, 1184, 1110, 996, 742, 723, 687. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 8.95 (br. s, 1 H), 7.70–
7.83 (m, 15 H), 3.75 (dt, 
2
J = 12.7, 
3
J = 7.6 Hz, 2 H), 3.05 (dt, 
3
J = 13.2, 
2
J = 7.6 Hz, 2 H). 
13
C NMR 
(101 MHz, CDCl3, ppm) δ: 171.20 (d, 
3
J = 13.87 Hz), 135.36 (d, 
4
J = 3.47 Hz), 133.55 (d, 
2
J = 10.40 
Hz), 130.63 (d, 
3
J = 12.14 Hz), 117.32 (d, 
1
J = 86.70 Hz), 28.20, 18.98 (d, 
1
J = 55.49 Hz). MS (EI) 
m/z: 335 [M−Br]+. HR-MS (EI) m/z calcd for C21H20O2P: 335.1201[M−Br]
+
; found: 335.1204. In 
agreement with the literature. 
1.25.13.44 6-(Hydroxymethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (348)238  
 
Potassium carbonate (202 mg, 1.46 mmol) in water (2.25 mL) was added to (2,2-dimethyl-4-oxo-4H-
1,3-dioxin-6-yl)methyl acetate (450 mg, 2.25 mmol) in methanol (9 mL) at 5 °C. The mixture was 
stirred for 0.5 h and then the methanol rotary evaporated. The residue was acidified with 1M aqueous 
HCl and extracted with CH2Cl2 (3 × 50 mL). The combined organics were dried (MgSO4), rotary 
evaporated and chromatographed (pentane/Et2O, 3:2 to 1:3) to give the title compound (156 mg, 44 
%) as a colourless solid. IR (cm
−1
): 1705, 1638, 1391, 1378, 1316, 1273, 1252, 1200, 1095, 1081, 
1044, 1007, 904, 869, 809, 659. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.57 (br. t, 1 H), 4.18 (br. d, 2 
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H), 2.93 (br. t, 1 H), 1.70 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 170.8, 161.6, 107.1, 91.9, 
60.7, 24.9. In agreement with the literature. 
1.25.13.45 2-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acetaldehyde (350) 
 
Palldium on charcoal (100% by wt. (10% Pd) and triethylsilane (250 µL, 1.57 mmol) were 
added sequentially to S-ethyl 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)ethanethioate (120 
mg, 0.522 mmol) in CH2Cl2 (1 mL) and stirred for 24 h. The mixture was filtered through 
celite and rotary evaporated then left to stand 5 d. The title compound (40 mg) was obtained 
as an impure red oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 9.71 (t, J = 1.5 Hz, 1 H), 5.41 (s, 1 
H), 3.37 (d, J = 1.6 Hz, 2 H), 1.69 ppm (s, 6 H). Cross peak in COSY for 9.71 and 3.37 ppm. 
1
H NMR (400 MHz, Acetone-d6, ppm) δ: (keto-form) 9.69 (t, J = 1.1 Hz, 1 H), 5.46 (s, 1 H), 
3.54 (d, J = 1.3 Hz, 2 H), 1.69 (s, 6 H);  (enol form) 7.46 (d, J = 12.1 Hz, 1 H), 5.51 (d, J = 
12.1 Hz, 1 H), 5.07 (s, 1 H), 1.65 (s, 6 H). 
1.25.13.46 2-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-N-methoxy-N-methylacetamide (351) 
 
2,2,6-Trimethyl-4H-1,3-dioxin-4-one (4.50 g, 0.032 mmol) in THF (15 ml) was added 
dropwise to LiHMDS (7.74 ml, 0.036 mmol) in THF (90 ml) at −78 oC. After 0.5 h, 2-chloro-
N-methoxy-N-methylacetamide xx (1.96 g, 0.016 mmol) was added and the mixture stirred 
for 0.5 h then stirred at 20 °C for 14 h. Saturated aqueous NH4Cl (100 mL) was added and the 
layers separated. The aqueous was extracted with EtOAc (2 × 75 ml) and the combined 
organics were dried (MgSO4), rotary evaporated, and chromatographed (petroleum 
ether/Et2O, 1:3 to 0:1) to give the title compound (2.6 g, 71 %) as colourless needles. IR 
(cm−1): 1726, 1661, 1394, 1372, 1273, 1198. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.37 (s, 1 
H), 3.71 (s, 3 H), 3.39 (s, 2 H), 3.19 (s, 3 H), 1.71 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, 
ppm) δ: 167.6, 165.1, 160.9, 107.2, 96.4, 61.4, 37.4, 32.2, 25.0. MS (CI) m/z: 230 (M+H)+. 
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HR-MS (CI) m/z calcd for C10H16NO5: 230.1031 [M+H]; found:  230.1028. Anal. calcd for 
C10H15O5N: C 52.40, H 6.60, N 6.11; found: C 52.56, H 6.51, N 5.99.  
1.25.13.47 S-Ethyl 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)ethanethioate (352) 
 
To 2-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acetic acid (448 mg, 2.41 mmol) was added Ghosez’s 
reagent (414 µL, 3.13 mmol) in CH2Cl2 (50 mL) and stirred for 5 min. Ethanethiol (178 µL, 24.2 
mmol) was then added dropwise and stirred 15 min and then pyridine (388 µL, 4.82 mmol) was added 
and stirred for 12 h. The mixture was poured in saturated aqueous NH4Cl and extracted with CH2Cl2 
(× 2), dried (MgSO4), rotary evaporated and chromatographed (pentane/Et2O, 7:3) to give the title 
compound (166 mg, 72%) as a pale yellow oil. IR (cm−1):  1725, 1686, 1634, 1389, 1372, 1270, 
1252, 1200, 1012, 961, 900, 808, 639. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.41 (s, 1 H), 
3.45 (s, 2 H), 2.94 (q, J = 7.5 Hz, 2 H), 1.71 (s, 6 H), 1.28 (t, J = 7.6 Hz, 3 H). 
13
C NMR (101 
MHz, CDCl3, ppm) δ: 192.1, 163.4, 160.5, 107.2, 96.8, 47.9, 24.9, 24.0, 14.5. MS (EI) m/z: 231 
[M+H]
+
. HR-MS (EI) m/z: calcd for C10H15O4S: 231.0691[M+H]
+
; found: 231.0697. 
1.25.13.48 2,2-Dimethyl-4,6-dioxo-1,3-dioxane-5-carbaldehyde (354)237 
 
Meldrums acid (5.06 g, 35.1 mmol) in triethylformate (18.94 mL, 113.7 mmol) was heated at 85 °C 
for 2.5 h then rotary evaporated and a solution of 2 M aqueous HCl added and stirred a further 1 h at 
25 °C. The mixture was diluted with brine (100 mL) and extracted with ether (3 × 100 mL), dried 
(Na2SO4), and rotary evaporated to give the title compound (3.40 g, 56%) as an orange solid. 
1
H NMR 
(400 MHz, CDCl3, ppm) δ: 10.81 (br. s., 2 H), 0.48 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 
177.0, 171.8, 168.0, 107.1, 95.4, 27.3. In agreement with literature.  
1.25.13.49 (2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)methyl acetate (355)238  
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Sodium acetate (1.04 g, 12.67 mmol) was added to 6-(bromomethyl)-2,2-dimethyl-4H-1,3-dioxin-4-
one (1.4 g, 6.33 mmol) in DMF (12.7mL) and heated at 70 °C for 2 h. The mixture poured into ice 
(100 g) and the aqueous was extracted with ether (3 × 60 mL) and the combined organics washed with 
brine (2 × 30 mL), dried (MgSO4), rotary evaporated and chromatographed (petroleum ether/Et2O, 7:3 
to 3:2) to give the title compound (563 mg, 44%) as a colourless oil used without further purification. 
IR (cm
−1
): 1728, 1647, 1413, 1393, 1378, 1326, 1273, 1218, 1203, 1180, 1070, 1045, 1012, 903, 813. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.45 (t, J = 1.2 Hz, 1 H), 4.61 (d, J = 1.0 Hz, 2 H), 2.14 (s, 3 H), 
1.70 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ:  169.8, 165.2, 160.4, 107.3, 93.6, 60.8, 24.9, 20.5. 
MS (CI) m/z: 218 [M+NH4]
+
, 201 [M+H]
+
. HR-MS (CI) m/z calcd for C9H16NO5: 218.1028 
[M+NH4]
+
; found: 218.1035. In agreement with the literature. 
1.25.13.50 5-(Hydroxymethyl)-2,2,6-trimethyl-4H-1,3-dioxin-4-one (358)  
 
 
2,2,6-Trimethyl-4H-1,3-dioxin-4-one (0.50 g, 3.5 mmol) was added dropwise to LDA (3.87 
mmol) in THF (2 ml) at −78 oC and stirred for 1 h in flask A. In flask B, THF (100 mL) was 
added to paraformaldehyde (3 g, 0.1 mol) and p-tolenesulfonic acid (0.49 g, 1.5 mmmol) and 
distilled. The formaldehyde/THF co-distillate (80 ml) was added dropwise to the flask A over 
30 min. The mixture was allowed to warm to room temperature and stirred for 14 h. Saturated 
aqueous NH4Cl (10 ml) and water (10 ml) were added and the mixture extracted with diethyl 
ether (3 × 40 ml). The combined organics were washed with brine (45 ml), dried (Na2SO4), 
filtered, rotary evaporated and chromatographed (petroleum ether/Et2O, 1:1 to 0:1) to give the 
title compound (54 mg, 9%) as a yellow oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ:  4.38 (s, 2 
H), 2.48 (br. s, 1 H), 2.12 (s, 3 H), 1.71 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 166.3, 
162.6, 105.7, 105.2, 56.8, 25.1, 17.3.  
1.25.13.51 5-(Methoxymethyl)-2,2,6-trimethyl-4H-1,3-dioxin-4-one (359)  
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2,2,6-Trimethyl-4H-1,3-dioxin-4-one (0.50g, 3.5 mmol) was added dropwise to LDA (3.87 
mmol) in THF (5 ml) at −78 oC. After 0.5 h, chloromethyl methyl ether (1.42 g, 17.6 mmol) 
was added dropwise and the mixture stirred for 3 h at −78 oC. Further chloromethyl methyl 
ether (0.36 g, 4.4 mmol) was added and the mixture warmed to 20 °C and stirred for a further 
16 h. Saturated aqueous NH4Cl (10 mL) and water (10 mL) was added and the mixture 
extracted with diethyl ether (3 × 50 mL). The combined organics were washed with brin (50 
mL), dried (Na2SO4), rotary evaporated and chromatographed (petroleum ether/Et2O, 1:1 to 
0:1) to yield the title compound (128 mg, 28%) as a colourless oil. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ:  4.19 (s, 2 H) 3.37 (s, 3 H) 2.11 (s, 3 H) 1.70 (s, 6 H); 
13
C NMR (101 MHz, 
CDCl3, ppm) δ: 168.8, 161.8, 105.6, 102.7, 65.1, 58.0, 25.1, 17.6. 
1.25.13.52 9H-Carbazole-9-carbaldehyde (361)241 
 
Carbazole (5.00 g, 29.9 mmol) in formic acid (37.5 mL) was refluxed for 9 h then rotary evaporated 
and recrystalized (EtOAc) to give the title compound (3.22 g, 55%) as a colourless solid. IR (cm−1): 
1699, 1482, 1446, 1420, 1361, 1324, 1301, 1225, 1215, 1155, 1079, 946, 752, 723, 686, 616.  
1
H NMR (400 MHz, CDCl3, ppm) δ: 9.67 (s, 1 H), 8.50–8.65 (m, 1 H), 7.97 (d, J = 7.8 Hz, 2 H), 
7.63–7.75 (m, 1 H), 7.37–7.57 (m, 4 H).13C NMR (101 MHz, CDCl3, ppm) δ: (101 MHz, 
CDCl3, ppm) δ: 157.4, 137.7, 137.1, 127.7, 127.0, 126.1, 124.6, 124.3, 120.7, 119.8, 116.7, 
109.8. MS (EI) m/z: 196 [M+H]
+
. HR-MS (EI) m/z: calcd for C13H10NO: 196.0762 [M+H]
+
; 
found: 196.0766. In agreement with the literature. 
1.25.13.53 Methoxy(methyl)carbamic chloride (364)242 
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N,O-Dimethylamine hydrochloride (8.33 g, 85.4 mmol) was added portionwise over 10 min 
to a solution of triphosgene (10.2 g, 34.2 mmol) in CH2Cl2 (85 ml) maintaining the 
temperature below -70 
o
C and stirred for 0.5 h. Pyridine (13.73 mmol, 170.8 mmol) in CH2Cl2 
(28 ml) was added dropwise over 1.5 h maintaining the temperature below -73 
o
C then stirred 
13.5 h at 20 °C. Water (100 ml) was added dropwise, the layers were separated and aqueous 
further extracted with CH2Cl2 (3 × 50 ml). The combined organics were washed with 0.5 M 
HCl (2 × 100 ml), NaHCO3 (75 ml), brine (75 ml), dried (MgSO4), rotary evaporated (CARE: 
water bath at 35 
o
C, no more than 500 torr below atmospheric pressure) and distilled (60 
o
C, 
1.0 torr) to give title compound (8.213 g, 78 %) as a colourless oil. IR (cm
−1
): 1719, 1459, 
1443, 1406, 1348, 1181, 1081, 980, 856, 668, 651. (
1
H NMR 400 MHz, CDCl3, ppm) δ: 3.76 
(s, 3 H), 3.32 (br. s., 3 H). MS (CI) m/z: 141 [M+NH4]
+
. HR-MS (CI) m/z calcd for 
C3H10N2O2Cl: 141.0431 [M+NH4]; found: 141.0431. Compound too volatile for 
microanalysis. In agreement with the literature. 
1.25.13.54 (E)-6-(2-(Methoxy(methyl)amino)vinyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (365) 
 
(
i
Bu2AlH)2 (1M in hexanes, 3.22 mL) was added dropwise to a solution of 2-(2,2-dimethyl-4-oxo-4H-
1,3-dioxin-6-yl)-N-methoxy-N-methylacetamide ( 0.74g, 3.22 mmol) in THF (32 mL) at −78 oC over 
10 min and stirred for a further 20 min. Phenol (0.41 g, 4.37 mmol) was added and stirred for 10 min. 
The mixture was then added to phenyl (triphenylphosphoranylidene)acetate (0.87g, 2.19 mmol) in 
THF (22 mL) at 50 
o
C and stirred for 4 h. Aqueous Sodium potassium tartrate was added and the 
aqueous extracted with ether (× 2) and ethyl acetate (× 2). The combined organics were washed with 
brine, dried (MgSO4), rotary evaporated and chromatographed (petroleum ether/Et2O, 1:1 to 0:1) to 
give the title compound (0.16 g, 35%) a yellow oil. IR (cm
−1
): 1702, 1609, 1581, 1365, 1267, 1247, 
1201, 1173, 1104, 1066, 1013, 944, 899, 792, 681. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.94 (d, J = 
12.7 Hz, 1 H), 5.19 (d, J = 12.7 Hz, 1 H), 5.05 (s, 1 H), 3.67 (s, 3 H), 3.07 (s, 3 H), 1.70 (s, 6 H). 
13
C 
NMR (400 MHz, CDCl3, ppm) δ: 165.5, 162.7, 143.7, 105.4, 92.8, 88.1, 60.2, 40.3, 25.1. MS (CI) 
m/z: 214 [M+H]
+
. HR-MS (EI) m/z calcd for C10H16NO4: 214.1079 [M+H]
+
; found: 214.1075. Anal. 
calcd for C10H15NO4: C 56.33, H 7.09, N 6.57; found: C 56.44, H 6.97, N 6.45. 
1.25.13.55 tert-Butyl (triphenylphosphoranylidene)acetate (366b)243 
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tert-Butyl bromoacetate (7.60 mL, 51.4 mmol) was added to to triphenylphosphine (12.00 g, 45.8 
mmol) in toluene (20 mL) and stirred for 2h and then a further 12 h at 3 °C. The solids were collected 
by filtration and washed sequentially with toluene and then hexane and dried in vacuo to give (tert-
butylcarbonylmethyl)triphenylphosphonium bromide (349a) as a colourless solid (16 g, 76%) used 
directly in the next step. 
A cold solution of 2 M aqueous NaOH was added to (tert-
Butylcarbonylmethyl)triphenylphosphonium bromide in cold water and stirred vigorously. The solids 
were collected by filtration, washed with cold water and dried in air to give the title compound.
 1
H 
NMR (400 MHz, CDCl3, ppm) δ: 7.70–7.61 (m, 6 H), 7.58–7.51 (m, 3 H), 7.49 (td, J = 7.6, 2.7 
Hz, 6 H), 2.71 (br. d, 1 H), 1.27 (br. d, 9 H). In agreement with the literature. 
1.25.13.56 Phenyl (triphenylphosphoranylidene)acetate (366c)244 
 
Phenylbromoacetate (2.15 g, 10 mmol) in chloroform (5 mL) was added to triphenylphosphine (2.62g, 
10 mmol) in chloroform (5 mL) at 0 °C and the mixture allowed to stir at 25 °C for 40 min. The 
mixture was rotary evaporated, suspended in ether and the solids collected by filtration, washing with 
further diethyl ether (× 3) and dried in vacuo. The salt obtained was dissolved in CH2Cl2 (60 mL) and 
washed with 2 M aqueous NaOH (50 mL), dried (MgSO4) and rotary evaporated to give the title 
compound (3.81 g, 96%) as a coulourless solid. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.80–7.65 (m, 
7 H), 7.61–7.45 (m, 9 H), 7.28 (br. s, 1 H), 7.22–7.08 (m, 1 H), 7.05 (br. s, 1 H), 6.65 (br. s, 1 H), 
3.19–2.85 (m, 1 H). 
1.25.13.57 PSB160-1 1(Benzoylmethylene)triphenylphosphorane (367a)245 
 
2-Bromoacetophenone (1.99 g, 10 mmol) in acetone (10 mL) was added to triphenylphosphine (2.62g, 
10 mmol) in acetone (10 mL) stirred for 30 min. The solids were collected by filtration and were 
washed with ether. The resulting salt was dissolved in CH2Cl2 (60 mL) and washed with 2 M aqueous 
NaOH (50 mL). dried (MgSO4) and rotary evaporated to give the title compound (2.67 g, 70%) as a 
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solourless solid. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 8.12–7.86 (m, 2 H), 7.86–7.62 (m, 5 H), 
7.62–7.42 (m, 10 H), 7.42–7.31 (m, 3 H), 4.45 (d, J = 24.9 Hz, 1 H). In agreement with the literature. 
1.25.13.58 [(p-Nitrobenzoyl)methylene]triphenylphosphorane (367b)245 
 
2-Bromo-4’-nitroacetophenone (2.44 g, 10 mmol) in chloroform (5 mL) was added to 
triphenylphosphine (2.62g, 10 mmol) in chloroform (5 mL) at 0 °C and allowed to stir at 25 °C for 40 
min. The mixture was rotary evaporated, suspended in ether and the solids collected by filtration, 
washing with further diethyl ether (× 3) and dried in vacuo. The salt obtained was dissolved in CH2Cl2 
(60 mL) and washed with 2 M aqueous NaOH (50 mL), dried (MgSO4) and rotary evaporated to give 
the title compound (3.47 g, 82%) as a yellow oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 8.20 (m, 2 
H), 8.14–8.04 (m, 2 H), 7.76–7.65 (m, 6 H), 7.63–7.44 (m, 9 H), 4.51 (d, J = 23.0 Hz, 1 H). MS (EI) 
m/z: 426 [M+H]
+
. HR-MS (EI) m/z calcd for C26H21NO3P: 426.1259 [M+H]
+
; found: 426.1258. In 
agreement with the literature. 
1.25.13.59 2-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acetic acid (368)  
 
Hydrogen was bubbled through a mixture of Benzyl 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-
yl)acetate (530 mg, 1.92 mmol) and Pd/C (53 mg, 10% by wt.) in EtOAc (19 mL) for 5 min and then 
the mixture was stirred under a hydrogen atmosphere (balloon) for 45 min. The mixture was filtered 
through celite and rotary evaporated to give the title compound (332 mg, 90%) as a colourless solid. 
IR (cm
−1
): 1734, 1701, 1646, 1422, 1393, 1373, 1340, 1275, 1235, 1200, 1177, 1014, 948, 917, 903, 
832, 752, 735.
 1
H NMR (400 MHz, CDCl3, ppm) δ: 10.75 (br. s, 1 H), 5.45 (s, 1 H), 3.32 (s, 2 H), 
1.71 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 172.2, 163.4, 161.2, 107.5, 96.5, 39.1, 24.8. MS 
(CI) m/z: 204 [M+NH4]
+
, 160 [M-CO2+NH4]
+
, 143 [M-CO2+H]
+
. HR-MS (CI) m/z calcd for 
C8H14NO5: 204.0872 [M+NH4]
+
; found: 204.0880. 
1.25.13.60 2,2-Dimethyl-6-vinyl-1,3-dioxan-4-one (372a)246246 
193 
 
 
Triethylamine (28.5 mL, 204 mmol) was added dropwise to a solution of 6-(2-chloroethyl)-2,2-
dimethyl-1,3-dioxan-4-one (19.5 g, 102 mmol) in CH2Cl2 (250 mL) at 0 °C and the mixture stirred at 
25 °C for 3 h. The mixture was diluted with CH2Cl2 (150 mL) then washed with 1 M aqueous HCl 
(200 mL), brine (200 mL), dried (MgSO4) rotary evaporated and chromatographed (petroleum 
ether/Et2O, 3:1 to 2:1) to give the title compound (11.29 g, 73% over 3 steps) as a colourless oil. 
1
H 
NMR (400 MHz, CDCl3, ppm) δ: 6.21 (dd, J = 17.1, 10.3 Hz, 1 H), 6.02 (dd, J = 17.1, 1.0 Hz, 1 H), 
5.60 (d, J = 10.3, 1.0 Hz, 1 H), 5.34 (s, 1 H), 1.71 (s, 6 H).
13
C NMR (101 MHz, CDCl3, ppm) δ: 
162.8, 161.7, 129.3, 123.8, 106.5, 95.2, 25.0. MS (CI) m/z: 155 [M+H]+; HR-MS (CI) m/z calcd 
for C8H11O3: 155.0708 [M+H]
+
; found: 155.0708. In agreement with the literature. 
1.25.13.61 2,2-Dimethyl-6-(prop-1-en-2-yl)-4H-1,3-dioxin-4-one (372b) 
 
(CF3CO)2O (5.72 mL, 37.4 mmol), CF3CO2H (28.4 mL, 370 mmol) and Ac2O (4.4 mL, 47 
mmol) were added dropwise with stirring to tert-butyl 4-methyl-3-oxopent-4-enoate in 
Me2CO at −78 °C and the mixture was allowed to warm to 25 °C. After 14 h, the mixture was 
poured into cold saturated aqueous NaHCO3 (800 mL) and extracted with EtOAc (2 × 100 
mL). The combined organic phases were dried (MgSO4), filtered, rotary evaporated and 
chromatographed (pentane/Et2O, 95:5 to 90:10) to give the title compound (353 mg, 33%) as 
a yellow oil. IR (cm−1): 1721, 1635, 1593, 1391 1369, 1283, 1253, 1202, 1146, 1016, 998, 
921, 903, 887, 820, 754, 617. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.80 (s, 1 H), 5.47 (s, 1 H), 
5.37–5.40 (m, 1 H), 1.92 (s, 3 H), 1.70 (s, 6 H). 13C NMR (101 MHz, CDCl3, ppm) δ: 164.5, 
162.0, 135.3, 121.1, 106.2, 92.8, 24.9, 18.1. MS (ES) m/z: 210 [M + MeCN + H]
+
, 169 [M + 
H]
+
. HR-MS (ES) m/z calcd for C9H13O3: 169.0865 [M + H]
+
; found: 169.0869. 
1.25.13.62 3,3-Dimethyl-9-phenyl-5,6-dihydro-[1,3]dioxino[5,4-c][1,2,4]triazolo[1,2-
a]pyridazine-1,8,10(9H)-trione (373) 
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4-Phenyl-1,2,4-triazole-3,5-dione (85 mg, 0.49 mmol) was added to 2,2-dimethyl-6-vinyl-4H-1,3-
dioxin-4-one (50 mg, 0.325 mmol) in CH2Cl2 (3 mL) and stirred for 14 h. Saturated aqueous NaHCO3 
was added and stirred for 0.5 h. The aqueous was extracted with CH2Cl2 (× 2) and the combined 
organics were washed with brine, dried (MgSO4), rotary evaporated and chromatographed 
(pentane/EtOAc, 1:1 to 3:7) to give the title compound (38 mg, 36%) as a yellow solid. IR (cm
−1
): 
1773, 1744, 1703, 1642, 1495, 1456, 1424, 1393, 1322, 1300, 1280, 1195, 1162, 1143, 1126, 1093, 
1069, 1029, 983, 913, 886, 856, 799, 779, 762, 749, 693, 733, 675, 650. 
1
H NMR (400 MHz, CDCl3, 
ppm) δ: 7.58–7.50 (m, 2 H), 7.49–7.41 (m, 2 H), 7.41–7.31 (m, 1 H), 4.05 (t, J = 5.6 Hz, 2 H), 2.66 (t, 
J = 5.6 Hz, 2 H), 1.79 (s, 6 H).
 13
C NMR (101 MHz, CDCl3, ppm) δ: 156.4, 153.5, 148.8, 148.4, 131.3, 
129.2, 128.4, 125.7, 107.7, 107.0, 37.9, 26.8, 24.9. MS (ES) m/z: 330 [M+H]
+
. HR-MS (ES) m/z calcd for 
C16H16N3O5: 330.1090 [M+H]
+
; found: 330.1104. 
1.25.13.63 6-Allyl-2,2-dimethyl-4H-1,3-dioxin-4-one (405) 
 
m-CPBA (32 mg, 0.185 mmol) in CH2Cl2 (1 mL) was added dropwise to 2,2-dimethyl-6-(3-
(phenylselanyl)propyl)-4H-1,3-dioxin-4-one (50 mg, 0.154 mmol) in CH2Cl2 (1 mL) and 
stirred for 30 min. This mixture was transferred into refluxing CH2Cl2 (6 mL) and after a 
further 2.5 h, rotary evaporated and chromatographed (petroleium ether/Et2O, 9 :1 to 7:3)  to give the 
title compound (15 mg, 58%) as a colourless oil.
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.87–5.70 (m, 1 
H), 5.29–5.25 (m, 2 H), 5.24–5.20 (m, 1 H), 3.03–2.95 (m, 2 H), 1.70 (s, 6 H). 13C NMR (101 MHz, 
CDCl3, ppm) δ: 169.9, 161.3, 130.1, 119.8, 106.5, 93.5, 37.9, 25.0. MS (ES) m/z: 210 
[M+MeCN+H]
+
, 169 [M+H]
+
. HR-MS (ES) m/z calcd for C9H12O3: 169.0865 [M+H]
+
; found: 
169.0859.  
1.25.13.64 1-Phenylbut-3-en-1-one (407)247 
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1-Phenylbut-3-en-1-ol (490 mg, 3.3 mmol) in CH2Cl2 (4 mL) was added dropwise to PCC (1.0 g, 4.8 
mmol) in CH2Cl2 (6 mL) and stirred for 14 h . The mixture was filtered through celite twice, rotary 
evaporated and chromatographed (petroleum ether/Et2O, 97:3) to give the title compound (308 mg, 64 
%) as a pale yellow oil 
1
H NMR (400 MHz, CDCl3, ppm) δ: 8.14–7.84 (m, 2 H), 7.80–7.52 (m, 1 H), 
7.52–7.36 (m, 2 H), 6.20–5.99 (m, 1 H), 5.31–5.13 (m, 2 H), 3.77 (dt, J = 6.8, 1.5 Hz, 2 H). HR-MS 
(EI) m/z calcd for C10H10O: 146.0732  [M]
+
; found: 146.0732. In agreement with the literature. 
1.25.13.65 tert-Butyl 2-phenylacetate (408c)248  
 
Thionyl chloride (5.47 mL, 75 mmol) was added to phenylacetic acid (6.81 g, 50 mmol) in CH2Cl2 
(50 mL) and DMF (387 µL, 5 mmol) and stirred for 1.2 h then rotary evaporated to give phenylacetyl 
chloride. 
tert-Butanol (4.78 mL, 50 mmol) and pyridine (6.03 mL, 75 mmol) were added to phenylacetyl 
chloride (from above) and stirred at reflux for 0.5 h and then at 25 °C for 2 h. Saturated aqueous 
NH4Cl and CH2Cl2 were added and the organics washed with saturated aqueous NaHCO3, brine, dried 
(MgSO4), rotary evaporated and chromatographed (pentane/Et2O, 99.5 to 49:1) to give the title 
compound (3.95 g, 41%) as a pale brown oil. IR (cm−1): 1729, 1497, 1455, 1393, 1368, 1343, 
1299, 1254, 1228, 1135, 1075, 1031, 954, 908, 864, 834, 742, 711, 695. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 7.23–7.36 (m, 5H), 3.54 (s, 2H), 1.45 (s, 9H). 
13
C NMR (101 MHz, CDCl3, 
ppm) δ: 170.9, 134.7, 129.2, 128.4, 126.8, 80.8, 42.6, 28.0
. 
MS (CI) m/z: 210 [M+NH4]
+
, 193 
[M+H]
+
.
 
HR-MS (CI) m/z: calcd for C12H20NO2: 210.1494 [M+NH4]
+
; found: 210.1489. In 
agreement with the literature. 
1.25.13.66 Ethyl but-3-enoate (409)249 
 
Sulfuric acid (0.2 mL)  was added to vinylacetic acid (2 g, 23.3 mmol) in ethanol (40 mL) and the 
mixture refluxed for 4 h. Ethyl acetate (100 mL) and water (100 mL) were added and organics were 
washed with saturated aqueous NaHCO3 (40 mL), dried (MgSO4), and the solvent removed at 
atmospheric pressure to give the title compound (0.55 g, 21 %) as a yellow oil. 
1
H NMR (400 MHz, 
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CDCl3, ppm) δ: 5.93 (ddt, J = 17.2, 9.9, 7.2 Hz, 1 H), 5.39–5.14 (m, 2 H), 4.15 (q, J = 7.3 Hz, 2 H), 
3.09 (dt, J = 7.2, 1.3 Hz, 2 H), 1.27 (t, J = 7.1 Hz, 3 H). In agreement with the literature. 
1.25.13.67 tert-Butyl 3-oxohex-5-enoate (410) 
 
tert-Butylacetate (1.1 mL, 8.3 mmol) was added to LDA (8.0 mmol) in THF (4 mL) at −78 °C and 
stirred 30 min. This mixture was added to ethyl but-3-enoate (0.45 g, 4.0 mmol) in THF (8 mL) at 
−78 oC by cannula and stirred for 15 min. Acetic acid (4.0 mL) was added and the mixture diluted 
with water (20 mL) and ether (60 mL). The organic phase was washed with 20% aqueous K2CO3 (3 × 
20 mL), brine (40 mL), dried (MgSO4) rotary evaporated and chromatographed (petroleum 
ether/Et2O, 1:0 to 9:1) to give the title compound (191 mg, 26%) as a colourless oil. 
1
H NMR (400 
MHz, CDCl3, ppm) δ: 5.92 (tdd, J = 17.2, 10.1, 7.1 Hz, 1 H), 5.26–5.06 (m, 2 H), 3.38 (s, 2 H), 
3.35–3.24 (m, 2 H), 1.47 (s, 9 H). 13C NMR (101 MHz, CDCl3, ppm) δ: 201.2, 166.2, 129.8, 119.5, 
82.1, 50.0, 47.6, 27.9. HR-MS (CI) m/z calcd for C10H20NO3: 202.1443  [M+NH4]
+
; found: 202.1444. 
1.25.13.68 (E)-2,2-Dimethyl-6-(prop-1-enyl)-1,3-dioxan-4-one (414)250 
  
Oxalyl chloride (2.71 mL, 32 mmol) was added to vinylacetic acid (2.5 g, 29 mmol) in CH2Cl2 (12 
mL) followed by a few drops of DMF at 0 
o
C and stirred for 30 min and then stirred a further 2 h at 25  
°C. Distallation (97–99 oC) gave vinylacetoyl chloride a a brown oil. IR (cm−1) 1792 cm-1. 
Pyridine (3.75 ml, 46 mmol) was added dropwise to meldrums acid (3.34 g, 23 mmol) in CH2Cl2 (50 
mL) at 0 
o
C over 10 min followed by vinylacetoyl chloride prepared above and the mixture was 
stirred for 1 h then for 14 h at 25 °C.  The mixture was washed with 1 M aqueous HCl (× 2), water (× 
2), dried ( MgSO4) and rotary evaporated to give a brown gum. This was dissolved in toluene (25 mL) 
and acetone (2 mL) and refluxed vigorously for 1 h. The mixture was rotary evaporated and 
chromatographed (petroleum ether/Et2O, 9:1 to 4:1) to give the title compound (53 mg, 2 %) as 
coulourless oil.
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.61 (dq, J = 15.6, 6.9 Hz, 1H), 5.96 (dq, J = 
15.4, 1.5 Hz, 1H), 5.26 (s, 1H), 1.93 (dd, J = 7.0, 1.7 Hz, 3H), 1.73 (s, 6H). HR-MS (CI) m/z calcd for 
C9H13O3 169.0865 [M+H]
+
; found: 169.0866. 
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1.25.13.69 Mixture of 6-allylidene-2,2-dimethyl-1,3-dioxan-4-one (415) and (E)-2,2-dimethyl-6-
(prop-1-enyl)-1,3-dioxan-4-one (414) 
 
LiHMDS (0.14 mmol) was added to (E)-2,2-dimethyl-6-(prop-1-enyl)-1,3-dioxan-4-one xx (18 mg, 
0.11 mmol) in THF (1 mL) with stirring at −78 °C. After 0.5 h acetic acid (0.1 mL) was added to the 
mixture to give the title compounds as a mixture (rr 1.0:0.9).  
6-Allylidene-2,2-dimethyl-1,3-dioxan-4-one (415): 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.73–6.44 
(m, 1 H), 5.39 (d, J = 10.8 Hz, 1 H), 5.13 (d, J = 17.1 Hz, 1 H), 5.00 (d, J = 9.9 Hz, 1 H), 3.41 (s, 2 
H), 1.65 (s, 6 H). 
1.25.13.70 tert-Butyl 6-chloro-3-oxohexanoate (417)251 
 
tert-Butylacetate (7.5 mL, 21.3 mmol) was added to LDA (53.0 mmol) in THF (25 mL) at −78 °C and 
stirred 30 min. This mixture was added to ethyl-4-chlorobutanoate (4.00 g, 27.0 mmol) in THF (50 
mL) at −78 oC by cannula and stirred for 15 min. Acetic acid (25 mL) was added and the mixture 
diluted with water (125 mL) and ether (375 mL). The organic phase was washed with 20% aqueous 
K2CO3 (3 × 125 mL), brine (250 mL), dried (MgSO4) rotary evaporated and chromatographed 
(petroleum ether/Et2O, 17:3 to 3:1) to give the title compound (3.95 g, 67%) as a pale yellow oil. IR 
(cm
−1
): 1733, 1713, 1368, 1319, 1252, 1149. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 3.61 (t, J = 6.4 
Hz, 2 H), 3.39 (s, 2 H), 2.77 (t, J = 7.1 Hz, 2 H), 2.09 (quin, J = 6.6 Hz, 2 H), 1.50 (s, 9 H). 
13
C NMR 
(101 MHz, CDCl3, ppm) δ: 202.2, 166.2, 82.2, 50.7, 44.2, 39.5, 27.9, 26.0. MS (CI) m/z: 238 
[M+NH4]
+
, 220 [M+H]
+
. HR-MS (CI) m/z calcd for C10H21NO3Cl: 238.1210 [M+NH4]
+
; found: 
238.1211.  Anal. calcd for C10H17ClO3: C 54.42, H 7.76; found: C 52.03, H 6.77. In agreement with 
the literature. 
1.25.13.71 6-(3-Chloropropyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (418) 
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Sulfuric acid (0.483 mL, 9.1 mmol) was added dropwise to a solution of tert-butyl 6-chloro-3-
oxohexanoate (2 g, 9.1 mmol) and acetic acnhydride (2.57 mL, 27.3 mmol) in acetone (1.33 mL, 18.1 
mmol) at 0 
o
C and the mixture allowed to stir at 25 °C for 15 h. The mixture was diluted with water 
(100 mL), layers separated and aqueous reextracted with CH2Cl2 (2 × 100 mL). The combine organics 
were washed with brine, dried (MgSO4), rotary evaporated and chromatographed (petroleum 
ether/Et2O, 3:1 to 3:2) to give the title compound (1.25 g, 67%) as a pale yellow oil. IR (cm
−1
): 1727, 
1634, 1391, 1376, 1273, 1204, 1013, 902, 808.  
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.29 (s, 1 H), 
3.58 (t, J = 6.4 Hz, 2 H), 2.45–2.38 (m, 2 H), 2.09–1.98 (m, 2 H), 1.69 (s, 6 H). 13C NMR (101 MHz, 
CDCl3, ppm) δ: 170.1, 161.0, 106.5, 93.8, 43.6, 30.8, 28.5, 25.0. MS (CI) m/z: 222[M+NH4]
+
, 205 
[M+H]
+
. HR-MS (CI) m/z calcd for C9H17NO3Cl: 222.0897 [M+NH4]
+
; found: 222.0901. Anal. calcd 
for C9H13ClO3: C 52.82, H 6.40; found: C 53.39, H, 6.17. 
1.25.13.72 tert-Butyl 3-cyclopropyl-3-oxopropanoate (419) 
 
Potassium tert-butoxide (0.23g, 1.96 mml) was added to 6-(3-chloropropyl)-2,2-dimethyl-4H-1,3-
dioxin-4-one (0.2 g, 0.98 mmol) in THF (1 mL) and tert-BuOH ( 1 mL) and stirred for 2 h. The 
mixture was then heated at 85 
o
C for a further 14 h. 1 M aqueous HCl was added and the aqueous 
extracted with ether (2 x 10 mL). The combined organics were rotary evaporated and 
chromatographed (petroleum ether/Et2O, 4:1) to give the title compound (30 mg, 17%) as a colourless 
oil. IR (cm
−1
): 1734, 1703, 1372, 1153. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 3.47 (s, 2 H), 2.09–
1.98 (m, 1 H), 1.48 (s, 9 H), 1.13–1.08 (m, 2 H), 0.98–0.91 (m, 2 H). MS (CI) m/z: 202 [M+NH4]
+
. 
HR-MS (CI) m/z calcd for C10H20NO3: 202.1443 [M+NH4]
+
; found: 202.1447. 
1.25.13.73 2,2-Dimethyl-6-(3-(phenylselanyl)propyl)-4H-1,3-dioxin-4-one (420) 
 
n
BuLi (2.5M in hexanes, 0.52 mL)was added to benzeneselenol (138 µL, 1.303 mmol) in THF 
(4.5 mL) at 0 
o
C the mixture stirred at 25 °C for 20 min. This solution was then added to 6-(3-
chloropropyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (222 mg, 1.083 mmol) in THF (11mL) at -5 
o
C and 
the mixture allowed to warm to 5 
o
C over 4.5 h. The mixture was warmed to 25 °C and further PhSeLi 
(0.2  equiv) was added and stirred for a further 1 h. Saturated aqueous NH4Cl (15 mL) and water (5 
mL) were added and the layers separated. The aqueous was reextracted with ether (3 × 15 mL) and 
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then the combined organics were washed with brine (20 mL), dried (MgSO4), rotary evaporated and 
chromatographed (petroleum ether/Et2O, 9:1 to 7:3) to give the title compound (255 mg, 72%) as a 
colourless oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.57–7.50 (m, 2 H), 7.34–7.26 (m, 3 H), 5.24 (s, 1 
H), 2.93 (t, J = 7.3 Hz, 2 H), 2.39 (t, J = 7.6 Hz, 2 H), 1.95 (quin, J = 7.3 Hz, 2 H), 1.67 (s, 6 H). 
13
C 
NMR (101MHz, CDCl3, ppm) δ: 170.7, 161.1, 133.1, 129.4, 129.2, 127.3, 106.4, 93.6, 33.3, 26.8, 
26.2, 25.0. MS (EI) m/z: 368 [M+MeCN+H]
+
, 327 [M+H]
+
. HR-MS (EI) m/z calcd for C15H19SeO3: 
327.0499 [M+H]
+
; found: 327.0487. Anal. calcd for C15H18SeO3: C 55.39, H 5.58, N 6.57; found: C 
55.48, H 5.44. 
1.25.13.74 tert-Butyl 5-chloro-3-oxopentanoate (425)251 
 
 
tert-Butylacetate (30.0 mL, 220 mmol) was added to LDA (200 mmol) in THF (200 mL) at −78 °C 
and stirred 30 min. This mixture was added to a  solution of ethyl 3-chloropropionate (13.6 mL, 100 
mmol) in THF (100 mL) at −78 oC by cannula and stirred for 15 min. Acetic acid (100 mL) was added 
and the mixture diluted with water (400 mL) and ether (800 mL). The organic phase was washed with 
20% aqueous K2CO3 (3 × 450 mL), brine (400 mL), dried (MgSO4) and rotary evaporated to give the 
title compound (23.4 g) as a pale yellow oil used without further purification. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 3.73 (t, J = 6.6 Hz, 2 H), 3.38 (s, 2 H), 3.02 (t, J = 6.6 Hz, 2 H), 1.46 (s, 9 H). In 
agreement with the literature. 
1.25.13.75 6-(2-Chloroethyl)-2,2-dimethyl-1,3-dioxan-4-one (426)246 
 
Sulfuric acid (6.02 mL, 113 mmol) was added dropwise to a solution of tert-butyl 5-chloro-3-
oxopentanoate (23.00 g, 113 mmol) and acetic anhydride (32.0 mL, 339 mmol) in acetone (16.86 mL, 
226 mmol) at 0 
o
C and the mixture allowed to stir at 25 °C 14 h. The mixture was poured into 20% 
aqueous K2CO3 (800 mL) and extracted with CH2Cl2 (3 × 400 mL). The combined organics were 
washed with brine, dried (MgSO4), rotary evaporated to give the title compound (19.5 g) as a yellow 
oil used without further purification. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.36 (s, 1 H), 3.69 (t, J = 
6.4 Hz, 2 H), 2.70 (t, J = 6.1 Hz, 2 H), 1.71 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 167.0, 
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160.6, 106.8, 95.6, 39.3, 36.4, 24.9. MS (CI) m/z: 208 [M+NH4]
+
. HR-MS (CI) m/z calcd for 
C8H15NO3Cl: 208.0740 [M+NH4]
+
; found: 208.0743. In agreement with the literature. 
1.25.13.76 1-Phenylbut-3-en-1-ol (430a)252 
 
According to general procedure D, benzaldehyde (3.6 mL, 3.5 mmol) and chromatography 
(petroleum ether/Et2O 9:1) gave alcohol 430a (398 mg, 77%) as a colorless oil. IR (cm
−1
): 1641, 
1453, 1044, 990, 913, 756, 698. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.51–7.25 (m, 5 H), 5.94–5.75 
(m, 1 H), 5.28–5.07 (m, 2 H), 4.75 (ddd, J = 7.7, 5.0, 2.9 Hz, 1 H), 2.58–2.50 (m, 2 H), 2.13 (d, J = 
2.9 Hz, 1 H). HR-MS (CI) m/z calcd for C10H16NO: 166.1232 [M+NH4]
+
; found: 166.1229. 
1.25.13.77 1-(4-Bromophenyl)but-3-en-1-ol (430b)253 
 
According to general procedure A, p-bromobenzaldehyde (648 mg, 3.50 mmol) and 
Kughelrohr distillation (0.4 Torr, 102–105 oC) gave the title compound (721 mg, 91%) as a 
colourless oil. IR (cm−1) 1641, 1593, 1488, 1404, 1069, 1010, 918, 824. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 7.51–7.44 (m, J = 8.3 Hz, 2 H), 7.24 (d, J = 8.3 Hz, 2 H), 5.87–5.71 (m, 1 H), 
5.24–5.10 (m, 2 H), 4.71 (ddd, J = 7.9, 4.8, 3.4 Hz, 1 H), 2.57–2.40 (m, 2 H), 2.11 (d, J = 2.9 
Hz, 1 H). 
13
C NMR (101MHz , CDCl3, ppm) δ: 142.8, 133.9, 131.4, 127.5, 121.2, 118.9, 
72.5, 43.8. MS (CI) 228 [M+H]
+
. HR-MS (CI) m/z calcd for C10H13NBr: 226.0231 [M-
H2O+NH4]; found: 226.0239. In agreement with the literature 
1.25.13.78 1-(4-Chlorophenyl)but-3-en-1-ol (430c)254 
 
According to general procedure A, p-chlorobenzaldehyde (506 mg, 3.5mmol) and 
Kughelrohr distillation (0.2 Torr, 94–96 oC) gave the title compound (557 mg, 85%) as a 
201 
 
colourless oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.35–7.26 (m, 4 H), 5.85–5.72 (m, 1 H), 
5.21–5.12 (m, 2 H), 4.72 (ddd, J = 7.8, 4.9, 3.4 Hz, 1 H), 2.57–2.38 (m, 2 H), 2.15 (d, J = 2.9 
Hz, 1 H). 
13
C NMR (101MHz , CDCl3, ppm) δ: 142.2, 133.9, 133.1, 128.5, 127.2, 118.9, 
72.5, 43.8. MS (CI) 200 [M-H2O+NH4
+
]. HR-MS (CI) m/z calcd for C10H15NOCl: 200.0842 
[M-H2O+NH4]; found: 200.0844. In agreement with the literature. 
1.25.13.79 1-(4-Fluorophenyl)but-3-en-1-ol (430d)254 
 
According to general procedure A, p-fluorobenzaldehyde (372 mg, 3.5mmol) and Kughelrohr 
distillation (0.10 Torr, 63–66 oC) gave the title compound (431 mg, 74%) as a colourless oil. 
IR (cm−1): 1621, 1604, 1509, 1221, 917, 833. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.37–7.29 
(m, 2 H), 7.09–6.99 (m, 2 H), 5.88–5.71 (m, 1 H), 5.23–5.11 (m, 2 H), 4.73 (ddd, J = 7.8, 5.1, 
3.2 Hz, 1 H), 2.57–2.39 (m, 2 H), 2.13 (d, J = 2.9 Hz, 1 H). 13C NMR (101MHz , CDCl3, 
ppm) δ: 162.1, 139.5, 134.1, 127.4, 118.7, 115.2, 72.6, 43.9. MS (CI) 166 [M+]. HR-MS (CI)  
m/z calcd for C10H13NF: 166.1032 [M-H2O+NH4]; found: :166.1035. 
1.25.13.80 1-(4-Methoxyphenyl)but-3-en-1-ol (430e)255 
 
According to general procedure A, p-anisaldehyde (425 µL, 3.50 mmol) and chromatography 
(petroleum ether/Et2O, 1:0 to 4:1) gave the title compound (541 mg, 87%) as a pale yellow 
oil. IR (cm−1): 1611, 1511, 1243, 1173, 1033, 914, 829. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 
7.31–7.24 (m, 2 H), 6.91–6.85 (m, 2 H), 5.86–5.74 (m, 1 H), 5.19–5.10 (m, 2 H), 4.69 (td, J = 
6.5, 2.2 Hz, 1 H), 3.80 (s, 3 H), 2.52–2.43 (m, 2 H), 1.99 (d, J = 2.4 Hz, 1 H); MS (CI) 178 
[M]
+
, 161, 61. In agreement with the literature 
1.25.13.81 1-(Furan-2-yl)but-3-en-1-ol (430f)256  
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According to general procedure A, furaldehyde (290 µL, 3.5 mmol) and Kughelrohr 
distillation (0.70 Torr, 78-80 
o
C) gave the title compound (400 mg, 83%) as a colourless oil. 
IR (cm−1): 1642, 1504, 1433, 1339, 1227, 1148, 1054, 1008, 917, 733. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 7.39 (d, J = 1.0 Hz, 1 H), 6.34 (dd, J = 3.2, 1.7 Hz, 1 H), 6.26 (d, J = 2.9 Hz, 
1 H), 5.81 (tdd, J = 17.2, 10.1, 7.1 Hz, 1 H), 5.25–5.12 (m, 2 H), 4.79–4.70 (m, 1 H), 2.70–
2.55 (m, 2 H), 2.14 (d, J = 4.9 Hz, 1 H). 
13
C NMR (101MHz , CDCl3, ppm) δ: 156.0, 142.0, 
133.6, 118.6, 110.1, 106.1, 66.9, 40.0. MS (CI) 138 [M-H2O+NH4
+
]. HR-MS (CI) m/z calcd 
for C12H12NO: 138.0919 [M-H2O+NH4]; found: 138.0921. In agreement with the literature.
  
1.25.13.82 Hex-5-en-3-ol (430h)257 
 
According to general procedure D acetaldehyde (252 µL, 3.5 mmol) gave the title compound 
(330 mg, 94%) as a colorless oil. This compound was used without further purification. IR 
(cm−1): 1641, 1460, 1438, 1112, 1016, 995, 969, 911. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 
5.78–5.90 (m, 1 H), 5.11– 5.18 (m, 2 H), 3.54–3.63 (m, 1 H), 2.26–2.37 (m, 1 H), 2.09–2.20 
(m, 1 H), 1.63 (d, J = 4.4 Hz, 1 H), 1.44– 1.57 (m, 2 H), 0.96 (t, J = 7.6 Hz, 3 H). 13C NMR 
(101 MHz, CDCl3, ppm) δ: 134.9, 118.0, 72.0, 41.4, 29.5, 9.9. 
1.25.13.83 6-Methylhept-1-en-4-ol (430i)257 
 
According to general procedure D iso-valeraldhyde (375 µL, 3.5 mmol) and chromatography 
(pentane/Et2O, 17 : 1 to 4 : 1)  gave the title compound (400 mg, 89%) as a colorless oil. IR 
(cm−1): 1643, 1468, 1367, 1137, 1058, 1025, 996, 976, 912. 
1
H NMR (400 MHz, CDCl3, 
ppm) δ : 5.80–5.90 (m, 1 H), 5.11–5.18 (m, 2 H), 3.70– 3.78 (m, 1 H), 2.26–2.34 (m, 1 H), 
2.10–2.19 (m, 1 H), 1.70–1.86 (m, 1 H), 1.59 (s, 1 H), 1.36–1.47 (m, 1 H), 1.20–1.30 (m, 1 
H), 0.94 (dd, J = 6.6, 5.1 Hz, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 134.9, 118.1, 68.7, 
46.0, 42.5, 24.6, 23.4, 22.1. 
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1.25.13.84 1-Mesitylbut-3-en-1-o (430j)256 
 
According to general procedure A, mesitaldehyde (534 mg, 3.5mmol) and Kughelrohr 
distillation (0.70 Torr, 95–97 oC) gave the title compound (560 mg, 82%) as a colourless oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.84 (s, 2 H), 5.94–5.80 (m, 1 H), 5.24–5.11 (m, 3 H), 
2.79–2.68 (m, 1 H), 2.55–2.47 (m, 1 H), 2.43 (s, 6 H), 2.27 (s, 3 H), 2.23 (s, 1 H). 13C NMR 
(101MHz , CDCl3, ppm) δ: 136.6, 136.0, 135.3, 130.1, 129.1, 117.7, 70.7, 40.3, 20.8, 15.8; 
MS (ES) 173 [M-H2O]. HR-MS (ES) m/z calcd for C13H17: 173.1330 [M-H2O]; found: 
173.1323. 
1.25.13.85 1-(Pyridin-2-yl)but-3-en-1-ol (430k)258  
 
According to general procedure A, 2-pyridine carboxaldehyde (333 µL, 3.5mmol) and 
Kughelrohr distillation (1.60 Torr, 110 
o
C) gave the title compound (434 mg, 83%) as a 
colourless oil. IR (cm−1): 1641 1594, 1435, 1056, 996, 914, 749, 610. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 8.52 (d, J = 4.9 Hz, 1 H), 7.67 (m, 1 H), 7.32–7.23 (m, 1 H), 7.22–7.14 (m, 1 
H), 5.82 (ddt, J = 17.1, 10.2, 6.9, Hz, 1 H), 5.15–4.94 (m, 2 H), 4.80 (dd, J = 7.3, 4.9 Hz, 1 
H), 4.14 (br. s., 1 H), 2.82–2.57 (m, 1 H), 2.52–2.43 (m, 1 H). 13C NMR (101MHz , CDCl3, 
ppm) δ: 161.4, 148.2, 136.6, 134.1, 122.3, 120.4, 118.0, 72.2, 42.8. MS (ES) 150 [M+H+]. 
HR-MS (CI) m/z calcd for C9H12NO: 150.0919 [M+H]
+
; found: 150.0908. In agreement with 
the literature. 
 
1.25.13.86 (E)-6-(4-Hydroxy-4-phenylbut-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (431a) 
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According to general procedure B, reaction of alcohol 430a (210 mg, 1.42 mmol) and 
dioxinone 372a (328 mg, 2.13 mmol) with catalyst 427a (45 mg, 0.071 mmol) for 14 h and 
chromatography (hexanes/Et2O, 7:3 to 1:1) gave dioxinone 431a (315 mg, 81%) as a brown 
oil. IR (cm−1): 3422, 1703, 1649, 1589, 1389, 1373, 1273, 1252, 1200, 1018, 967, 903, 757, 
700. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.40–7.32 (m, 5 H), 6.64–6.55 (m, 1 H), 6.02–5.95 
(m, 1 H), 5.25 (s, 1 H), 4.84 (dd, J = 7.8, 4.9  Hz, 1 H), 2.70–2.60 (m, 2 H), 2.27 (br s, 1 H), 
1.70 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 162.9, 162.0, 143.5, 137.9, 128.6, 128.0, 
125.6, 125.0, 106.4, 93.9, 73.3, 42.3, 25.0. MS (EI) m/z: 275 [M + H]
+
. HR-MS 
(EI) m/z calcd for C16H19O4: 275.1283 [M + H]
+
; found: 275.1288. Anal. calcd for C16H18O4: 
C 70.06, H 6.61; found: C 70.15, H 6.71. 
1.25.13.87  (E)-6-(4-(4-Bromophenyl)-4-hydroxybut-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 
(431b) 
 
According to general procedure B, reaction of alcohol 430b (491 mg, 2.16 mmol) and 
dioxinone 372a (500 mg, 3.25 mmol) with catalyst 427a (68 mg, 0.11 mmol) for 16 h and 
chromatography (hexanes/Et2O, 7:3 to 1:3) gave dioxinone 431b (577 mg, 76%) as a brown 
solid; mp 85–90 °C (Et2O/pentane). IR (cm
−1): 3451, 1689, 1651, 1590, 1391, 1375, 1275, 
1201, 1010, 971, 820, 600. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.49 (d, J = 8.3 Hz, 2 H), 
7.23 (d, J = 8.3 Hz, 2 H), 6.56 (dt, J = 15.6, 7.8 Hz, 1 H), 5.97 (d, J = 15.6 Hz, 1 H), 5.24 (s, 
1 H), 4.81 (t, J = 6.1 Hz, 1 H), 2.64–2.56 (m, 2 H), 2.31 (br s, 1 H), 1.70 (s, 6 H). 13C NMR 
(101 MHz, CDCl3, ppm) δ: 162.8, 162.0, 142.5, 137.3, 131.7, 127.4, 125.3, 121.7, 106.4, 
94.0, 72.6, 42.3, 25.0. MS (ES) m/z: 355 [M(
81
Br) + H]
+
, 353 [M(
79
Br) + H]
+
. HR-MS 
(ES)m/z calcd for C16H18BrO4: 353.0388 [M + H]
+
; found: 353.0389. Anal. calcd for 
C16H17BrO4: C 54.41, H 4.85; found: C 54.25, H 4.73. 
1.25.13.88  (E)-6-(4-(4-Chlorophenyl)-4-hydroxybut-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 
(431c) 
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According to general procedure B, reaction of alcohol 430c (183 mg, 1 mmol) and 
dioxinone 372a (308 mg, 2 mmol) with catalyst 427a (63 mg, 0.1 mmol) for 18 h and 
chromatography (hexanes/Et2O, 3:2 to 2:3) gave dioxinone 431c (271 mg, 88%) as a brown 
solid; mp 76–80 °C (Et2O/pentane). IR (cm
−1): 3457, 1690, 1652, 1591, 1394, 1376, 1279, 
1203, 1087, 1021, 971, 830. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.36–7.26 (m, 4 H), 6.55 
(dt, J = 15.7, 7.8 Hz, 1 H), 5.97 (d, J = 15.6 Hz, 1 H), 5.24 (s, 1 H), 4.85–4.77 (m, 1 H), 2.66–
2.56 (m, 2 H), 2.14 (d, J = 3.4 Hz, 1 H), 1.70 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 
162.7, 161.9, 141.9, 137.2, 133.6, 128.8, 127.0, 125.4, 106.4, 94.1, 72.6, 42.4, 25.0. MS 
(ES) m/z: 311 [M(
37
Cl) + H]
+
, 309 [M(
35
Cl) + H]
+
. HR-MS (ES) m/z calcd for C16H18ClO4: 
309.0894 [M + H]
+
; found: 309.0887. Anal. calcd for C16H17ClO4: C 62.24, H 5.55; found: C 
62.18, H 5.43. 
1.25.13.89  (E)-6-(4-(4-Fluorophenyl)-4-hydroxybut-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 
(431d) 
 
According to general procedure B, reaction of alcohol 430d (166 mg, 1 mmol) and 
dioxinone 372a (308 mg, 2 mmol) with catalyst 427a (63 mg, 0.1 mmol) for 18 h and 
chromatography (hexanes/Et2O, 3:2 to 2:3) gave dioxinone 431d (244 mg, 84%) as a brown 
gum. IR (cm−1): 3429, 1701, 1650, 1603, 1508, 1390, 1375, 1274, 1202, 1156, 1018, 835. 
1
H 
NMR (400 MHz, CDCl3, ppm) δ: 7.35–7.30 (m, 2 H), 7.08–7.03 (m, 2 H), 6.56 (dt, J = 15.2, 
7.8 Hz, 1 H), 5.98 (d, J = 15.6 Hz, 1 H), 5.25 (s, 1 H), 4.83 (dd, J = 7.8, 4.9 Hz, 1 H), 2.70–
2.55 (m, 2 H), 2.21 (br s, 1 H), 1.70 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 162.8, 
162.0, 162.3 (d, J = 245.7 Hz), 139.3, 137.5, 127.3 (d, J = 8 Hz), 125.2, 115.4 (d, J = 
22.5 Hz), 106.4, 94.0, 72.6, 42.4, 25.0. MS (ES) m/z: 293 [M + H]
+
. HR-MS (ES) m/z calcd 
for C16H18FO4: 293.1189 [M + H]
+
; found: 293.1177. Anal. calcd for C16H17FO4: C 65.74, H 
5.86; found: C 65.90, H 5.90. 
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1.25.13.90  (E)-6-(4-Hydroxy-4-(4-methoxyphenyl)but-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-
one (431e) 
 
According to general procedure B, reaction of alcohol 430e (120 mg, 0.67 mmol) and 
dioxinone 372a (156 mg, 1.01 mmol) with catalyst 427a (21 mg, 0.034 mmol) for 18 h and 
chromatography (hexanes/Et2O, 3:2 to 2:3) gave dioxinone 431e (158 mg, 78%) as a brown 
oil. IR (cm−1): 3424, 1702, 1650, 1512, 1389, 1374, 1245, 1018, 831. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 7.30–7.27 (m, 2 H), 6.92–6.89 (m, 2 H), 6.59 (dt, J = 15.7, 7.8 Hz, 1 H), 5.99 
(d, J = 15.6 Hz, 1 H), 5.26 (s, 1 H), 4.79 (dd, J = 7.8, 4.9 Hz, 1 H), 3.82 (s, 3 H), 2.73–2.54 
(m, 2 H), 1.90 (br s, 1 H), 1.71 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 162.9, 162.0, 
159.3, 138.0, 135.6, 126.9, 125.0, 114.0, 106.4, 93.9, 73.0, 55.3, 42.3, 25.0. MS (ES) m/z: 
305 [M + H]
+
. HR-MS (ES) m/z calcd for C17H21O5: 305.1389 [M + H]
+
; found: 305.1382. 
Anal. calcd for C17H20O5: C 67.09, H 6.62; found: C 66.96, H 6.55. 
1.25.13.91  (E)-6-(4-(Furan-2-yl)-4-hydroxybut-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 
(431f) 
 
According to general procedure B, reaction of alcohol 430f (138 mg, 1 mmol) and 
dioxinone 372a (308 mg, 2 mmol) with catalyst 427a (63 mg, 0.1 mmol) for 18 h and 
chromatography (hexanes/Et2O, 3:2 to 1:1) gave dioxinone 431f (228 mg, 86%) as a brown 
gum. IR (cm−1): 3400, 1689, 1654, 1590, 1379, 1280, 1197, 1017, 1003, 973, 728, 596. 
1
H 
NMR (400 MHz, CDCl3, ppm) δ: 7.41–7.38 (m, 1 H), 6.58 (dt, J = 16.1, 7.8 Hz, 1 H), 6.36 
(dd, J = 2.9, 2.0 Hz, 1 H), 6.27 (d, J = 3.4 Hz, 1 H), 6.02 (d, J = 15.6 Hz, 1 H), 5.27 (s, 1 H), 
4.89–4.80 (m, 1 H), 2.80–2.72 (m, 2 H), 2.19 (d, J = 4.4 Hz, 1 H), 1.70 (s, 6 H). 13C NMR 
(101 MHz, CDCl3, ppm) δ: 162.8, 162.0, 155.5, 142.2, 137.0, 125.2, 110.3, 106.4, 106.3, 
94.0, 66.6, 38.8, 25.0. MS (ES) m/z: 265 [M + H]
+
. HR-MS (ES) m/z calcd for C14H17O5: 
265.1076 [M + H]
+
; found: 265.1075. Anal. calcd for C14H16O5: C 63.63, H 6.10; found: C 
63.53, H 6.05. 
207 
 
1.25.13.92 (E)-6-(4-Hydroxypent-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (431g) 
 
According to general procedure B, reaction of alcohol 430g (103 µL, 1.00 mmol) and 
dioxinone 372a (308 mg, 2.00 mmol) with catalyst 427a (63 mg, 0.10 mmol) for 18 h and 
chromatography (pentane/Et2O, 55:45 to 1:3) gave dioxinone 431g (173 mg, 82%) as a 
brown oil. IR (cm−1): 3435¸ 1702, 1650, 1590, 1389, 1374, 1273, 1253, 1201, 1123, 1017, 
971, 903, 816, 796, 603. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.60 (dt, J = 15.4, 7.5 Hz, 1 H), 
6.01 (dt, J = 15.6, 1.0 Hz, 1 H), 5.28 (s, 1 H), 3.99 (m, 1 H), 2.35–2.42 (m, 2 H), 1.72–1.75 
(m, 7 H), 1.26 (d, J = 6.4 Hz, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 163.0, 162.1, 138.2, 
124.9, 106.4, 93.8, 67.0, 42.3, 25.1, 25.0, 23.4. MS (ES) m/z: 213 [M + H]
+
. HR-MS 
(ES) m/z calcd for C11H17O4: 213.1127 [M + H]
+
; found: 213.1123. Anal. calcd for C11H16O4: 
C 62.25, H 7.60; found: C 62.12, H 7.48. 
1.25.13.93  (E)-6-(4-Hydroxyhex-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (431h) 
 
According to general procedure B, reaction of alcohol 430h (300 mg, 3.00 mmol) and 
dioxinone 372a (693 mg, 4.80 mmol) with catalyst 427a (94 mg, 0.15 mmol) for 18 h and 
chromatography (hexanes/Et2O, 1:1 to 2:3) gave dioxinone 431h (372 mg, 55%) as a brown 
oil. IR (cm−1): 3427, 1707, 1650, 1591, 1340, 1375, 1274, 1254, 1203, 1019, 971, 904, 801, 
603. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.60 (dt, J = 15.4, 7.5 Hz, 1 H), 5.99 (dt, J = 15.7, 
1.5 Hz, 1 H), 5.26 (s, 1 H), 3.63–3.74 (m, 1 H), 2.37–2.47 (m, 1 H), 2.28–2.37 (m, 1 H), 1.70 
(s, 7 H), 1.45–1.57 (m, 2 H), 0.97 (t, J = 7.6 Hz, 3 H). 13C NMR (101 MHz, CDCl3, ppm) δ: 
162.9, 162.0, 138.5, 124.7, 106.3, 93.7, 72.1, 40.1, 30.0, 25.0, 9.8. MS (ES)m/z: 227 [M + 
H]
+
. HR-MS (ES) m/z calcd for C12H19O4: 227.1283 [M + H]
+
; found: 227.1283. Anal. calcd 
for C12H18O4: C 63.70, H 8.02; found: C 63.75, H 8.13. 
1.25.13.94  (E)-6-(4-Hydroxy-6-methylhept-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (431i) 
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According to general procedure B, reaction of alcohol 430i (128 mg, 1.00 mmol) and 
dioxinone 372a (308 mg, 2.00 mmol) with catalyst 427a (63 mg, 0.10 mmol) for 18 h and 
chromatography (hexanes/Et2O, 55:45 to 45:55) gave dioxinone 431i (185 mg, 73%) as a 
brown gum. IR (cm−1): 3421, 1703,1650, 1590, 1389, 1374, 1273, 1253, 1202, 1017, 969, 
903. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.63 (dt, J = 15.4, 7.5 Hz, 1 H), 6.01 (dt, J = 15.6, 
1.5 Hz, 1 H), 5.28 (s, 1 H), 3.81–3.91 (m, 1 H), 2.38–2.48 (m, 1 H), 2.26–2.37 (m, 1 H), 
1.77–1.84 (m, 1 H), 1.73 (s, 6 H), 1.65 (d, J = 4.4 Hz, 1 H), 1.43–1.50 (m, 1 H), 1.24–1.32 
(m, 1 H), 0.93–0.97 (m, 6H). 13C NMR (101 MHz, CDCl3, ppm) δ: 163.0, 162.0, 138.5, 
124.9, 106.4, 93.8, 68.8, 46.5, 41.2, 25.1, 25.0, 24.6, 23.4, 22.0. MS (ES) m/z: 277 [M + Na]
+
, 
255 [M + H]
+
. Anal. calcd for C14H22O4: C 66.12, H 8.72; found: C 66.10, H 8.65. 
1.25.13.95  (E)-6-(4-Hydroxy-4-mesitylbut-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (431j) 
 
According to general procedure B, reaction of alcohol 430j (350 mg, 1.84 mmol) and 
dioxinone 372a (426 mg, 2.76 mmol) with catalyst 427a (58 mg, 0.09 mmol) for 16 h and 
chromatography (hexanes/Et2O, 4:1 to 1:1) gave dioxinone 431j (377 mg, 65%) as a brown 
gum. IR (cm−1): 3442, 2951, 1702, 1650, 1591, 1389, 1373, 1273, 1202, 1017, 967, 851, 
801. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.84 (s, 2 H), 6.64 (dt, J = 15.7, 7.8 Hz, 1 H), 6.02 
(d, J = 15.6 Hz, 1 H), 5.29–5.22 (m, 2 H), 2.97–2.85 (m, 1 H), 2.63–2.49 (m, 1 H), 2.41 (s, 6 
H), 2.26 (s, 3 H), 2.00 (d, J = 2.4 Hz, 1 H), 1.71 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) 
δ: 163.0, 162.0, 138.8, 137.0, 135.8, 135.6, 130.3, 124.6, 106.3, 93.8, 70.5, 39.0, 25.0, 24.9, 
20.7. MS (ES) m/z: 317 [M + H]
+
. HR-MS (ES) m/z calcd for C19H25O4: 317.1753 [M + H]
+
; 
found: 317.1753. Anal. calcd for C19H24O4: C 72.13, H 7.65; found: C 71.97, H 7.59. 
1.25.13.96 (E)-4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-1-phenylbut-3-ene-1,2-dione (433a) 
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According to general procedure L (E)-6-(4-hydroxy-4-phenylbut-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-
4-one (0.5 g, 1.82 mmol) and chromatography (pentane/Et2O, 3:17 to 1:3) gave the title compound 
(234 mg, 45%) as a yellow amorphous solid. IR (cm
−1
): 1719, 1671, 1580, 1394, 1377, 1275, 1253, 
1199, 1115, 1016, 819, 738, 687, 635. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 8.04 (m, 2 H), 7.69 (m, 1 
H), 7.54 (m, 2 H), 7.27 (d, J = 15.7 Hz, 1 H), 7.11 (d, J = 15.7 Hz, 1 H), 5.71 (s, 1 H), 1.76 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 191.2, 190.0, 160.4, 160.3, 137.1, 135.1, 132.0, 130.4, 129.0, 
128.4, 107.4, 101.7, 25.0.  
1.25.13.97 (E)-5-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)pent-4-ene-2,3-dione (433b) 
 
According to general procedure L oxidation of (E)-6-(4-Hydroxypent-1-enyl)-2,2-dimethyl-4H-1,3-
dioxin-4-one (191 mg, 0.90 mmol) and chromatography (pentane/Et2O, 4:1 to 1:1) gave the title 
compound (39 mg, 19 %) as an amorphous yellow solid. 
1
H NMR (400 MHz, CDCl3, ppm) 
δ: 7.48 (d, J = 15.7 Hz, 1 H), 7.15 (d, J = 15.6 Hz, 1 H), 5.70 (s, 1 H), 2.45 (s, 3 H), 1.76 (s, 
6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 197.3, 185.7, 160.5 (2C), 136.9, 125.0, 107.4, 101.6, 
25.0, 24.0. MS (CI) m/z:242 [M+NH4]
+
,  225 [M+H]
+
. HR-MS (CI) m/z: calcd for C11H16NO5: 
242.1028 [M+NH4]
+
; found: 242.1035. 
1.25.13.98 1-Ethyl 7-isopropyl 5-oxo-3-(phenylthio)heptanedioate (447) 
 
n-BuLi (2.5M in hexanes, 0.84 mL) was added to thiophenol (0.22 mL, 0.021 mmol) in THF (1.40 
ml) at 0 °C. After 5 min, titanium isopropoxide (0.68 mL) was added dropwise to give an orange 
solution stirred for 15 min. 
The complex prepared above (0.05 mL, 16 mol%) was added to 1-ethyl 7-isopropyl 5-oxohept-2-
enedioate (50 mg, 0.207 mmol) in THF (0.5 mL) at −78 oC and allowed to stir for 14 h between −40 
and −10 oC. Further complex (0.05 mL, 16 mol%) was added at r.t. and stirred for a further 3 h 
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followed by a further identical addition of complex and stirring for 12 h. The mixture was acidified by 
addition of cold 0.1 M aqueous HCl and extracted with CH2Cl2 (× 3). The combined organics were 
washed with 1 M aqueous KOH, dried (MgSO4) rotary evaporated and chromatographed (petroleum 
ether/Et2O, 9:1 to 4:1) to give the title compound (32 mg, 44%) as a colourless oil. 
1
H NMR (400 
MHz, CDCl3, ppm) δ: 7.51–7.45 (m, 2 H), 7.36–7.28 (m, 3 H), 5.04 (quin, J = 6.4 Hz, 1 H), 4.16–
4.10 (m, 2 H), 3.92 (m, 1 H), 3.41 (s, 2 H), 2.93 (dd, J = 3.7, 6.6 Hz, 2 H), 2.63 (dd, J = 5.1, 6.6 Hz, 2 
H), 1.27–1.23 (m, 9 H). MS (EI) m/z: 375 [M+Na]+. HR-MS (EI) m/z calcd for C18H24O5SNa: 
375.1242 [M+Na]; found: 375.1232. 
1.25.13.99 Mixture of (E)-7-isopropyl1-methyl 5-oxohept-3-enedioate (338c) and (E)-7-
isopropyl 1-phenyl 5-oxohept-2-enedioate 338d); Isopropyl 2-(2-oxo-2H-pyran-6-yl)acetate 
448 
 
 
A mixture of (E)-phenyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-2-enoate and (E)-ethyl 4-(2,2-
dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-2-enoate (200mg, 0.694 mmol) and isopropanol (0.27 mL 
3.17 mmol) in toluene (3.5 mL) was heated to reflux for 15 h. The mixture was rotary evaporated and 
chromatographed (petroleum ether/Et2O, 3:1 to 1:1) to give a mixture of phenyl/methyl esters 338c 
and 338d as shown and isopropyl 2-(2-oxo-2H-pyran-6-yl)acetate 448 as a yellow oil, all in impure 
form. Peaks of Pyrone 448: 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.31 (dd, J = 9.5, 6.5 Hz 1 H), 
6.22 (d, J = 9.3 Hz, 1 H), 6.16 (d, J = 6.4 Hz, 1 H), 5.04 (hept, J = 6.3 Hz, 1 H), 3.48 (s, 2 H), 1.24 (d, 
J = 6.3 Hz, 6 H). 
1.25.13.100 Benzyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxybutanoate (449a) 
 
Sodium borohydride (358 mg, 9.43 mmol) was added to 3-(benzyloxy)-3-oxopropanoic acid (3 g, 
9.43 mmol) in EtOH (90 mL) at 0 °C and stirred for 0.5 h. Further sodium borohydride (358 mg, 9.43 
mmol) was added and stirred for 0.5 h. The mixture was quenched by addition of acetic acid and 
rotary evaporated. The mixture was dissolved in EtOAc (130 mL) and washed with saturated aqueous 
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NaHCO3. The aqueous was then reexctracted with EtOAc (2 × 100 mL) and the combined organics 
were dried (MgSO4), filtered, rotary evaporated and chromatographed (pentane/Et2O, 1:1 to 1:3) to 
give the title compound (2.49 g, 83%) as a pale yellow oil. IR (cm
−1
): 1727, 1635, 1391, 1275, 1204, 
1014, 904, 806, 751, 699. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.31–7.42 (m, 5 H), 5.34 (s, 1 H), 5.17 
(s, 2 H), 4.34 (tt, J = 8.0, 4.5 Hz, 1 H), 3.17 (br. s., 1 H), 2.51–2.65 (m, 2 H), 2.32–2.49 (m, 2 H), 1.69 
(m, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 171.9, 168.0, 160.9, 135.2, 128.6, 128.5, 128.3, 106.7, 
95.5, 66.8, 65.0, 40.7, 40.4, 25.4, 24.6. MS (CI) m/z: 338 [M+NH4]
+
, 321 [M+H]
+
. HR-MS (CI) m/z 
calcd for C17H21O6: 321.1338 [M+H]
+
; found: 321.1337.  
1.25.13.101 1-Benzyl 7-isopropyl 3-hydroxy-5-oxoheptanedioate (450a) 
 
Benzyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxybutanoate (80 mg, 0.25 mol) and iso-
PrOH (0.76 mL, 10 mmol) in EtOAc (5 mL) were microwave irradiated 120 °C for 30 min, rotary 
evaporated and chromatographed (pentane/Et2O, 7:3 to 2:3) gave the title compound (51 mg, 63 %) as 
a colourless oil. IR (cm
−1
): 1732, 1376, 1313, 1266, 1168, 1105, 968, 751, 697. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 7.31–7.41 (m, 5 H), 5.16 (s, 2 H), 5.02–5.09 (m, 1 H), 4.48–4.57 (m, 1 H), 3.44 (s, 2 
H), 3.30 (d, J = 3.9 Hz, 1 H), 2.76–2.83 (m, 2 H), 2.56–2.61 (m, 2 H), 1.26 (d, J = 6.4 Hz, 6 H). 13C 
NMR (101 MHz, CDCl3, ppm) δ: 202.3, 171.6, 166.4, 135.5, 128.6, 128.4, 128.2, 69.2, 66.6, 64.2, 
50.1, 48.6, 40.5, 21.8, 21.7. Anal. calcd for C17H22O6: C 63.34, H 6.88; found: C 63.41, H 6.95. 
1.25.13.102 3-(Benzyloxy)-3-oxopropanoic acid (451a)259 
 
Benzyl alcohol (15 g, 139 mmol) and Meldrum’s acid (20 g, 139 mmol) in toluene (15 mL) were 
refluxed for 3 h. The organics were extracted with NaHCO3 (3 × 150 mL) and the combined aqueous 
layers were acidified to pH 2 with 1M aq. HCl. The aqueous was then extracted with ether (5 × 200 
mL) and the combined organics were dried (MgSO4), filtered and rotary evaporated to give the title 
compound (20.7g, 77%) as a colourless solid used without further purification. IR (cm
−1
): 1728, 1713, 
1701, 1433, 1381, 1334, 1354, 1309, 1200, 1167, 982, 951, 925, 903, 842, 756. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 11.01 (br. s, 1 H), 7.29–7.43 (m, 5 H), 5.22 (s, 2 H), 3.50 (s, 2 H). 
13
C NMR (101 
MHz, CDCl3, ppm) δ: 171.7, 166.4, 134.9, 128.6, 128.5, 128.3, 67.6, 40.8. MS (ES) m/z: 194 [M]
+
. 
212 
 
HR-MS (ES) m/z calcd for C10H10O4: 194.0579 [M]
+
; found: 194.0593. In agreement with the 
literature. 
1.25.13.103 Benzyl 3-(tert-butyldimethylsilyloxy)-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-
yl)butanoate (452) 
 
 
tert-Butyldimethylsilyl chloride (1.18 g, 7.830 mmol) was added to benzyl 4-(2,2-dimethyl-4-oxo-4H-
1,3-dioxin-6-yl)-3-hydroxybutanoate (1.00 g, 3.125 mmol) and imidazole (1.06 g, 15.588 mmol) in 
DMF (3.1 mL) and stirred at 25 °C for 15 h. The mixture was washed with saturated aqueous NH4Cl 
(100 mL) and the aqueous reextracted with ether (100 mL). The combined organics were washed with 
brine (50 mL), dried (MgSO4), rotary evaporated and chromatographed (pentane/Et2O, 1:4 to 3:7) to 
give the title compound (1.22 g, 90%) as a colourless oil. IR (cm
−1
): 1730, 1636, 1389, 1376, 1272, 
1252, 1203, 1152, 1087, 1013, 967, 908, 828, 809, 739, 697. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 
7.32–7.39 (m, 5 H), 5.28 (s, 1 H), 5.06–5.17 (m, 2 H), 4.42 (quin, J = 6.0 Hz, 1 H), 2.58 (dd, J = 6.1, 
4.2 Hz, 2 H), 2.45 (d, J = 6.4 Hz, 2 H), 1.69 (s, 3 H), 1.67 (s, 3 H), 0.84–0.86 (m, 9 H), 0.07 (s, 3 H), 
0.05 (s, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 170.6, 168.2, 160.9, 135.6, 128.6, 128.4, 128.3, 
106.5, 95.8, 66.5, 66.4, 42.2, 41.8, 25.7, 25.6, 24.4, 17.9, −4.8, −4.9. MS (ES) m/z: 457 [M+Na]+, 435 
[M+H]
+
. HR-MS (ES) m/z calcd for C23H34O6Si: 435.2203 [M+H]
+
; found: 435.2217. Anal. calcd for 
C23H34SiO6: C 63.56, H 7.89; found: C 63.48, H 7.99. 
1.25.13.104 1-Benzyl 7-isopropyl 3-(tert-butyldimethylsilyloxy)-5-oxoheptanedioate (453) 
. 
Benzyl 3-(tert-butyldimethylsilyloxy)-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)butanoate (600 mg, 
1.380 mmol) and 
i
PrOH (4.21 mL, 55.3 mmol) in toluene (14 mL) was refluxed for 7.5 h then rotary 
evaporated and chromatographed (pentane/Et2O, 1:0 to 7:3) to give xx (540 mg, 90%) as a pale 
yellow oil. IR (cm
−1
): 1736, 1375, 1310, 1250, 1167, 1146, 1081, 977, 828, 811, 777, 737, 697. 
1
H 
NMR (400 MHz, CDCl3, ppm) δ: 7.33–7.38 (m, 5 H), 5.02–5.13 (m, 3 H), 4.60 (quin, J = 6.0 Hz, 1 
H), 3.41 (s, 2 H), 2.81 (d, J = 6.4 Hz, 2 H), 2.54–2.60 (m, 2 H), 1.26 (d, J = 6.4 Hz, 6 H), 0.84 (s, 9 
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H), 0.05–0.08 (m, 6 H). 13C NMR (101 MHz, CDCl3, ppm) δ: 201.1, 170.7, 166.4, 135.7, 128.5, 
128.3, 128.2, 69.0, 66.3, 65.5, 50.7, 49.8, 42.2, 25.7, 21.7, 17.9, −4.9, −5.0. MS (ES) m/z: 459 
[M+Na]
+
. HR-MS (ES) m/z calcd for C23H36O6NaSi: 459.2179 [M+H]
+
; found: 459.2170. Anal. calcd 
for C23H36SiO6: C 63.27, H 8.31; found: C 63.37, H 8.39. 
1.25.13.105 Isopropyl 2-(4-(tert-butyldimethylsilyloxy)-6-oxotetrahydro-2H-pyran-2-
ylidene)acetate (455) 
 
Hydrogen was bubbled through a mixture of palladium on activated charcoal (10 mg, 10% by wt.) and 
1-benzyl 7-isopropyl 3-(tert-butyldimethylsilyloxy)-5-oxoheptanedioate (100 mg, 0.229 mmol) in 
EtOAc (2.5 mL) for 10 min, and then stirred for a further 50 min under an atmosphere of hydrogen 
(balloon). Filtration through celite and rotary evaporation gave 3-(tert-butyldimethylsilyloxy)-7-
isopropoxy-5,7-dioxoheptanoic acid 454 as a pale yellow oil used directly without further 
purification. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 10.18 (br. s, 1 H), 5.07 (hept, J = 6.3 Hz, 1 H), 4.59 (p, J 
= 5.9 Hz, 1 H), 3.44 (s, 1 H), 2.83 (d, J = 6.0 Hz, 2 H), 2.56 (qd, J = 15.2, 5.9 Hz, 2 H), 1.27 (d, J = 6.3 Hz, 6 
H), 0.86 (s, 9 H), 0.10 (s, 3 H), 0.08 (s, 3H). 
Ghosez’s reagent (30 µL, 0.229 mmol) was added to the above oil in CH2Cl2 (5 mL) and stirred for 40 
min then collidine (60 µL, 0.458 mmol) was added and stirred for 1 h.The mixture was quenched with 
1M aq. HCl (5mL) and the layers separated. The aqueous was reextracted with CH2Cl2 (2 × 10 mL) 
and the combined organics were washed with water (10 mL), brine (10 mL), dried (MgSO4), rotary 
evaporated and chromatographed (pentane/Et2O, 3:1 to 0:1) to give the title compound (34 mg, 45%) 
as a pale yellow solid; mp 46–48 °C (CH3Cl3). IR (cm
−1
): 1779, 1706, 1650, 1254, 1192, 1081, 
1057, 990, 867, 836, 824, 808, 777, 721. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.67 (d, J = 2.0 Hz, 1 
H), 5.03 (spt, J = 6.3 Hz, 1 H), 4.26–4.36 (m, 1 H), 3.61–3.72 (m, 1 H), 2.84 (dt, J = 17.1, 2.4 Hz, 1 
H), 2.72–2.77 (m, 2 H), 1.23–1.27 (dd, J = 6.4, 3.4 Hz, 6 H), 0.84 (s, 9 H), 0.06–0.09 (m, 6 H). 13C 
NMR (101 MHz, CDCl3, ppm) δ: 166.1, 165.5, 163.3, 104.2, 67.5, 62.5, 39.9, 32.9, 25.5, 21.8, 17.8, 
−5.0, −5.1. MS (CI) m/z 351 [M+Na]+, 329 [M+H]+. HR-MS (CI) m/z calcd for C16H28O5NaSi: 
351.1604 [M+H]
+
; found: 351.1591. Anal. calcd for C16H30SiO6: C 55.46, H 8.73; found: C 57.56, H 
8.63. 
1.25.13.106 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxybutanoic acid (456) 
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Hydrogen gas was bubbled through a vigorously stirred mixture of benzyl 4-(2,2-dimethyl-4-oxo-4H-
1,3-dioxin-6-yl)-3-hydroxybutanoate (199 mg, 0.62 mmol) and palladium on charcoal (20 mg, 10% 
wt.) in ethyl acetate (6.5 mL) for 5 min. The mixture was then stirred under an atmosphere of 
hydrogen (balloon) for 30 min. The mixture was filtered through celite and rotary evaporated to give 
the title compound (142 mg, quantitative) as a colourless waxy solid. IR (cm
−1
): 1714, 1687, 1639, 
1394, 1374, 1350, 1276, 1258, 1197, 1183, 1083, 1028, 1012, 812, 617. 
1
H NMR (400 MHz, CD3OD, 
ppm) δ: 7.37 (br. s, 1 H), 5.37 (s, 1 H), 4.22–4.34 (m, 1 H), 2.35–2.59 (m, 4 H), 1.71 (s, 6 H). 13C 
NMR (101 MHz, CD3OD, ppm) δ: 175.1, 171.7, 163.7, 108.3, 96.0, 66.5, 43.2, 42.1, 25.6, 24.9. MS 
(CI) m/z: 248 [M+NH4]
+
, 231 [M+H]
+
. HR-MS (CI) m/z calcd for C10H14O6: 231.0869 [M+H]
+
; 
found: 231.0862. Anal. calcd for C10H14O6: C 52.17, H 6.13; found: C 52.07, H 5.80. 
1.25.13.107 5-Hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (457a)260 
 
According to general procedure K, aromatization of acid 458a (100 mg, 0.472 mmol) and 
chromatography (pentane/Et2O, 95:5) gave resorcylate 457a (70 mg, 76%) as a colorless 
solid; mp 63–64 °C (CH2Cl2–pentane). IR (cm
−1): 1687, 1631, 1584, 1469, 1385, 1343, 1277, 
1249, 1205, 1167, 1151, 1079, 1056, 1047, 970, 920, 850, 803, 778, 688, 666, 631, 620. 
1
H 
NMR (400 MHz, CDCl3, ppm) δ: 10.35 (s, 1 H), 7.42 (t, J = 8.3 Hz, 1 H), 6.64 (dd, J = 8.3, 
1.0 Hz, 1 H), 6.45 (dd, J = 7.8, 1.0 Hz, 1 H), 1.76 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) 
δ: 165.5, 161.4, 155.6, 137.9, 110.8, 107.2, 107.1, 99.3, 25.7. MS (CI) m/z: 195 [M + H]+. 
HR-MS (CI) m/z calcd for C10H11O4: 195.0657 [M + H]
+
; found: 195.0654. In agreement 
with the literature.  
1.25.13.108 5-Hydroxy-2,2,7-trimethyl-4H-benzo[d][1,3]dioxin-4-one (457b) 
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According to general procedure K, aromatization of acid 458e (192 mg, 0.850 mmol) and 
chromatography (pentane/Et2O, 49:1 to 19:1) gave resorcylate 457b (110 mg, 62%) as a 
colorless solid. Alternatively, according to general procedure F, aromatization of acid 479a 
(100 mg, 0.410 mmol) and chromatography (pentane–Et2O, 19 : 1) gave resorcylate 457b (36 
mg, 42%) as a colorless solid; mp 97–100 °C (CH2Cl2–pentane). IR (cm
−1): 1689, 1643, 
1585, 1466, 1381, 1361, 1273, 1204, 1059, 1091, 996, 964, 906, 831, 797, 707, 677, 627. 
1
H 
NMR (400 MHz, CDCl3, ppm) δ: 10.24 (s, 1 H), 6.46 (s, 1 H), 6.28 (s, 1 H), 2.32 (s, 3 H), 
1.74 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 165.4, 161.1, 155.3, 150.0, 111.2, 108.0, 
107.0, 96.9, 25.6, 22.5. MS (CI) m/z: 226 [M + NH4]
+
, 209 [M + H]
+
. HR-MS (CI) m/z calcd 
for C11H13O4: 209.0814[M + H]
+
; found: 229.0808. 
1.25.13.109 5-Hydroxy-2,2,6-trimethyl-4H-benzo[d][1,3]dioxin-4-one (457c) 
 
 
 
According to general procedure K, aromatization of acid 458b (67 mg, 0.30 mmol) and 
chromatography (hexanes/Et2O, 98:2 to 98:5) gave resorcylate 457c (30 mg, 49%) as a 
colorless solid; mp 70–73 °C (CH2Cl2–pentane). IR (cm
−1): 1739, 1681, 1598, 1473, 1421, 
1395, 1304, 1269, 1248, 1199, 1074, 992, 972, 940, 882, 798, 779, 704. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 10.55 (s, 1 H), 7.27 (d, J = 8.3 Hz, 1 H), 6.37 (d, J = 8.3 Hz, 1 H), 2.20 (s, 3 
H), 1.74 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 165.9, 159.3, 153.4, 138.5, 119.7, 
107.2, 106.3, 98.8, 25.6, 14.8. MS (CI) m/z: 226 [M + NH4]
+
, 209 [M + H]
+
. HR-MS (CI) m/z 
calcd for C11H16NO4: 226.1079 [M + NH4]
+
; found: 226.1079. Anal. calcd for C11H12O4: C 
63.45, H 5.81; found: C 63.38, H, 5.92. 
1.25.13.110 6-Benzyl-5-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (457d) 
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According to general procedure K, aromatization of acid 458c (82 mg, 0.27 mmol) and 
chromatography (pentane/Et2O, 90:10) gave resorcylate 457d (45 mg, 58%) as a colorless 
solid; mp 100–103 °C (CH2Cl2–pentane). IR (cm
−1): 1692, 1631, 1498, 1446, 1390, 1379, 
1352, 1272, 1241, 1205, 1093, 927, 809, 699, 631. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 
10.66 (s, 1 H), 7.17–7.35 (m, 6 H), 6.39 (d, J = 8.3 Hz, 1 H), 3.95 (s, 2 H), 1.75 (s, 6 H. 13C 
NMR (101 MHz, CDCl3, ppm) δ: 165.8, 159.0, 153.8, 140.1, 138.4, 128.9, 128.4, 126.2, 
123.1, 107.3, 106.6, 99.0, 34.7, 25.6. MS (ES) m/z: 285 [M + H]
+
. HR-MS (ES) m/z calcd for 
C17H17O4: 285.1127 [M + H]
+
; found: 285.1130. Anal. calcd for C17H16O4: C 71.82, H 5.67; 
found: C 71.92, H 5.77. 
1.25.13.111 5-Hydroxy-2,2,6,7-tetramethyl-4H-benzo[d][1,3]dioxin-4-one (457e) 
 
According to general procedure K, aromatization of acid 458f (100 mg, 0.417 mmol) and 
chromatography (pentane/Et2O, 90:10) gave resorcylate 457e (40 mg, 43%) as a colorless 
solid; mp 94–97 °C (CH2Cl2–pentane). IR (cm
−1): 1678, 1630, 1580, 1536, 1505, 1453, 1418, 
1393, 1377, 1354, 1318, 1269, 1200, 1180, 1134, 1099, 1047, 1021, 993, 966, 907, 865, 849, 
816, 797, 734, 695, 651, 638, 608. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 10.54 (s, 1 H), 6.29 
(s, 1 H), 2.27 (s, 3 H), 2.11 (s, 3 H), 1.72 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 
165.9, 158.8, 152.7, 148.3, 118.1, 108.2, 106.9, 96.8, 25.6, 21.1, 10.5. MS (ES) m/z: 222 [M 
+ H]
+
. HR-MS (ES) m/z calcd for C12H15O4: 223.0970 [M + H]
+
; found: 223.0972. Anal. 
calcd for C12H14O4: C 64.85, H 6.35; found: C 64.96, H 6.46. 
1.25.13.112 5-Hydroxy-2,2,7-trimethyl-6-phenyl-4H-benzo[d][1,3]dioxin-4-one (457f) 
 
According to general procedure K, aromatization of acid 458g (137 mg, 0.454 mmol) and 
chromatography (pentane/Et2O, 90:10) gave resorcylate 457f (68 mg, 53%) as a colorless 
solid; mp 148–150 °C (CH2Cl2–pentane). IR (cm
−1): 1719, 1672, 1636, 1577, 1509, 1490, 
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1455, 1436, 1388, 1377, 1364, 1319, 1308, 1290, 1259, 1236, 1202, 1189, 1143, 1088, 1052, 
1031, 1020, 998, 968, 910, 860, 842, 808, 798, 758, 742, 722, 703, 670, 641, 611. 
1
H NMR 
(400 MHz, CDCl3, ppm) δ: 10.54 (s, 1 H), 7.36–7.49 (m, 3 H), 7.24–7.29 (m, 2 H), 6.43 (s, 1 
H), 2.13 (s, 3 H), 1.80 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 165.6, 158.5, 154.1, 
148.2, 135.3, 130.1, 128.4, 127.4, 124.3, 108.4, 107.2, 97.0, 25.7, 21.6. MS (ES) m/z: 285 [M 
+ H]
+
. HR-MS (ES) m/z calcd for C17H17O4: 285.1127 [M + H]
+
; found: 285.1138. Anal. 
calcd for C17H16O4: C 71.82, H 5.67; found: C 71.73, H 5.85. 
1.25.13.113 8-Benzyl-5-hydroxy-2,2,7-trimethyl-4H-benzo[d][1,3]dioxin-4-one (457h) 
 
According to general procedure K, aromatization of acid 479b (121 mg, 0.362 mmol) and 
chromatography (pentane/Et2O, 9:1) gave resorcylate 457h (50 mg, 46%) as a colorless solid; 
mp 80–81 °C (CH2Cl2–pentane). IR (cm
−1): 1688, 1634, 1585, 1494, 1481, 1453, 1390, 1379, 
1364, 1338, 1264, 1247, 1208, 1097, 1071, 1040, 1075, 1002, 980, 903, 849, 823, 792, 727, 
697, 646, 616. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 10.23 (s, 1 H), 7.24–7.29 (m, 2 H), 7.17–
7.22 (m, 1 H), 7.08–7.12 (m, 2 H), 6.54 (s, 1 H), 3.93 (s, 2 H), 2.27 (s, 3 H), 1.64 (s, 6 H). 13C 
NMR (101 MHz, CDCl3, ppm) δ: 165.7, 159.4, 153.2, 149.1, 140.0, 128.3, 128.0, 126.0, 
118.0, 112.2, 107.1, 97.3, 30.7, 25.5, 20.9. MS (ES) m/z: 299 [M + H]
+
. HR-MS (ES) m/z 
calcd for C18H19O4: 299.1283 [M + H]
+
; found: 299.1280. 
1.25.13.114 5-Hydroxy-7-(4-methoxyphenyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (457i) 
 
According to general procedure K, aromatization of acid 479c (300 mg, 0.893 mmol) and 
chromatography (pentane/Et2O, 7:3 to 1:1) gave resorcylate 457i (102 mg, 38%) as a 
colorless solid; mp 108–110 °C (CH2Cl2–pentane). IR (cm
−1): 1676, 1634, 1604, 1583, 1563, 
1518, 1499, 1489, 1459, 1444, 1389, 1375, 1341, 1312, 1289, 1272, 1256, 1207, 1183, 1117, 
1094, 1060, 1046, 1028, 967, 926, 855, 841, 824, 733, 718, 698, 666, 625, 603. 
1
H NMR 
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(400 MHz, CDCl3, ppm) δ: 10.33 (s, 1 H), 7.52–7.57 (m, 2 H), 6.93–7.01 (m, 2 H), 6.85 (d, J 
= 1.5 Hz, 1 H), 6.67 (d, J = 1.5 Hz, 1 H), 3.87 (s, 3 H), 1.78 (s, 6 H). 
13
C NMR (101 MHz, 
CDCl3, ppm) δ: 165.4, 161.4, 160.5, 155.7, 150.6, 131.4, 128.3, 114.3, 108.5, 107.2, 105.3, 
97.5, 55.4, 25.7. MS (ES) m/z: 301 [M + H]
+
. HR-MS (ES) m/z calcd for C17H17O5: 301.1076 
[M + H]
+
; found: 301.1084. Anal. calcd for C17H16O5: C 67.99, H 5.37; found: C 67.85, H 
5.47. 
1.25.13.115 6-(1-Chloroethyl)-5-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one  (457j) 
 
According to general procedure K reaction of 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2-(1-
hydroxyethyl)but-3-enoic acid (135 mg, 0.527 mmol) and chromatography (pentane/Et2O, 
19:1 to 9:1) gave the title compound (7 mg, 5%) as a colourless solid. IR (cm−1): 1685, 1629, 
1594, 1503, 1439, 1393, 1376, 1353, 1266, 1241, 1203, 1182, 1099, 1085, 1062, 976, 924, 
975, 852, 826, 803, 746, 719, 698, 639, 628. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 10.60 (s, 1 
H), 7.55 (d, J = 8.3 Hz, 1 H), 6.49 (d, J = 8.8 Hz, 1 H), 4.72 (q, J = 6.4 Hz, 1 H), 1.76 (s, 6 
H), 1.41 (d, J = 6.4 Hz, 3 H). 
13
C NMR (101, MHz, CDCl3, ppm) δ: 165.8, 158.3, 154.5, 134.9, 
125.1, 107.3, 107.1, 98.8, 56.6, 25.7, 25.6, 22.0. MS (CI) m/z: 221 [M−Cl]+, 359. HR-MS 
(CI) m/z: calcd for C12H13O4: 221.0814 [M−Cl]
+
; found: 221.0820. 
1.25.13.116  (E)-4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-3-enoic acid (458a) 
 
According to general procedure G, deprotection of ester 337a (1.504 g, 5.61 mmol) for 2 h 
gave carboxylic acid 458a (1.130 g, 95%) as an amorphous tan solid. IR (cm−1): 1743, 1682, 
1621, 1586, 1399, 1379, 1277, 1264, 1201, 1136, 1096, 1024, 979, 938, 909, 859, 834, 797, 
752, 681. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 9.94 (br. s, 1 H), 6.61 (dt, J = 15.6, 7.3 Hz, 
1 H), 6.06 (d, J = 15.6 Hz, 1 H), 5.34 (s, 1 H), 3.31 (d, J = 7.3 Hz, 2 H), 1.72 (s, 6 H). 
13
C 
NMR (101 MHz, CDCl3, ppm) δ: 175.6, 162.3, 162.0, 131.8, 126.0, 106.7, 94.9, 37.2, 25.0. 
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MS (ES) m/z: 213 [M + H]
+
. HR-MS (ES) m/z calcd for C10H13O5: 213.0763 [M + H]
+
; 
found: 213.0753. Additional HMBC spectrum provided in the additional NMR spectra 
section. 
 
In one instance the title compound was obtained with the regioisomeric compound (E)-4-(2,2-
dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-2-enoic acid (rr, 9:1). 
1
H NMR (400 MHz, CDCl3, ppm) δ: 
6.99 (dt, J = 15.6, 7.1 Hz, 1 H), 6.82 (br.s, 1 H), 6.00 (dt, J = 15.6, 1.5 Hz, 1 H), 5.33 (t, J = 0.8 Hz, 
1 H), 3.17 (ddd, J = 7.1, 1.5, 0.8 Hz, 2 H), 1.71 (s, 6 H). 
1.25.13.117 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2-methylbut-3-enoic acid (±) (458b) 
 
According to general procedure G, deprotection of ester 337e (108 mg, 0.383 mmol) for 1.5 h 
gave carboxylic acid 458b (84 mg, 97%, 1.0:0.9 rr) as a brown oil. IR (cm−1): 1698, 1649, 
1591, 1458, 1391, 1376, 1273, 1200, 1125, 1097, 1015, 970, 903, 857, 805, 744, 683, 614. 
1
H 
NMR (400 MHz, CDCl3, ppm) δ: 8.78 (br. s, 1.9 H), 6.86 (t, J = 7.3 Hz, 1 H),  6.63 (dd, J = 
15.7, 7.8 Hz, 0.9 H), 6.04 (d, J = 15.6 Hz, 0.9 H), 5.36 (s, 0.9 H), 5.32 (s, 1 H), 3.34–3.38 (m, 
J = 7.1 Hz, 0.9 H), 3.16 (d, J = 7.3 Hz, 2 H), 1.89 (s, 3 H), 1.72 (m, 11.4 H), 1.40 (d, J = 6.8 
Hz, 2.7 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 178.6, 172.1, 167.9, 162.5, 161.0, 140.0, 
138.3, 134.9, 131.2, 123.9, 106.9, 106.6, 94.9, 94.1, 42.3, 32.9, 25.0, 24.9, 16.5, 12.3. MS 
(ES) m/z: 225 [M–H]–. HR-MS (ES) m/z calcd for C11H13O5: 225.0763 [M–H]
–
; found: 
225.0762. 
1.25.13.118 2-Benzyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-3-enoic acid (±) (458c) 
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According to general procedure G, deprotection of ester 337f (120 mg, 0.335 mmol) for 6 h 
gave carboxylic acid 458c (97 mg, 96%, 1.0:0.8 rr) as a brown oil. IR (cm−1): 1707, 1649, 
1592, 1391, 1377, 1275, 1255, 1200, 1101, 1017, 968, 905, 857, 803, 738, 698. 
1
H NMR 
(400 MHz, CDCl3, ppm) δ: 8.37 (br. s, 1.8 H), 7.12–7.36 (m, 9 H), 7.03 (t, J = 7.6 Hz, 0.8 H), 
6.53 (dd, J = 15.7, 8.8 Hz, 1 H), 5.89 (d, J = 15.6 Hz, 1 H), 5.27 (s, 1 H), 5.26 (s, 0.8 H), 3.73 
(s, 1.6 H), 3.40–3.57 (m, 1.8 H), 3.15–3.26 (m, 1.8 H), 2.88–2.97 (m, 1 H), 1.72 (s, 6 H), 1.69 
(s, 4.8 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 177.2, 171.6, 167.6, 162.2, 161.9, 161.0, 
138.1, 137.3, 136.8, 136.4, 134.2, 129.0, 128.7, 128.6, 128.1, 127.0, 126.6, 125.4, 107.0, 
106.7, 95.1, 94.4, 50.5, 38.2, 33.2, 32.1, 25.0, 25.0. MS (ES) m/z: 320 [M + NH4]
+
, 303 [M + 
H]
+
. HR-MS (ES) m/z calcd for C17H19O5: 303.1232 [M + H]
+
; found: 303.1239. 
1.25.13.119 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2-(1-hydroxyethyl)but-3-enoic acid 
(458d) 
 
According to general procedure G deprotection of 337g (300 mg, 0.704 mmol) for 1.5 h gave the 
carboxylic acid 458d (164 mg, 91%, dr 1:0.6) as a colourless gum. IR (cm−1): 1707, 1653, 1592, 
1394, 1378, 1278, 1203, 1021, 977, 907, 805. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.96 (br. 
s., 3.2 H), 6.65 (dd, J = 15.6, 9.8 Hz, 1.0 H), 6.50 (dd, J = 15.6, 9.8 Hz, 0.6 H), 6.15 (d, J = 
15.6 Hz, 0.6 H), 6.14 (d, J=15.7 Hz, 1 H), 5.41 (s, 1.6 H), 4.29– 4.38 (m, 1 H), 4.17–4.23 (m, 
0.6 H), 3.18–3.33 (m, 1.6 H), 1.74 (s, 9.6 H), 1.30 (d, J = 6.4 Hz, 1.8 H), 1.27 (d, J = 6.8 Hz, 
3 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 176.0, 176.0, 162.8, 162.6, 162.5, 162.4, 134.1, 
133.5, 127.5, 126.6, 107.0, 107.0, 95.2, 94.9, 68.7, 68.0, 56.6, 55.2, 25.0, 24.8, 21.0, 20.3. 
MS (ES) m/z: 274 [M+NH4]
+
, 256 [M+H]
+
. HR-MS (ES) m/z: calcd for C12H17O6: 257.1025 
[M+H]
+
; found: 257.1030. 
1.25.13.120 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-methylbut-3-enoic acid (458e) 
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According to general procedure G, deprotection of ester 337h (440 mg, 1.56 mmol) for 0.5 h 
gave carboxylic acid 458e (268 mg, 76%, 1.0:0.6:0.5:0.4 rr) as a brown gum. IR (cm−1): 1698, 
1642, 1582, 1561, 1391, 1375, 1275, 1251, 1201, 1163, 1015, 969, 902, 856, 827, 805, 752, 
694, 639, 612. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 8.01 (br. s, 2.5 H), 6.09 (s, 1 H), 5.83 (s, 
0.4 H), 5.79 (s, 1 H), 5.34–5.36 (m, 1 H), 5.33 (s, 1 H), 5.21 (s, 0.6 H), 5.18 (s, 0.6 H), 3.56 (s, 
1.2 H), 3.21 (s, 2 H), 3.17 (s, 1.2 H), 3.13 (s, 1 H), 3.08 (s, 0.8 H), 2.22 (s, 1.2 H), 2.18 (s, 
1.5 H), 2.15 (s, 3 H), 1.64–1.80 (m, 15 H). 13C NMR (101 MHz, CDCl3, ppm) δ: 176.3, 175.5, 
172.6, 171.0, 169.0, 167.4, 164.4, 162.9, 162.4, 161.1, 156.3, 155.7, 154.5, 144.1, 134.7, 
121.5, 119.7, 119.2, 112.1, 108.8, 107.0, 106.8, 106.4, 95.5, 95.2, 95.1, 94.3, 46.1, 44.7, 40.9, 
40.1, 39.3, 38.9, 25.1, 24.9, 21.4, 19.6, 19.0. MS (ES) m/z: 249 [M + Na]
+
, 227 [M + H]
+
. 
HR-MS (ES) m/z calcd for C11H15O5: 227.0919[M + H]
+
; found: 227.0930. 
1.25.13.121 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2,3-dimethylbut-3-enoic acid (±) (458f) 
 
According to general procedure G, deprotection of ester 337i (550 mg, 1.86 mmol) for 1 h 
gave carboxylic acid 458f (433 mg, 97%, 1.0:0.5:0.5 rr) as a yellow oil. IR (cm−1): 1718, 
1642, 1579, 1392, 1377, 1276, 1204, 1078, 1018, 905, 810. 
1
H NMR (400 MHz, CDCl3, 
ppm) δ: 8.61 (br. s, 2 H), 6.04 (s, 0.5 H), 5.78 (s, 1 H), 5.33 (s, 0.5 H), 5.32 (s, 1 H), 5.23 (s, 
0.5 H), 5.14 (s, 0.5 H), 3.52 (s, 1 H), 3.27 (q, J = 6.8 Hz, 1 H), 3.20 (q, J = 7.2 Hz, 0.5 H), 
3.02–3.11 (m, 1 H), 2.13 (s, 1.5 H), 2.07 (s, 3 H), 2.04 (s, 1.5 H), 1.73 (s, 9 H), 1.67–1.68 (m, 
3 H), 1.32–1.38 (m, 4.5 H). 13C NMR (101 MHz, CDCl3, ppm) δ: 179.1, 178.3, 173.0, 169.3, 
164.6, 164.0, 162.3, 161.5, 152.0, 149.8, 149.5, 140.3, 120.1, 119.8, 117.1, 109.9, 106.7, 
106.3, 95.6, 94.3, 49.6, 44.9, 39.2, 38.7, 25.2, 25.1, 25.0, 24.8, 19.5, 17.3, 15.8, 15.4, 12.2. 
MS (ES) m/z: 241 [M + H]
+
. HR-MS (ES) m/z calcd for C12H17O5: 241.1076 [M + H]
+
; 
found: 241.1087. Anal. calcd for C12H16O5: C 59.99, H 6.71; found: C 59.87, H 6.63. 
1.25.13.122 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-methyl-2-phenylbut-3-enoic acid (±) 
(458g) 
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According to general procedure G, deprotection of ester 337j (470 mg, 1.31 mmol) for 2.5 h 
gave carboxylic acid 458g (390 mg, 98%, 1.0:1.0:0.8 rr) as a yellow gum. IR (cm−1): 1710, 
1631, 1581, 1494, 1455, 1390, 1375, 1274, 1254, 1200, 1165, 1078, 1017, 984, 963, 904, 875, 
807, 783, 752, 699, 640, 617. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 9.93 (br. s, 2.8 H), 7.18–
7.46 (m, 14 H), 6.19 (s, 0.8 H), 5.79 (s, 1 H), 5.31 (s, 1 H), 5.24–5.29 (m, 3 H), 4.46 (s, 1 H), 
4.40 (s, 1 H), 3.60 (s, 1.6 H), 3.02 (d, J = 15.7 Hz, 1 H), 2.90 (d, J = 15.7, 1 H), 2.04–2.08 (m, 
5.4 H), 1.72 (s, 10.8 H), 1.66 (s, 3 H), 1.65 (s, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 
176.7, 176.1, 172.7, 168.9, 164.4, 162.7, 162.1, 161.4, 153.8, 151.3, 147.9, 139.1, 135.1, 
134.9, 133.4, 129.8, 128.9, 128.8 128.8, 128.4, 128.1, 124.8, 120.6, 118.3, 109.9, 106.7, 
106.4, 95.9, 94.5, 61.0, 56.7, 39.4, 38.8, 25.1, 25.0, 24.9, 24.8, 20.4, 18.8. MS (ES) m/z: 320 
[M + NH4]
+
, 303 [M + H]
+
. HR-MS (ES) m/z calcd for C17H19O5: 303.1232 [M + H]
+
; found: 
303.1235. 
1.25.13.123 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2-methyl-3-methylene-5-
phenylpentanoic acid (±) (458h) 
 
According to general procedure G, deprotection of ester 337k (300 mg, 0.777 mmol) for 2 h 
gave carboxylic acid 458h (217 mg, 85%) as a yellow oil. IR (cm−1): 1702, 1455, 1391, 1377, 
1273, 1201, 1166, 1076, 1018, 905, 854, 810, 731, 698, 647, 606. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 9.90 (br. s, 1 H), 7.05–7.33 (m, 5 H), 5.37 (s, 1 H), 5.35 (s, 1 H), 5.26 (s, 1 
H), 3.36 (m, 1 H), 3.17 (q, J = 7.3 Hz, 1 H), 2.97–3.09 (m, 2 H), 1.60 (s, 3 H), 1.55 (s, 3 H), 
1.24 (d, J = 6.8 Hz, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 179.1, 170.9, 161.7, 144.3, 
138.0, 128.8, 128.4, 126.7, 115.7, 106.7, 94.1, 49.8, 45.2, 37.4, 25.0, 24.5, 15.9. MS (ES) 
m/z: 348 [M + NH4]
+
, 331 [M + H]
+
. HR-MS (ES) m/z calcd for C19H23O5: 331.1545 [M + 
H]
+
; found: 331.1541. Anal. calcd for C19H22O5: C 69.07, H 6.71; found: C 69.20, H 6.63. 
1.25.13.124 3-(Tert-butyldimethylsilyloxy)-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)butanoic 
acid (459)
261
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Hydrogen was bubbled through a mixture of palladium on activated charcoal (60 mg, 10% by wt.) and 
benzyl 3-(tert-butyldimethylsilyloxy)-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)butanoate (600 mg, 
1.380 mmol) in EtOH (14 mL) for 10 min, and then stirred for a further 50 min under an atmosphere 
of hydrogen (balloon). The mixture was filtered through celite and rotary evaporated to give the title 
compound (475 mg, quantitative) as a colourless oil. IR (cm
−1
): 1708, 1632, 1391, 1377, 1274, 1254, 
1202, 1087, 1013, 829, 808, 776. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 8.85 (br. s, 1 H), 5.31 (s, 1 H), 
4.40 (quin, J = 6.0 Hz, 1 H), 2.56 (d, J = 6.4 Hz, 2 H), 2.48 (d, J = 5.9 Hz, 2 H), 1.71 (s, 3 H), 1.69 
(s, 3 H), 0.86 (s, 9 H), 0.06–0.09 (m, 6 H). 13C NMR (101 MHz, CDCl3, ppm) δ: 176.4, 168.1, 161.0, 
106.6, 95.8, 66.3, 42.2, 41.7, 25.7, 25.6, 24.5, 17.9, −4.8, −5.0. MS (CI) m/z: 362 [M+NH4]
+
, 345 
[M+H]
+
. HR-MS (CI) m/z calcd for C16H34NO6Si: 362.1999 [M+NH4]
+
; found: 362.2004. In 
agreement with the literature. 
1.25.13.125 Methyl 3-(Tert-butyldimethylsilyloxy)-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-
yl)butanoylcarbamate (460) 
 
3-(tert-Butyldimethylsilyloxy)-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)butanoic acid (38 mg, 
0.110 mmol) and Burgess reagent (58 mg, 0.243 mmol) in acetonitrile (2 mL) was heated at 70 °C for 
4 h. Saturated aqueous NH4Cl (5 mL) was added and the layers separated. The aqueous was 
reextracted with EtOAc (2 x 5 mL) and the combined organics washed with brine, dried (MgSO4), 
filtered, rotary evaporated and Chromatographed (hexanes/Et2O, 7:3 to 1:1) to give the title compound 
(34 mg, 77 %) as a colourless oil. IR (cm
−1
): 1763, 1709, 1634, 1504, 1390, 1377, 1273, 1252, 1202, 
1075, 1014, 951, 902, 829, 809, 775. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 8.01 (br. s., 1 H), 5.30 (s, 1 
H), 4.47 (quin, J = 5.9 Hz, 1 H), 3.78 (s, 3 H), 2.80–3.06 (m, 2 H), 2.41–2.52 (m, 2 H), 1.70 (s, 3 H) 
1.69 (s, 3 H), 0.86 (s, 9 H), 0.08 (d, J = 7.3 Hz, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 171.2, 
168.1, 160.9, 151.8, 106.6, 95.8, 66.0, 53.0, 43.4, 41.6, 30.3, 25.7, 25.6, 24.4, −4.9 (2C). MS (ES) 
m/z: 424 [M+Na]
+
. HR-MS (ES) m/z calcd for C18H31NO7NaSi: 424.1768 [M+H]
+
; found: 424.1761. 
1.25.13.126 tert-Butyl but-3-enoate (462a)262 
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Crotonyl chloride (5.10 mL, 52.27 mmol) was added dropwise to triethylamine (7.37 mL, 52.27 
mmol) in benzene (9.2 mL) over 25 min and stirred a further 1 h. The mixture was poured into 
saturated aqueous NH4Cl and extracted with EtOAc. The aqueous was furhter extracted with ether and 
the combined organics dried (MgSO4) and rotary evaporated to give the title compound (5.40 g, 73%) 
as a pale brown oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.97–5.84 (m, 1 H), 5.22–5.05 (m, 2 H), 
3.00 (dt, J = 6.9, 1.5 Hz, 2 H), 1.45 (s, 9 H).
 13
C NMR (101 MHz, CDCl3, ppm) δ: 170.9, 130.9, 
117.9, 80.6, 40.4, 28.0. In agreement with the literature. 
1.25.13.127 tert-Butyl 2-methylbut-3-enoate (462b)263 
 
According to general procedure E alkylation with methyl iodide (526 µL, 8.45 mmol) and distillation 
(75 °C, 30 Torr) gave the title compound (692 mg, 63 %) as a colourless oil. IR (cm−1): 1728, 1367, 
1272, 1256, 1141, 916, 851.1H NMR (400 MHz, CDCl3, ppm) δ: 5.90 (ddd, J = 17.2, 10.1, 7.3 
Hz, 1 H), 5.05–5.15 (m, 2 H), 2.96–3.09 (m, 1 H), 1.45 (s, 9 H), 1.23 (d, J = 6.8 Hz, 3 H). 13C 
NMR (101 MHz, CDCl3, ppm) δ: 173.8, 137.7, 115.3, 80.3, 44.6, 28.0, 16.7. In agreement with 
the literature. 
1.25.13.128 tert-Butyl 2-benzylbut-3-enoate (462c)264 
 
According to general procedure E reaction with benzyl bromide (838 µL, 7.04 mmol) and 
chromatography (pentane/Et2O, 1:0 to 99:1) gave the title compound (1.022 g, 63%) as a colourless 
oil. IR (cm−1): 1725, 1367, 1248, 1144, 993, 919, 846, 740, 698. 
1
H NMR (400 MHz, CDCl3, 
ppm) δ: 7.31–7.26 (m, 2 H), 7.23–7.20 (m, 3 H), 5.93–5.81 (m, 1 H), 5.13 (m, 1 H), 5.09 (m, 
1 H), 3.30–3.18 (m, 1 H), 3.13–3.02 (m, 1 H), 2.83 (dd, J = 6.8, 13.7 Hz, 1 H), 1.38 (s, 9 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 172.6, 138.9, 136.0, 129.1, 128.2, 126.2, 117.0, 80.6, 52.8, 
38.5, 27.9. MS (EI) m/z: 231 [M-H]
+
. HR-MS (EI) m/z: calcd for C15H19O2: 231.1385 [M-
H]
+
; found: 231.1392. In agreement with the literature. 
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1.25.13.129 tert-Butyl 3-phenylbut-3-enoate (462d)265  
 
According to general procedure E, reaction of (E)-tert-Butyl 3-phenylbut-2-enoate (1.00 g, 4.59 
mmol) with acetic acid and chromatography (pentane/Et2O, 99.5:0.5 to 99:1) gave the title compound 
(516 mg, 52%) as a colourless oil. IR (cm−1): 1725, 1367, 1291, 1256, 1143, 969, 900, 842, 776, 
700. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.48–7.40 (m, 2 H), 7.36–7.22 (m, 3 H), 5.50 (s, 1 
H), 5.23–5.19 (m, 1 H), 3.45–3.43 (m, 2 H), 1.36 (s, 9 H). 13C NMR (101 MHz, CDCl3, ppm) δ: 
170.6, 141.7, 140.2, 128.2, 127.6, 125.9, 115.7, 80.7, 42.7, 27.9. MS (EI) m/z: 217 [M-
H]
+
.HR-MS (EI) m/z: calcd for C14H17O2: 217.1229 [M-H]
+
; found: 217.1232. In agreement 
with the literature. 
1.25.13.130 tert-Butyl 2-(1-hydroxyethyl)but-3-enoate (462e) 
 
According to general procedure E reaction with acetaldehyde (791 µL, 14.08 mmol) and 
chromatography (pentane/Et2O, 19:1 to 3:1) gave the title compound (829 mg, 63%) as a colourless 
oil. IR (cm−1): 1724, 1638, 1458, 1383, 1368, 1253, 1205, 1148, 994, 920, 873, 842, 797, 744, 
611. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.70–6.00 (m, 1 H), 5.17–5.32 (m, 2 H), 3.92–4.08 
(m, 1 H), 2.84–2.98 (m, 1 H), 2.64–2.77 (m, 1 H), 1.46 (2 × s, 9 H), 1.18 (m, 3 H). 13C NMR 
(101 MHz, CDCl3, ppm) δ: 172.5, 172.5, 133.3, 132.3, 120.1, 118.9, 81.4, 68.6, 67.6, 58.9, 
58.1, 28.0, 20.7, 19.9. MS (CI) m/z: 204 [M+NH4]
+
, 186 [M+H]
+
. HR-MS (CI) m/z: calcd for 
C10H19O3: 187.1334 [M+H]
+
; found: 187.1327. 
1.25.13.131 tert-Butyl 2-(1-(tert-butyldimethylsilyloxy)ethyl)but-3-enoate  (462f) 
 
4-Dimethylaminopyridine (19 mg, 0.16 mmol) was added to a mixture of tert-butyl 2-(1-
hydroxyethyl)but-3-enoate (590 mg, 3.17 mmol),  imidazole (280 mg, 4.12 mmol) and tert-
butyldimethylsilyl chloride (526 mg, 3.49 mmol) in DMF (2 mL) and stirred for 7 h, before 
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addition of water and stirring for an additional 12 h. The mixture was extracted with ether 
(× 3), washed with saturated aqueous NH4Cl, saturated aqueous NaHCO3, brine, dried 
(MgSO4), rotary evaporated and chromatographed  (pentane/Et2O, 49:1) to give the title 
compound (894 mg, 94 %, dr 1:1) as a colourless oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 
5.87 (ddd, J = 17.1, 10.3, 9.3 Hz, 0.5 H), 5.75 (ddd, J = 17.1, 10.3, 9.3 Hz, 0.5 H), 5.04–5.22 
(m, 2 H), 4.03–4.15 (m, 1 H), 2.82–2.96 (m, 1 H), 1.45 (2 × s, J = 2.4 Hz, 9 H), 1.17 (2 × s, J 
= 5.9 Hz, 1.5 H), 1.12 (2 × s, 1.5 H), 0.87–0.88 (m, 9 H), 0.01–0.08 (m, 6 H). 13C NMR (101 
MHz, CDCl3, ppm) δ: 171.8, 134.4, 133.9, 118.4, 118.0, 80.5, 80.3, 69.5, 69.4, 60.6, 59.9, 28.1, 
28.0, 25.8, 25.8, 25.7, 25.6, 21.8, 21.3, 18.0, −3.0, −4.3, −4.7, −4.9.  MS (CI) m/z: 300 
[M+H]
+
. HR-MS (CI) m/z: calcd for C16H33SiO3: 301.2199 [M+H]
+
; found: 301.2188. 
1.25.13.132 2,2-Dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-7-yl formate (464)266  
   
Oxalyl chloride (120 µL, 1.415 mmol) and DMF (110 µL, 1.415 mmol) were added to (E)-4-(2,2-
Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-3-enoic acid (100 mg, 0.472 mmol) and stirred for 
20 h. The mixture was diluted with CH2Cl2  and washed with 1 M aqueous HCl, brine, dried 
(MgSO4), filtered, rotary evaporated and chromatographed (pentane/Et2O, 9:1 to 0:1 to give 
the title compound (32 mg, 33%) as a colourless solid. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 
9.91–10.07 (br. s, 1 H), 8.48 (d, J = 1.8 Hz, 1 H), 8.13 (ddd, J = 8.6, 2.1, 0.9 Hz, 1H), 7.12 
(d, J = 8.5 Hz, 1 H), 1.75–1.83 (m, 6 H). 13C NMR (101 MHz, CDCl3, ppm) δ: 189.6, 160.4, 
159.8, 135.7, 133.4, 131.4, 118.4, 113.5, 107.3, 25.9 ppm 
1.25.13.133 tert-Butyl 4-methyl-3-oxopent-4-enoate (465a)267Error! Bookmark not defined. 
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DMSO (2.86 mL, 40.3 mmol) in CH2Cl2 (20 mL) was added dropwise to oxalyl chloride (1.77 mL, 
20.97 mmol) in CH2Cl2 (140 mL) and stirred for 10 min. tert-Butyl 3-hydroxy-4-methylpent-4-enoate 
(3.00 g, 16.13 mmol) was added dropwise and stirred for 10 min. Triethylamine (22.6 mL, 161.3 
mmol) was then added dropwise over 10 min and the mixture warmed to 25 °C for 30 min. NaHCO3 
was added and the mixture extracted with CH2Cl2, dried (MgSO4), rotary evaporated and 
chromatographed (pentane/Et2O, 9:1 to 17:3) to give the title compound (1.321 g, 45%) as a 
colourless oil. IR  (cm−1): 1735, 1708, 1684, 1596, 1368, 1296, 1252, 1144, 1071, 1012, 984, 
922, 831. 
1
H NMR (400 MHz, CDCl3, ppm) δ:  Keto-form : 5.95(s, 1 H), 5.88(s, 1 H), 3.64 
(s, 2 H), 1.90 (s, 3 H), 1.46 (s, 9 H). MS (CI) m/z: 202 [M+NH4]
+
. HR-MS (CI) m/z: calcd for 
C10H20NO3: 202.1443 [M+NH4]
+
; found: 202.1452. In agreement with the literature.  
1.25.13.134 (E)-tert-Butyl 3-phenylbut-2-enoate (466a)268  
 
tert-Butyl 2-(diethoxyphosphoryl)acetate (5.00 g, 19.84 mmol)  was added to sodium hydride 
(60% in mineral oil; 794 mg, 19.84 mmol) in THF (35 mL) at 0 °C and stirred for 0.5 h. 
Acetophenone (1.85 mL, 15.87 mmol) was added and stirring continued for 20 h at 25 °C, 
before addition of saturated aqueous NH4Cl (40 mL). The mixture was extracted with ether (3  
× 60), washed with brine (3 × 50 mL), dried (MgSO4), rotary evaporated and 
chromatographed (pentane/Et2O, 99:1 to 97:3) to give the title compound (2.35 g, 68%) as a 
colourless oil. IR (cm−1): 1706, 1627, 1366, 1348, 1274, 1140, 1012, 873, 769, 759, 693. 
1
H 
NMR (400 MHz, CDCl3, ppm) δ:  7.49–7.44 (m, 2 H), 7.41–7.33 (m, 3 H), 6.07 (q, J = 1.0 
Hz, 1 H), 2.55 (d, J = 1.5 Hz, 3 H), 1.53 (s, 9 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 166.4, 
154.0, 142.5, 128.7, 128.4, 126.2, 119.1, 80.0, 28.3, 17.7. MS (EI) m/z: 217 [M-H]
+
. HR-MS 
(EI) m/z: calcd for C14H17O2: 217.1229 [M+-H]
+
; found: 217.1233. 
1.25.13.135 tert-Butyl 2-(diethoxyphosphoryl)acetate (467a) 269 
 
tert-Butyl bromoacetate (4.88g, 25 mmol) and triethyl phosphite (4.15g, 25 mmol) were heated at 
60 °C for 6 h to give the title compound (5.85 g, 93%) as a colourless oil. IR (cm−1): 1725, 1394, 
1367, 1287, 1255, 1211, 1164, 1114, 1050, 1020, 956, 882, 828, 790, 769, 752, 700, 612. 
1
H 
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NMR (400 MHz, CDCl3, ppm) δ: 4.24–4.12 (m, 4 H), 2.91 (s, 1 H), 2.86 (s, 1 H), 1.48 (s, 9 
H), 1.35 (t, J = 7.1 Hz, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 164.9 (d, J = 5.2 Hz), 82.0, 
62.4 (d, J = 5.2 Hz), 35.6 (d, J = 131.8 Hz) , 27.9, 16.3 (d, J = 5.2 Hz). MS  (EI) m/z: 275 
[M+Na]
+
. HR-MS (EI) m/z: calcd for C10H21O4NaP: 275.1024 [M+Na]
+
; found: 275.1011. In 
agreement with the literature. 
1.25.13.136 tert-Butyl 2-(diethoxyphosphoryl)-2-phenylacetate (469a)  
 
tert-Butyl 2-bromo-2-phenylacetate (1.5 g, 5.54 mmol) and triethyl phosphite (920 mg, 5.54 mmol) in 
acetonitrile (2 mL) were heated under microwave irradiation for 6 h at 100 °C and chromatography 
(pentane/Et2O, 1:1 to 7:13)  gave the title compound (1.183 g, 65 %) as a colourless oil. IR (cm
−1
): 
1727, 1479, 1497, 1455, 1393, 1368, 1346, 1278, 1254, 1218, 1136, 1098, 1049, 1019, 960, 887, 854, 
820, 782, 743, 697, 610. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.48–7.54 (m, 2H), 7.28–7.37 (m, 3H), 
4.16 (d, J = 24.0 Hz, 1H), 3.91–4.11 (m, 4H), 1.47 (s, 9H), 1.26 (t, J = 7.1 Hz, 3H), 1.20 (t, J = 7.1 
Hz, 3H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: ppm) 166.6 (d, J = 3.5 Hz),   131.3 (d, J = 8.7 Hz), 
129.6 (d, J = 5.2 Hz), 128.4 (d, J = 3.5 Hz), 127.7 (d, J = 3.5 Hz), 82.3, 63.1 (d, J = 6.9 Hz), 62.9 (d, J 
= 6.9 Hz), 53.2 (d, J = 133.5 Hz), 27.9, 16.3(2 × d, J = 6.9 Hz). 
31
P NMR (162MHz, CDCl3, ppm) δ: 
19.33. MS (ES) m/z: 329 [M+H]
+
. HR-MS (ES) m/z: calcd for C16H26PO5: 329.1518[M+H]
+
; found: 
329.1527. 
1.25.13.137 tert-Butyl 3-hydroxy-4-methylpent-4-enoate (472)267 
 
tert-Butyl acetate (3.51 mL, 26.1 mmol) was added dropwise to LDA (31.3 mmol) in THF (42 mL) at 
−78 °C and stirred for 1 h. Methacrolein (2.48 mL, 30 mmol) was added dropwise and stirred for 15 
min followed by addition of saturated aqueous NH4Cl. The mixture was partitioned between ether and 
water then extracted with EtOAc, dried (MgSO4) and rotary evaporated to give the title compound 
(4.857 g, 87%) as a pale yellow oil used without further purification. IR (cm−1): 1708, 1368, 1255, 
1147, 1046, 1027, 954, 889, 843, 765. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.02 (s, 1 H), 
4.87 (s, 1 H), 4.38–4.45 (m, 1 H), 3.15 (br. s, 1 H), 2.41–2.54 (m, 2 H), 1.75 (s, 3 H), 1.46 (s, 
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9 H).
13
C NMR (101 MHz, CDCl3, ppm) δ: 172.0, 145.5, 111.2, 81.3, 71.6, 40.9, 28.0, 18.2.MS 
(CI) m/z: 204 [M+NH4]
+
, 187 [M+H]
+
. HR-MS (CI) m/z: calcd for C10H22NO3: 204.1600 
[M+NH4]
+
; found: 204.1609. In agreement with the literature. 
1.25.13.138 tert-Butyl 2-bromo-2-phenylacetate (475)270   
 
Thionyl chloride (13.5 mL, 186 mmol) was added to α-bromophenylacetic acid (10 g, 46.5 mmol) and 
DMF (50 µL, 0.685 mmol) and stirred for 18 then rotary evaporated to give α-bromophenylacetyl 
chloride (IR (cm
−1
): 1796). This was added to tert-butanol (8.9 mL, 93 mol) and triethylamine (13 
mL, 93 mmol) in CH2Cl2 (10 mL) an sitrrred for 2 h. The mixture was washed with saturated aqueous 
NH4Cl and extracted with CH2Cl2, dried (MgSO4), rotary evaporated and chromatographed 
(pentane/Et2O, 19:1) to give the title compound (5.1 g, 40%) as a colourless oil. IR (cm
−1): 1737, 
1478, 1497, 1455, 1369, 1306, 1285, 1255, 1223, 1031, 1076, 1031, 1004, 959, 916, 846, 
745, 693. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.44–7.58 (m, 2H), 7.31–7.42 (m, 3H), 5.22–
5.28 (m, 1H), 1.44–1.48 (m, 9H). 13C NMR (101 MHz, CDCl3, ppm) δ: 167.2, 136.3, 129.0, 
128.7, 128.6, 127.8, 83.1 (2C), 60.0, 48.3, 27.7. MS (CI) m/z: 288 [M+NH4]
+
(Br
79
), 290 
[M+NH4]
+
(Br
81
). HR-MS (CI) m/z: calcd for C12H19NO2Br: 288.0599 [M+NH4]
+
; found: 
288.0602. In agreement with the literature. 
1.25.13.139 tert-Butyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxy-3-methylbutanoate 
(±) (476a) 
 
According to general procedure H, aldol reaction of ester 408a (731 µL, 5.43 mmol) and 
dioxinone ketone 248a (1.00 g, 5.43 mmol) gave, after chromatography (pentane/Et2O, 7:3 to 
3:2), dioxinone ester 476a (775 mg, 48%) as a yellow oil. IR (cm−1): 1713, 1629, 1390, 1369, 
1273, 1249, 1202, 1150, 116, 1091, 1014, 963, 901, 814. 
1
H NMR (400 MHz, CDCl3, ppm) 
δ: 5.31 (s, 1 H), 4.06 (s, 1 H), 2.40–2.53 (m, 4 H), 1.70 (s, 3 H), 1.70 (s, 3 H), 1.48 (s, 9 H), 
1.30 (s, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 172.0, 168.0, 160.9, 106.5, 96.2, 82.1, 
70.5, 45.4, 45.3, 28.0, 27.4, 25.2, 25.1. MS (ES) m/z: 623 [M2 + Na]
+
, 601 [M2 + H]
+
. HR-MS 
(ES) m/z calcd for C30H49O12: 601.3224 [M2 + H]
+
; found: 601.3231. 
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1.25.13.140 tert-Butyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxy-2,3-
dimethylbutanoate (±) (476b) 
 
According to general procedure H, aldol reaction of ester 408b (820 µL, 5.43 mmol) and 
dioxinone ketone 248a (1.00 g, 5.43 mmol) gave, after chromatography (pentane/Et2O, 7:3 to 
1:1), dioxinone ester 476b (845 mg, 50%, 1.0:0.6 dr) as a yellow oil. IR (cm−1): 1721, 1630, 
1458, 1390, 1368, 1273, 1255, 1204, 1148, 1008, 1076, 1013, 933, 901, 847, 811. 
1
H NMR 
(400 MHz, CDCl3, ppm) δ: 5.32 (s, 1.0 H), 5.31 (s, 0.6 H), 3.91 (br. s, 0.6 H), 3.55 (br. s, 
1.0 H), 2.41–2.53 (m, 3.8 H), 2.33 (d, J = 13.7, 1.0 H), 1.70 (s, 9.6 H), 1.46–1.48 (m, 14.4 H), 
1.29 (s, 3 H), 1.19–1.22 (m, 6.6 H). 13C NMR (101 MHz, CDCl3, ppm) δ: 176.0, 175.3, 168.3, 
168.2, 160.9, 106.5, 106.4, 96.4, 96.2, 81.9, 81.8, 72.7, 72.5, 48.7, 47.5, 45.3, 42.4, 28.0, 26.0, 
25.2, 25.0, 23.9, 12.4, 12.3. MS (CI) m/z: 332 [M + NH4]
+
, 315 [M + H]
+
. HR-MS (CI) m/z 
calcd for C16H30NO6: 332.2073 [M + NH4]
+
; found: 332.2070. Anal. calcd for C16H26O6: C 
61.13, H 8.34; found: C 60.95, H 8.45. 
1.25.13.141 tert-Butyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxy-3-methyl-2-
phenylbutanoate (±) (476c) 
 
According to general procedure H, aldol reaction of ester 408c (1.04 g, 5.43 mmol) and 
dioxinone ketone 284a (1.00 g, 5.43 mmol) gave, after chromatography (pentane/Et2O, 9:1 to 
1:1), dioxinone ester 476c (853 mg, 42 %, 1:0.8 dr) as a colorless gum. IR (cm−1): 1721, 1630, 
1455, 1390, 1369, 1273, 1251, 1203, 1146, 1088, 1014, 955, 900, 863, 808, 754, 701, 622. 
1
H 
NMR (400 MHz, CDCl3, ppm) δ: 7.29–7.41 (m, 9 H), 5.34 (s, 0.8 H), 5.26 (m, 1 H), 4.42 (s, 
0.8 H), 3.97 (s, 1 H), 3.57 (s, 1 H), 3.54 (s, 0.8 H), 2.62 (d, J = 13.7 Hz, 0.8 H), 2.57 (d, J = 
13.7 Hz, 0.8 H), 2.36 (d, J = 14.2 Hz, 1 H), 2.13 (d, J = 13.7 Hz, 1 H), 1.75 (s, 2.4 H), 1.74 (s, 
2.4H), 1.71 (s, 3 H), 1.70 (s, 3 H), 1.40–1.42 (m, 19.2 H), 1.04 (s, 2.4 H). 13C NMR (101 
MHz, CDCl3, ppm) δ: 173.6, 173.0, 168.4, 168.1, 160.9, 160.9, 134.7, 134.6, 129.7, 129.5, 
128.4, 128.4, 127.8, 127.7, 106.6, 106.4, 96.6, 96.4, 82.5, 82.3, 73.4, 73.2, 60.4, 59.0, 46.1, 
42.9, 27.9, 26.6, 25.3, 25.2, 25.1, 24.8. MS (CI) m/z: 394 [M + NH4]
+
, 376 [M]
+
. HR-MS (CI) 
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m/z calcd for C21H32NO6: 394.2230 [M + NH4]
+
; found: 394.2219. Anal. calcd for C21H28O6: 
C 67.00, H 7.50; found: C 66.73, H 7.64. 
1.25.13.142 tert-Butyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxy-2,3-dimethyl-5-
phenylpentanoate (±) (476d) 
 
According to general procedure H, aldol reaction of ester 408b (341 µL, 2.26 mmol) and 
dioxinone ketone 248d (620 mg, 2.26 mmol) gave, after chromatography (pentane/Et2O, 4:1 
to 13:7), dioxinone ester 476d (452 mg, 50%) as a colorless gum. IR (cm−1): 1731, 1699, 
1629, 1494, 1456, 1392, 1374, 1366, 1345, 1320, 1291, 1272, 1258, 1203, 1160, 1141, 1095, 
1069, 1018, 972, 944, 900, 855, 845, 832, 809, 753, 736, 702, 983, 658, 615. 
1
H NMR (400 
MHz, CDCl3, ppm) δ: 7.22–7.29 (m, 2 H), 7.10–7.21 (m, 3 H), 5.06 (s, 1 H), 4.29 (s, 1 H), 
3.30–3.42 (m, 1 H), 2.75–2.83 (m, 2 H), 2.49 (q, J = 7.3 Hz, 1 H), 1.55 (s, 3 H), 1.52 (s, 3 H), 
1.48 (s, 9 H), 1.30 (d, J = 7.3 Hz, 3 H), 1.22 (s, 3H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 
177.0, 170.0, 160.5, 139.3, 128.7, 128.4, 126.4, 106.4, 96.7, 82.2, 74.3, 55.9, 46.1, 32.7, 27.9, 
25.0, 20.1, 12.9. MS (CI) m/z: 405 [M + H]
+
. HR-MS (CI) m/z calcd for C23H33O6: 405.2277 
[M + H]
+
; found: 405.2267. Anal. calcd for C23H32O6: C 68.29, H 7.97; found: C 68.44, H 
8.11. 
1.25.13.143 tert-Butyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxy-3-(4-
methoxyphenyl)butanoate (±) (476e) 
 
According to general procedure H, aldol reaction of ester 408a (729 µL, 5.43 mmol) and 
dioxinone ketone 248c (1.50 g, 5.43 mmol) gave, after chromatography (pentane/Et2O, 4:1 to 
3:1), dioxinone ester 476e (1.10 g, 52%) as a yellow gum. IR (cm−1): 1721, 1644, 1583, 1458, 
1390, 1369, 1319, 1373, 1251, 1203, 1147, 1084, 1047, 1015, 901, 877, 848, 805, 744, 605. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.29–7.35 (m, 2 H), 6.82–6.88 (m, 2 H), 5.14 (s, 1 H), 
4.61 (s, 1 H), 3.80 (s, 3 H), 2.88 (d, J = 15.2 Hz, 1 H), 2.79 (d, J = 15.7 Hz, 1 H), 2.68 (s, 
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2 H), 1.56 (s, 3 H), 1.51 (s, 3 H), 1.29 (s, 9 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 171.5, 
167.4, 161.0, 158.8, 135.9, 126.3, 113.4, 106.4, 96.5, 82.2, 74.2, 55.3, 46.7, 46.2, 27.8, 25.0, 
24.9. MS (CI) m/z: 410 [M + NH4]
+
. HR-MS (CI) m/z calcd for C21H32NO7: 410.2179 [M + 
NH4]
+
; found: 410.2171. Anal. calcd for C21H28O7: C 64.27, H 7.19; found: C 64.19, H 7.30. 
1.25.13.144 2-(4-(4-Methoxyphenyl)-2-oxo-2H-pyran-6-yl)acetic acid (478) 
 
According to general procedure G, reaction of ester 337l (329 mg, 0.880 mmol) for 2 h gave 
pyrone 478 (206 mg, 74%) as a yellow solid; decomposition (-CO2) 148 °C (MeOH). IR 
(cm−1): 1729, 1671, 1619, 1598, 1580, 1544, 1517, 1433, 1401, 1323, 1314, 1291, 1272, 1248, 
1186, 1146, 1122, 1055, 1019, 1006, 895, 862, 846, 827, 802, 741, 730, 712, 694, 640, 624. 
1
H NMR (400 MHz, CD3OD, ppm) δ: 7.36–7.44 (m, 2 H), 6.69–6.78 (m, 2 H), 6.34 (d, J = 
1.5 Hz, 1 H), 6.07 (d, J = 1.5 Hz, 1 H), 3.56 (s, 3 H), 3.27 (s, 2 H). 
13
C NMR (101 MHz, 
CD3OD, ppm) δ: 151.3, 144.6, 143.9, 140.9, 136.0, 110.8, 110.4, 97.0, 89.6, 86.4, 37.4, 21.5. 
MS (ES) m/z: 302 [M + MeCN + H]
+
, 261 [M + H]
+
. HR-MS (ES) m/z calcd for C14H13O5: 
261.0763 [M + H]
+
; found: 261.0779. Anal. calcd for C14H12O5: C 64.61, H 4.65. found: C 
64.46, H 4.74. 
1.25.13.145 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxy-3-methylbutanoic acid (±) 
(479a) 
 
According to general procedure J, aldol reaction of dioxinone ketone 284a (1.00 g, 5.43 
mmol) and benzyl acetate 480a (815 mg, 5.43 mmol) gave, after hydrogenolysis, carboxylic 
acid 479a (500 mg, 38%) as a yellow gum. IR (cm−1): 1714, 1658, 1624, 1501, 1463, 1435, 
1419, 1390, 1378, 1326, 1289, 1258, 1205, 1188, 1159, 1116, 1098, 1052, 1021, 972, 964, 
928, 905, 886, 865, 848, 821, 790, 754, 698, 677, 621. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 
6.00 (br. s, 2 H), 5.39 (s, 1 H), 2.69 (d, J = 17.1, 1 H), 2.62 (d, J = 16.1, 1 H), 2.56 (s, 2 H), 
1.73 (s, 3 H), 1.72 (s, 3 H), 1.39 (s, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 175.6, 167.8, 
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161.2, 106.8, 96.5, 70.5, 45.4, 44.2, 27.6, 25.1 (2C). MS (CI) m/z: 262 [M + NH4]
+
, 245 [M + 
H]
+
. HR-MS (CI) m/z calcd for C11H20NO6: 262.1291 [M + NH4]
+
; found: 262.1285. 
1.25.13.146 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxy-3-methyl-5-phenylpentanoic 
acid (±) (479b) 
 
According to general procedure J, aldol reaction of dioxinone ketone 284d (204 mg, 0.745 
mmol) and benzyl acetate 480a (112 mg, 0.745 mmol) gave, after hydrogenolysis, carboxylic 
acid 479b (140 mg, 56%, 1.0:0.4 dr) as a colorless gum. IR (cm−1): 1702, 1623, 1497, 1456, 
1391, 1377, 1272, 1255, 1200, 1120, 1075, 1020, 956, 858, 811, 731, 699, 647. 
1
H NMR 
(400 MHz, CDCl3, ppm) δ: 7.12–7.29 (m, 7.0 H), 5.23 (s, 0.4 H), 5.21 (s, 1.0 H), 3.25 (dd, J 
= 13.4, 3.2 Hz, 1.0 H), 3.14 (d, J = 11.7 Hz, 0.4 H), 2.60–2.93 (m, 5.6 H), 1.49–1.54 (m, 
8.4 H), 1.45 (s, 1.2 H), 1.41 (s, 3.0 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 176.2, 176.1, 
170.0, 161.2, 138.5, 138.2, 128.7, 128.5, 126.7, 126.6, 106.8, 97.1, 96.7, 72.2, 55.7, 55.4, 
43.3, 43.0, 32.8, 32.3, 25.8, 25.2, 25.1, 24.8, 24.7, 24.5. MS (ES) m/z: 376 [M + MeCN + H]
+
, 
352 [M + NH4]
+
, 335 [M + H]
+
. HR-MS (ES) m/z calcd for C18H23O6: 335.1495 [M + H]
+
; 
found: 335.1507. 
1.25.13.147 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxy-3-(4-methoxyphenyl)butanoic 
acid (±) (479c) 
 
According to general procedure J, aldol reaction of dioxinone ketone 284c (1.00 g, 5.43 
mmol) and benzyl acetate 480a (815 mg, 5.43 mmol) gave, after hydrogenolysis, carboxylic 
acid 479c (784 mg, 43%) as a yellow gum. IR (cm−1): 1712, 1680, 1621, 1586, 1515, 1461, 
1430, 1393, 1375, 1332, 1288, 1257, 1200, 1168, 1122, 1101, 1046, 1022, 936, 907, 889, 846, 
829, 817, 775, 754, 717, 701, 677, 637, 616. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.28–7.34 
(m, 2 H), 6.83–6.90 (m, 2 H), 5.15 (s, 1 H), 3.80 (s, 3 H), 2.89–3.05 (m, 2 H), 2.69–2.80 (m, 
2 H), 1.51, (s, 3 H), 1.50 (s, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 176.0, 167.3, 161.3, 
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159.0, 135.4, 126.1, 113.7, 106.6, 96.6, 74.0, 55.2, 46.4, 44.9, 24.9, 24.8.  (ES) m/z: 354 [M + 
NH4]
+
, 336 [M + H]
+
. HR-MS (ES) m/z calcd for C17H21O7: 337.1287 [M + H]
+
; found: 
337.1304. 
1.25.13.148 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxy-2,3-dimethyl-5-
phenylpentanoic acid (±) (479d) 
 
According to general procedure J, aldol reaction of dioxinone ketone 284d (204 mg, 0.745 
mmol) and benzyl propanoate 480b (122 mg, 0.745 mmol) gave, after hydrogenolysis, 
carboxylic acid 479d (106 mg, 41%, 1.0:0.4 dr) as a colorless gum. IR (cm−1): 1702, 1622, 
1497, 1456, 1391, 1377, 1273, 1255, 1200, 1101, 1074, 1019, 905, 859, 810, 730, 699, 648. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 8.46 (br. s, 0.4 H), 7.11–7.29 (m, 7.0 H), 5.20 (s, 1.0 H), 
5.16 (s, 0.4 H), 3.94 (br. s, 0.4 H), 3.26–3.38 (m, 1.4 H), 2.67–2.91 (m, 5.2 H), 1.52–1.57 (m, 
4.2 H), 1.46–1.49 (m, 4.2 H), 1.41 (s, 1.2 H), 1.33–1.39 (m, 5.2 H), 1.28 (s, 3 H). 13C NMR 
(101 MHz, CDCl3, ppm) δ: 180.1, 179.8, 170.2, 169.8, 161.3, 160.9, 138.7, 128.9, 128.7, 
128.5, 126.6, 106.8, 106.7, 96.7, 96.6, 74.5, 73.5, 55.2, 52.7, 46.6, 45.3, 32.6, 32.4, 25.4, 25.1, 
24.7, 24.5, 23.1, 20.4, 12.8, 11.9. MS (ES) m/z: 390 [M + MeCN + H]
+
, 366 [M + NH4]
+
, 349 
[M + H]
+
. HR-MS (ES) m/z calcd for C19H25O6: 349.1651 [M + H]
+
; found: 349.1643. 
1.25.13.149 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxy-3-methyl-2-phenylbutanoic 
acid (±) (479e) 
 
According to general procedure J, aldol reaction of dioxinone ketone 284a (1.00 g, 5.43 
mmol) and benzyl phenylacetate 480c (1.23 g, 5.43 mmol) gave, after hydrogenolysis, 
carboxylic acid 479e (325 mg, 19%, 1.0:0.8 dr) as a yellow oil. Alternatively, carboxylic acid 
479e was synthesized by addition of the dianion derived from PhCH2CO2H to dioxinone 
ketone 284a. n-BuLi in hexanes (13.6 mL, 32.6 mmol) was added dropwise with stirring to 
(
i
Pr)2NH (4.61 mL, 32.6 mmol) in THF (30 mL) at 0 °C. After 15 min, PhCH2CO2H (2.22 g, 
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16.3 mmol) in THF (20 mL) was added dropwise with stirring. After 30 min, the solution was 
heated at 50 °C for 2 h. After cooling to −78 °C, dioxinone ketone 284a (3.00 g, 16.3 mmol) 
in THF (10 mL) was added dropwise. After a further 20 min, AcOH (2.42 mL, 42.3 mmol) in 
THF (10 mL) was added dropwise. Water (100 mL) was added and the mixture extracted 
with EtOAc (3 × 100 mL). The combined organic extracts were washed with brine, dried 
(MgSO4), rotary evaporated, and chromatographed (CH2Cl2/MeOH/AcOH, 99:0.9:0.1 to 
95:4.9:0.1) to give carboxylic acid 479e (2.00g, 38%, 1.0 : 0.8 dr) as a yellow oil. IR (cm−1): 
1702, 1626, 1497, 1455, 1390, 1375, 1275, 1257, 1200, 1175, 1088, 1016, 906, 810, 725, 700, 
644, 624. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.32–7.44 (m, 9.0 H), 5.40 (s, 1.0 H), 5.29 (s, 
0.8 H), 3.75 (s, 0.8 H), 3.72 (s, 1.0 H), 2.59 (s, 2.0 H), 2.49 (d, J = 14.2 Hz, 0.8 H), 2.16–2.22 
(m, 0.8 H), 1.72 (s, 3 H), 1.71 (s, 3 H), 1.69, (s, 2.4 H) 1.68 (s, 2.4 H), 1.42 (s, 2.4 H), 1.11 (s, 
3.0 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 177.3, 177.0, 168.3, 168.1, 161.6, 161.4, 133.9, 
133.8, 129.8, 129.7, 128.7, 128.6, 128.3, 128.2, 106.9, 106.7, 96.6, 96.6, 73.5, 73.2, 59.9, 
58.6, 45.8, 42.6, 26.5, 25.2, 25.0, 24.7. MS (ES) m/z: 362 [M + MeCN + H]
+
, 338 [M + 
NH4]
+
, 321 [M + H]
+
. HR-MS (ES) m/z calcd for C17H21O6: 321.1338 [M + H]
+
; found: 
321.1365. 
1.25.13.150 Benzyl acetate (480a)271  
 
4-Dimethylaminepyridine (244 mg, 2 mmol) was added to phenylacetic acid (2.72 g, 20 mmol), 
benzyl alcohol (2.28 mL, 22 mol), and EDCI (4.22g, 22 mmol) at 0 °C and then stirred at 25 °C for 3 
h. The mixture was diluted with CH2Cl2 and washed with 1 M aqueous HCl (× 2), water, brine, dried 
(MgSO4), rotary evaporated and chromatographed (pentane/Et2O, 99:1 to 97: 3) to give the title 
compound (4.43 g, 98%) as a pale yellow oil. In agreement with the literature. IR (cm−1): 1736, 
1498, 1456, 1380, 1362, 1222, 1081, 1025, 964, 921, 903, 836, 736, 696, 643, 611. 
1
H NMR 
(400 MHz, CDCl3, ppm) δ: 7.31–7.43 (m, 5H), 5.12 (s, 2H), 2.12 (s, 3H). MS (CI) m/z: 168 
[M+NH4]
+
. HR-MS (CI) m/z: calcd for C9H14NO2: 168.1025 [M+NH4]
+
; found: 168.1029. In 
agreement with the literature. 
1.25.13.151 Benzyl propionate (480b)272 
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Triethylamine (21.0 mL, 150 mmol) was added dropwise to a stirred solution of benzyl alcohol (5.17 
mL, 50 mmol) and propionic anhydride (9.62 mL, 75 mmol) in CH2Cl2 (50 mL) at 0 °C. After stirring 
for 2 h at 25 °C, saturated ammonium chloride was added and the organics washed with water, brine, 
dried (MgSO4), and rotary evaporated to give the title compound (8.00 g, 98%) as a colourless oil. 
1
H 
NMR (400 MHz, CDCl3, ppm) δ: 7.46–7.29 (m, 5 H), 5.15 (s, 2 H), 2.41 (q, J = 7.5 Hz, 2 H), 1.19 (t, J = 7.6 
Hz, 3 H). In agreement with the literature. 
1.25.13.152 Benzyl 2-phenylacetate (480c)273 
 
EDCI (4.22g, 22 mmol) was added with stirring to phenylacetic acid (2.72 g, 20 mmol), benzyl 
alcohol (2.28 mL, 22 mmol) and DMAP (244 mg, 2.0 mmol) in CH2Cl2 (20 mL) at 0 °C. After 
stirring for 3 h at 25 °C, the mixture was diluted with CH2Cl2, washed with 1 M aqueous HCl (× 2), 
water, and brine, dried (MgSO4), rotary evaporated and chromatographed (pentane/Et2O, 99:1 to 97:3) 
to give the title compound (4.43 g, 98%) as a colourless oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 
7.44–7.29 (m, 10 H), 5.18 (s, 2 H), 3.72 (s, 2 H). In agreement with the literature. 
1.25.13.153 5-Hydroxy-8-isobutyryl-2,2,6-trimethyl-4H-benzo[d][1,3]dioxin-4-one (482) 
 
Ghosez’s reagent (22 µL, 0.161 mmol) was added to 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-
2-methylbut-3-enoic acid (±)  (28 mg, 0.124 mmol) in CH2Cl2 (1.5 mL) and the mixture stirred for 
12 h. The mixture was poured into saturated aqueous NaHCO3, extracted with CH2Cl2, washed with 
brine, dried (MgSO4), rotary evaporated and chromatographed  (pentane/Et2O, 19:1 to 9:1) to give the 
title compound (5 mg, 15%) as a colourless solid. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 11.19 (s, 
1 H), 7.87 (s, 1 H), 3.40 (spt, J = 6.8 Hz, 1 H), 2.22 (s, 3 H), 1.82 (s, 6 H), 1.16 ppm (d, J = 
6.8 Hz, 6 H).
13
C NMR (101 MHz, CDCl3, ppm) δ: 202.4, 165.7, 163.4, 152.8, 139.9, 121.0, 
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117.2, 107.4, 98.1, 39.5, 25.7, 18.7, 14.8. MS (CI) m/z: 279 [M+H]+. HR-MS  (CI) m/z: calcd 
for C15H19O5: 279.1232[M+H]
+
; found: 279.1239. 
1.25.13.154 6-(1-(2,3-Dimethyl-4-oxooxetan-2-yl)-2-phenylethyl)-2,2-dimethyl-4H-1,3-dioxin-4-
one (±) (483a) 
 
According to general procedure K, attempted aromatization of carboxylic acid 479d (85 mg, 
0.24 mmol) and chromatography (pentane/Et2O, 7:3 to 1:1) gave β-lactone 483a (50 mg, 
62%, 1.0 : 0.15 dr) as a colorless solid; decomposition (-CO2) 104 °C (CH2Cl2–pentane). IR 
(cm−1): 1815, 1723, 1634, 1499, 1454, 1376, 1273, 1253, 1199, 1041, 1014, 958, 901, 809, 
744, 721, 700, 649, 616. 
1
H NMR (400 MHz, CDCl3, ppm) (data for major diastereoisomer 
only) δ: 7.19–7.32 (m, 3 H), 7.13–7.18 (m, 2 H), 5.19 (s, 1 H), 3.66 (q, J = 7.8 Hz, 1 H), 
3.04–3.15 (m, 1 H), 2.86–2.97 (m, 2 H), 1.58 (s, 6 H), 1.58 (s, 3 H), 1.30 (d, J = 7.8 Hz, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) (data for major diastereoisomer only) δ: 170.7, 167.2, 
160.0, 137.2, 128.7, 128.5, 127.0, 107.0, 97.0, 81.4, 55.4, 52.1, 32.5, 25.3, 24.6, 17.7, 9.2. 
MS (ES) m/z: 372 [M + MeCN + H]
+
, 348 [M + NH4]
+
, 331 [M + H]
+
. HR-MS (ES) m/z 
calcd for C19H23O5: 331.1545 [M+H]
+
; found: 331.1544. 
1.25.13.155 2,2-Dimethyl-6-((2-methyl-4-oxo-3-phenyloxetan-2-yl)methyl)-4H-1,3-dioxin-4-one 
(±) (483b) 
 
According to general procedure K, attempted aromatization of carboxylic acid 479e (547 mg, 
1.71 mmol) and chromatography (pentane/Et2O, 1:1 to 0:1) gave β-lactone 483b (160 mg, 
31%, 1.0 : 0.25 dr) as a yellow oil. IR (cm−1): 1818, 1722, 1633, 1496, 1455, 1392, 1378, 
1343, 1327, 1303, 1279, 1252, 1202, 1174, 1149, 1111, 1075, 1041, 1014, 972, 948, 905, 848, 
831, 802, 729, 699, 648. 
1
H NMR (400 MHz, CDCl3, ppm) (data for major diastereoisomer 
only) δ: 7.37–7.43 (m, 3 H), 7.20–7.25 (m, 2 H), 5.45 (s, 1 H), 4.88 (s, 1 H), 2.93–2.94 (m, 
2 H), 1.76 (s, 3 H), 1.73(s, 3 H), 1.28 (s, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) (data for 
major diastereoisomer only) δ: 167.9, 165.4, 160.2, 130.5, 129.1, 128.6, 128.3, 107.3, 97.1, 
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80.7, 63.5, 44.6, 25.4, 24.8, 21.4. MS (ES) m/z: 344 [M + MeCN + H]
+
, 320 [M + NH4]
+
, 303 
[M + H]
+
. HR-MS (ES) m/z calcd for C17H19O5: 303.1232 [M + H]
+
; found: 303.1236. 
1.25.13.156 Methyl 2,6-dihydroxy-3,4-dimethylbenzoate (484)274 
 
Caesium carbonate (60 mg, 0.18 mmol) was added to 5-hydroxy-2,2,6,7-tetramethyl-4H-
benzo[d][1,3]dioxin-4-one (20.0 mg, 0.09 mmol) in methanol (0.2 mL) and stirred for 7 h. The 
mixture was rotary evaporated and partitioned between ether and saturated aqueous NH4Cl. The 
organics were washed with brine, dried (MgSO4), rotary evaporated and chromatographed 
(pentane/Et2O, 19:1) to give the title compound (15 mg, 85%) as a colourless solid; mp 104–105 °C 
(CH2Cl2–pentane). IR (cm
−1
): 1665, 1633, 1575, 1429, 1387, 1337, 1310, 1248, 1209, 1152, 1095, 
1074, 1008, 978, 936, 860, 799, 778, 736, 632.  
1
H NMR (400 MHz, CDCl3, ppm) δ: 10.17 (br. s, 1 
H), 9.20 (br. s, 1 H), 6.34 (s, 1 H), 4.06 (s, 3 H), 2.23 (s, 3 H), 2.07 (s, 3 H). 
13
C NMR (101 MHz, 
CDCl3, ppm) δ: 170.4, 158.1, 157.8, 147.1, 115.4, 109.3, 97.6, 52.8, 21.0, 11.0. MS (CI) m/z: 197 
[M+H]
+
. HR-MS (CI) m/z calcd for C10H13O4: 197.0814 [M+H]
+
; found: 197.0820. In agreement with 
the literature. 
1.25.13.157 2,2,7-Trimethyl-5-(pyrrolidin-1-yl)-4H-benzo[d][1,3]dioxin-4-one (492a) 
 
2,2-Dimethyl-6-(2-methyl-4-oxo-4-(pyrrolidin-1-yl)but-1-enyl)-4H-1,3-dioxin-4-one (30 mg, 
0.108 mmol) and 2,4,6-collidine (16 µL, 0.118 mmol) in CH2Cl2 (1 mL) was added dropwise 
to triflic anhydride (20 µL, 0.118 mmol) in CH2Cl2 (1 mL) at reflux over 1 h and heated for a 
further 13 h. Mixture poured into saturated aqueous NaHCO3 and extracted with CH2Cl2, 
washed with brine, dried (MgSO4) rotary evaporated and chromatographed  (pentane/Et2O, 
7:3 to 1:1) to give the title compound (7 mg, 25%) as beige oil. IR (cm−1): 1706, 1613, 1552, 
1481, 1443, 1388, 1375, 1346, 1323, 1294, 1261, 1232, 1208, 1141, 1105, 1035, 1107, 969, 
914, 881, 851, 838, 827, 809, 781, 815, 670, 633, 611. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 
6.26 (s, 1 H), 6.12 (s, 1 H), 3.29– 3.38 (m, 4 H), 2.30 (s, 3 H), 1.93–2.03 (m, 4 H), 1.75 (s, 6 
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H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 159.2, 157.4, 150.7, 146.4, 107.9, 104.0, 103.6, 97.9, 
51.9, 25.9, 25.3, 22.5.
 
MS (ES) m/z: 262 [M+H]
+
. HR-MS (ES) m/z: calcd for C15H20NO3: 
262.1443 [M+H]
+
; found: 262.1446. 
1.25.13.158 2,2-Dimethyl-6-(2-methyl-4-oxo-4-(pyrrolidin-1-yl)but-1-enyl)-4H-1,3-dioxin-4-one 
(498) 
 
According to general procedure I, dehydration of β-hydroxy amide 499 (286 mg, 0.963 
mmol) for 3 h and chromatography (pentane/EtOAc, 1:1 to 0:1) gave dioxinone amide 498 (138 
mg, 51%, 1.0:1.0:0.7 rr) as a yellow oil. IR (cm−1): 1718, 1627, 1582, 1432, 1388, 1373, 1321, 
1272, 1251, 1200, 1014, 964, 901, 872, 805. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.82 (s, 0.7 
H), 5.66 (s, 1.0 H), 5.29 (s, 1.0 H), 5.25 (s, 1.7 H), 5.08 (s, 1.0 H), 5.04 (s, 1.0 H), 3.34–3.51 
(m, 12.2 H), 3.15 (s, 2 H), 3.10 (s, 2 H), 3.06 (s, 2 H), 2.08–2.11 (m, 3 H), 1.82–2.00 (m, 12.9 
H), 1.71 (s, 6 H) 1.65–1.68 (m, 10.2 H) 13C NMR (101 MHz, CDCl3, ppm) δ: 169.3, 168.2, 
167.7, 167.6, 164.5, 164.2, 162.0, 161.9, 161.1, 146.3, 146.1, 136.5, 120.3, 120.1, 117.9, 
106.5, 106.1, 95.0, 94.8, 94.2, 47.2, 46.9, 46.8, 46.6, 45.9, 45.8, 42.0, 40.3, 40.2, 26.9, 26.1, 
25.1, 24.9, 24.3, 19.8. MS (ES) m/z: 302 [M+Na]
+
,  280 [M+H]
+
. HR-MS (ES) m/z: calcd for 
C15H21NO4Na: 302.1368 [M+H]
+
; found: 302.1379. Anal. calcd for C15H21NO4: C 64.50, H 
7.58, N 5.01; found: C 64.39, H 6.70, N 5.11. 
1.25.13.159 6-(2-Hydroxy-2-methyl-4-oxo-4-(pyrrolidin-1-yl)butyl)-2,2-dimethyl-4H-1,3-dioxin-
4-one (499) 
 
According to general procedure H reaction of N-acetyl pyrrolidine (614 mg, 5.43 mmol) and 2,2-
dimethyl-6-(2-oxopropyl)-4H-1,3-dioxin-4-one (1.00 g, 5.43 mmol) and chromatography 
(pentane/EtOAc, 1:1 to 0:1) gave the title compound (413 mg, 26%) as a pale yellow oil. IR (cm−1): 
1721, 1613, 1451, 1389, 1373, 1273, 1252, 1202, 1118, 1090, 1014, 971, 901, 860, 911, 783, 
613. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.75 (s, 1H), 5.27 (s, 1H), 3.47 (t, J = 6.8 Hz, 2H), 
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3.36 (t, J = 6.6 Hz, 2H), 2.44–2.60 (m, 3H), 2.35–2.44 (m, 1H), 1.82–2.01 (m, 4H), 1.69 (s, 
6H), 1.31 (s, 3H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 170.7, 168.7, 161.0, 106.4, 95.9, 70.9, 
46.7, 45.7, 45.5, 42.7, 27.9, 25.8, 25.2, 25.0, 24.2. MS (ES) m/z: 298 [M+H]
+
. HR-MS (ES) 
m/z: calcd for C15H24NO5: 298.1654 [M+H]
+
; found: 298.1668. Anal. calcd for C15H23NO5: C 
60.59, H 7.80, N 4.71; found: C 60.47, H 7.89, N 4.82.  
1.25.13.160 N-Acetyl pyrrolidine (500)275  
 
Acetic anhydride (12.29 mL, 130 mmol) and triethylamine (28.0 mL, 200 mL) were added to 
pyrrolidine (8.27 mL, 100 mmol) in CH2Cl2 (100 mL) and stirred for12 h. The mixture was washed 
with saturated aqueous NH4Cl (× 2), water, brine, dried (MgSO4), and rotary evaporated to give the 
title compound (5.00 g, 44%) as a pale pink oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 3.34–3.46 
(m, 4H), 2.01 (s, 3H), 1.87–1.97 (m, 2H), 1.76–1.87 (m, 2H). 13C NMR (101 MHz, CDCl3, 
ppm) δ: 169.0, 47.3, 45.4, 26.0, 24.5, 22.4.
 
MS (APCI) m/z: 114 [M+H]
+
.
 
HR-MS (APCI) m/z: 
calcd for C16H12NO: 114.0913 [M+H]
+
; found: 114.0914. In agreement with the literature. 
1.25.13.161 (E)-tert-Butyl 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)vinylcarbamate (503) 
. 
(E)-isopropyl 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)vinylcarbamate (158 mg, 0.709 
mmol) was heated with tert-butanol (3.40 mL, 35.43 mmol) in toluene (7 mL) at 75 °C for 3 
h. The mixture was rotary evaporated and chromatographed (pentane/ether, 4:1 to 1:1) to give 
the title compound (142 mg, 75%) as a colourless solid. IR (cm−1): 1730, 1730, 1691, 1628, 
1501, 1458, 1392, 1376, 1303, 1248, 1227, 1203, 1143, 1108, 1052, 1017, 974, 961, 908, 
879, 848, 796, 759, 730, 678, 660, 609. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.48 (t, J = 12.7 
Hz, 1H), 6.91 (d, J = 11.7 Hz, 1H), 5.45 (d, J = 14.2 Hz, 1H), 5.14 (s, 1H), 1.70 (s, 6H), 1.50 
(s, 9H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 164.2, 162.2, 151.8, 133.6, 106.1, 100.7, 91.2, 
82.5, 28.1, 25.0. MS (ES) m/z: 270 [M+H]
+
. HR-MS(ES) m/z: calcd for C13H20NO5: 270.1341 
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[M+H]
+
; found: 270.1339. Anal. calcd for C13H19NO5: C, 57.98; H, 7.11; N, 5.20; found: C, 
57.85; H, 7.21; N, 5.07. 
1.25.13.162 (E)-2,2-Dimethyl-6-(4-oxo-4-(pyrrolidin-1-yl)but-1-enyl)-4H-1,3-dioxin-4-one (505) 
 
EDCI (99 mg, 0.52 mmol) was added to (E)-4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-3-enoic 
acid (100 mg, 0.47 mmol), pyrrolidine (43 µL, 0.52 mmol) and DMAP (6 mg, 0.05 mmol) in CH2Cl2 
(0.5 mL) and stirred for 4 h. The mixture was diluted with CH2Cl2, washed with 1 M aqueous HCl (× 
2), saturated aqueous NaHCO3 and brine, dried (MgSO4), rotary evaporated and chromatographed 
(EtOAc) to give the title compound (70 mg, 56%) as a pale yellow amorphous solid. 
1
H NMR (400 
MHz, CDCl3, ppm) δ: 6.73 (dt, J = 15.7, 7.0 Hz, 1 H), 5.99 (d, J = 15.7 Hz, 1 H), 5.26 (s, 1 H), 3.45 (dt, J = 
19.4, 6.9 Hz, 4 H), 3.22 (d, J = 7.0 Hz, 2 H), 1.98 (p, J = 6.7 Hz, 2 H), 1.87 (p, J = 6.7 Hz, 2 H), 1.69 (s, 6 H).
 
13
C NMR (101 MHz, CDCl3, ppm) δ: 167.8, 162.8, 162.0, 134.8, 125.0, 106.6, 94.4, 46.9, 46.0, 38.6, 26.2, 
25.1, 24.5. MS (CI) m/z: 266 [M+H]
+
. HR-MS (CI) m/z calcd for C14H20NO4: 266.1391 [M+H]
+
; 
found: 266.1392. 
1.25.13.163 (E)-6-(2-(5,5-Dichloro-4-oxo-2-(pyrrolidin-1-yl)-4,5-dihydrofuran-3-yl)vinyl)-2,2-
dimethyl-4H-1,3-dioxin-4-one (506) 
   
(E)-2,2-Dimethyl-6-(4-oxo-4-(pyrrolidin-1-yl)but-1-enyl)-4H-1,3-dioxin-4-one (28.0 mg, 0.106 
mmol) and oxalyl chloride (18 µL, 0.21 mmol) were refluxed in CH2Cl2 (1 mL) for 2.5 h then rotary 
evaporated and chromatographed (pentane/EtOAc, 1:1 to 2:3) to give the title compound (35 mg, 
89%) as a colourless solid. IR (cm
−1
) 1709, 1598, 1450, 1380, 1372, 1353, 1267, 1250, 1201, 1169, 
1083, 1020, 953, 922, 842, 814, 800, 742, 724, 712, 698, 666, 651. 
1
H NMR (400 MHz, CDCl3, ppm) 
δ: 7.20 (d, J = 15.4 Hz, 1 H), 7.06 (d, J = 15.0 Hz, 1 H), 5.34 (s, 1 H), 3.86 (br. s, 4 H), 2.22 (br. s, 2 H), 2.08 
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(br. s, 2 H), 1.73 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 183.1, 168.0, 164.3, 162.3, 124.1, 117.6, 
106.1, 103.5, 93.4, 87.2, 50.3, 49.4, 26.3, 25.3, 24.1. 
1.25.13.164 (E)-tert-Butyl 3-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acrylate (507) 
 
2,2-Dimethyl-6-vinyl-1,3-dioxan-4-one (300 mg, 1.95 mmol) and tert-butyl acrylate (856 µL, 5.84 
mmol) in CH2Cl2 (20 mL) were refluxed in the presence of catalyst 427a (20 mg, 0.032 mmol) for 24 
h. The mixture was rotary evaporated and chromatographed (pentane/Et2O, 17:3 to 4:1) to give the 
title compound (368 mg, 74 %) as a colourless solid. IR (cm−1): 1705, 1644, 1590, 1401, 1392, 
1378, 1368, 1274, 1257, 1245, 1206, 1160, 1097, 1025, 980, 909, 857, 844, 811, 785, 739. 
1
H 
NMR (400 MHz, CDCl3, ppm) δ: 6.93 (d, J = 15.7 Hz, 1 H), 6.47 (d, J = 15.7 Hz, 1 H), 5.57 
(s, 1 H), 1.73 (s, 6 H), 1.51 (s, 9 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 164.3, 160.9, 160.8, 
133.9, 128.7, 107.0, 99.3, 81.8, 28.0, 25.0. MS (EI) m/z: 296 [M+MeCN]
+
, 255 [M+H]
+
. HR-
MS (EI) m/z: calcd for C13H19O5: 255.1232 [M+H]
+
; found: 255.1229. Anal. calcd for 
C13H18O5: C 61.40, H 7.14; found: C 61.28, H 7.24. 
1.25.13.165 (E)-3-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acrylic acid (508) 
 
According to general procedure G, deprotection of ester 507 (150 mg, 0.591 mmol) for 16 h gave the 
title compound (111 mg, 92 %) as a colourless solid. IR (cm−1): 1720, 1689, 1645, 1592, 1422, 
1392, 1377, 1311, 1275, 1259, 1206, 1096, 1025, 976, 965, 944, 911, 891, 871, 855, 807, 
743, 713, 643. 
1
H NMR (400 MHz, THF-d8, ppm) δ:  11.42 (br. s., 1 H), 7.09 (d, J = 15.6 Hz, 
1 H), 6.46 (d, J = 15.7 Hz, 1 H), 5.69 (s, 1 H), 1.69 (s, 6 H). 
13
C NMR (101 MHz THF-d8, ppm) 
δ: 166.5, 161.5, 160.2, 136.1, 127.5, 107.6, 100.9, 25.1. MS (EI) m/z: 199 [M+H]
+
. HR-MS 
(EI) m/z: calcd for C9H11O5: 199.0606 [M+H]
+
; found: 199.0610. Anal. calcd for C9H10O5: C 
54.55, H 5.09; found: C 54.03, H 5.64. 
1.25.13.166 (E)-3-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acryloyl azide (509) 
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Ghosez’s reagent (321 µL, 2.42 mmol) was added dropwise to (E)-3-(2,2-dimethyl-4-oxo-
4H-1,3-dioxin-6-yl)acrylic acid (400 mg, 2.02 mmol) in THF (5 mL) and stirred for 10 min. 
This mixture was then added to a vigourously stirred mixture of sodium azide in water. After 
5 min, the mixture was diluted with ether, washed with saturated aqueous NaHCO3 (× 7), 
dried (MgSO4), rotary evaporated and chromatographed (pentane/Et2O, 3:1) to give the title 
compound (220 mg, 49%) as a colourless solid. IR (cm
−1
): 1722, 1675, 1637, 1586, 1393, 
1375, 1288, 1270,1249, 1204, 1176, 1155, 1125, 1104, 1078, 1018, 1005, 981, 963, 905, 877, 
856, 821, 784, 741, 718, 648, 605. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.09 (d, J = 15.6 Hz, 
1H), 6.51 (d, J = 15.2 Hz, 1H), 5.65 (s, 1H), 1.74 (s, 6H). 
13
C NMR (101 MHz, CDCl3, ppm) 
δ: 170.7, 160.4, 159.9, 136.3, 126.9, 107.3, 101.0, 25.0. MS (CI) m/z: 256 [M+H]+. HR-MS 
(CI) m/z: calcd for C12H18NO5: 256.1185 [M+H]
+
; found: 256.1190. Anal. calcd for 
C9H9N3O4: C 48.43, H 4.06, N 18.83; found: C 48.59, H 3.97, N 18.75. 
1.25.13.167 (E)-Isopropyl 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)vinylcarbamate (510) and 
(Z)-Isopropyl 5-(isopropoxycarbonylamino)-3-oxopent-4-enoate (511) 
  
(E)-Isopropyl 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)vinylcarbamate (30 mg, 0.135 
mmol) was heated with iso-propanol (584 µL, 7.65 mmol) in toluene (3 mL) at 75 °C for 12 
h. The mixture was rotary evaporated and chromatographed (pentane/ether, 4:1 to 1:1) to give  
(E)-isopropyl 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)vinylcarbamate (26 mg, 76%) as a 
colourless solid and (Z)-isopropyl 5-(isopropoxycarbonylamino)-3-oxopent-4-enoate (3 mg, 
9%).  
(E)-Isopropyl 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)vinylcarbamate (510): IR (cm−1): 
1731, 1695, 1630, 1502, 1375, 1295, 1254, 1225, 1203, 1168, 1102, 1043, 1021, 966, 909, 
844, 799, 735, 679, 611. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.48 (app. t, J = 12.7 Hz, 1H), 
7.14 (d, J = 12.2 Hz, 1H), 5.50 (d, J = 13.7 Hz, 1H), 5.15 (s, 1H), 5.02 (spt, J = 6.3 Hz, 1H), 
1.71 (s, 6H), 1.29 (d, J = 6.4 Hz, 6H), 
13
C NMR (101 MHz, CDCl3, ppm) δ: 164.2, 162.2, 152.6, 
133.5, 106.2, 101.3, 91.4, 70.5, 25.0, 21.9.
 
MS (ES) m/z: 241 [M+NH4]
+
, 224 [M+H]
+
. HR-
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MS (ES) m/z: calcd for C9H13N4O4: 241.0937[M+H]
+
; found: 241.0931. Anal. calcd for 
C12H17NO5: C 56.46, H 6.71, N 5.49; found: C 56.32, H 6.78, N, 5.62. 
(Z)-Isopropyl 5-(isopropoxycarbonylamino)-3-oxopent-4-enoate (511): IR (cm−1): 1734, 
1662, 1591, 1470, 1387, 1376, 1311, 1257, 1223, 1196, 1180, 1146, 1094, 1046, 972, 916, 
828, 773, 727. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 10.59 (d, J = 10.8 Hz, 1H), 7.30 (dd, J = 
12.0, 8.6 Hz, 1H), 5.51 (d, J = 8.3 Hz, 1H), 4.97–5.13 (m, 2H), 3.43 (s, 2H), 1.27 (d, J = 6.4 
Hz, 6H), 1.30 (2 × s, J = 6.4 Hz, 6H). MS (ES) m/z: 258 [M+H]
+
. HR-MS (ES) m/z: calcd for 
C12H20NO5: 258.1341[M+H]
+
; found: 258.1342. 
1.25.13.168 Isopropyl 3,6-dihydroxybiphenyl-2-carboxylate (514a) 
  
According to general procedure D, dione 433a (50 mg, 0.175 mmol) gave, after chromatography 
(hexanes/Et2O, 9:1 to 7:3) the title compound (15 mg, 32%) as a pale yellow solid. IR (cm
−1
): 1678, 
1662, 1597, 1559, 1365, 1317, 1290, 1216, 1176, 1099, 895, 826, 767, 728, 699. 
1
H NMR (400 MHz, 
CDCl3, ppm) δ: 10.74 (s, 1 H, 3), 7.39–7.51 (m, 3 H, Ar-H), 7.20–7.25 (m, 2 H, Ar-H), 7.13 (d, J = 
8.8 Hz, 1 H, 5×), 6.98 (d, J = 9.3 Hz, 1 H, 4), 4.92 (spt, J = 6.3 Hz, 1 H, 2), 4.52 (s, 1 H, 6), 0.80 (d, J 
= 6.4 Hz, 6 H, 1). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 169.9 (q, C), 156.0 (q, E), 145.8 (q, H), 
136.5 (q, J), 129.5 (CH, K), 129.0 (CH, K), 127.9 (CH, K), 127.4 (q, I), 122.5 (CH, F), 118.3 (CH, 
G), 111.9 (q, D), 68.9 (CH, B), 20.9 (CH, A). MS (CI) m/z: 290 [M+NH4]
+
, 273 [M+H]
+
. HR-MS 
(CI) m/z calcd for C16H16O4: 273.1127 [M+H]
+
; found: 273.1138. Anal. calcd for C16H16O4: C 70.57, 
H 5.92; found: C 70.43; H 6.05. A HMBC NMR spectrum is provided in the additional NMR spectra 
section. 
1.25.13.169 Propyl 3,6-dihydroxybiphenyl-2-carboxylate (514b) 
 
According to general procedure D with n-propanol, dione 433a (50 mg, 0.175 mmol) gave, after 
chromatography (hexanes/Et2O, 9:1 to 7:3) the title compound (15 mg, 31%) as a pale yellow solid. 
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IR (cm
−1
): 1656, 1594, 1458, 1442, 1400, 1350, 1324, 1287, 1228, 1208, 1180, 1161, 1142, 133, 
1088, 889, 840, 828, 806, 762, 731, 699. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 10.69 (s, 1 H), 7.39–
7.50 (m, 3 H), 7.20–7.26 (m, 2 H), 7.14 (d, J = 8.8 Hz, 1 H), 6.99 (d, J = 8.8 Hz, 1 H), 4.53 (s, 1 H), 
3.86 (t, J = 6.6 Hz, 2 H), 1.00–1.12 (m, 2 H), 0.59 (t, J = 7.3 Hz, 3 H). 13C NMR (101 MHz, CDCl3, 
ppm) δ: 170.7, 156.1, 145.8, 136.4, 129.4, 129.0, 128.0, 127.3, 122.7, 118.4, 111.6, 66.9, 21.0, 10.3. 
MS (CI) m/z: 290 [M+NH4]
+
., 273 [M+H]
+
. HR-MS (CI) m/z calcd for C16H17O4: 273.1127 [M+H]
+
; 
found: 273.1117. Anal. calcd for C16H16O4: C 70.57, H 5.92; found: C 70.53, H 6.01. 
1.25.13.170 Isopropyl 3,6-dihydroxy-4'-methoxybiphenyl-2-carboxylate (514c) 
 
According to general procedures L  and D (E)-6-(4-Hydroxy-4-(4-methoxyphenyl)but-1-enyl)-
2,2-dimethyl-4H-1,3-dioxin-4-one (274 mg, 0.9 mmol) gave the title compound (40 mg, 15%) as a 
brown oil. IR (cm−1): 3512, 1655, 1611, 1514, 1455, 1361, 1321, 1289, 1248, 1197, 1168, 
1135, 1102, 1086, 1024, 830, 813, 803, 791, 722. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 10.69 
(s, 1 H), 7.10–7.16 (m, 3 H), 6.98–7.04 (m, 2 H), 6.96 (d, J = 8.8 Hz, 1 H), 4.94 (spt, J = 6.3 
Hz, 1 H), 4.58 (s, 1 H), 3.88 (s, 3 H), 0.86 (d, J = 5.9 Hz, 6 H). 
13
C NMR (101 MHz, CDCl3, 
ppm) δ: 170.0, 159.6, 155.9, 146.1, 130.7, 128.3, 127.1, 122.2, 118.2, 114.5, 112.4, 68.8, 55.4, 
21.1. MS (EI) m/z: 303 [M+H]
+
. HR-MS (EI) m/z: calcd for C17H19O5: 303.1232[M+H]
+
; found: 
303.1243. 
1.25.13.171 Isopropyl 4'-bromo-3,6-dihydroxybiphenyl-2-carboxylate (514d) 
 
According to general procedure L and D (E)-6-(4-Hydroxy-4-(4-bromophenyl)but-1-enyl)-
2,2-dimethyl-4H-1,3-dioxin-4-one (318 mg, 0.9 mmol) gave the title compound (47 mg, 
15%) as a brown oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 10.78 (s, 1 H), 7.60–7.65 (m, 2 H), 
7.10–7.15 (m, 3 H), 6.99 (d, J = 8.8 Hz, 1 H), 4.95 (spt, J = 6.2 Hz, 1 H), 4.38 (s, 1 H), 0.87 
(d, J = 6.4 Hz, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 169.7, 156.3, 145.5, 135.6, 132.1, 
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131.3, 126.1, 122.9, 122.1, 118.8, 111.7, 69.2, 21.0. MS (EI) m/z: 352 [M
81
]
+
, 350 [M
79
]
+
. 
HR-MS (EI) m/z calcd for C16H15BrO5: 350.0154[M+H]
+
; found: 350.0155. 
1.25.13.172 (E)-6-(3-Hydroxy-3-(2-(4-methoxyphenyl)-1,3-dithian-2-yl)prop-1-enyl)-2,2-
dimethyl-4H-1,3-dioxin-4-one (516a) 
 
n-BuLi (76 µL, 0.181 mmol) was added to 2-(4-methoxyphenyl)-1,3-dithiane xx (41 mg, 0.181 mmol) 
at −78 °C and then stirred at −30 °C for 5 min. (E)-3-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-
yl)acrylaldehyde (30 mg, 0.165 mmol) in THF (2 mL) was added at −78 °C and stirred for 10 min 
then poured into water. The mixture was extracted with ether (× 2), washed with brine, dried 
(MgSO4), rotary evaporated and chromatographed (pentane/Et2O, 3:1, 1:1) to give the title compound 
(11 mg, 16%) as a colourless impure oil. IR (cm−1): 1720, 1654, 1603, 1505, 1391, 1251, 1033. 
1
H NMR (400 MHz, CDCl3, ppm)(product peaks only) δ: 7.85–7.80 (m, 2 H), 6.99–6.88 (m, 
2 H), 6.47 (dd, J = 15.2, 4.9 Hz, 1 H), 6.10 (dd, J = 15.7, 1.7 Hz, 1 H), 5.29 (s, 1 H), 4.53 (dd, 
J = 4.9, 1.5 Hz, 1 H), 3.85 (s, 3 H), 2.82–2.66 (m, 4 H), 2.63 (d, J = 4.9 Hz, 1 H), 2.01–1.92 
(m, 2 H), 1.69 (s, 6 H). MS (EI) m/z: 431 [M+Na]
+
, 409 [M+H]
+
. HR-MS (EI) m/z: calcd for 
C20H25S2O5: 409.1143 [M+H]
+
; found: 409.1148. 
1.25.13.173 (E)-3-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acrylaldehyde (518) 
 
2,2-Dimethyl-6-vinyl-1,3-dioxan-4-one (100 mg, 0.649 mmol) and acrolein (128 µL, 1.948 mmol) in 
CH2Cl2 (6.5 mL) were refluxed in the presence of catalyst 427a (20 mg, 0.032 mmol) for 16 h. The 
mixture was rotary evaporated and chromatographed (pentane/Et2O, 4:1 to 1:1) to give the title 
compound (49 mg, 41%) as a pale yellow solid. IR (cm−1): 1711, 1669, 1638, 1582, 1388, 1375, 
1273, 1261, 1236, 1201, 1118, 1092, 1020, 985, 967, 905, 872, 860, 825. 
1
H NMR 
(400 MHz, CDCl3, ppm) δ: 9.74 (d, J = 7.3 Hz, 1 H), 6.89 (d, J = 16.1 Hz, 1 H), 6.73 (dd, J = 
7.3, 15.6 Hz, 1 H), 5.71 (s, 1 H), 1.76 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 191.8, 
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160.3 (2C), 140.7, 134.2, 107.4, 100.8, 25.0. MS (EI) m/z: 183 [M+H]
+
, 182 [M]
+
. HR-MS 
(EI) m/z: calcd for C9H10O4: 182.0579 [M]
+
; found: 182.0584. 
 
1.25.13.174 1-(1,3-Dithian-2-yl)prop-2-en-1-ol (517)276  
 
n-Buli (3.81 mL, 9.15 mmol) was added dropwise to 1,3-dithiane (1.00 g, 8.32 mmol) at −30 °C and 
stirred for 1 h. Acrolein (1.64 mL, 25 mmol) was added dropwise at −78 °C and stirred for 0.5 h then 
saturated aqueous NH4Cl was added. The mixture was extracted with EtOAc (× 2), washed with 
brine, dried (MgSO4), rotary evaporated and chromatographed (pentane/EtOAc, 17:3 to 4:1) to give 
the title compound (1.124 g, 77%) as a colourless oil. IR (cm−1): 1421, 1276, 1244, 1126, 1108, 
1023, 986, 826, 873, 790, 665.
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.07–5.92 (m, 1 H), 
5.49–5.39 (m, 1 H), 5.34–5.23 (m, 1 H), 4.43–4.30 (m, 1 H), 3.96 (d, J = 6.4 Hz, 1 H), 3.02–
2.88 (m, 2 H), 2.85–2.70 (m, 2 H), 2.54 (d, J = 3.9 Hz, 1 H), 2.19–1.90 (m, 2 H). MS (ES) 
m/z: 176 [M-H]
+
. HR-MS (ES) m/z: calcd for C7H11S2O: 175.0251 [M-H]
+
; found: 175.0253. 
In agree ment with the literature. 
1.25.13.175 (E)-6-(3,3-Diethoxyprop-1-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (520) 
 
According to general procedure F, cross metathesis of acrolein diethylacetal (148 µL, 0.974 mmol) 
and dioxinone 372a (50.0 mg, 0.325 mmol) with catalyst 427a (20.3 mg, 0.03 mmol) in C6F5CF3 
(3.5 mL) at 70 °C for 6 h and chromatography (pentane/Et2O, 9:1 to 4:1) gave the title 
compound (55 mg, 66%) as a pale yellow oil. IR (cm−1): 1725, 1660, 1596, 1390, 1373, 1273, 
1203, 1174, 1120, 1094, 1051, 1018, 961, 902, 854, 803. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 6.42 
(dd, J = 15.7, 4.2 Hz, 1 H), 6.21 (dd, J = 15.8, 1.4 Hz, 1 H), 5.35 (s, 1 H), 5.03 (dd, J = 4.3, 1.3 Hz, 1 H), 3.63 
(dq, J = 9.4, 7.0 Hz, 2 H), 3.50 (dq, J = 9.3, 7.0 Hz, 2 H), 1.68 (s, 6 H), 1.21 (t, J = 7.1 Hz, 6 H).
 13
C NMR 
(101 MHz, CDCl3, ppm) δ: 162.3, 161.6, 136.8, 124.9, 106.7, 99.4, 95.9, 61.5, 25.1, 15.3. MS (CI) m/z: 
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274 [M+NH4]
+
, 257 [M+H]
+
. HR-MS (CI) m/z calcd for C13H21O5: 257.1389 [M+H]
+
; found: 
257.1379. 
1.25.13.176  (1-(1,3-Dithian-2-yl)allyloxy)(tert-butyl)dimethylsilane (522)277 
 
4-Dimethylaminopyridine (10 mg, 0.082 mmol) was added to a mixture of 1-(1,3-dithian-2-
yl)prop-2-en-1-ol (300 mg, 1.70 mmol),  imidazole (151 mg, 2.22 mmol) and tert-
butyldimethylsilyl chloride (283 mg, 1.875 mmol) in DMF (0.6 mL) and stirred for 3 h, 
before addition of 1M aqueous HCl.  The mixture was extracted with ether (× 3) and washed 
with saturated aqueous NaHCO3, water, brine, dried (MgSO4) , rotary evaporated and 
chromatographed (pentane/Et2O, 19:1 to 9:1) to give the title compound (410 mg, 83%) as a 
colourless oil. IR (cm−1): 1472, 1463, 1422, 1261, 1276, 1251, 1078, 1034, 1006, 986, 928, 909, 876, 
854, 834, 775, 670, 627. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 5.93 (ddd, J = 17.0, 10.3, 6.6 Hz, 1 H), 
5.34–5.18 (m, 2 H), 4.34–4.22 (m, 1 H), 4.14 (d, J = 6.1 Hz, 1 H), 2.97–2.73 (m, 4 H), 2.17–2.03 (m, 
1 H), 1.98–1.77 (m, 1 H), 0.94 (s, 9 H), 0.14 (s, 3 H), 0.08 (s, 3 H). 13C NMR (101 MHz, CDCl3, 
ppm) δ: 138.1, 117.0 ,76.7, 53.9, 30.0, 26.1, 25.9, 18.3, -4.3, -4.8. 
1.25.13.177 2-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acetyl chloride (551) 
 
A reactIR spectrometer was used to monitor formation of the title compound. IR measurements (16 
scans) were taken every 15 seconds. In a reactor cell 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acetic 
acid (201 mg, 1.08 mmol) was added in CH2Cl2 (27 mL) and cooled to −14 °C. After equilibriation at 
this temperature, Ghosez’s reagent (186 µL, 1.4 mmol) was added. The reaction was then allowed to 
warm to 25 °C at a rate of 2.5 °C/min and further Ghosezs reagent (186 µL, 1.4 mmol) was added at 
25 °C. IR (solution cell, cm
−1
): 1798, 1737. 
1.25.13.178 Benzyl 2,2,6-trimethyl-4-oxo-4H-1,3-dioxine-5-carboxylate (552) and Benzyl 2-(2,2-
dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acetate (553)
278
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2,2,6-Trimethyl-4H-1,3-dioxin-4-one (1.00 g, 7.04 mmol) was added dropwise to LiN(SiMe3)2 (14.79 
mmol) at −78 °C in THF (15 mL) and stirred for 30 min. Benzyl chloroformate (1.11 mL, 7.75 mmol) 
was added dropwise at −94 °C and the mixture allowed to warm to 20 °C over 2 h. The mixture was 
quenched by addition of 1 M Aqueous HCl and the layers separated. The organics were further 
extracted with EtOAc (2 × 50 mL) and the combined organics were washed with brine (50 mL), dried 
(MgSO4), rotary evaporated and chromatographed (petroleum ether/Et2O, 4:1 to 1:1) to  give Benzyl 
2,2,6-trimethyl-4-oxo-4H-1,3-dioxine-5-carboxylate (617 mg, 32%) as a colourless solid and Benzyl 
2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acetate (804 mg, 42%) as a colourless oil. 
Benzyl 2,2,6-trimethyl-4-oxo-4H-1,3-dioxine-5-carboxylate (552): IR (cm
−1
): 1732, 1710, 1583, 
1391, 1381, 1354, 1289, 1269, 1216, 1200, 1102, 1088, 1073, 1061, 1034, 1009, 982, 966, 891, 867, 
794, 786, 732, 695.
 1
H NMR (400 MHz, CDCl3, ppm) δ: 7.41–7.48 (m, 2 H), 7.29–7.41 (m, 3 H), 5.30 
(s, 2 H), 2.29 (s, 3 H), 1.71 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 175.1, 163.8, 157.4, 135.6, 
128.5, 128.1, 128.0, 106.3, 101.7, 66.9, 25.1, 20.1. MS (CI) m/z: 294 [M+NH4]
+
, 277 [M+H]
+
. HR-
MS (CI) m/z calcd for C15H20NO5: 294.1341 [M+NH4]
+
; found: 294.1333. 
Benzyl 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acetate (553): IR (cm
−1
): 1724, 1640, 1391, 1375, 
1271, 1201, 1151, 1015, 977, 902, 809, 240, 697. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 7.35–7.38 (m, 
5 H), 5.39 (s, 1 H), 5.17 (s, 2 H), 3.31 (s, 2 H), 1.64 (s, 6 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 
166.9, 163.5, 160.6, 134.9, 128.7, 128.6, 128.5, 107.2, 96.4, 67.3, 39.4, 24.8, 24.6. MS (CI) m/z: 294 
[M+NH4]
+
, 277 [M+H]
+
. HR-MS (CI) m/z calcd for C15H20NO5: 294.1341 [M+NH4]
+
; found: 
294.1341. In agreement with the literature. 
1.25.13.179 Ethyl 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acetate (554)278 
 
Ghosez’s reagent (26 µL, 0.194 mmol) was added to 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acetic 
acid (30 mg, 0.161 mmol) in CH2Cl2 (2.0 mL) at 0 °C and stirred for 10 min. EtOH (47 µL, 0.806 
mmol) and pyridine (13µL, 0.161 mmol) was then added and after 5 min saturated aqueous NH4Cl (3 
mL) was added. The layers were separated and the organics dried (MgSO4), rotary evaporated and 
chromatographed (petroleum ether/Et2O, 7:3 to 3:2) to give the title compound (15 mg, 44%) as a 
colourless oil. IR (cm
−1
) 1725, 1640, 1391, 1375, 1272, 1251, 1201, 1158, 1013, 902, 811. 
1
H NMR 
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(400 MHz, CDCl3, ppm) δ: 5.39 (s, 1 H), 4.20 (q, J = 7.3 Hz, 2 H), 3.26 (s, 2 H), 1.71 (s, 6 H), 1.28 (t, 
J = 7.1 Hz, 3 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 167.1, 163.7, 160.7, 107.2, 96.4, 61.7, 39.4, 
24.9, 14.1. MS (CI) m/z: 232 [M+NH4]
+
, 215 [M+H]
+
. HR-MS (CI) m/z calcd for C10H18NO5: 
232.1185 [M+NH4]
+
; found: 232.1187. In agreement with the literature. 
1.25.13.180 Allyl 2-acetyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-oxobutanoate (555) 
 
MgCl2 (85 mg, 0.896 mmol) and pyridine (97µL, 1.209 mmol) were added to allyl 4-(2,2-dimethyl-4-
oxo-4H-1,3-dioxin-6-yl)-3-oxobutanoate (120 mg, 0.448 mmol) in CH2Cl2 at 0 °C and stirred for 30 
min.   
Ghosez’s reagent (83 µL, 0.627 mmol) was added to acetic acid in CH2Cl2 (4 mL) at 0 °C and stirred 
for 10 min. This was then added to the magnesium enolate prepared above and stirred for 10 min at 
0 °C followed by addition of saturated aqueous NH4Cl (5 mL). The organics were washed with brine 
(5 mL) dried (MgSO4), rotary evaporated and chromatographed (petroleum ether/Et2O, 3:7) to give 
the title compound (100 mg, 79%) as a colourless oil. IR (cm
−1
): 1721, 1666, 1635, 1391, 1375, 1271, 
1251, 1202, 1161, 1064, 1015, 995, 936, 902, 807. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 17.66 (s, 1 
H), 5.96 (dd, J = 17.2, 10.2 Hz, 1 H), 5.27–5.41 (m, 3 H), 4.70 (d, J = 5.7 Hz, 2 H), 3.73 (s, 2 H), 
2.42 (s, 3 H), 1.68 (s, 6 H).
 13
C NMR (101 MHz, CDCl3, ppm) δ: 196.0, 193.7, 165.8, 165.1, 160.7, 
131.4, 119.6, 108.1, 107.1, 96.4, 65.8, 43.2, 25.5, 24.9. MS (EI) m/z: 310 [M]
+
. HR-MS (EI) m/z calcd 
for C15H18O7: 310.1053 [M]
+
; found: 310.1049. 
1.25.13.181 6-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-5,7-dihydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (557) 
  
Ghosez’s reagent (1.50 mL, 10.68 mmol) was added to 2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-
yl)acetic acid (903 mg, 4.85 mmol) at −78 °C and allowed to warm 25 °C over 18 h. The mixture was 
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rotary evaporated and chromatographed (petroleum ether/Et2O, 1:1 to 0:1) to give a yellow solid. 
Recrystalization from hot CHCl3/pentane gave the title compound (221 mg, 27%) as a colourless 
solid. IR (cm
−1
): 1728, 1682, 1607, 1389, 1316, 1274, 1257, 1194, 1122, 1098, 1017, 1003, 823, 752. 
1
H NMR (400 MHz, CD3OD, ppm) δ:  6.02 (s, 1 H), 5.54 (s, 1 H), 1.78 (s, 6 H), 1.73 (s, 6 H). 
13
C 
NMR (101 MHz, CD3OD, ppm) δ:  166.5, 166.3, 164.2, 163.7, 163.1, 159.8, 108.6, 108.3, 104.3, 
99.5, 96.1, 92.9, 25.8, 25.1. MS (ES) m/z: 337 [M+H]
+
. HR-MS (ES) m/z calcd for C16H17O8: 
337.0923 [M+H]
+
; found: 337.0925. 
1.25.13.182 6-(Chloromethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (559)279 
 
2,2,6-Trimethyl-4H-1,3-dioxin-4-one (8.00 g, 56.3 mmol) was added dropwise to LiN(
i
Pr)2 (73.2 
mmol) at −78 °C in THF (50 mL) and stirred for 1 h. This mixture was then added dropwise via 
cannula to a suspension of hexachloroethane (18.67 g, 78.9 mmol) in THF (75 mL) at −50 °C over 20 
min. The mixture was warmed to −20 °C over 1 h and stirred for a further 15 min. The mixture was 
acidified with cold 1 M aqueous HCl and extracted with Et2O. The combined organics were washed 
with saturated aqueous NaHCO3 dried (MgSO4), rotary evaporated and chromatographed (petroleum 
ether/CH2Cl2, 1:1) to give the title compound (5.5 mg, 55%) as a pale yellow oil. IR (cm
−1
): 1723, 
1639, 1390, 1376, 1272, 1249, 1200, 1184, 1013, 902, 808, 740, 656. 
1
H NMR (400 MHz, CDCl3, 
ppm) δ: 5.55 (s, 1 H), 4.02 (s, 2 H), 1.70 (s, 6 H). 13C NMR (101 MHz, CDCl3, ppm) δ: 164.4, 160.4, 
107.5, 95.5, 40.9, 24.7. MS (CI) m/z: 194 [M+NH4]
+
, 177 [M+H]
+
. HR-MS (CI) m/z calcd for 
C7H10O5Cl: 177.0318 [M+H]
+
; found: 177.0322. In agreement with the literature. 
1.25.13.183 Methyl 3-(5,7-dihydroxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-6-yl)-3-
oxopropanoate (561) 
 
6-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-5,7-dihydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-
one (20 mg, 0.06 mmol) in Methanol (4 mL) was microwave irradiated at 120 °C for 30 min, then 
rotary evaporated to give the title compound (19 mg, quantitative) as a colourless solid.  
1
H NMR 
(400 MHz, THF-d8, ppm) δ: 14.04 (s, 1 H), 12.54 (s, 1 H), 6.04 (s, 1 H), 4.04 (s, 2 H), 3.66 (s, 3 H), 
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1.74 (s, 6 H).
 13
C NMR (101 MHz, THF-d8, ppm) δ:
 
199.1, 173.6, 168.4, 167.4, 166.2, 162.0, 108.7, 
106.6, 97.5, 92.4, 52.3, 51.0, 25.8. 
1.25.13.184 6-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-5-hydroxy-7-methoxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (564) 
 
Methyl iodide (6 µL, 0.10 mmol) was added to 6-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-5,7-
dihydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (20 mg, 0.06 mmol) and potassium carbonate 
(83 mg, 0.06 mmol) in acetone (2.4 mL) and refluxed for 6 h, then rotary evaporated to give  the title 
compound (21 mg, quantitative) as a colourless solid.
 1
H NMR (400 MHz, THF-d8, ppm) δ: 10.91 (s, 
1 H), 6.28 (s, 1 H), 5.39 (s, 1 H), 3.87 (s, 3 H), 1.72 (s, 12H). 
1.25.13.185 1-(1-Methyl-1H-pyrrol-2-yl)butane-1,3-dione (572) 
 
N-Methyl pyrrole (315 µL, 3.52 mmol) and 2,2,6-trimethyl-4H-1,3-dioxin-4-one (0.50 g, 3.52  mmol) 
in toluene (14.1 mL) were heated by microwave irradiation at 120 
o
C for 1.5 h and then rotary 
evaporated and chromatographed (petroleum ether/Et2O, 19:1) to give the the title compound  (358 
mg, 62%) as a beige oil. IR (cm
−1
): 1718, 1616, 1528, 1455, 1375, 1320, 1247 cm
-1
; 
1
H NMR (400 
MHz, CDCl3) δ:  (keto form) 6.96 (m, 1 H), 6.87 (m, 1 H) , 6.15 (m, 1 H), 3.95 (s, 3 H), 3.88 (s, 2 H), 
2.28 (s, 3 H); (enol form) 15.62 (br s, 1 H), 6.87 (m, 1 H), 6.81 (m, 1 H), 6.15 (m, 1 H), 5.91(s, 1 H), 
3.98(s, 3 H), 2.05 (s, 3 H); 
13
C NMR (101 MHz, CDCl3) 202.8, 183.8, 183.4, 180.8, 132.4, 131.1, 
130.4, 129.3, 121.2, 117.5, 108.7, 108.5, 96.9, 55.7, 37.9, 37.8, 30.4, 22.7; HRMS (EI) m/z calc for 
C9H12NO2 166.0871 [M+H], found 166.0868. 
1.25.13.186 (E)-tert-Butyl 7-(1-methyl-1H-pyrrol-2-yl)-5,7-dioxohept-3-enoate (573) 
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N-Methyl pyrrole (27 µL, 0.30 mmol) and 2,2,6-trimethyl-4H-1,3-dioxin-4-one (80 mg, 0.30  mmol) 
in EtOAc (5 mL) were heated by microwave irradiation at 120 
o
C for 0.5 h and then rotary evaporated 
and chromatographed (petroleum ether/Et2O, 19:1 to 4:1) to give the the title compound  (47 mg, 
54%) as a yellow oil. 
1
H NMR (400 MHz, CDCl3, ppm) δ: 15.04 (s, 1 H), 6.90 (dd, J=4.2, 1.7 Hz, 1 
H), 6.74 - 6.84 (m, 2 H), 6.15 (dd, J=3.9, 2.4 Hz, 1 H), 5.98 (d, J=15.7 Hz, 1 H), 5.93 (s, 1 H), 3.99 (s, 
3 H), 3.17 (dd, J=7.3, 1.5 Hz, 2 H), 1.47 ppm (s, 9 H). 
13
C NMR (101 MHz, CDCl3, ppm) δ: 184.9, 
171.2, 169.6, 132.4, 131.2, 130.1, 128.3, 117.9, 108.5, 98.1, 81.3, 39.2, 37.8, 28.0. MS (EI) m/z: 292 
[M+H]
+
. HR-MS (EI) m/z: calcd for C16H22NO4: 292.1549 [M+H]
+
; found: 292.1560. 
1.25.14 X-Ray Crystallography Information
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1.25.14.1 2,2-Dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-7-yl formate (464) 
Table 1. Crystal data and structure refinement for AB1313. 
 
Identification code AB1313 
Formula C11 H10 O4 
Formula weight 206.19 
Temperature 173 K 
Diffractometer, wavelength Agilent Xcalibur 3 E, 0.71073 Å 
Crystal system, space group Orthorhombic, P b c a 
Unit cell dimensions a = 12.6471(4) Å α = 90° 
 b = 7.9916(2) Å β = 90° 
 c = 19.1936(6) Å γ = 90° 
Volume, Z 1939.90(10) Å3, 8 
Density (calculated) 1.412 Mg/m3 
Absorption coefficient 0.108 mm-1 
F(000) 864 
Crystal colour / morphology Colourless blocky needles 
Crystal size 0.56 x 0.50 x 0.36 mm3 
θ range for data collection 2.664 to 27.463° 
Index ranges -16<=h<=15, -10<=k<=6, -24<=l<=24 
Reflns collected / unique 9306 / 2026 [R(int) = 0.0342] 
Reflns observed [F>4σ(F)] 1752 
Absorption correction Analytical 
Max. and min. transmission 0.967 and 0.954 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2026 / 0 / 139 
Goodness-of-fit on F2 1.048 
Final R indices [F>4σ(F)] R1 = 0.0352, wR2 = 0.0794 
R indices (all data) R1 = 0.0431, wR2 = 0.0839 
Largest diff. peak, hole 0.248, -0.181 eÅ-3 
Mean and maximum shift/error 0.000 and 0.001 
 
Table 2. Bond lengths [Å] and angles [°] for AB1313. 
 
C(1)-O(1) 1.2022(15) 
C(1)-O(2) 1.3590(15) 
C(1)-C(10) 1.4723(17) 
O(2)-C(3) 1.4503(15) 
C(3)-O(4) 1.4392(15) 
C(3)-C(12) 1.5054(18) 
C(3)-C(11) 1.5093(19) 
O(4)-C(5) 1.3609(15) 
C(5)-C(6) 1.3909(17) 
C(5)-C(10) 1.3949(17) 
C(6)-C(7) 1.3765(18) 
C(7)-C(8) 1.4026(18) 
C(8)-C(9) 1.3858(18) 
C(8)-C(13) 1.4675(18) 
C(9)-C(10) 1.3851(17) 
C(13)-O(13) 1.2100(17) 
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O(1)-C(1)-O(2) 119.04(11) 
O(1)-C(1)-C(10) 125.35(12) 
O(2)-C(1)-C(10) 115.48(10) 
C(1)-O(2)-C(3) 118.52(9) 
O(4)-C(3)-O(2) 109.62(10) 
O(4)-C(3)-C(12) 106.45(11) 
O(2)-C(3)-C(12) 106.05(10) 
O(4)-C(3)-C(11) 110.38(10) 
O(2)-C(3)-C(11) 110.04(11) 
C(12)-C(3)-C(11) 114.11(12) 
C(5)-O(4)-C(3) 114.71(9) 
O(4)-C(5)-C(6) 118.59(11) 
O(4)-C(5)-C(10) 120.05(11) 
C(6)-C(5)-C(10) 121.32(11) 
C(7)-C(6)-C(5) 118.89(11) 
C(6)-C(7)-C(8) 120.62(11) 
C(9)-C(8)-C(7) 119.73(11) 
C(9)-C(8)-C(13) 118.84(12) 
C(7)-C(8)-C(13) 121.42(12) 
C(10)-C(9)-C(8) 120.33(11) 
C(9)-C(10)-C(5) 119.08(11) 
C(9)-C(10)-C(1) 121.35(11) 
C(5)-C(10)-C(1) 119.42(11) 
O(13)-C(13)-C(8) 125.08(13) 
1.25.14.2 (E)-6-(2-(5,5-Dichloro-4-oxo-2-(pyrrolidin-1-yl)-4,5-dihydrofuran-3-yl)vinyl)-2,2-
dimethyl-4H-1,3-dioxin-4-one (506) 
Table 1. Crystal data and structure refinement for AB1404. 
 
Identification code AB1404 
Formula C16 H17 Cl2 N O5, C H2 Cl2 
Formula weight 459.13 
Temperature 173 K 
Diffractometer, wavelength Agilent Xcalibur 3 E, 0.71073 Å 
Crystal system, space group Monoclinic, P 21/n 
Unit cell dimensions a = 14.6907(8) Å α = 90° 
 b = 9.5478(5) Å β = 99.279(5)° 
 c = 14.8016(8) Å γ = 90° 
Volume, Z 2049.0(2) Å3, 4 
Density (calculated) 1.488 Mg/m3 
Absorption coefficient 0.605 mm-1 
F(000) 944 
Crystal colour / morphology Pale yellow blocks 
Crystal size 0.69 x 0.59 x 0.38 mm3 
θ range for data collection 2.789 to 28.178° 
Index ranges -18<=h<=16, -11<=k<=12, -12<=l<=19 
Reflns collected / unique 7072 / 4090 [R(int) = 0.0174] 
Reflns observed [F>4σ(F)] 3184 
Absorption correction Analytical 
Max. and min. transmission 0.842 and 0.740 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4090 / 39 / 254 
Goodness-of-fit on F2 1.027 
Final R indices [F>4σ(F)] R1 = 0.0395, wR2 = 0.0810 
R indices (all data) R1 = 0.0577, wR2 = 0.0902 
Largest diff. peak, hole 0.338, -0.393 eÅ-3 
Mean and maximum shift/error 0.000 and 0.000 
 
Table 2. Bond lengths [Å] and angles [°] for AB1404. 
 
O(1)-C(1) 1.208(2) 
C(1)-O(2) 1.372(3) 
C(1)-C(6) 1.440(3) 
O(2)-C(3) 1.444(2) 
C(3)-O(4) 1.437(2) 
C(3)-C(7) 1.502(3) 
C(3)-C(8) 1.508(3) 
O(4)-C(5) 1.361(2) 
C(5)-C(6) 1.348(3) 
C(5)-C(9) 1.441(3) 
C(9)-C(10) 1.347(3) 
C(10)-C(11) 1.436(3) 
C(11)-C(15) 1.410(3) 
C(11)-C(12) 1.421(3) 
C(12)-O(12) 1.221(2) 
C(12)-C(13) 1.547(3) 
255 
 
C(13)-O(14) 1.399(3) 
C(13)-Cl(2) 1.764(2) 
C(13)-Cl(1) 1.769(2) 
O(14)-C(15) 1.378(2) 
C(15)-N(16) 1.301(3) 
N(16)-C(20) 1.474(3) 
N(16)-C(17) 1.487(3) 
C(17)-C(18) 1.505(4) 
C(17)-C(18') 1.536(6) 
C(18)-C(19) 1.524(7) 
C(19)-C(20) 1.525(5) 
C(18')-C(19') 1.508(9) 
C(19')-C(20) 1.542(8) 
C(30)-Cl(4) 1.751(3) 
C(30)-Cl(3) 1.761(2) 
 
O(1)-C(1)-O(2) 117.66(19) 
O(1)-C(1)-C(6) 126.7(2) 
O(2)-C(1)-C(6) 115.50(19) 
C(1)-O(2)-C(3) 118.40(16) 
O(4)-C(3)-O(2) 109.75(16) 
O(4)-C(3)-C(7) 106.44(17) 
O(2)-C(3)-C(7) 106.09(17) 
O(4)-C(3)-C(8) 110.46(17) 
O(2)-C(3)-C(8) 110.34(17) 
C(7)-C(3)-C(8) 113.58(19) 
C(5)-O(4)-C(3) 115.59(16) 
C(6)-C(5)-O(4) 120.37(18) 
C(6)-C(5)-C(9) 125.1(2) 
O(4)-C(5)-C(9) 114.45(17) 
C(5)-C(6)-C(1) 120.8(2) 
C(10)-C(9)-C(5) 122.5(2) 
C(9)-C(10)-C(11) 125.63(19) 
C(15)-C(11)-C(12) 107.16(17) 
C(15)-C(11)-C(10) 128.52(19) 
C(12)-C(11)-C(10) 124.20(18) 
O(12)-C(12)-C(11) 132.49(19) 
O(12)-C(12)-C(13) 122.30(19) 
C(11)-C(12)-C(13) 105.20(17) 
O(14)-C(13)-C(12) 106.70(16) 
O(14)-C(13)-Cl(2) 109.24(14) 
C(12)-C(13)-Cl(2) 111.47(15) 
O(14)-C(13)-Cl(1) 108.12(15) 
C(12)-C(13)-Cl(1) 111.31(15) 
Cl(2)-C(13)-Cl(1) 109.88(12) 
C(15)-O(14)-C(13) 108.08(15) 
N(16)-C(15)-O(14) 113.06(17) 
N(16)-C(15)-C(11) 134.09(19) 
O(14)-C(15)-C(11) 112.86(18) 
C(15)-N(16)-C(20) 125.16(17) 
C(15)-N(16)-C(17) 123.19(17) 
C(20)-N(16)-C(17) 111.59(17) 
N(16)-C(17)-C(18) 102.9(2) 
N(16)-C(17)-C(18') 102.1(3) 
C(17)-C(18)-C(19) 104.8(4) 
C(18)-C(19)-C(20) 102.5(4) 
C(19')-C(18')-C(17) 103.0(5) 
C(18')-C(19')-C(20) 104.5(5) 
N(16)-C(20)-C(19) 103.0(2) 
N(16)-C(20)-C(19') 103.3(3) 
Cl(4)-C(30)-Cl(3) 111.45(14) 
 
1.25.14.3 6-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-5,7-dihydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (557) 
Table 1. Crystal data and structure refinement for AB1205b. 
Identification code AB1205b 
Formula C16 H16 O8 
Formula weight 336.29 
Temperature 203 K 
Diffractometer, wavelength OD Xcalibur PX Ultra, 1.54184 Å 
Crystal system, space group Triclinic, P-1 
Unit cell dimensions a = 7.8746(3) Å α = 114.468(5)° 
 b = 9.6386(6) Å β = 90.215(4)° 
 c = 11.0491(5) Å γ = 91.686(4)° 
Volume, Z 762.87(7) Å3, 2 
Density (calculated) 1.464 Mg/m3 
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Absorption coefficient 1.017 mm-1 
F(000) 352 
Crystal colour / morphology Colourless tabular needles 
Crystal size 0.22 x 0.14 x 0.07 mm3 
θ range for data collection 4.40 to 72.44° 
Index ranges -5<=h<=9, -11<=k<=11, -13<=l<=12 
Reflns collected / unique 5475 / 2942 [R(int) = 0.0223] 
Reflns observed [F>4σ(F)] 2541 
Absorption correction Analytical 
Max. and min. transmission 0.933 and 0.854 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2942 / 2 / 225 
Goodness-of-fit on F2 1.058 
Final R indices [F>4σ(F)] R1 = 0.0399, wR2 = 0.1110 
R indices (all data) R1 = 0.0453, wR2 = 0.1177 
Largest diff. peak, hole 0.221, -0.223 eÅ-3 
Mean and maximum shift/error 0.000 and 0.000 
 
Table 2. Bond lengths [Å] and angles [°] for AB1205b. 
O(1)-C(10) 1.3626(15) 
O(1)-C(2) 1.4380(15) 
C(2)-O(3) 1.4527(17) 
C(2)-C(12) 1.5010(19) 
C(2)-C(11) 1.507(2) 
O(3)-C(4) 1.3473(16) 
C(4)-O(4) 1.2214(17) 
C(4)-C(5) 1.4464(18) 
C(5)-C(10) 1.3952(19) 
C(5)-C(6) 1.4096(18) 
C(6)-O(13) 1.3414(16) 
C(6)-C(7) 1.3987(18) 
C(7)-C(8) 1.4082(18) 
C(7)-C(14) 1.4712(17) 
C(8)-O(22) 1.3417(15) 
C(8)-C(9) 1.3991(17) 
C(9)-C(10) 1.3789(18) 
C(14)-C(19) 1.3427(18) 
C(14)-O(15) 1.3495(15) 
O(15)-C(16) 1.4407(15) 
C(16)-O(17) 1.4483(16) 
C(16)-C(20) 1.505(2) 
C(16)-C(21) 1.509(2) 
O(17)-C(18) 1.3495(17) 
C(18)-O(18) 1.2218(16) 
C(18)-C(19) 1.4410(18) 
 
C(10)-O(1)-C(2) 115.56(10) 
O(1)-C(2)-O(3) 110.06(10) 
O(1)-C(2)-C(12) 106.42(11) 
O(3)-C(2)-C(12) 105.85(11) 
O(1)-C(2)-C(11) 110.90(11) 
O(3)-C(2)-C(11) 109.58(11) 
C(12)-C(2)-C(11) 113.85(12) 
C(4)-O(3)-C(2) 117.78(10) 
O(4)-C(4)-O(3) 118.53(11) 
O(4)-C(4)-C(5) 124.76(12) 
O(3)-C(4)-C(5) 116.63(11) 
C(10)-C(5)-C(6) 118.92(11) 
C(10)-C(5)-C(4) 120.02(12) 
C(6)-C(5)-C(4) 120.78(12) 
O(13)-C(6)-C(7) 118.82(11) 
O(13)-C(6)-C(5) 120.47(11) 
C(7)-C(6)-C(5) 120.63(11) 
C(6)-C(7)-C(8) 118.24(11) 
C(6)-C(7)-C(14) 120.10(11) 
C(8)-C(7)-C(14) 121.61(11) 
O(22)-C(8)-C(9) 120.85(11) 
O(22)-C(8)-C(7) 117.31(11) 
C(9)-C(8)-C(7) 121.83(11) 
C(10)-C(9)-C(8) 118.37(11) 
O(1)-C(10)-C(9) 118.58(11) 
O(1)-C(10)-C(5) 119.37(11) 
C(9)-C(10)-C(5) 121.99(12) 
C(19)-C(14)-O(15) 121.01(12) 
C(19)-C(14)-C(7) 125.07(11) 
O(15)-C(14)-C(7) 113.91(10) 
C(14)-O(15)-C(16) 116.05(10) 
O(15)-C(16)-O(17) 110.00(10) 
O(15)-C(16)-C(20) 106.10(11) 
O(17)-C(16)-C(20) 106.36(12) 
O(15)-C(16)-C(21) 110.32(11) 
O(17)-C(16)-C(21) 109.70(11) 
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C(20)-C(16)-C(21) 114.21(12) 
C(18)-O(17)-C(16) 117.89(10) 
O(18)-C(18)-O(17) 117.67(12) 
O(18)-C(18)-C(19) 125.41(12) 
O(17)-C(18)-C(19) 116.72(11) 
C(14)-C(19)-C(18) 119.79(12) 
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1.25.15 Selected 1D and 2D NMR spectra 
1.25.15.1 (E)-4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)but-3-enoic acid (357a) 
 
Spectrum 1. HMBC spectrum for compound 458a.  
/4 
 
/2 
 
/2 
 
/2 
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1.25.15.2 Isopropyl 3,6-dihydroxybiphenyl-2-carboxylate (514a)  
 
 
Spectrum xx. HMBC spectrum for 514a.
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